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 Summary 
 
The patellazoles are a family of marine polyketide natural products first isolated from Lissoclinum 
patella in 1988 by both the Moore and Ireland groups. They exhibit significant cytotoxicity against the 
HCT 116 human colon tumour cells. To date however, their full 3D stereostructure have yet to be 
elucidated, which has hindered their development as potential drugs, and hampered full investigation 
into their biological mechanism of action and has deterred total synthesis efforts. This thesis describes 
synthetic efforts towards Patellazole B, which exhibits the highest potency of the three main congeners. 
To fully elucidate the structure and renew interest in the patellazoles as anticancer compounds, we have 
developed a flexible and modular synthesis that aims to define the unknown stereocentres within the 
pertinent region and allow for rapid fragment union. Compound 36 has been chosen as an initial target 
for NMR comparison studies. The synthesis of all eight diastereomers of this macrocycle should aid 
determination of the four unknown stereocentres.  
Chapter 2 describes the synthesis of the C1–C12 fragment, focusing on the configuring of the C5 methyl 
stereocentre and the construction of the C7-C10 stereotetrad via a boron-mediated anti aldol with an in-
situ reduction. In the third chapter, the synthesis of the C13-C19 fragment is outlined.  A boron-mediated 
glycolate aldol has been used to install the C16-C17 anti stereochemistry and a substrate-controlled 
reduction at C15 delivered the hydroxyl with high diastereoselectivity. Studies into the C17 methylation 
are also described.   
Chapter 4 describes the synthesis of one possible diastereomer of the C20-C25 fragment, as a template 
for the preparation of the other 7 possible diastereomers. The route therefore employs only catalyst 
based control methods to install the three stereocentres, utilising a Sharpless asymmetric epoxidation 
and Evans aldol to construct the stereotriad. The 22R, 23S, 24S diastereomer has been initially chosen 
to investigate the later chemistry. 
Chapter 5 contains discussion of the ongoing work investigating fragment union and formation of the 
macrocycle. A Heck coupling reaction has been employed to construct the C19-C20 bond and a Suzuki 
coupling reaction has been developed to facilitate the C12-C13 bond formation. These two cross couplings 
have delivered the C1-C25 fragment, 360, the final compound reported in this thesis, which is three steps 
away from the completed macrocycle and six from compound 36.  
The experimental procedures and spectroscopic characterisation of the synthesised intermediates can 
be found in Chapter 6 and the Appendix. 
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FT-IR   Fourier transform infra-red spectroscopy 
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Nomenclature 
Compound Numbering 
Numbering priorities according to the IUPAC numbering system are used for the naming of compounds 
in the experimental section. However, for compounds relating to patellazole B and its fragments, the 
numbering used is that proposed by Moore, with the exception of the methyl groups, which are denoted 
by the skeletal carbon to which they are appended (Figure 1).1 This numbering system is given on 
structures and also used in 1H NMR assignments. For compounds not related to patellazole B, atom 
numbers are denoted by a prime.  
 
Figure 1: Numbering convention for patellazole B 
Syn and Anti Isomers 
The syn and anti convention for assigning the relative stereochemistry of adjacent stereocentres is 
used. Considering the carbon backbone of the compound to lie in a plane, a syn product is defined as 
having both vicinal substituents (R3 and R4) on the same side of the plane. Conversely, an anti product 
will have these substituents on opposite sides of the plane (Figure 2). This follows the convention for 
aldol adducts described by Masamune.2 
 
Figure 2: Examples of stereochemical relationships
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Chapter 1: Introduction 
1.1 Marine Natural Products as Therapeutic Agents 
 
Throughout history, compounds found in nature have been used in traditional medicines.3,4 Although 
natural products from marine sources have been used less in traditional medicine than those from 
terrestrial sources, primarily for reasons of accessibility, the size and varied nature of the oceans lead 
them to hold great potential as a source of chemotherapeutic agents.5,6 Notably 32 of the 33 animal 
phyla have some representation in aquatic environments meaning that the oceans represent one of the 
most ecologically diverse environments on the planet.7 The unique environment of the oceans also 
often causes marine natural products to belong to unique chemotypes not found in terrestrial sources.8,9 
The need to combat environmental and predatorial pressures has led even the simplest of marine bio-
organisms to evolve the production of secondary metabolites as a means to survive. Whilst these 
metabolites are not essential to life, they provide an evolutionary advantage in self-defence or 
attracting prey. Despite being evolved for a specific target, these compounds frequently display 
interesting biological activity against a wide range of other targets, providing a useful source of 
inspiration and lead structures for the drug discovery industry.10 Natural products also typically display 
greater bioavailability (and structural diversity) than compounds developed from a combinatorial 
library, due to their evolution within nature.11 
 
Studies show that 50% of all new drugs released between 1981 and 2014 can be categorised as being 
‘naturally inspired’ and for the 155 chemical-based anti-cancer drugs available in the West and Japan 
between 1940 and 2006, this rises to 73% (113 in total).12 These include natural products, those derived 
from a natural product (typically having undergone a semisynthetic modification) and drugs made by 
total synthesis, but where the pharmacophore was from a natural product.5 
  
Technological advances in the second half of the 20th century, such as the use of self-contained 
underwater breathing apparatus (SCUBA) diving equipment have made marine natural products far 
more accessible to the isolation chemist.11,13 Prior to 2004 only two marine natural product inspired 
drugs, cytarabine and vidarabine had been approved for market (in 1969 and 1976 respectively). Since 
the turn of the century though, a series marine natural product derived drugs have been released, 
including trabectedin14 and ziconotide15 and as of 2010 a further 11 compounds were in the clinical 
pipeline.16 
 
  
  
 
 
 
 
 
 
 
Figure 3: Structural deletion of halichondrin B to give HalavenTM (Eribulin mesylate) 
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A perpetual issue with natural products as drug candidates however, is their scarce natural abundance. 
Typical isolation yields are extremely low and thus the extraction of clinically useful quantities requires 
the collection and slaughter of multi-tonne quantities of the organism. Artificial attempts to produce 
greater quantities of the bioactive material through farming of the marine organism often fail due to 
the significant effect of environmental influences on the production of secondary metabolites. For these 
reasons, organic synthesis still represents one of the only realistic options to produce these compounds, 
in the quantities required for clinical evaluation. Moreover, fragment or total synthesis provides the 
opportunity for the unambiguous confirmation of the structural configuration and also the development 
of new synthetic methods. Furthermore, a synthetic investigation may also provide insight into the likely 
biosynthesis.17  
 
Polyketides represent one such class of natural products and have been isolated from a variety of 
different marine invertebrates, such as corals, sponges, algae and other microorganisms.18 These 
compounds have complex molecular architectures, with high levels of oxygenation, dense arrays of 
stereocentres and exhibit potent biological activities. A large number of these compounds have now 
succumbed to total synthesis, due to their interest to synthetic chemists as potential drug targets.3 
Recent developments in the field have led to more concise routes, allowing the synthesis of increasingly 
complex targets.8,19–21 Despite this, the total synthesis of complex polyketide natural products still 
represents a significant, yet rewarding challenge for the synthetic chemist.  
 
Total synthesis also usefully provides the possibility of producing structurally related analogues, 
allowing for structure-activity relationship studies to be undertaken, with a view to further 
understanding the mode of action of the compound. These modifications could also be used to make 
the molecule more ‘drug-like’, with improved pharmacokinetics and reduced toxicity. Danishefsky has 
described the art of ‘Diverted Total Synthesis’; reducing the complexity in natural products, simplifying 
their syntheses and making them more amenable to the pharmaceutical industry.22 
 
A compelling example of this theory in practice is that of the marine natural product halichondrin B from 
which the anticancer drug eribulin mesylate (Halaven®) is inspired (Figure 3).23 The natural product 
underwent significant structural deletion, particularly of the side chain, which was found not to have 
any effect on the compound’s cytotoxicity. A functional group modification from the macrolactone to a 
cyclic ketone was also discovered to improve the in vivo stability.24 The final manufacturing route is still 
more than 30 steps in the longest linear sequence, representing a major industrial undertaking and  
proof that total synthesis can provide a viable and realistic supply route to even the most complex 
  
 
 
 
 
 
 
 
 
 
Scheme 1: Complete structure of mycolactone C, as determined by total synthesis 
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molecules. Moreover, this work was only made possible by the total synthesis of the full natural product, 
halichondrin B by Kishi.25 X-ray crystallography had unambiguously assigned the full stereostructure of 
norhalichondrine A, but this wasn’t possible for halichondrin B. Comparison of spectral data between 
the synthetic material and the both natural products allowed unambiguous assignment of the absolute 
and relative stereochemistry within halichondrin B for the first time.  
 
In summary, the fields of natural product chemistry and organic synthesis increasingly complement one 
another. Natural products provide great inspiration for the drug discovery chemist and in attempting to 
realise their potential and produce these highly complex compounds, the synthetic chemist is 
encouraged to develop new methodology and advance the field of organic chemistry.  
 
 
1.2 Use of Total Synthesis as a Means of Structural Determination 
 
Improvements in purification and analytical techniques, such as high performance liquid 
chromatography (HPLC) and high field NMR spectroscopy have made full structural determination 
possible on sub-milligram quantities of material.26 Despite these developments though, more than 300 
structural revisions to natural products have been made since 1990.27 Synthetic efforts have been 
critical in almost all these revisions and ultimately total synthesis has proved to be a powerful tool in 
providing categorical validation of the true chemical structure. A key aspect of total synthesis therefore 
is its ability to determine, confirm or correct the true structure of a natural product.  
 
Kishi’s synthesis of mycolactone C is a useful example of using a total synthesis as a means of structural 
determination (Scheme 1).28 Whilst he could determine the stereochemistry of the macrocycle and 
northern side chain via a process of fragment synthesis and NMR comparison to the natural product in 
that region, this proved impossible in the southern side chain. The natural product exists as a 1:1 mixture 
of E/Z geometric isomers across the C4’-C5’ bond, complicating spectroscopic analyses, particularly of the 
polyunsaturated side chain. The remote nature of the C13’-C15’ diol, away from the macrocyclic core also 
provided a challenge as to how to predict the relative stereochemistry between these two regions with 
confidence. Limited natural product availability also perturbed degradation studies. Synthesis of all four 
stereoisomers followed by a combination of NMR and HPLC analysis was used to determine the 
stereochemistry of the natural product.   
 
  
Figure 4: The structures of leiodermatolide (7) and its lactone anitpode (8) 
 
 
 
 
Figure 5: Chemical structures of callipeltoside A, phorbaside A and its (18S, 19R) diastereomer 
 
 
 
 
 
 
Figure 6: Proposed and revised structures of baulamycin A 
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The full stereostructure of leiodermatolide could also not be assigned from the isolated sample. Despite 
the use of advanced NMR techniques, combined with molecular modelling and computational NMR 
prediction, only the relative configurations of the macrolide core and the δ-lactone could be 
determined. The pentadienyl spacer unit between these two regions made correlating these two 
stereoclusters impossible. Through synthesis and attachment of both antipodes of the δ-lactone to the 
macrocycle, Furstner could identify the true structure.29,30 Comparison of A and B (Figure 4), by NMR 
indicated the former as leiodermatolide. Only very subtle spectroscopic differences between A and B 
were observed, highlighting the critical role of total synthesis in the structural determination.  
 
The Paterson synthesis of phorbaside A also provided configurational validation.31 Spectroscopic 
analysis of phorbaside A showed significant structural similarity to callipeltoside A.32–34 Semiquantitative 
circular dichroism using model fragments however, indicated the configuration of the cyclopropane ring 
(18R, 19S) in phorbaside A to be opposite to that of the callipeltosides (Figure 5). Paterson proceeded 
to synthesise both the proposed structure (10) and its (18S, 19R) diastereomer (11). Whilst 1H and 13C 
NMR spectra of both samples were identical to the natural product, they were distinguishable by circular 
dichroism, validating the proposed structure, with an antipodal cyclopropane configuration to the 
callipeltosides.  
 
Initial synthetic attempts by both Aggarwal35 and Goswami36 towards total synthesis of baulamycin A 
found that the spectroscopic data for the synthetic material did not match that of the natural material, 
indicating a misassignment of the stereochemistry (Figure 6). The inherent flexibility of the carbon 
chain, along which there are seven stereogenic centres, leads to multiple conformations of the molecule 
being present in solution. The weighted average of these displayed in the natural NMR spectrum, 
severely complicates the configurational analysis. With synthesis of all 128 possible stereoisomers an 
implausible solution, extensive NMR analysis of individual fragments alongside computational 
modelling was carried out by Aggarwal. ROESY data from the natural sample aided deduction of the 
relative stereochemistry in the C11-C14 region. With the stereocentres in the C4-C8 region non-contiguous 
however, such an approach was not possible. Assembly-line synthesis37 was used to produce a mixture 
of four stereoisomers of the baulamycins, with the newly assigned stereochemistry in the C11-C14 region, 
but differing configurations at C4, C6 and C8. These stereoisomers were produced in an unequal (but 
predetermined) mixture by variation of the reagent stoichiometry in the assembly line synthesis. 
Analysis of the signal intensities in the 13C spectrum of the mixture was used to determine which 
stereoisomer in the mixture most closely replicated the natural sample. This method established the 
relative stereochemistry of the C10-C1 fragment and synthesis of the C11/C8 syn and C11/C8 anti 
Figure 7: Photograph of L. patella sample L3 at collection site in the 
Solomon Islands49 
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diastereomers was used to determine which diastereomer was the natural one. Optical rotation then 
aided identification of the correct enantiomer.  
 
All these examples illustrate the power of total synthesis in structural determination. Despite the 
advances in NMR spectroscopy and computational prediction, often it is only the synergy of these tools 
alongside synthetic efforts that is able to provide elucidation or validation of a correct natural product 
structure.  
 
1.3  The Patellazoles 
 
1.3.1 Isolation Attempts  
 
The patellazoles are a family of marine natural products isolated from Lissoclinum Patella, a didemnid 
tunicate found in various locations of the Pacific Ocean.38 Didemnid tunicates are a type of marine 
chordate recognised for their symbiotic relationship with unicellular algae.39,40 It has been reported that 
algae of the genus Prochloron are the only known symbionts of L. Patella,41 but this was not further 
investigated at the time of patellazole isolation. This cyanobacterial symbiont can be seen as a dark 
green mottling below the surface of the tunicate (Figure 7).38  
 
In 1988 the Ireland42 and Moore1 groups simultaneously reported  that L. Patella, collected from the Fiji 
and Guam respectively, contained a family of thiazole-containing polyketide metabolites, which they 
named the patellazoles. The original interest in the tunicate was prompted by the apparent geographical 
dependency on the secondary metabolite composition and abundance.38 Evaluation of L. Patella 
extracts from the Philippines, Australia and Indonesia for instance, had failed to yield any of the 
patellazoles. Other biologically active compounds isolated from L. Patella extracts include patellins 1-6 
and Ulithiacyclamide B.43,44 Prochloron didemni has also been shown to produce a series of cyclic 
peptides; the patellamides, which are far more ubiquitous amongst L. Patella samples.45 
 
Crude lipophilic extracts (extracted using hexanes, carbon tetrachloride and chloroform) showed 
promising cytotoxic potency (IC50 15 ng / mL) against the KB human cancer cell line, which is a 
contaminated human oral epidermoid carcinoma cell line.46,47 Purification of the crude extracts by silica 
gel chromatography and reverse phase HPLC yielded three congeners of the patellazole family, namely 
patellazoles A - C.  Both groups published proposed 2D structures, with Zabrinske and Ireland describing 
the structural elucidation of patellazole C and Corley, Moore and Paul that of patellazole B. Isolation 
  
Figure 8: Sub-units A-J identified in 2D structural determination by Moore 
 
 
 
Figure 9: Other bioactive natural products isolated from L. patella 
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yields by Ireland were as follows: 96.5 mg of patellazole A, 144.3 mg of patellazole B and 312 mg of 
patellazole C from 220 g of freeze-dried organism. These are notably high, compared with typical natural 
product isolation yields. Paul reported the isolation of 12 mg of patellazole B (0.75% from crude 
extracts). 
 
The 2D structural elucidation of patellazole B was carried out by Moore utilising numerous 
characterisation techniques.1 IR data indicated the presence of both a ketone and an ester as well as 
several hydroxyl groups. High resolution electron ionisation mass spectrometry (EIMS) established a 
molecular formula of C49H77NSO12. Further analysis by 13C and 1H NMR identified one ketone carbonyl, 
two ester carbonyls and a thiazole system. An attempt to desulfurise patellazole A was made by 
Zabriskie.38 Treatment with excess Raney nickel instead proceeded to confirm the presence of an 
epoxide (through its subsequent reduction). The observed resistance to desulfurisation with Raney 
nickel did however rule out the existence of a thiol, thioether or thioamide. Ozonolysis of patellazole C 
proceeded to deliver a single UV active product, with high field 13C NMR signals closely matching those 
of 2-t-Bu-4-methylthiazole, serving to confirm the presence of a thiazole moiety in the patellazole 
family.  
 
72 protons were identifiable from investigation of the DEPT edited 13C NMR data, indicating the 
presence of five hydroxyl moieties. A series of 2D 1H NMR techniques (COSY, TOCSY, phase-sensitive 
NOESY and ROESY) were used to identify ten partial sub-units (as shown in Figure 8), which could then 
be connected into a complete 2D structure using 1H-13C correlation experiments (HMBC and HSQC). NOE 
analysis was used to establish the E and Z geometries of the C18-C19 and C25-C26 alkenes respectively, as 
well as the cis geometry of the epoxide and the location of the C17 methoxy group. Vicinal coupling 
constant analysis was used to determine the E and Z geometries of the remaining macrocycle olefins in 
patellazole B. Ireland used other 1D and 2D NMR experiments, including selective INEPT, phase-sensitive 
INADEQUATE and DQCOSY to elucidate the structure of patellazole C.  
 
The three major patellazole congeners share many of the same features; a 24-membered macrolide 
ring, with a side chain containing a thiazole and an epoxide, and 15 or 16 stereocentres. These congeners 
differ only by oxygenation at the C10 methyl group and C34 positions (Figure 10). Interestingly, a common  
feature across almost all the natural products extracted from L. patella, including the patellins, the 
patellamides and ulithiacyclamide is the presence of a thiazole or thiazoline (Figure 9). 
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In addition to the three major congeners (A-C), a further four minor secondary metabolites were 
isolated, although their structures were not fully assigned, due, in part, to the very low isolation yields. 
Patellazoles D and E (2.5 mg combined, in a 5:3 ratio) were extracted as an inseparable mixture. With 
parent ions at m/z 938 and m/z 906 they were postulated to be an additionally hydroxylated isomer of 
patellazole C and a dihydropatellazole B. Patellazole F (6.8 mg) was hypothesised to be the C7 epimer of  
Patellazole C, based on the similarity in elution times and only minor differences in 13C shifts. Patellazole 
G (3.5 mg) was solely isolated from the hexane fraction during the extraction of the crude material. The 
12 olefinic signals in the 13C NMR, alongside a parent ion at m/z 872 indicated that patellazole G might 
be 31,32-deoxypatellazole A. Initial NMR comparison was promising, with the 1H NMR spectrum 
superimposable with the semi-synthetic compound produced by treatment of the corresponding 
natural product with Raney nickel as described previously. Sample degradation prohibited full 
assignment however.    
 
 
Figure 10: Congeners of the patellazole family 
 
Recollection of L. patella in January and August of 2001 from the same site as in 1984, 1987 and 1997 
(the Astrolobe Reef, Kandavu) aimed to provide enough samples of the patellazoles for further biological 
testing. These extracts however, failed to yield any of the patellazoles. A further effort, by the Ireland 
group, to re-isolate these compounds from samples of L. patella collected around the Navula pass in Fiji 
in July and September 2001 however, did produce patellazoles in similar yield to previous collections. 
This would suggest the occurrence of localised incidents resulting in patellazole biosynthesis being 
turned on or off in L. patella, rather than a seasonal environmental factor such as temperature or 
nutrient availability.   
 Figure 11: Proposed biosynthetic pathway by Schmidt 
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However this re-extraction proved far from trivial and also resulted in the isolation of several new 
analogues, patellazoles H-J (Figure 10).48 These differ from patellazoles A-B only in the lack of an epoxide 
moiety and appear to exist as an artefact of the isolation procedures used, with the epoxide having 
undergone nucleophilic opening by the HPLC solvents used (MeOH and i-PrOH). Although originally 
postulated that the epoxide had been opened at C32, further characterisation indicated that nucleophilic 
attack had instead taken place at the carbon alpha to the thiazole ring, with a developing positive charge 
best stabilised that this position. Isolation yields of these artefacts were low (1.7 mg, 0.7 mg and 0.6 mg 
of patellazole H, patellazole I and patellazole J respectively), but provided sufficient material for initial 
biological testing.  
 
1.3.2  Stereochemical assignment 
 
In 2012, Schmidt sought to investigate the likely biosynthetic pathway to the patellazoles.49 Genetic 
analysis of Prochloron didenmi and the cloacal habitats failed to yield any polyketide synthase (PKS) 
genes, but DNA sequencing of the zooid region surrounding the cloacal cavity led to the discovery of 
Candidatus ‘Endolissoclinum faulkneri’, an α-proteobacterium; the likely producer of the 
patellazoles.45,49 A retrobiosynthetic analysis indicated the incorporation of 15 acetate units and a 
cyclised serine, plus the addition of a further two acetate units in the side chain. Schmidt has proposed 
a plausible biosynthetic pathway to the patellazoles (Figure 11) and using genetic analysis of the 
ketoreductase domains in the pathway, he has been able to predict the configuration of five out of the 
16 stereocentres, specifically the oxygenated centres at C7, C15, C17, C31 and C47.49  
 
An unusual feature within the patellazole biosynthesis is the presence of two β-γ cis-double bonds. 
These are rare in polyketide-synthase-produced natural products and the lack of a dehydratase domain 
within the relevant module, indicates a novel pathway may be involved in their biosynthesis. Schmidt 
has proposed the synthesis of a thioester-conjugated 1,3-diene, which subsequently undergoes a 
reductive mechanism. Action of a 2,4-dienoyl-CoA-reductase enzyme on the diene, generates a 1,2,3,4-
dieneolate, which is then protonated to give the β-γ cis-alkene.   
  
 
 
 
 
 
 
 
 
 
 
Figure 12: Key structural truncates identified by Yoshida for NMR studies 
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Various accessory proteins are required in the proposed biosynthetic pathway. Unlike most PKS 
proteins, which contain an acyl transferase (AT) domain in each module, the patellazole synthesis 
utilises ATs on a separate protein to deliver malonate units onto the acyl-carrier proteins to install most 
of the methyl groups along the backbone. Additional accessory proteins are responsible for the β-
methylation at C5. Several post-cyclisation processes are required, including a regio- and stereoselective 
P450 oxidation at C2 and optionally at Me10, attachment of the ester side chain and an as yet 
undetermined process to install the epoxide moiety.  
 
Studies by Moore and Yoshida50 in 2002 attempted to elucidate the stereochemical configuration of 
patellazole B, using various NMR techniques, including analysis of NOE and coupling constant data. 
Using the J-based configurational analysis method developed by Murata,51 Yoshida was able to 
determine the predominant conformer in solution for a series of C-C bonds along the backbone by 
combining the analysis of 2JC-H, 3JC-H and 3JH-H data. Each set of data follows a Karplus style relationship,52 
thus allowing gauche or anti relationships to be determined. When one of these stereogenic carbons is 
oxygenated, the relative configuration can also be determined. The electronegativity of the oxygen has 
a sufficient effect on the 2JC-H value between the oxygenated carbon and a proton on the adjacent carbon 
that the spatial relationship between the two can also be identified as anti or gauche. For each C-C 
bond, the two possible diastereomers will collectively have six rotamers. Through a process of 
elimination, the coupling constant information can be combined to ascertain the relative conformation 
and configuration of the two adjacent stereocentres. NOE analysis is still required though to distinguish 
between the two anti-diastereomers. Since the exploration of the biosynthetic pathway by Schmidt has 
proposed the stereochemistry at the majority of the oxygenated centres, these relative conformations 
could be reassigned as absolute configurations. 
Yoshida fragmented patellazole B down into five key stereoclusters, namely C1-C9, C14-C17, C22-C24, C31-
C32, and C45-C48 (Figure 12). NOE analysis was sufficient to determine the cis-relationship between the 
two methyl substituents on the epoxide at C31 and C32. For the other side chain (34), the adjacent 
stereocentres fitted well into a characteristic 1,2-methine system and an anti-relationship was 
determined between C46 and C47. For the C14-C17 stereotetrad, a syn-relationship between C15 and C16 
was elucidated alongside C14-C15 and C16-C17 anti relationships. Anti-relationships were established 
between both C5 and C7 stereocentres and across the C7-C8 bond. Murata’s method also aided the C2 
stereocentre to be determined as having an S configuration. 
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However, for the C22-C24 stereotriad, 2,3JC,H couplings were found to be of intermediate magnitude, 
possibly due to the molecule not adopting a staggered conformation in this region close to the 
macrocycle junction, or multiple conformers being present. For these regions, Murata’s method is 
therefore not appropriate. NOE data was insufficient to determine the conformation unambiguously, 
so the full stereochemistry remains undetermined. Combining the studies by Schmidt and Yoshida, the 
configuration at 12 of the 16 stereocentres have been assigned with confidence (Figure 13).  
 
 
Figure 13: Currently assigned stereochemistry in patellazole B 
 
Investigations carried out by Kenneth Ng in the Paterson group53 aimed to help assign the configuration 
of the remaining unknown stereocentres by use of Goodman’s DP4-based NMR prediction technique.54 
This technique uses a statistical method to compare the predicted chemical shift data for a compound 
to the experimental spectrum. Initially, a conformational search is undertaken and single point energy 
calculations carried out using DFT to deduce the lowest energy conformers for each candidate 
diastereomer. An NMR prediction for both the 1H and 13C chemical shifts is then carried out for each of 
these conformers and spectra combined to represent the calculated weighted average of these 
conformers. With predicted spectra produced for each candidate diastereomer, they can be compared 
with those spectra obtained from the natural product. A statistical model is then used to assign a 
confidence rating to each diastereomer based on the errors in the 1H and 13C shifts. Unfortunately, this 
work was unsuccessful in providing further insight into the unknown stereochemistry. It was postulated 
that the macrocycle is simply too flexible, causing there to be too many low energy conformers, for this 
methodology to offer sufficient confidence in a single diastereomer.  
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However, it was concluded that sufficient stereochemical information was in place to embark upon 
synthetic studies with the objective of assigning the remaining stereocentres though a total synthesis.  
 
 
1.3.3  Biological evaluation 
 
Besides the challenge of fully assigning the stereostructure of patellazole B, the interesting biological 
activity reported in the literature makes it a valuable target to pursue. The patellazoles were found to 
have significant cytotoxicity towards HCT 116 human colon tumour cells. A series of MTT assays, each 
of 72 hours and using DMSO as a vehicle were carried out to determine the cytotoxicity. This assay 
observes the activity of cellular mitochondria as a measure of total cell growth inhibition.55 Actively 
respiring mitochondria produce succinate dehydrogenase, which converts the MTT (a soluble dye) into 
an insoluble crystal. Patellazoles A and B showed the greatest toxicity with both exhibiting low 
nanomolar IC50 values across wild-type and p53 cell lines.56 Patellazole B exhibited slightly higher 
potency in the wild-type case with an IC50 value of 0.39 nM (Table 1). Patellazole C typically exhibited 
cytotoxicities an order of magnitude lower.  
 
 
Table 1: Comparison of biological activity between patellazole congeners 
 
The mode of action is still not fully understood, but it is known that all the different congeners show 
cytotoxicity via the same mechanism of action. Moreover, whilst the epoxide opening observed in 
patellazoles H-J does not completely abrogate their bioactivities, they exhibited cytotoxicities typically 
one to two orders of magnitude lower. This suggests that the relative cytotoxicity of the epoxide-opened 
patellazoles could be as a result of either an altered affinity with the target protein binding site or 
pharmacokinetic effects. These could lead to either a reduced ability of the compound to enter the cells 
or affect its distribution within the cell.  
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Studies by Ireland57 have shown that the treatment of tumour cells with IC50 concentrations of the 
patellazoles activates apoptotic pathways leading to cell death (Table 2). HCT 116 wild type cells were 
arrested at the G0/G1 and S phases of the cell cycle. After 24 hours, a greater percentage of cells were 
in the G0/G1 phase for all patellazole congeners compared with the control sample. After 48 hours, a 
decrease in the G0/G1 percentage was counterbalanced with a significant increase in the amount of 
cellular debris. So it is likely that cells which had arrested in the G0/G1 phase had either died or passed 
slowly to the S phase and re-arrested there.  
 
 
Table 2: Cell cycle effect of IC50 concentrations of patellazoles on HCT 116 wild-type cells 
 
The third response observed was the effect on macromolecule synthesis. Radiolabelled precursors were 
injected into HCT 166 wild type cells which had been treated with a 30 nM solution of patellazole H. [3H] 
Thymidine, [3H] uracil and [3H] lysine were used to detect for DNA, RNA and protein production 
respectively. Comparison between the radioactivity of the treated cells and control samples then 
determined the level of macromolecule synthesis. An increase in DNA production upon treatment with 
patellazole H was initially observed, although this returned to control levels after 30 hours and it is 
unclear whether this would have continued to drop. Both RNA production and protein synthesis were 
shown to be decreased however. The inhibition of the latter appears to begin at around three hours 
and continues to decrease protein synthesis to only 13% of that of the control culture after 30 hours.  
 
Lissoclinolide, another natural product isolated from L. patella had exhibited interesting cytotoxicity 
against three other cells lines; Caco2 (another colon tumour cell line) and two breast cancer lines (MDA-
MB-435S and MDA-MB-468). Disappointingly, none of the patellazole congeners displayed promising 
biological activity against these lines.57   
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Several approaches are known to elucidate the cellular target of a cytotoxin, including high throughput 
screening, photoaffinity labelling and affinity chromatography. The latter of these was attempted by 
Richardson,48 aiming to utilise a biotin-streptavidin linker to bind the patellazole to a solid phase 
support. Although the cytotoxicities of patellazole B and its epoxide-opened analogue patellazole H are 
different, it was considered that their bioactivities were similar enough to make use of this epoxide 
functional group as a linker junction. With no partial or total syntheses of the patellazoles to date, 
attachment of a linker selectivity to a single hydroxyl group on the natural sample would have been 
challenging. Unfortunately, all attempts at linker addition by epoxide opening though proved fruitless.   
With greater quantities of the patellazoles available, ideally produced by total synthesis, far more 
extensive biological testing could be carried out. This might include further attempts at affinity 
chromatography or photo affinity labelling to determine the protein target and binding site. Synthesis 
of appropriate analogues would also allow structure-activity relationships to be determined.  
 
 
1.4  Project Aims and Retrosynthetic Analysis.  
To date there have been no attempted syntheses of any of the patellazoles disclosed, presumably 
because of continued uncertainty in the stereochemistry, where there are 65536 possible 
stereoisomers. However, as a result of the studies described in section 1.3.2, and only four of the 16 
stereocentres remaining unassigned, it was felt that sufficient structural understanding of the 
patellazoles had been gained to embark upon a total synthesis. With biosynthetic, NMR and 
computational methods exhausted in pursuit of the complete 3D assignment, it was concluded that a 
key aspect of the project would be a complete structure determination by total synthesis.  
 
A successful total synthesis should, in turn, allow for further biological testing to take place and 
structure-activity relationships to be investigated. With promising cytotoxic data obtained from natural 
sources, but an unknown mechanism of action,57 this is an enticing prospect.  
 
Patellazole B has numerous challenging structural features, which make it a motivating and thought-
provoking target for the synthetic chemist. Alongside controlling the 16 stereocentres; the C9 ketone, 
E,E-diene, unsequential cis-double bonds at C11/C12 and C25/C26 and the epoxide moiety all provide 
significant synthetic challenges.  
  
 
 
 
Scheme 2: Retrosynthetic analysis for patellazole B 
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As outlined in Scheme 2, we envisaged that the molecule could be dissembled into five key fragments. 
Three of these (37, 38 and 39) would form the macrocycle and the other two (40 and 41) the side chains. 
This modular approach of constructing highly functionalised fragments, with all the desired 
stereochemistry in place and at the correct oxidation level, should allow for efficient fragment coupling 
and a step-reduced endgame strategy.  
 
With three of the four unknown stereocentres lying contiguously, we proposed to isolate them into a 
single fragment, which could be synthesised as the eight different stereoisomers and attached in turn 
to the rest of the macrocycle. We intended to ensure flexibility in the order of fragment coupling, 
although we envisaged that for the synthesis of multiple macrocycle stereoisomers, the attachment of 
any isomer of the C20-C26 fragment to a complete C1-C19 fragment would be the most convergent. 
Macrocycle formation could also either be carried out via a macrolactonisation or an intramolecular 
cross coupling reaction.  
 
The C10 methyl stereocentre has not been assigned, but we have decided to target the 10S configuration 
as the 1,4-syn boron aldol methodology developed in the Paterson group should provide an efficient 
approach to construct it.58 
 
Key disconnections could take place at the C1 lactone, adjacent to the C11/12 alkene and across the C18/21 
diene region, thus dividing the macrocycle into three key components, 37, 38 and 39. The side chains 
would then be attached via an esterification at C45 and a cross coupling across C26-C27.  
 
As outlined previously, we propose to install the C20-C26 piece as the final fragment prior to 
macrolactonisation, with the C19-C20 bond being constructed via a cross coupling. An attractive feature 
of using a Heck coupling for this purpose would be the simplified terminal functionality, with only an 
alkene required at the C20 position. Alternatively, Stille or Negishi cross coupling should also afford this 
bond connection from the respective vinyl stannane or vinyl zinc species.   
 
A Suzuki coupling or Negishi coupling could be employed for the challenging sp2-sp3 coupling to 
construct the C12-C13 bond. Alternatively, we imagine that a vinyl silane at the C19 position could act as a 
‘protecting group’ for the corresponding vinyl iodide, allowing the construction of the C12-C13 bond via 
such a palladium-catalysed coupling, prior to the revealing of the vinyl iodide in preparation for C19-C20 
bond formation.   
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We envisage that NMR analysis of the individual fragments alone will not provide sufficient insight into 
the likely natural stereochemistry, due to the flexibility of these fragments and the significant effect of 
the macrocycle on the conformation of the C21-C24 region. To reduce the total amount of work required 
to determine the configuration, we aim to synthesise the simplest structure that will provide meaningful 
stereochemical information to guide the remainder of the synthesis. To this end, we propose the initial 
construction of a truncated macrocycle (36). We anticipate that the side chains should not have a 
significant effect on the chemical shifts or coupling constants of the macrocycle environments. We 
therefore hope that the synthesis and spectroscopic analysis of eight stereoisomers of this truncated 
macrocycle (varying the stereochemistry at the C22, C23 and C24 positions) followed by comparison to 
NMR spectra for the natural product, will identify the likely stereochemistry of the three unknown 
macrocycle stereocentres, namely those at C10, C22 and C23. With some confidence in the configuration 
at these sites, permutations of the C24 stereochemistry could be investigated through a partial synthesis 
of the C23-C32 side chain. We also considered that the stereochemistry of the linear fragment may 
influence its ability to macrolactonise, thus eliminating certain diastereomers from consideration at this 
stage. The truncated synthetic target (36) proposed, consequently also simplifies the synthesis of the 
south-eastern fragment (39). 
 
It is critical that the synthesis allows for the late-stage introduction of the sensitive epoxide moiety, 
which is unlikely to survive any strongly acidic or nucleophilic conditions, as evidenced by the observed 
epoxide opening with HPLC solvents. To this end, it may need to be introduced as a protected diol and 
revealed at a late stage. The ketone functionality will also need to be masked (as the corresponding 
secondary alcohol) for much of the proposed route. Both the presence of two α-chiral methyl groups 
and the reduction steps required later in the synthesis make the ketone an incompatible functional 
group for much of the proposed route. Whilst the stereochemistry of this alcohol is therefore 
inconsequential, installing it with high diastereocontrol will simplify the characterisation of 
intermediates. This alcohol will require an orthogonal protecting group, to enable the alcohol to be 
selectively deprotected and oxidised prior to global deprotection of the other hydroxyl groups. The C2 
and C23 alcohols will also need to be selectively deprotected for their respective esterifications. 
 
The polyketide derived backbone of the macrocycle naturally lends itself to the use of highly 
diastereoselective aldol reactions for its construction. We propose that the key stereotriad in the C1-C12 
south-western fragment 37 could be installed using a boron-mediated aldol reaction to form the C7-C8 
bond, using a chiral ketone building block derived from Roche ester. The isolated C5 methyl-bearing 
stereocentre could be installed via an enantioselective conjugate addition. The C14-C17 
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stereotetradcould be set up via a glycolate aldol reaction,59 followed by stereoselective  reduction of 
the C15 ketone. The unknown stereochemistry in the C20-C26 fragment will need to be installed entirely 
via reagent control, to enable access to all eight possible stereoisomers. With this consideration, a 
Sharpless epoxidation and crotylation or proparylation are proposed to install the C22, C23 and C24 
stereocentres. 
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Chapter 2: Results and Discussion – Part I 
Synthesis of the C1-C12 Vinyl Iodide 
 
2. 1 Retrosynthesis 
 
Scheme 3: Retrosynthetic analysis for the C1-C12 fragment 
 
Key to the synthesis of the C1-C12 fragment is the ability to install a variety of coupling handles at the C12 
position, with the C11 aldehyde 42 being targeted as a common intermediate. With one proposal to form 
the C12-C13 bond via a cross coupling, the prerequisite C11-C12 vinyl iodide could be installed via a Stork-
Wittig olefination,60 from this aldehyde. Alternatively, this aldehyde could be converted into the related 
terminal alkyne using a Seyferth-Gilbert homologation61–63 or Corey Fuchs olefination,64,65 to investigate 
alternative fragment union strategies.  
 
 As discussed in section 1.4, the C9 ketone functionality will be masked as a secondary alcohol, 
necessitating orthogonality in the protecting group strategy. A PMB group will allow selective 
deprotection in the presence of multiple silyl protecting groups and oxidation of the resulting alcohol.  
 
  
 
 
 
 
 
 
 
Figure 14: Mnemonic for predicting the facial attack in SAD reactions 
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We envisage constructing the key C7-C10 stereotetrad via a boron-mediated aldol reaction, followed by 
an in-situ reduction. This Narasaka type reduction,66 should install the 1,3-syn diol 43 with high 
diastereoselectivity, although the absolute stereochemistry at the C9 position is inconsequential. Ketone 
45 can be derived from (S)-Roche ester in three steps. We propose that aldehyde 44 could be dissembled 
into crotonaldehyde and Grignard reagent 48, making use of an asymmetric conjugate addition. We 
anticipate the required C1-C2 oxygenation arising from a Sharpless asymmetric dihydroxylation on 
homoallylic alcohol 50.  
 
2.2 Synthesis of the C1-C7 aldehyde 
 
2.2.1 Investigations into Sharpless Asymmetric Dihydroxylations to Install the C1-C2 Diol 
 
The first challenge in the synthesis of aldehyde 44 was to install the tertiary hydroxyl group in an 
enantioselective manner. To this end, a Sharpless asymmetric dihydroxylation was initially 
investigated.67 The following mnemonic (Figure 14) can be used to predict which ligand series is required 
to install the desired stereochemistry. Given the 1,1 disubstitution pattern of the olefin, the methyl 
group is determined to be the ‘small’ group, hence bottom face attack is required and thus ADmixα 
should be used. The comparative size of this methyl group means that 1,1-disubstituted alkenes are 
typically challenging substrates to carry out SAD reactions on, as there is only a small steric difference 
between the RS and RL groups. 
 
An encouraging report by Jutand68 describes modified Sharpless conditions employing iodine as an 
alternative stoichiometric oxidant and both di- and tri-potassium phosphate as buffers, giving diol 52 
from alkene 51 in excellent ee (Scheme 4).  
 
 
Scheme 4: Reported dihydroxylation conditions by Jutland 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 15: Sharpless ligands used in SAD screen 
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Esterification of commercial alcohol 50 with benzoic anhydride and triethylamine proceeded in good 
yield (82%), but the subsequent SAD of alkene 51 under Jutand’s conditions (albeit using the 
pseudoenantiomeric ligand to give the correct patellazole B C2 configuration) gave a disappointing 18% 
ee. Issues were encountered with solubility and solvent freezing using t-BuOH/H2O at 0 °C.   
 
Scheme 5: Benzoate protection and dihydroxylation reaction 
 
At this point, more conventional Sharpless dihydroxylation conditions were turned to. Under the 
standard ADmixα conditions, employing (DHQ)2PHAL as the chiral ligand, an increased enantiometric 
excess of 53.4% was observed by HPLC analysis (CHIRALPAC column IA). Whilst this was an advance on 
the previous conditions, there remained room for improvement.  
 
The use of methane sulfonamide has been reported to improve both conversion rates and 
enantioselectivities for osmium-catalysed dihydroxylation reactions.67 It is claimed that this aids the 
breakdown of the osmate ester during the catalytic cycle, thus increasing the rate of the catalyst 
turnover, allowing the reaction to take place at a lower temperature and consequently giving an 
improvement in ee. Although Sharpless67 has suggested that this effect is less pronounced and possibly 
even detrimental in 1,1-disubstituted systems, it was nonetheless explored for completeness, but 
accordingly addition of methanesufonamide led to a diminished ee of 40% (Table 3, entry 3).  
 
 
Table 3: Conditions screens for Sharpless asymmetric dihydroxylation 
  
 
 
 
 
 
 
 
 
 
 
 
Scheme 6: Enantioselective conjugate addition of a Grignard nucleophile to crotonaldehyde by Feringa 
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Next, other ligands and temperatures were investigated. (DHQD)2PYR and (DHQ)2AQN were chosen for 
the ligand screen with varying success. Using the (DHQD)2PYR1 ligand afforded (the enantiomer of) the 
desired product ent-56 in 47% ee (entry 4), however (DHQ)2AQN gave the product diol in a promising 
85% ee. All these reactions were run between   ̶2 °C and 0 °C, so in order to investigate the effect of 
temperature, the reaction with (DHQ)2AQN was run again at   ̶7 °C. Due to issues with the t-BuOH/H2O 
solvent freezing, a small quantity of THF was added to reduce the freezing point of the solvent mixture. 
This temperature change (entry 6) did improve the enantiometric excess to 86%, but this improvement 
is likely to lie within experimental error. Attempts at recrystallisation to improve the ee of the product 
proved fruitless.   
 
All the enantiomeric excesses of diol 56 were calculated by HPLC analysis, measured against the 
corresponding racemic diol which was synthesised using standard Upjohn dihydroxylation conditions69 
(OsO4, NMO) in 87% yield.  
 
With a suitable method to access diol 56 in good ee established, the subsequent steps in the route could 
be explored. Diol 56 was successfully protected as the corresponding acetonide 49 with PPTS and 1,1-
dimethoxypropane in excellent yield (99%). Benzoyl deprotection then proceeded, under basic 
conditions, to give primary alcohol 61 in 88% yield (Scheme 7). 
 
 
Scheme 7: Protecting group adjustment to give alcohol 61 
 
2.2.2 Asymmetric Conjugate Additions into Crotonaldehyde 
 
We envisaged that the somewhat isolated nature of the C5 methyl stereocentre would provide a 
challenge to install. Inspired by studies by Feringa,70 an enantioselective conjugate addition of a 
Grignard reagent such as 63 (Scheme 8) into crotonaldehyde catalysed by a chiral phosphoramidite-
copper complex was proposed to meet this challenge. This is in effect an SN2´ reaction, rather than a 
true Michael addition, requiring the chloroacetate to be formed first. Feringa utilises known chemistry 
to turn aldehydes into α-haloacetates, such as 47 to 57 (Scheme 6), a reaction catalysed by zinc chloride. 
                                                 
1 Pseudoenantiomeric ligand used due to availability within our laboratory. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8: Conjugate addition with Grignard reagent 63 
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Copper 2-thiophene (CuTC) is then used with a chiral phosphoramidite ligand (58) to catalyse the 
asymmetric SN2’ displacement with a Grignard reagent. The chiral enol acetate 59 can then be easily 
transformed back into the aldehyde 60 with basic methanol. 
Investigations into this proposed route began with synthesis of the requisite phosphoramidite ligands 
(Scheme 8). Chiral phosphoramidite 58 was synthesised in 73% yield, using (R)-bis((R)-1-
phenylethyl)amine, (S)-BINOL and PCl3 in THF.71  
 
Scheme 9: Synthesis of chiral phosphoramidite ligand 58 
 
With ligand 58 in hand, attention turned to reproducing the results described by Feringa, initially using 
hexyl magnesium iodide (Scheme 9).72 Regrettably, this was far from a formality, due to the 
operationally delicate conditions. The reaction appears to be extremely moisture sensitive, requiring 
both the zinc chloride to be freshly fused and the crotonaldehyde to be freshly distilled. Temperature is 
also crucial and with the requirement to add the Grignard solution very slowly, a cryostat must be used 
over 16 hours. After several attempts, a small amount of product aldehyde 60 was obtained, albeit in a 
disappointing 25% yield.  
 
Scheme 10: Conjugate addition of an alkyl Grignard nucleophile into crotonaldehyde 
 
Several attempts were made to generate a more elaborate Grignard reagent. Bromide 62 was prepared 
from alcohol 50 via an Appel reaction (NBS, PPh3) in 57% yield, which was then converted into the 
corresponding Grignard reagent and used immediately in the conjugate addition reaction. 
Unfortunately, only trace amounts of product 64 were detected (Scheme 10). This could either be due 
to low conversion of the allyl bromide to the Grignard reagent or poor reaction with the chloroacetate 
owing to the increased bulk of the nucleophile.  
 
  
 
 
 
 
 
 
 
 
 
 
Scheme 11: Revised proposal for the synthesis of aldehyde 72 
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2.2.3 Asymmetric Conjugate Additions of a Methyl Nucleophile 
 
At this juncture, with difficulties in realising the proposed C4-C5 bond formation, a new approach to the 
C1–C7 fragment was sought. The installation of the challenging C5 methyl group was inspired by the work 
of Loh,73 who reports the asymmetric Michael addition of a methyl nucleophile into unsaturated esters 
(Scheme 12).  
 
Scheme 12: Conjugate addition with a cuprate nucleophile into 73 by Loh 
 
Feringa has also shown that conjugate methyl addition can be achieved in good yield and 
enantioselectivity with α,β-unsaturated thioesters (Scheme 13). Due to the increased reactivity of the 
thioester, these reactions are typically run at lower temperature. Tol-BINAP/CuI or Josiphos/CuBr can 
be used, but Tol-BINAP/CuI appears to be the more active catalyst system and tolerates a wider range 
of Grignard reagents, giving good yields and enantioselectivities even for the relatively unreactive 
MeMgBr.  
 
Scheme 13: Conjugate methyl additions reported by Feringa 
 
 
Therefore, the strategy remains to configure the C5 methyl group via a conjugate addition, but it will use 
a more experimentally straightforward variant. Simple oxidation state manipulation of ester 70 or 
thioester 71 should then give aldehyde 72 ready for the key aldol transformation. The starting materials 
for the conjugate addition, enoate 68 and thioenoate 69, could be constructed from alkene 67 via a 
cross metathesis or ozonolysis and HWE olefination. 
 
The proposed route to this alkene (67) was the epoxidation of an alkene (65), followed by nucleophilic 
ring opening to give the necessary quaternary hydroxyl stereocentre.  Several epoxidation methods 
were considered including the Shi epoxidation74 and a racemic epoxidation followed by a Jacobsen 
hydrolytic kinetic resolution.75 However, with an oxygen required at the C1 position, the preferred option 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Sharpless mnemonic for asymmetric epoxidation 
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was to exploit a Sharpless asymmetric epoxidation (SAE)76 on allylic alcohol 65. Therefore, a new route 
was proposed originating from methallyl alcohol (Scheme 11). 
Investigations into this revised route began with epoxide formation and opening. Analysis of the 
Sharpless mnemonic (Figure 16) allows for prediction of the correct chiral tartrate ligand to use to obtain 
the required enantiomer of the epoxy alcohol.77 
 
Under standard conditions (Ti(OiPr4), (D)  ̶ DET, TBHP), epoxide 77 was synthesised in 11% yield. 
Unfortunately, with a free hydroxyl required as a directing group, epoxidation of 65 must take place 
prior to protection of the primary alcohol. This led to numerous challenges owing to the low molecular 
weight of the resulting epoxide, notably high water solubility and volatility. Several different work-up 
procedures were trialled, including iron sulfate, tartaric acid followed by NaOH/NaCl, NaK tartrate, and 
quenching with anhydrous citric acid. None of these proved successful and a poor yield of epoxide 77 
was always obtained.  
 
 
Scheme 14: Attempted syntheses of epoxide 66 
 
A paper by Sharpless in 1987 described the in situ derivatisation of epoxides.78  Given the difficulties in 
isolation of the unprotected epoxy-alcohol, this seemed the most sensible avenue to explore. Sharpless 
suggests that switching to cumene hydroperoxide as the oxidant and diisopropyl tartrate as the ligand 
allows lower catalyst loadings to be employed. Trimethyl phosphite is then used to quench the excess 
cumene hydroperoxide in the second step, followed by in-situ protection using TBSCl, which makes the 
compound easier to isolate and purify. Pleasingly the reaction proved to be highly scalable and, after 
some optimisation, an overall yield of 70% of epoxide 66 was obtained (Scheme 14). The enantiometic 
excess was determined as 95% ee by HPLC analysis of the corresponding benzoyl protected alcohol, 
produced by the same methodology (Sharpless epoxidation followed by in situ protection with benzoyl 
chloride). 
 
  
 
 
 
 
Figure 17: Catalytic cycle for the Sharpless asymmetric epoxidation 
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The observed enantioselectivity can be explained by consideration of the catalytic cycle shown in Figure 
17.79 Exposure of Ti(Oi-Pr)4 to the appropriate tartrate ligand results in the reversible formation of 
dimeric complex I. Crucially, the ligands in this complex are able to bind reversibly.80 Accordingly, upon 
the addition of a peroxide source a second complex is generated (II), with the peroxide displacing two 
of the ligands and its facial selectivity determined by the geometry of the chiral ligand. Addition of an 
allylic alcohol produces a third complex (III), wherein the allylic hydroxyl group coordinates to the 
metal.81 Bis-complexation of the peroxide to the electrophilic titanium species results in a weakening of 
the peroxide bond, facilitating its transfer to the upper face of the alkene. The steric bulk of the cumene 
hydroperoxide enhances the enantioselectivity afforded by the chiral environment of the tartrate 
ligands.82 The co-ordinated epoxy alcohol can then be displaced by ligand exchange with either ROH 
(another allylic alcohol) or R’OH (i-PrOH), returning the dimeric titanium complex to the catalytic cycle. 
The inclusion of molecular sieves ensures the reaction is carried out under strictly anhydrous conditions 
and ligand exchange with water doesn’t occur, which would remove the titanium species from the 
catalytic cycle. 
 
With epoxide 66 in hand and the C2 stereocentre set with high ee, attention turned to examining the 
ring opening step (Scheme 15). Initial attempts at forming the enoate (82) directly from the opening of 
epoxide 802 with an extended enolate (81) proved unsuccessful. Formation of the requisite silyl ketene 
acetal from methyl crotonate proceeded in 84% yield, but a small screen of Lewis acids to promote the 
epoxide opening failed to give any of the desired product. Instead, ring opening at the more hindered 
end of the epoxide (stabilised by the tertiary carbocation), gave the regioisomeric product 84 (in 32% 
yield) when BF3 was used. With chloride containing Lewis acids (TiCl4, and Ti(Oi-Pr)2Cl2), dissociation of 
the halide was followed by nucleophilic attack at the tertiary carbocation to give chloride 83 in 37% and 
41% yield respectively.  
 
Scheme 15: Attempted epoxide opening with silyl ketene acetal 81 
 
                                                 
2 Racemic epoxide 80 was synthesised using mCPBA for use in initial epoxide opening investigations.  
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A multi-step route (Scheme 16) was, therefore, proposed instead. This would proceed via addition of 
an allyl Grignard reagent to the less hindered end of epoxide 66. Protection of the newly formed alcohol 
should give silyl ether 67. Conversion to the desired enoate (68) could proceed via ozonolysis of the 
terminal alkene followed by an HWE olefination.   
 
 
Scheme 16: Proposed opening of epoxide 66 and subsequent elaboration into enoate 68 
 
Preliminary studies began by investigating the epoxide opening reaction. Treatment of epoxide 66 with 
allyl magnesium bromide led to a mixture of products, obtained in part from bromide opening of the 
epoxide. Modification of the procedure to use allyl magnesium chloride proved more fruitful, giving 
alkene 86 as the sole product in 85% yield. The following two steps proceeded smoothly. As shown in 
Scheme 17, treatment of alcohol 86 with TMSCl and imidazole afforded silyl ether 67 in 64% yield, which 
was then subjected to ozonolysis conditions, giving the desired aldehyde 85 in 95% yield. 
 
Scheme 17: Opening of epoxide 66 and subsequent elaboration into aldehyde 85 
 
 
 
  
 
 
 
 
 
 
 
Table 4: Optimisation of thioenoate formation  
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It was envisaged that two separate HWE olefinations could be used to convert the common 
intermediate, aldehyde 85, into enoate 68 and thioenoate 69 respectively. To this end, aldehyde 85 was 
then reacted with commercial phosphonate 87 under barium hydroxide mediated conditions to give the 
required enoate (68) in 80% yield (Scheme 18). 
 
Scheme 18: Ba(OH)2 mediated HWE reaction to give 68 
 
Phosphonate 88 was prepared from diethylphosphonoacetic acid via a DCC-mediated thioesterification 
with thiophenol in 80% yield. In keeping with this route, it was anticipated that the required α,β-
unsaturated thioester 89 could be formed via a similar barium hydroxide mediated HWE reaction  
(Scheme 19). Unfortunately, using the standard conditions with aldehyde 85 and 1.5 equivalents of 
phosphonate 88, an inseparable mixture of products was obtained. The product ratio isolated was 
roughly 1:1 between the desired product, thioenoate 89, and the corresponding product 90 from the 
supplementary 1,4-addition of a thiolate anion into the ensuring thioenoate. Hydrolysis of the remaining 
phosphonate thioester, potentially with the water used in the solvent mixture, would give free phenyl 
thiolate anions in solution which could then react with the ensuing thioenoate to give 90 as a 1:1 mixture 
of diastereomers (Table 4, entry 1) 
 
Scheme 19: Optimisation of HWE olefination to form α,β-unsaturated thioester 89 
 
With this result, an alternative HWE protocol was sought and the milder conditions detailed by 
Masamune and Roush were utilised.83 Although a similar outcome was obtained at 0 °C, pleasingly when 
the reaction was run at a lower temperature (as demonstrated on a similar substrate in the Paterson 
synthesis towards madeirolide84) improved selectivity was observed and at   ̶35 °C (entry 7) only the 
desired product was isolated. The corresponding tolyl and ethyl thioesters were also synthesised in 85% 
and 80% yield respectively (entries 8 and 9) 
 
  
 
 
 
 
 
 
Scheme 20: Synthesis of racemic enoate 94 
 
 
 
 
 
 
Scheme 21: Mixture of products obtained from conjugate addition into enoate 94 
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Following  the precedent  established by Loh,73 it was envisaged that the challenging C5 methyl-bearing 
stereocentre could be installed via an asymmetric conjugate addition of methyl magnesium bromide 
into an α,β - unsaturated ester. Methodology using Tol-BINAP and copper (I) iodide has been developed, 
giving good accessibility to both enantiomers and making use of a readily available catalyst system. 
Carrying out a solvent screen, Loh established that Et2O and TBME both gave good results, although 
with slight improvements using the latter. Loh also discovered that the reaction has a noteworthy 
temperature dependency. There is a small window around    ̶20 °C for both high yield and selectivity. 
Below    ̶30 °C a significant decrease in the yield was observed, which was reported to be as a result of 
formation of a side product, namely the 1,2/1,4 double addition methyl ketone product. 
 
The reaction was initially trialled on a model system. With material available from the epoxide opening 
in the benzyl ether series, enoate 94 was synthesised over three steps from alkene 93 in 70% overall 
yield (Scheme 20). 
However, issues of product mixtures were constantly observed, from the combination of direct and 
conjugate addition to the enoate (Scheme 21). Significant proportions of methyl ketone 96 were 
consistently isolated. Only a minor effect was observed in varying the copper loadings (Table 5, entry 2) 
and a decrease in the equivalents of the Grignard reagent added resulted in only recovery of starting 
material (entry 4). Slight improvements were observed with a solvent switch to TBME however. Unable 
to reproduce the results described by Loh and with double addition products consistently observed, this 
unsatisfactory reaction was abandoned and attention turned to the corresponding reaction on 
thioenoate 89. 
 
Table 5: Attempted conjugate additions to enoate 94 
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Feringa described the thioenoates as a more reactive substrate class, amenable to reaction at lower 
temperature, so the reactions are typically carried out at   ̶ 70 °C. No issues of 1,2 vs. 1,4 selectivity have 
been reported in the literature.  
 
Regrettably, after an extensive screen of conditions, including variation of thioester derivative, copper 
catalyst loading, Grignard reagent excess, solvent and temperature, it became apparent that this 
methodology was not compatible with this substrate class (Scheme 22). No reaction was ever observed 
with the tolyl thioester derivative 95 (Table 6, entries 1-2). The ethyl derivate 69 was more reactive, but 
varying ratios of thioester 71 and methyl ketone 100 were produced. Raising the temperature to   ̶45 °C 
led to ketone 100 being obtained as the major product (entry 6). Numerous attempts were made at 
repeating the single positive result (entry 5), but without success.  
 
 
Scheme 22:: Attempted conjugate addition into thioenoates 89, 95 and 69 
 
 
 
Table 6: Screen of conditions for conjugate addition into thioenoates 97 and 69 
 
 
  
  
 
 
 
 
 
Scheme 23: Proposed alternative route from (+)-citronellol 
 
 
 
 
 
 
 
Scheme 24: Conversion of ( ̶)-citronellol to aldehyde 107 
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2.2.4 Citronellol Dehomologation Studies 
 
At this point, it became apparent that a different approach to the aldol precursor aldehyde would be 
required. Drawing on our experiences in attempting to install the C5 stereocentre asymmetrically, it 
seemed pertinent to look for naturally available sources instead. Citronellol contains an isolated methyl 
stereocentre, so was proposed as a possible starting material. With a slight modification to the original 
retrosynthesis; requiring construction of the C2-C3 bond at a later stage in the synthesis, the revised 
target compound became aldehyde 111 (Scheme 25). We envisaged that the C1-C2 could be installed 
using a Sharpless asymmetric dihydroxylation, as precedented in section 2.2.1.  
 
 
Scheme 25: Revised retrosynthesis for the C1-C12 fragment 
 
(+)-Citronellol would be the ideal enantiomer to use, since simple oxidation of the primary alcohol 
should give the corresponding aldehyde (with the correct stereochemistry of the methyl group) suitable 
for an aldol reaction with ketone 45. Manipulation of the tertiary alkene later in the synthesis would 
then provide the requisite terminal C1/C2 alkene for dihydroxylation (Scheme 23). With (+)-Citronellol 
considered prohibitively expensive for what would be the starting material in a long synthesis though, 
a route was proposed originating from (  ̶)-Citronellol instead. The primary alcohol could be protected 
as a silyl ether to be manipulated into a suitable functional handle for C2-C3 bond formation later in the 
synthesis. Ozonolysis of the alkene would then give aldehyde 107 requiring a single dehomologation to 
afford aldehyde 111, in preparation for the aldol reaction with ketone 45. 
 
Silyl protection of ( )̶-Citronellol with TBSCl, DMAP and imidazole, followed by ozonolysis of the 
trisubstituted alkene, delivered aldehyde 107 in 73% yield over two steps (Scheme 24). 
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It was envisaged that dehomologation of aldehyde 107 could be achieved though formation of the 
corresponding silyl enol ether or enamine, followed by a second ozonolysis step. Although attempted 
formation of the TMS silyl enol either (112) with LDA and TMSCl failed to yield any of the silyl enol ether, 
treatment with TMSCl and triethylamine in DMF led to good conversion. Submission of the crude 
intermediate to ozonolysis however, provided a disappointingly low yield of the desired aldehyde (30%). 
Enamine 113 was formed by condensation of aldehyde 107 with pyrollidine and submitted crude to 
ozonolysis, but only degradation was observed (Scheme 26). 
 
 
Scheme 26: Attempted dehomologation of aldehyde 107 
 
Alkene 106 was then submitted to ozonolysis with oxidative work up, providing ester 114 in 76% yield 
(Scheme 27). It was proposed that oxidation in the α-position (to give 115) followed by reduction of the 
ester and periodate cleavage of the ensuing diol should yield the desired aldehyde 111. Regrettably 
neither Rubottom conditions,85 nor oxidation of the silyl ketene acetal with triethyl phosphite and 
molecular oxygen86 provided the desired alcohol, so this route was not pursued further. 
 
 
Scheme 27: Attempted a-oxidation of ester 114 
 
 
  
 
 
 
Scheme 28: Mechanism of the Grieco elimination 
 
 
 
 
 
 
 
Scheme 29: Use of an enzyme catalysed desymmetrisation in Furstner's synthesis of tulearin C 
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An alternative dehomologation strategy invoking elimination across the C7-C8 bond was also attempted. 
Ozonolysis of alkene 114 followed by a reductive work up gave alcohol 116 in 62% yield (Scheme 30). 
Conversion to the corresponding tosylate (123) proceeded smoothly in 94% yield, but unfortunately an 
attempted E2 elimination with neither potassium tert-butoxide nor DBU afforded the requisite alkene 
119, with just starting material being recovered in both cases.  
 
Scheme 30: Attempted conversion of alkene 114 to alkene 119 
A Grieco elimination87 was explored as an alternative dehydration method from alcohol 116. The 
proposed mechanism is shown in Scheme 28. Reaction of a primary alcohol with o-
nitrophenylselenocyanate and tributylphosphine gives the organo-selenide 117. Oxidation of the 
selenium with hydrogen peroxide to the corresponding selenoxide 118, then initiates decomposition 
via an Ei elimination to afford the alkene and selenol. This protocol delivered alkene 119 in 60& yield 
Ozonolysis of alkene 119 gave the desired aldehyde 111 in 78% yield (Scheme 31). Although this 
synthesis provided useful material to investigate the chemistry further along the route, it was deemed 
unsatisfactory due to the high step count and use of expensive reagents, especially with this in the 
longest linear sequence.  
 
Scheme 31: Conversion of alcohol 116 to aldehyde 111 
 
2.2.5    Enzyme-mediated Desymmetrisation Reactions  
 
With only modest success from the dehomologation reactions attempted, it became apparent that a 
new approach to aldehyde 111 was required. Inspired by Fürstner’s synthesis of tulearin C,88 which 
employs an enzymatic desymmetrisation to furnish both the C5 and C15 stereocentres, it was envisaged 
that the same acid intermediate (121) could provide access to the desired aldehyde 111 (Scheme 29). 
This route has also recently been utilised in the second-generation Paterson synthesis of aplyronine C.89   
  
 
 
 
 
 
 
 
 
 
Scheme 32: Proposed route to aldehyde 111 via an enzymatic desymmetrisation 
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A new route to aldehyde 111 was therefore established. Desymmetrisation of diester 120 would give 
acid 121, which could then undergo two chemoselective reductions with an intermediate protection 
step to give aldehyde 111 (Scheme 32).  
 
Methylation of diacid 124 with acetyl chloride and methanol smoothly delivered diester 120 in good 
yield (89%) (Scheme 33). Diester 120 was then submitted to the desymmetrisation procedure using pig 
liver esterase and sodium hydroxide, under buffered conditions, maintaining a pH of between 6.5 and 
7.5. Recrystallisation of the crude material as its cinchonidine salt furnished the product with excellent 
enantiopurity (96% ee) and good yield (60%) The acid moiety was then selectively reduced to alcohol 
127 with borane dimethyl sulphide complex. The standard work up procedure of azeotroping with 
methanol unfortunately led to significant quantities (20-40%) of lactone side product 125 being isolated. 
It was envisaged that the corresponding lactol 126 (provided by Mike Housden) might lead directly to 
aldehyde 111 under silyl protection conditions, but unfortunately was not successful.  
 
Gratifyingly though, switching to an aqueous work up procedure under basic conditions predominantly 
eliminated formation of the lactone (to around 2%). Due to its volatile nature, alcohol 127 was just 
purified though a short plug of silica and submitted directly to the silyl protection with TBSCl and 
imidazole, giving silyl ether 128 in 84% yield over both steps. Ester 128 was then smoothly reduced to 
aldehyde 111 in excellent yield (92%). Maintaining a reaction temperature of  ̶ 78 °C and careful 
monitoring of the reaction time and equivalents of DIBAL, ensured over reduction to the corresponding 
alcohol was kept to a minimum.  
 
 
Scheme 33: Enzymatic desymmetrisation of diester 120 and subsequent elaboration to aldehyde 111 
 
  
 
 
 
 
 
 
Scheme 34: Mechanism for the addition of a Grignard reagent into Weinreb amide 129 
 
 
 
 
 
 
 
 
Scheme 35:  Boron-mediated anti-aldol with in situ reduction 
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2.3 Completion of the C1-C12 Fragment 
 
2.3.1 Boron-mediated anti-Aldol with in situ Reduction 
 
With aldehyde 111 in hand, attention turned to the construction of the stereotetrad, via a boron-
mediated anti aldol with in-situ reduction. Ketone 45 was synthesised following well established 
methodology (Scheme 36).90 (S)-Roche ester (46) was protected as PMB ether 133 with PMBTCA and 
PPTS, and the product converted to Weinreb amide 129 with (N,O)-dimethylhydoxylamine 
hydrochloride in the presence of isopropyl magnesium chloride. Addition of ethyl magnesium bromide 
then gave ethyl ketone 45 in 61% yield over the three steps. The use of a Weinreb amide prevents over 
addition of the Grignard nucleophile (Scheme 34). Tetrahedral intermediate 130 is stabilised at low 
temperature by chelation to the magnesium from the methoxy group. Quenching at low temperature 
ensures this intermediate doesn’t break down in the presence of excess Grignard reagent, delivering 
the ketone selectively and none of the corresponding tertiary alcohol. 
 
 
Scheme 36: Synthesis of ethyl ketone 45 
  
With both ketone 45 and aldehyde 111 in hand, the boron mediated aldol reaction was investigated. 
Enolate formation at 0 °C using a bulky Lewis acid (dicyclohexylboron chloride) and an unhindered amine 
base (triethylamine) selectively gave the (E)-enolate, which was then cooled to   ̶ 78 °C prior to the 
addition of aldehyde 111. After four hours at this temperature and 16 hours at  ̶ 20 °C, the reaction 
mixture was recooled to   ̶78 °C before the addition of LiBH4, affording the reduced aldol adduct 110 in 
excellent yield (84%, Scheme 35). 
 
It was found however, that the product, diol 110, and the secondary alcohol (132) derived from the 
reduction of excess ketone, were inseparable by flash column chromatography. A modified purification 
procedure was therefore developed, whereby the reduced aldol adduct was kept as the boronate ester 
(131) during the first round of chromatography, thereby allowing separation from the unwanted 
byproduct. At this point, the oxidative work up with sodium hydroxide and hydrogen peroxide was 
carried out, before a second round of chromatography provided the clean product.  
  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 18: The lowest energy structure for BH2F complexed to butanone 
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The selective boron-mediated enolization of ethyl ketones has been well documented in the literature.91 
Small alkyl groups on the boron Lewis acid (e.g. n-butyl), a good leaving group (e.g. triflate) and a bulky 
base (e.g. DIPEA) will selectively give the (Z)-enolate. The opposite conditions to this however; bulky 
ligands on the boron (e.g. cyclohexyl), a poor leaving group (e.g. Cl) and a less sterically demanding base 
(e.g triethylamine) have been shown to give the (E)-enolate selectively. The rationale for this difference 
involves both steric and electronic factors. Molecular modelling studies by Paterson and Goodman on 
the complexation of dialkyl boron fluorides with butanone, indicated that the boron preferentially lies 
on the same side of the carbonyl as the methyl group rather than the ethyl group (Figure 18). The 
fluoride also adopted a position eclipsing the carbonyl, with the H-F interatomic distance found to be 
less than the sum of their Van der Waals radii. This can be explained by an anomeric effect, whereby 
the uncomplexed carbonyl lone pair can donate electron density into the B-F σ*. A separate NMR study 
by Forsén with BF3 and butanone had also suggested that the boron was disposed to favouring the 
methyl side. A shielding effect of 2.0 ppm at the methyl carbon was observed, indicating a partial build 
up of negative charge at this site. Moreover, with unsymmetrical ketones such as 45, the boron will 
favourably complex to the lone pair on the same side of the carbonyl as the less substituted α-centre 
(Me>Et>i-Pr), i.e. that best able to stabilise the development of negative change. With the requirement 
for the enolized proton to be perpendicular to the carbonyl, i.e. for good overlap between the C-H σ 
molecular orbital and the C-O π*, the enolate geometry formed will be determined by the relative 
geometries of the second proton and the methyl group. The bulkier dicyclohexyl ligands force the 
methyl group to be trans to the carbonyl (Figure 19). 
 
Figure 19: Selective formation of (E)-enolates with bulky boron ligands, poor leaving groups and unhindered 
tertiary amine bases. 
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DFT analysis by Goodman and Paton92 has proposed that the aldol reaction between enolate 136 and 
an aldehyde proceeds via a boat like transition state (TS-141). A formyl hydrogen bond between the 
PMB protected ether lone pair and the aldehydic proton provides a stabilising interaction. This also 
enhances the preference for the aldehyde substituent to adopt an equatorial position. The α-methyl 
stereocentre then dictates the π-facial selectivity of the enolate. In the favoured transition state, 1,3-
allylic strain is minimised by placing the methyl group away from the transition state and the 
corresponding proton eclipsing the enolate double bond. The high selectivity for TS-141 over TS-143 
can be attributed to the short B-O bond length, leading to a compact transition state and accentuating 
these steric effects. Consequently, the 1,2-anti, 1,4-syn product is strongly favoured over the 1,2-anti, 
1,4-anti product. (Figure 20). With the aldehyde in question containing only a β-chiral centre and no α-
chiral centre, the influence of this stereocentre should be insignificant. 
 
Figure 20: Rationale for facial selectivity in boron-mediated anti-aldol reactions 
 
The C9 oxygenated stereocentre in patellazole B exists in the ketone oxidation state, but due to the 
presence of two α-chiral stereocentres and a reduction step later in the synthesis, it seemed prudent to 
mask this ketone as the corresponding protected secondary alcohol, which could be selectively 
deprotected and oxidised during the endgame. Taking this into consideration, the absolute 
stereochemistry of this secondary alcohol is inconsequential, and can be generated via the in-situ 
reduction of aldol adduct 153. Although the same transformation (albeit giving the opposite 
stereochemistry) could be afforded by an Evans-Saksena or Evans-Tischenko reduction, the reduced 
step count is clearly an attractive feature of this Narasaka-type approach. With the boron already 
  
 
 
 
 
 
 
 
 
 
 
Figure 21: Characteristic 13C resonances for 1,3-anti and 1,3-syn acetonides (literature values) 
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chelated between the alcohol and adjacent ketone, the aldol adduct adopts a half-chair conformation, 
placing the larger substituents in equatorial positions. Attack of the hydride is favoured from the lower 
face, since this results in the transition state adopting the lower energy chair-like conformation (as 
opposed to the higher energy twist boat conformation). This follows the Fürst-Plattner rule of diaxial 
ring opening (Scheme 37).93 
 
Scheme 37: Stereoselective in situ 1,3-syn reduction 
 
The relative stereochemistry of the diol was established by formation of the corresponding acetonide 
(151) with 2,2-dimethoxypropane in the presence of PPTS (Scheme 38). Analysis of the 13C NMR shifts 
by the method described by Rychnovsky94 and coworkers allows for differentiation between syn- and 
anti-acetonides. To minimise 1,3-diaxial strain, the anti-acetonide will adopt a twist boat conformation, 
placing the two methyl groups in similar pseudo-equatorial environments. The syn-acetonide however 
will adopt a chair conformation, allowing both side chains to be positioned equatorially. This places one 
methyl group equatorial and one axial, giving them significantly different environments (Figure 22). 
Diagnostic 13C NMR shifts of 19.5, 30.1 and 97.6 ppm for the acetonide carbons served to confirm the 
syn relationship between the C7 and C9 alcohols.  
 
Scheme 38: Formation of acetonide 151 
 
The absolute configuration of the diol was confirmed by Mosher ester analysis.95–97 Aldol adduct 153 
was isolated without in situ reduction. The C7 alcohol was converted to the corresponding Mosher 
esters, from the appropriate Mosher acids, using Steglich esterification conditions (DCC, DMAP, Scheme 
39).98  
 
 
 
  
 
 
 
 
 
 
 
 
Table 7: Mosher ester analysis for aldol adduct 153 
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Scheme 39: Synthesis of Mosher esters 154 and 155 from aldol adduct 153 
 
The preferred conformation for Mosher esters to adopt in solution, places the carbinol proton, MTPA 
carbonyl and trifluoromethyl group in the same plane. The phenyl ring has a diamagnetic shielding effect 
on protons in its vicinity, causing a lowering in their chemical shift (Figure 22). In the (S)-MTPA ester, 
those protons in the β’, γ’ and δ’ positions will therefore have upfield shifts relative those in the β, γ and 
δ positions (which lie closer to the methoxy substituent). The opposite will be true however in the (R)-
MTPA ester case. Comparison between these two cases by subtraction of the (R)-MTPA ester shifts from 
those for the (S)-MTPA ester allows determination of the configuration at the carbonyl centre. 
Assignments of proton environments with Δδ<0 belong on the left-hand side of the MTPA plane (from 
the perspective of the trifluoromethyl group), whereas those with Δδ>0 belong on the right-hand side.  
Analysis of the 1H NMR data from the (R)-MPTA and (S)-MTPA esters (Table 7) gave confirmation that 
the configuration of the C7 stereocentre had been set as 7S as predicted from the stereochemical models 
for the Cy2BCl mediated aldol reaction. 
 
 
Figure 22: Mosher ester conformation and analysis 
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2.3.2 Differential Protection of Diol 110 
 
With aldol adduct 110 in hand, attention turned to how best to differentially protect diol 110. Two 
routes were considered for the transformation to compound 109, in which silyl protection of the C7 
alcohol and PMP-acetal formation between C9 and C11 could take place in either order. Initial attempts 
were made to form PMP acetal 157 from PMB ether 110, but yields were modest at best (65%). Varying 
amounts of the equivalent ortho-ester were formed as an unwanted side product. Silyl protection of 
the remaining free alcohol again proceeded in a somewhat disappointing 68% yield (Scheme 40). 
 
With this route deemed unsatisfactory, the order of protection was reversed. Pleasingly, diol 110 was 
selectively protected as the C7 silyl ether (156) with TBSOTf and 2,6-lutidine in 88% yield. Careful 
monitoring by TLC allowed the reaction to be quenched before significant quantities of the bis-silyl 
protected product were formed. This positive result would appear to confirm that the C7 alcohol is the 
less sterically hindered. Conveniently, with this alcohol protected, we would postulate that the 
remaining free C9 alcohol is sufficiently more hindered as to prohibit bis-protection. With only one free 
alcohol remaining, treatment of PMB ether 156 with DDQ under strictly anhydrous conditions (freshly 
powdered and microwaved molecular sieves), smoothly delivered PMP acetal 109 in 80% yield as a 1.4:1 
ratio of diastereomers at the acetal.   
 
Scheme 40: Differential protection of diol 110 
 
 
 
  
 
 
 
 
 
 
Scheme 41: Mechanism for the DDQ induced PMP acetal formation and over-reaction 
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The mechanism of the PMP acetal formation proceeds as shown in Scheme 41. Treatment of the PMB 
ether with DDQ effects a single electron transfer giving radical cation 160, with the radical stabilised 
adjacent to the methoxy group. Deprotonation at the benzylic position, followed by a second single 
electron transfer generates oxonium species 163. Under strictly anhydrous conditions, this is trapped 
by an internal nucleophile, furnishing PMP acetal 164. Reaction of the PMP acetal with a second 
equivalent of DDQ results in the formation of oxonium species 116, which, in the presence of a second 
free alcohol, can form orthoester 167.  
 
2.3.3 Initial studies into C2-C3 Coupling Strategy 
 
At this junction, it seemed opportune to construct the C2-C3 bond and install the terminal olefin in 
preparation for C1/C2 dihydroxylation. Surveying the literature, we identified a paper by by Nagumo, 
describing the displacement of halide 168 with a soft nucleophile; namely the cuprate derived from 2-
bromopropene (Scheme 42).  
 
Scheme 42: Cuprate displacement of iodide 168 by Nagumo 
 
To investigate this methodology, and others making use of an alkyl halide as a functional handle, a series 
of model substrates were synthesised as detailed in Scheme 43. Alcohol 171 was converted into the 
corresponding tosylate 172, which was then displaced with a range of lithium halide salts to form model 
iodide 173, bromide 174 and chloride 175 in 83, 75 and 58% yield respectively. 
 
 
Scheme 43: Synthesis of model halides 173, 174 and 175 
Disappointingly, the reaction led only to recovery of the starting material, when attempted on both the 
iodide and bromide (Scheme 45). The use of freshly dried copper (I) iodide and copper (I) cyanide did 
not lead to an improvement in reactivity. Attempts at cuprate formation were made via both the 
Grignard reagent and organolithium species derived from 2-bromopropene, but neither delivered any 
desired displacement product. Successful lithiation was confirmed by addition of the vinyl lithium 
intermediate into benzaldehyde.  
  
 
 
 
 
 
 
 
 
 
Scheme 44: Model system to investigate in-situ Suzuki coupling 
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Scheme 45: Attempted displacement of iodide 173 with a propenyl cuprate 
 
Marshall’s synthesis of Discodermolide, makes use of a lithiation-borylation-Suzuki coupling sequence 
to construct the C14-C15 bond. Alkyl iodide 179 was transformed into boronate 180 via a lithium-halogen 
exchange with t-BuLi and subsequent trapping of the intermediate alkyllithium with B-methoxy-9-BBN. 
An in-situ Suzuki coupling with vinyl iodide 181 as the coupling partner, catalysed by Pd(dppf)Cl2, then 
gave the trisubstituted olefin (182) in 74% yield (Scheme 46). 
 
Scheme 46: Use of a Suzuki coupling in Marshall's Discodermolide synthesis 
 
In order to trial this new approach, model iodide 173 was submitted to Marshall’s conditions (although 
using Pd(PPh3)4 as the palladium source instead). In our hands, a side product 177 was observed 
(Scheme 44). Frustratingly, this was inseparable from alkene 176 by flash column chromatography. 
Despite extensive efforts to exclude moisture from the reaction, the high reactivity of the alkyl lithium 
species led to some proton abstraction before the anion could be trapped out as the boronate. Despite 
this, a 2.3:1 ratio of alkene 176 to alkane 177 in an 82% combined yield proved encouraging enough to 
pursue this route.  
Although the halide displacement studies had proved unsuccessful, the promising results from the 
Suzuki coupling provided confidence in an alkyl iodide providing a useful functional handle from which 
to form the C2-C3 bond. Attention therefore turned to the conversion of silyl ether 109 into iodide 108 
(Scheme 47). Primary silyl ether 109 was selectively deprotected under standard conditions with TBAF 
in good yield (85%). Again, careful monitoring by TLC and portionwise addition of TBAF allowed for the  
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minimum of bis-deprotection, with some starting material recovered in most cases. 
 
 Conversion of the resultant primary alcohol to the corresponding iodide was explored via two routes. 
Appel conditions (I2, PPh3, imidazole) delivered the product cleanly, but consistently in 75-80% yield. A 
two-step procedure was therefore attempted. Treatment of primary alcohol 183 with tosyl chloride in 
CH2Cl2 and pyridine afforded tosylate 184 in 91% yield, which was then displaced with lithium iodide at 
60 °C furnishing the desired iodide in 93% yield. This two-step procedure therefore provided a small 
improvement in the overall yield (85%).  
 
 
Scheme 47: Conversion of silyl ether 109 to iodide 108  
 
With iodide 108 in hand, Marshall’s conditions could be employed to form the C2-C3 bond. A similar 
result was obtained to that observed with the model system. The product ratio between alkene 104 and 
side product alkane 185 was always between 1.5:1 and 3:1 in favour of the desired alkene, generally 
improving with increased scale. As well as the Pd(PPh3)4 catalyst used in the model studies, Pd(dppf)Cl2 
(as used by Marshall) was trialled although results were comparable (Table 8, entries 1 and 5) 
A significant improvement in the product ratio of the Suzuki coupling was observed when a new bottle 
of t-BuLi was used (entry 6), indicating the noteworthy influence of reagent quality on the reaction.  
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Ultimately, the best results were obtained on larger scales (320 mg and 400 mg), when product ratios 
between alkene 104 and alkane 185 around 3:1 were reliably observed). 
A palladium-catalysed Negishi coupling, replacing the OMe-9-BBN with freshly dried zinc (II) chloride, 
was also attempted (entry 7). Whereas the Suzuki coupling necessitated the addition of the OMe-9-BBN 
subsequent to that of the t-BuLi, it was hoped that pre-mixing of the alkyl iodide and zinc (II) chloride 
prior to t-BuLi addition would improve the alkene:side product ratio. Disappointingly, transmetallation 
to the appropriate organozinc species appeared to be ineffective and only side product 185 was isolated. 
 
 
Scheme 48: Construction of C2-C3 bond via a lithiation, borylation, Suzuki coupling sequence 
 
 
 
Table 8: Attempted optimisation of C2-C3 bond formation via an in-situ Suzuki coupling 
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In pursuit of obtaining a higher yield and minimising the production of unwanted side products, a nickel-
catalysed Negishi coupling using conditions developed by Knochel was trialled.99 Grignard formation 
from 2-bromopropene was followed by transmetallation to the corresponding organozinc species. 
Knochel discovered that the use of electron-poor aryl additives, such as acetophenone, promoted the 
cross coupling of diorganozinc species with primary alkyl iodides, by binding to nickel and promoting 
reductive elimination. 
 
By avoiding the high-energy alkyl lithium species required in the previous methodology, it was hoped 
that formation of the proto-deiodinated product 185 would be reduced. Disappointingly though, the 
reaction was not successful and only starting material was recovered (Scheme 49). With the 
lithiation/borylation/Suzuki coupling procedure providing sufficient material throughput for fragment 
completion, attempts to further optimise this step were not carried out.  
 
 
Scheme 49: Attempted nickel-catalysed Negishi coupling 
 
2.3.4 Elaboration of C12 Terminus 
 
With a view to constructing a truncated analogue of the C1-C12 fragment for coupling studies (and also 
providing material to investigate a late stage regio- and stereoselective dihydroxylation strategy), 
studies were carried out to elaborate the C12 terminus at this junction. It was envisaged that a 
regioselective reduction of acetal 104 should give the primary alcohol, which could then be oxidised to 
the corresponding aldehyde. From this aldehyde, a Stork-Wittig olefination should provide (Z)-vinyl 
iodide 186 (Scheme 50). Alternatively, the aldehyde could be converted into the terminal alkyne (via a 
Seyferth-Gilbert homologation), providing flexibility in the fragment coupling approach.  
 
 
Scheme 50: Proposed route to truncated analogue 186  
  
 
 
 
 
 
 
Scheme 51: Regioselective PMP acetal reduction to give the more substituted PMB ether 192 
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PMP acetal 104 was treated with DIBAL at   ̶78 °C before slowly warming to 0 °C to afford the secondary 
PMB ether 193 in 81% yield.  
 
DIBAL coordinates selectively to the less hindered side of the PMP acetal, effecting opening of the acetal 
to give oxonium species 191 and subsequent internal hydride delivery, placing the PMB ether on the 
more hindered secondary alcohol. The steric clash between the bulky iso-butyl groups on the aluminium 
and the congested C7 and C8 centres led to the product (190) from intermediate 189 not being observed 
(Scheme 51).  
 
Oxidation of the primary alcohol under Swern conditions (oxalyl chloride, DMSO, triethylamine) 
disappointingly delivered the product (194) in only 70% yield. A switch to Dess-Martin periodinane 
however, afforded this transformation in an excellent 96% yield.  (Z)-vinyl iodide 186 was then installed 
from aldehyde 194 making use of the Stork-Zhao reagent ([PPh3CH2I]I) and NaHMDS as a base. Initial 
attempts with 1.5 equivalents of both the Wittig salt and base led to incomplete reaction (~50% 
conversion), but increasing this to 3.5 and 3.0 equivalents respectively pushed the reaction to 
completion, giving the product in a satisfactory 82% yield (Scheme 52).  
 
Scheme 52: Elaboration of C12 terminus into (Z)-vinyl iodide 186 
 
2.3.5 Sharpless Dihydroxylation and Completion of the Fully Elaborated C1-C12 Fragment 
 
Synthesis of the full C1-C12 fragment, however, requires oxygenation at the C1 and C2 positions. Previous 
investigations (as described in section 2.2.1) showed the suitability of this alkene for Sharpless 
asymmetric dihydroxylation as a method to install the requisite diol. The previous ligand screen had 
highlighted (DHQ)2AQN as the optimum ligand. Transferring these conditions to alkene 104 pleasingly  
 
  
 
 
 
 
 
 
 
 
 
Scheme 53: Completion of the fully elaborated C1-C12 fragment 
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appeared to give the diol 197 as a single product (Scheme 54). At this stage in the synthesis, separation 
of the diol from side product 185 is possible. Bis-TES protection of the diol with TESOTf and 2,6-lutidine 
then gave silyl ether 198 in an excellent 97% yield. The Lewis acidic nature of the TESOTf also served to 
equilibrate the PMP acetal to a single diastereomer. Coordination of the Lewis acid to one of the acetal 
oxygens promotes ring opening to give an oxonium species, which can then be reattacked by the free 
alcohol reforming the PMP acetal.  
 
The PMP acetal 198 was then opened to give primary alcohol 195. Unfortunately, under the same 
conditions as used previously (addition of DIBAL at   ̶ 78 °C followed by warming to 0 °C), significant 
primary TES deprotection was observed giving a 1:1 product ratio between 195 and 199. With no 
obvious method to distinguish between the two primary alcohols in the side product, eliminating its 
production was highly desirable. Careful monitoring of the reaction by TLC showed no discernible acetal 
opening below   ̶35 °C, but little TES deprotection was observed below   ̶25 °C, providing a useful, but 
tight window. An optimum reaction temperature of   ̶30 °C was therefore identified and the product 
was isolated in 58% yield. 
 
Scheme 54: Elaboration of alkene 104 to alcohol 195 
 
Oxidation of primary alcohol 195, under Dess-Martin conditions, gave the resultant aldehyde (200) in 
97% yield, which was subsequently subject to a Stork-Zhao olefination, as described previously, 
providing the vinyl iodide 196 in 82% yield (Scheme 53). This completed the synthesis of the fully-
elaborated C1-C12 fragment in 4.5% yield over 17 steps. 
  
 
 
Scheme 55: Fragment union options originating from vinyl silane 202 or vinyl iodide 201 
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Chapter 3: Results and Discussion – Part II 
Synthesis of the C13-C19 Vinyl Iodide 
 
Some of the work described in the chapter was carried out by T Balan.100 For clarity and 
completeness some of his results are also included below. Unless otherwise stated however, all 
reactions were performed by the author and all stated yields are those obtained by the author.  
 
3.1 Retrosynthesis 
 
Scheme 56: Retrosynthetic analysis for the C13-C19 fragment 
 
In attempting to leave as much flexibility in the fragment union strategy as possible, two functional 
groups at the C19 position were proposed, specifically a vinyl iodide and a vinyl silane. It was envisaged 
that the latter could act as a ‘protecting group’ for the iodide, facilitating C12-C13 bond formation via a 
palladium catalysed cross coupling, prior to revealing the vinyl iodide with an electrophilic iodine 
source101,102 and subsequent C19-C20 bond construction (Scheme 55, route A). Alternatively, a fragment 
union strategy originating from the C18-C19 vinyl iodide could proceed via either of two possible routes. 
Initial construction of the C12-C13 bond in a non-metal catalysed reaction (which should be compatible 
with the vinyl iodide) would give intermediate 206. This could then undergo a cross coupling with the 
C20-C25 fragment to give the complete C1-C25 piece (route B). Otherwise, the cross coupling to construct 
the C19-C20 bond could take place first, giving intermediate 203. With the vinyl iodide no longer in place, 
a palladium catalysed cross coupling could then be used to afford the fragment union with the C1-C12 
piece (route C).  
We imagine that the C14-C17 stereotetrad could be constructed from two stereocontrolling reactions; 
namely a boron mediated anti-glycolate aldol and a stereoselective reduction of the C15 ketone (Scheme 
56). Felkin control should hopefully install the latter with high diastereoselectivity.   
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Although this C15/C17 1,3-anti stereochemistry could also be generated via an Evan-Saksena103,104 or 
Evans-Tischenko105 reduction, the methylation required at C17 and thus the orthogonality of protecting 
groups required leads this to be a less desirable route. Our proposed strategy involving direct 
methylation of the aldol adduct followed by a Felkin controlled reduction should afford alcohol 208/209 
in only three steps from ketone 216. The glycolate aldol is well precedented on similar α-hydroxy 
ketones, based on investigations into solid-supported aldol reactions by Paterson.106 The aldol precursor 
216, could arise from the appropriate methyl ketone, derived from Roche ester in three steps.  
 
3.2 Synthesis of Aldol Adducts 212 and 213 
 
3.2.1 Optimisation of the alpha-Hydroxylation of Methyl Ketone 220 
Note: Much of the chemistry in this fragment was explored in the enantiomeric series, using (R)-Roche 
ester as the corresponding starting material, due to its greater availability within our laboratory. Results 
where the chemistry was only carried out in this enantiomeric series will be noted accordingly.  
 
Previously in the Paterson group, α-alkoxy ketones derived from Roche ester had been constructed from 
the appropriate Weinreb amide (218) and organotin reagent shown in Scheme 57.107,108 Unfortunately, 
this methodology has been shown to be incompatible with silyl protecting groups. In order to keep the 
endgame as concise as possible a silyl protecting group at this position is highly desirable. The use of 
toxic organotin reagents on large scale is also non-ideal.  
 
Scheme 57: Previous methodology used to construct alkoxy ketones derived from Roche ester 
 
Balan sought to investigate alternative methodology for the formation of such α-alkoxy ketones. A 
Rubottom-type oxidation was proposed, forming the silyl enol ether in situ before treatment with 
mCPBA. Rearrangement of the ensuing epoxide with silyl migration affords the protected hydroxy 
ketone. Typically, the silyl migration is incomplete, so a mixture of the protected (216) and unprotected 
(222) alcohols is recovered, which can be converted to a single product by subsequent treatment with 
TBSCl and imidazole.  
  
 
 
 
 
 
Scheme 58: Rubottom and Upjohn oxidations to afford a-alkoxy ketone 216 
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Synthesis of methyl ketone precursor (220) began from (S)-Roche ester via the same methodology as 
described in section 2.3.1. Protection of the primary alcohol as the PMB ether under mild conditions 
(PMBTCA, PPTS), followed by reaction with (N,O)-dimethylhydroxylamine hydrochloride in the presence 
of isopropyl magnesium chloride, delivered Weinreb amide (218) in 69% yield over both steps. 
Treatment with methyl magnesium bromide then furnished methyl ketone 220 in 83% yield (Scheme 
59).  
 
Scheme 59: Synthesis of methyl ketone 220 
 
Disappointingly, yields for the Rubottom oxidation were consistently low (40-45%), with significant 
amounts of starting material recovered (Scheme 58). Whilst this could be recycled to improve the 
overall conversion, it was deemed an inelegant solution to the problem. It was surmised that the acidic 
nature of the mCPBA (especially considering the presence of the corresponding carboxylic acid found in 
the commercially available product), was somewhat incompatible with the silyl enol ether.  
An alternative oxidation strategy was therefore sought. Unpublished investigations into the synthesis 
of spirastrellolide by Paterson made use of an Upjohn dihydroxylation of a silyl enol ether to furnish the 
same α-hydroxy ketone intermediate.109 Whereas the silyl migration in the previous route necessitated 
the use of a TBS enol ether to produce the desired TBS protected alcohol, in this case any silyl 
electrophile could be utilised in forming the silyl enol ether, so TMSCl provided an inexpensive 
alternative.   
Silyl enol ether 221 was therefore produced using LDA and TMSCl at   ̶78 °C. A relatively high osmium 
loading of 5 mol% was required for the dihydroxylation to reach completion. Pleasingly though, this 
transformation delivered alcohol 222 in 82% yield. The primary alcohol then underwent silyl protection 
with TBSCl and imidazole to afford the α-silyloxy ketone 216 in 88% yield, providing a far more 
satisfactory route to this aldol precursor.  
 
 
 
 
  
 
 
Scheme 3: Selective deprotection of alkynyl silane 224 with K2CO3 and MeOH 
 
 
 
Scheme 61: Attempted carbocupration of alkyne 224 with a Gilman reagent 
 
 
 
 
 
 
 
 
Scheme 62: Synthesis of aldehyde 214 
  
Chapter 3: Results and Discussion – Part II  
49 
 
3.2.2 Synthesis of Vinyl Silane 215 
The synthesis of vinyl silane 215 proved more challenging than anticipated. Propargyl alcohol was 
doubly-deprotonated with n-BuLi and the ensuing dianion bis-silylated with TMSCl. An acidic work up 
then selectively deprotected the silyl ether, giving TMS alkyne 224 in 84% yield. The copper-catalysed 
carbomagnesiation of the same alkyne has been reported in the literature by Spino and coworkers,110 
giving the resulting vinyl silane in 93% yield after silyl protection of the alcohol. Disappointingly in our 
hands, although the reaction proceeded very cleanly, it was prone to stalling and at best a 60% 
conversion was observed (Scheme 63). Balan reported a variation in conversions based on the batch of 
the copper (I) iodide used. Unfortunately, the starting material and proved inseparable by TLC. Although 
some separation was possible after deprotection of the remaining alkynyl silane with potassium 
carbonate in methanol (Scheme 60), this was an inelegant solution. The attempted use of a pre-formed 
Gilman reagent (between MeLi and CuI)111 also proved ineffective, only returning starting material 
(Scheme 61).  
 
Scheme 63: Synthesis of vinyl silane 215 
3.2.3 Revised Strategy and Synthesis of Vinyl Iodide 214 
Synthesis of the corresponding vinyl iodide 214 fortunately proved less challenging and began with 
diethyl methylmalonate following a known literature procedure by Baker and coworkers (Scheme 62).112 
Deprotonation with sodium hydride and subsequent trapping with iodoform gave intermediate 229. 
Hydrolysis of the bis-ester with potassium hydroxide generated bis-acid 230 which could then undergo 
an E2 elimination to give vinyl iodide 227. Placement of the two larger groups anti to each other, during 
the elimination, selectively gives the (E)-vinyl iodide. Reduction of the resultant carboxylic acid with 
lithium aluminium hydride proceeded smoothly to give allylic alcohol 228. This was subsequently 
oxidised to aldehyde 214 with manganese dioxide, the reaction mixture filtered and excess solvent 
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removed carefully in vacuo to give a concentrated solution of the aldehyde in Et2O, which could then be 
dried over CaH2 and cannulated directly into the glycolate aldol reaction without further purification. 
 
Attempts were also made to convert vinyl iodide 214 to vinyl silane 215 via a lithium-halogen exchange, 
followed by subsequent trapping with TMSCl (Scheme 64). Regrettably, even with the prior addition of 
sodium hydride to deprotonate the primary alcohol, significant amounts of the isobutenol side product 
were observed, so this alternative synthesis was not pursued. 
 
Scheme 64: Attempted conversion of vinyl iodide 228 into vinyl silane 226 
 
3.2.4 Glycolate Boron Aldol 
With ketone 220 and both aldehydes 214 and 215 in hand, the boron-mediated glycolate aldol could be 
attempted. Enolisation of α-silyloxy ketone 220 with dicyclohexylboron chloride and triethylamine 
selectively gave the (E)-enolate, via a similar proposed transition state (TS-232) to that described in 
section 2.3.1. A favourable H-bonding interaction between one of the α-protons and the chloride, and 
the preference for the bulky silyl ether to sit trans to the carbonyl dictates the selectivity for enolate 
geometry (Figure 23). 
Again, a boat transition state (TS-233) is proposed for the aldol reaction, with a formyl hydrogen bond 
between the PMB ether lone pair and aldehydic proton stabilising the transition state and allylic strain 
minimised by placing the C14 methyl out of the transition state and the corresponding proton eclipsing 
the double bond.  
 
Figure 23: Proposed transition states for enolate formation and glycolate aldol  
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Pleasingly the reaction proceeded smoothly in both cases with the vinyl silane and vinyl iodide- bearing 
aldehydes producing aldol adducts ent-213 and 212 in 81% and 82% yields respectively (both in >20:1 
d.r.), following an oxidative work up with hydrogen peroxide and pH 7 buffer (Scheme 65). The excess 
of aldehyde used did appear to have an influence on the yield, with that for adduct ent-213 dropping to 
56% when only 3 equiv. of aldehyde 215 was used. Raising this to 4.5 equiv. increased the yield to 81%  
Mosher ester analysis97 was carried out on vinyl iodide aldol adduct 235 by Balan, confirming the 
absolute stereochemistry of the newly-formed alcohol.100  
 
 
Scheme 65: Boron-mediated glycolate aldol reactions 
 
3.3 Completion of the C13-C19 Fragment 
3.3.1 Studies into C17 Methylation 
With both aldol adducts in hand, attention turned to the methylation of the C17 alcohol (Scheme 66). 
Whilst this alcohol could be protected and methylated at a later stage of the synthesis, direct 
methylation of the aldol represented the most attractive option. Balan focussed on investigating this 
transformation on the vinyl silane bearing aldol adduct, with the author repeating several experiments 
to confirm the results as well as exploring the vinyl iodide series.  
 
Scheme 66: Attempted methylation of aldol adducts ent-212 and ent-213 
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Reacting the vinyl silane with Meerwein’s salt (Me3OBF4) in the presence of either Proton-sponge® or 
2,6-ditertbutyl pyridine (Table 9, entries 1 and 2) led to a mixture of three products being formed. 
Unfortunately, when the methylating reagent was changed to methyl triflate, no reaction was observed 
at room temperature. Moreover, the same epimerisation result was observed when the reaction was 
carried out at 40 °C.  Only starting material was recovered with iodomethane and silver (I) oxide.  
With the vinyl silane proving incompatible with all the conditions attempted, attention turned to the 
vinyl iodide. Disappointingly, treatment with sodium hydride and iodomethane (entry 6) led to the 
isolation of ketone 220, attributable to a retro-aldol process. Employment of Meerwein’s salt and 
Proton-sponge® at 0 °C resulted in only the recovery of starting material, but gratifyingly when the 
reaction was carried out at room temperature the desired product could be isolated in 82% yield. 
Despite large excesses of both reagents being used (8 and 10 equivalents of Meerweins’s salt and 
Proton-sponge® respectively), the reaction could only be pushed to completion on small scale. Allowing 
the reaction to continue for 16 hours didn’t appear to lead to any appreciable degradation of the 
product and afforded a slightly higher conversion rate. Yields based on recovered starting material were 
typically greater than 90%, facilitating the recycling of unreacted material.  
 
Table 9: Conditions for C17 methylation of aldol adducts ent-212 and ent-213 
With no promising methylation results in the vinyl silane series and recognition of the difficulties in 
preparing aldehyde 215, it was concluded that the silane was no longer a viable functional group to use 
in the synthesis. Whilst there were attractive features of the approach, in relation to the later fragment 
union strategy, it became apparent that it was not sufficiently compatible with the earlier chemistry 
required in the fragment synthesis. Therefore the synthesis was progressed from this point forward 
solely in the vinyl iodide series.   
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3.3.2 Studies into Stereoselective C15 Reduction 
As outlined previously, it was envisaged that the C15 stereocentre could be formed via the substrate-
controlled reduction of ketone 210 (Scheme 67). Three possible transition state models were 
considered for this transformation, namely the Felkin-Ahn, polar Felkin-Ahn or Evan polar models. These 
take the influence of each of the neighbouring C14, C16 and C17 stereocentres into consideration.  
 
Scheme 67: Stereoselective reduction of ketone 210 with DIBAL 
 
In the Felkin-Ahn model113 (Figure 24), the two lowest energy conformers are defined as those where 
the largest group (in this case, CH2OPMB) is placed perpendicular to the carbonyl. The dipoles of the 
PMB ether and carbonyl are also opposed. In the more reactive of these conformers, the nucleophile 
can attack at the Bürgi-Dunitz angle (107 °) on the side of the smallest group (H), giving the Felkin 
product, in which the C14 methyl and C15 alcohol are anti. The less reactive conformer experiences 
unfavourable steric interactions between the C14 methyl group and the incoming nucleophile.  
 
Figure 24: Analysis of the Felkin-Ahn model for the reduction of the C15 ketone 
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The polar Felkin-Ahn model takes into consideration the effect of the C16 stereocentre (Figure 25). In 
this model, the most polar group α to the carbonyl is considered to be the largest. This can be attributed 
to the favourable overlap between the σ*C-OTBS and the π*C=O, increasing the carbonyl reactivity. Attack 
of the nucleophile, again at the Bürgi-Dunitz angle on the side of the hydrogen, leads to the same Felkin 
product as in Figure 24. 
 
Figure 25: Analysis of the polar Felkin-Ahn model for the reduction of the C15 ketone 
The other possible model which could be considered  is the Evans’ polar model,114 which would take 
into account the stereochemistry at the C17 position to influence the stereoselectivity of  the reduction  
(Figure 26). Again, the largest group is placed perpendicular to the carbonyl with the carbonyl and 
methoxy dipoles opposed. Attack of the nucleophile over the smallest group in this instance would lead 
to the anti-Felkin product. However, we postulated that this transition state would be high in energy 
due to steric clashing between the bulky silyl protecting group and the carbonyl.  
 
Figure 26: Analysis of the Evans polar model for the reduction of the C15 ketone 
  
 
 
 
 
 
 
 
Figure 27: Key NOE interactions used to determine the C15 stereochemistry 
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Analysis of these three models gave us sufficient confidence that substrate control should provide the 
required selectivity. Reduction with DIBAL at   ̶78 °C led to a single product diastereomer being isolated. 
Attempts at forming the C15 Mosher esters to identify the configuration of the newly formed alcohol 
unfortunately proved unsuccessful. We postulated this was hampered by the considerable steric bulk 
of the surrounding stereogenic centres. The stereochemistry at C15 was instead confirmed by NOE 
studies on acetonide 242. We proposed that formation of a five-membered ring would introduce a 
degree of rigidity to the molecule, allowing NOE interactions to confirm the unknown stereochemistry. 
J-based coupling constant analysis of both the linear and cyclic compounds was unlikely to elucidate the 
structure with any degree of confidence. Unlike six membered rings, five membered rings do not exhibit 
clear axial and equatorial proton environments.115 Silyl ether 208 was therefore deprotected with TBAF 
to reveal diol 244, which was then protected as the corresponding acetonide, with 2,2-
dimethoxypropane in the presence of PPTS (Scheme 68). 
 
Scheme 68: Formation of acetonide 242 for NOE studies to confirm C15 stereochemistry 
Analysis of a series of 1D NOEs was carried out to determine the acetonide stereochemistry. We 
hypothesised that in the anti-acetonide case, the C15 and C16 protons would exhibit asymmetric NOEs 
with respect to the two geminal methyl groups. A strong NOE was observed between the C16 proton and 
Mea (combined with a weak NOE to Meb), whereas the opposite was true for the C15 proton. In the syn-
acetonide case, it was expected that both protons should observe similarly strong NOEs to one methyl 
group and correspondingly weak ones to the other. 
We had envisaged that with the C15 and C16 protons diaxial, no NOE between them would be observed. 
Instead, an interaction was observed, originally assigned to a strong coupling effect providing an 
alternative pathway.115 A conformational search and reoptimisation of the lowest energy conformers 
with DFT  (Geometries B3LYP/LANVCP**) however, provided the left-hand structure shown in Figure 
27.116 With the C15 and C16 protons now both pseudoequatorial, this interaction is more logical. 
Importantly however, no NOE was observed between the C14 and C17 protons, providing good evidence 
for the left-hand structure opposite.  
 
 
  
 
 
 
 
 
 
 
 
Scheme 69: Mechanism of the Pinnick oxidation 
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The high stereocontrol observed can be attributed to both the α-stereocentres directing the reduction 
from the same face, reinforcing the influence of each other.   
Despite only a single equivalent of DIBAL being required in theory, the reaction suffered from 
incomplete conversion, necessitating the use of a greater reagent excess. Mostly starting material was 
returned upon the addition of 1.2 equiv. of DIBAL, but the reaction could be pushed to completion when 
this was increased to 5.0 equiv., affording the product in an excellent 90% yield.  
 
3.3.3 Elaboration into the C13 alcohol 
The resultant alcohol (208), was silyl protected under standard conditions with TBSOTf and 2,6-lutidine, 
affording the TBS-ether (252) in 89% yield. The primary PMB ether was then deprotected with DDQ in 
the presence of pH 7 buffer (Scheme 70). The anisaldehyde by-product proved to be inseparable from 
alcohol 207, so the crude mixture was subjected to Pinnick conditions to selectively oxidise the aldehyde 
to p-anisic acid. Protonation of the aldehyde by chlorous acid (generated in situ from sodium chlorite 
and sodium dihydrogen phosphate) promoted addition of the chlorate anion to provide intermediate 
249. Decomposition of this species delivered p-anisic acid (which could easily be removed with a basic 
wash). 2-methyl-but-2-ene was added to sequester out the hypochlorous acid, forming chlorohydrin 
250, preventing any unwanted side reactions (Scheme 69). Gratifyingly, this process provided the clean 
alcohol in 90% yield and the full fragment in 15% overall yield in 10 steps.  
 
Scheme 70: Protection/deprotection to complete C13-C19 fragment 
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Chapter 4: Results and Discussion – Part III 
Synthesis of the C20-C25 alkene 
Some of the work described in the chapter was carried out by M Anketell. For clarity and 
completeness some of his results are also included below. Unless otherwise stated however, all 
reactions were performed by the author and all stated yields are those obtained by the author.  
 
4.1 Retrosynthesis 
 
Scheme 71: Retrosynthetic analysis for C20-C25 fragment 
 
With all eight possible stereoisomers of the C20-C25 fragment requiring construction, it was of paramount 
importance that all three stereocentres could be installed via reagent control rather than substrate 
control (Scheme 71). Several different routes were considered including a potential crotylation or 
propargylation which would lead to alkene 202 from aldehyde 257, following silyl protection (and 
reduction of the resultant alkyne in the propargylation case). Numerous methods for this can be found 
in the literature, which will be discussed in due course.  
Alternatively, the syn stereochemistry across the C22-C23 bond could be installed via an Evans aldol,117 
with subsequent auxiliary cleavage, oxidation and olefination. The corresponding anti diastereomer 
could be constructed utilising an aldol reaction of a lactate derived ketone,118,119 followed by auxiliary 
reduction, periodate cleavage and olefination. 
  
 
 
 
 
 
 
Scheme 72: Synthesis and attempted opening of epoxide 258 
 
 
 
 
 
Table 10: Selected results for the attempted opening of epoxide 258 
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Both the crotylation and aldol strategies derive from the same key aldehyde intermediate 257, so the 
synthesis of this fragment became the initial target. It was envisaged that the aldehyde could arise from 
the opening an epoxide, followed by protection and oxidation steps, with the key C24 stereocentre being 
installed via the Sharpless asymmetric epoxidation of isobutenol.   
 
4.2 Synthesis of the C23-C25 aldehyde 
Work on the C23-C25 aldehyde was commenced in 2015 by Anketell120 in close collaboration with the 
author. Drawing on the experience of our initial studies into the C1-C12 fragment, it was known that the 
synthesis of silyl-protected epoxy alcohol 258 was reliable and scalable, so this was deemed a suitable 
starting point.  
With all eight stereoisomers of this fragment ultimately required, the choice of catalyst for the SAE76 at 
this juncture was inconsequential. Sharpless epoxidation of isobutenol (using Ti(i-PrO)4, (+)-DIPT and 
cumene hydroperoxide) with in-situ TBS protection proceeded smoothly to deliver the silyl-protected 
epoxy alcohol (258) in 70% yield (Scheme 72). 
We postulated that under Lewis or Brønsted acidic conditions, it was likely that epoxide opening would 
occur at the C24 position to give a tertiary carbocation. This would lead to a partial or complete loss of 
the enantiopurity developed in the first step. We therefore considered that this would necessitate the 
use of a basic nucleophile for the epoxide opening instead. Frustratingly, extensive attempts at opening 
the epoxide with a range of hydroxide and softer oxygen nucleophiles failed to afford any of the desired 
product. Treatment of the epoxide with sodium hydroxide (Table 10, entries 1-3) in a range of solvents 
and temperatures led only to the recovery of starting material. With the soft nature of the epoxide 
electrophile taken into account, some softer oxygen nucleophiles were trialled (entries 4 and 5), but 
similarly neither sodium acetate or sodium peroxide yielded any product. With sulfur based 
nucleophiles known to react well with epoxides, thiophenol in the presence of triethylamine was tried 
and gratifyingly provided the requisite thiohydrin. We envisaged that a Pummerer rearrangement could 
then be used to convert this sulphide into the desired aldehyde. Choice of solvent for the epoxide 
opening was found to be important. When the reaction was run in dichloromethane only a 50% yield of 
the product was obtained. However, a switch to a protic solvent (methanol chosen for ease of removal), 
enabled protonation of the ensuing tertiary alkoxide and gave the product in 89% yield. 
  
  
 
 
 
 
 
 
 
Scheme 73: Mechanism of the Pummerer rearrangement 
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Protection of the tertiary alcohol, with TESOTf and 2,6-lutidine, proceeded smoothly generating the silyl 
ether in 97% yield. The Pummerer rearrangement121,122 can be used to convert sulfoxides into aldehydes. 
Oxidation of sulfide 261 into the prerequisite sulfoxide was somewhat hampered by overoxidation to 
the corresponding sulfone. Anketell obtained sulfoxide 262 in good yield (80%) through reaction with 
mCPBA at 0 °C, but with most of the remaining mass recovery being the sulfone. With overoxidation 
ostensibly rapid under these conditions, we surmised that lowering the temperature would diminish 
this. Gratifyingly, when the reaction was carried out at   ̶10 °C, the desired sulfoxide was obtained in 
88% yield, with only small amounts of the sulfone isolated (Table 11, entry 2). 
Sodium periodate has been shown to afford the oxidation of sulfides to sulfoxides selectively, without 
over-oxidation. Unfortunately, standard conditions in methanol and water (entry 3) led to no reaction; 
attributed to poor substrate solubility in the solvent mixture. Sodium periodate on silica gel in 
dichloromethane (entry 4) did show some conversion to product (and no over-oxidation), but the 
reaction proceeded very slowly and appeared to stall despite a large excess of reagent (20 equivalents). 
With neither of these alternative procedures providing an improvement on the optimised conditions 
with mCPBA, they were not pursued.  
  
Table 11: Optimisation of selective sulfide oxidation 
 
With sulfoxide 262 in hand, the Pummerer rearrangement proceeded under standard conditions of 
sodium acetate in refluxing acetic anhydride to give α-acetoxysulfide 266 as a mixture of diastereomers. 
The proposed mechanism proceeds as shown in Scheme 73.123 The sulfoxide oxy-anion reacts with 
acetic anhydride to form S-acetate 264. The α-proton can then be removed, with subsequent loss of the 
acetate, generating sulfonium species 265. 1,2-attack of a second equivalent of acetate then produces 
the diastereomeric α-acetoxysulfides. The 1.2:1 ratio of epimers at this position is indicative of a small 
degree of stereoinduction from the OTES bearing α-stereocentre. This epimeric ratio is inconsequential 
however, with the stereocentre being eliminated in the following step. It does imply however, that any 
subsequent mismatched aldol or crotylation reactions employing reagent control, should overcome this 
inherent substrate control.  
  
 
 
 
 
 
 
Scheme 78: Leighton's use of crotylsilanes for the highly enantio- and diastereo-selective crotylation of aldehydes  
 
 
 
 
 
Scheme 79: Improved one-pot procedure developed by Leighton 
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Reduction of the acetate with DIBAL at   ̶78 °C , with subsequent collapse of the tetrahedral intermediate 
and loss of phenyl thiolate, revealed the desired aldehyde 257 in 88% yield. Maintaining a low reaction 
temperature was found to be crucial to avoid premature breakdown of the intermediate and 
subsequent over-reduction of the ensuing aldehyde (Scheme 75). 
 
Scheme 75: Final route to aldehyde 257 developed with Anketell 
 
4.3 Initial Strategy via a Crotylation/Propargylation Route 
4.3.1 Attempted Leighton Crotylation 
With a route to aldehyde 257 established, attention turned to its conversion into the full fragment. 
Several crotylation procedures are detailed in the literature. Notably those by Brown124,125 and 
Roush,126,127 making use of chiral boranes and boronic esters respectively, are reported to proceed in 
good to excellent enantio- and diastereoselectivity. Unfortunately however, the lack of availability of 
the but-2-ene starting material renders these methods unviable. It has also been noted that the Brown 
methodology can suffer from an inability to fully overcome the inherent facial selectivity of chiral 
aldehydes.128 
In 2004, Leighton published a highly enantio- and diastereoselective method for the crotylation of 
aldehydes employing a crotylsilane reagent based on a chiral diamine ligand.129 Bis-amine 267 reacts 
with DBU and crotyl chlorosilane 268 to form the active catalyst 269, which, whilst being relatively 
moisture sensitive, can be isolated. This then reacts with the aldehyde via an open transition state to 
give homoallylic alcohol 271 in modest to good yield and excellent enantioselectivity (Scheme 74). 
Diastereoselectivity is controlled by the E/Z ratio of the crotyl chlorosilane reagent. Moreover, control 
over this E/Z ratio and the diamine enantiomer used, allows all four possible product stereoisomers to 
be synthesised. Investigations into this route began with synthesis of bis-amine 267 and silane 26.  
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The (L)-tartrate salt of (R,R)-1,2-diaminocyclohexane was treated with potassium carbonate in ethanol 
and water to produce the free amine in situ before the addition of para-bromobenzaldehyde and mesic 
acid. The resultant bis-imine was then reduced to the bis-amine to give 267 in 72% yield over both steps 
(Scheme 76).  
 
Scheme 76: Synthesis of bis-secondary amine 267 
 
Crotyl chlorosilane 268 was synthesised in a single step from crotyl bromide and trichlorosilane in the 
presence of triethylamine and catalytic copper (I) chloride. The E/Z ratio of the commercial crotyl 
bromide was a disappointing 3.7:1, but deemed acceptable for initial studies. Higher purity material 
could be made from the reduction and subsequent bromination of crotonaldehyde. The analogous (Z)-
crotyl chlorosilane can be produced from butadiene with trichlorosilane and palladium (0) 
tetrakistriphenylphosphine (Scheme 77). 
 
Scheme 77: Synthesis of crotylchlorosilane 268 
 
In 2011,128 Leighton noted that the system previously reported in the literature, wherein the crotylation 
reagent and aldehyde are merely stirred together for 20 hours, is generally only successful in the cases 
where the aldehyde is aliphatic and sterically unhindered, giving no product at all in many other cases. 
A screen of Lewis acids was carried out, aimed at increasing the aldehyde reactivity whilst not degrading 
the enantioselectivity, with Sc(OTf)3 highlighted as the most amenable. Since aldehyde 257 has 
considerable steric bulk adjacent to the carbonyl, this appeared to be a critical development. Attempts 
by Leighton and co-workers to employ this as part of a one-pot procedure led to no catalysis, indicating 
an incompatibility between the DBU salts (more specifically the chloride ions) and the Lewis acid, 
deactivating the scandium (III) triflate.   
  
 
 
 
 
 
 
 
 
Scheme 74: Attempted crotylation of aldehydes 258 and 277 with crotyl silane 269 and Sc(OTf)3 
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With amine 267 and silane 268 in hand, they were subjected to the reaction conditions with DBU in 
dichloromethane. The product was concentrated and redissolved in pentane to precipitate the DBU 
hydrochloride salts. This solution could then be submitted straight into the following reaction with the 
aldehyde and Sc(OTf)3. Both aldehyde 258 and the less sterically hindered valeraldehyde were tried, but 
without success (Scheme 78). Since the intermediate silyl chloride was not found to be amenable to 
purification, characterisation to determine its successful production is challenging. It was anticipated 
that dissolution in deuterated chloroform (even treated with molecular sieves) may be too wet to avoid 
degradation of the intermediate. Leighton notes that whilst the intermediate can be isolated and stored 
indefinitely, it is very moisture sensitive and should ideally be purified and stored in a glovebox. In our 
hands, without the appropriate apparatus, isolation was not deemed possible. After some perseverance 
and no positive results, this route was abandoned.  
Leighton has also reported a more reactive catalyst system that doesn’t require the use of a Lewis acid 
and can thus be employed in a one-pot procedure (Scheme 79).130   
The synthesis of the 2nd generation Leighton crotylation catalyst began, as previously, with (R,R)-
diaminocyclohexane. Mono-protection of the diamine proved challenging. With the enantioenriched 
diamine 227 only available as the tartrate salt, standard conditions of HCl and di-tert-butyl decarbonate 
in methanol to afford mono-Boc protection proved ineffective. Treatment with sodium carbonate and 
di-tert-butyl dicarbonate led almost exclusively to the bis-Boc protected product 280 (alongside 
recovery of starting material). With the racemic diamine 281 available as the free amine, mono-
protection proceeded smoothly, so this was carried forward as a means explore the later chemistry 
(Scheme 80). 
 
Scheme 80: Attempted mono-Boc protection of diaminocyclohexane 227 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 81: Synthesis of 2nd generation Leighton reagent 278 
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Treatment of 2-tert-butylphenol with paraformaldehyde, magnesium chloride and triethylamine gave 
aldehyde 284 in 62% yield. The reaction has been shown to effect selective ortho-formylation of phenols 
via the following mechanism.131 Deprotonation of the phenol, followed by trapping out with magnesium 
chloride gives oxy-magnesium species 285, which can coordinate to formaldehyde, promoting addition 
at the ortho position. Following rearomatisation, the salicyl alcohol derivative can then undergo an 
Oppenauer oxidation to aldehyde 284 in a redox process using a second equivalent of formaldehyde 
(Scheme 81).  
Condensation with racemic diamine 282 in refluxing ethanol, produced the corresponding imine, which 
was then reduced to the amine with concomitant reduction of the Boc protecting group to the N-methyl 
moiety, affording 278 in 48% over both steps.  
Alcohol 289 was oxidised under Swern conditions to afford aldehyde 290 in 89% yield for use as a model 
substrate. Disappointingly, despite several attempts at the crotylation reaction, no product was ever 
observed (Scheme 82). It was difficult to ascertain whether intermediate 288 ever formed, or if it wasn’t 
reactive enough to afford the desired crotylation. Since this model aldehyde was significantly less 
sterically hindered than substrate 258, it was deemed unlikely that this methodology would prove 
fruitful without a significant degree of optimisation.  
 
Scheme 82: Attempted crotylation of aldehyde 290 with 2nd generation reagent 
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4.3.2 Marshall-Tamaru Propargylation Studies 
With no positive results arising from the crotylation studies it became apparent that a different 
approach would be required. Once again inspired by Marshall’s Discodermolide synthesis,132 an 
asymmetric propargylation was proposed. Marshall describes the treatment of Roche ester derived 
aldehyde 292 with asymmetric mesylate 293, palladium (0) tetrakistriphenylphosphine and diethyl zinc 
to deliver homo propargyl alcohol 294 in good yield (Scheme 83).132  An attractive feature of the 
approach is the additional flexibility afforded with respect to the C20-C21 olefin functionality, and thus 
with C19-C20 fragment coupling. A Lindlar reduction133,134 of the alkyne should deliver the terminal olefin, 
amenable for a Heck coupling, whereas a hydrostannylation could alternatively provide the appropriate 
vinyl stannane for a Stille cross coupling.135  
 
Scheme 83: Propargylation of aldehyde 292 in Marshall's synthesis of Discodermolide 
 
In order the test out the compatibility of the methodology with our substrate, the propargylation was 
initially attempted on racemic material. 3-butyn-2-ol was converted into mesylate 296 in 83% yield with 
mesyl chloride and triethylamine at   ̶78 °C. Exposure of the mesylate to diethyl zinc and palladium (0) 
tetrakistriphenylphosphine, followed by the addition of aldehyde 258 afforded the homopropargylic 
alcohol in a pleasing 82% yield (Scheme 84). Due to the racemic nature of the mesylate used, the 
product was isolated as a 1:1.4 ratio of anti-diastereomers across the C22-C23 bond. This observed 
diastereoselectivity for the reaction can be attributed to the facial selectivity of the aldehyde, with the 
result comparable to that observed during the Pummerer rearrangement described in section 4.2. This 
inherent substrate selectivity was deemed small enough to be overcome by reagent control.  
 
Scheme 84: Racemic mesylate formation and propargylation with aldehyde 258 
  
 
 
 
 
 
Figure 28: Proposed catalytic cycle for Noyori transfer hydrogenation 
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With this promising result, attention turned to the synthesis of the appropriate enantioenriched 
mesylate. A survey of the literature highlighted a Noyori reduction of the corresponding ketone as the 
most common route to these chiral mesylates. In 1997, Noyori reported the asymmetric reduction of 
acetylenic ketones via transfer hydrogenation utilising a ruthenium catalyst with a chiral diamine ligand 
and i-PrOH as a hydrogen source.136 Prior to this, no chemo- and regioselective asymmetric 
hydrogenation had been published. He noted however, that whilst this reduction was not amenable to 
terminal alkynes, silyl protected alkyne 304 could be reduced in 99% yield and 98 %ee. 2-propanol is 
reported to be the best hydrogen donor for these acetylenic ketones. Whilst a 1:1 mixture of formic 
acid/triethylamine is known to afford numerous other transfer hydrogenation products, on these 
systems it delivered the products in only ~55% yield.  
The proposed mechanism proceeds as shown in Figure 28. Ruthenium complex 299 can either be 
isolated and stored prior to used, or generated in situ from the treatment of the corresponding 
ruthenium chloride (298) species with potassium hydroxide. Initial coordination of 2-propanol to 
complex 299 followed by concerted hydrogen transfer and formation of dihydride species 303, 
generates acetone as the by-product. Coordination of the ketone starting material then produces 
intermediate 305 delivering dihydrogen across the carbonyl to afford the enantioenriched secondary 
alcohol 306. The enantioselectivity is derived from the chirality of the diamine ligand. Favourable CH-π 
interaction between the polyalkylated arene and, in this case, the π-bonds of the substrate alkyne, 
enhance the steric interactions with the chiral ligand.137  Notably, neither the ketone or the alcohol are 
proposed to coordinate to the metal directly.  
Several routes to propargylic ketone 304 were considered. Brandsma and cowkorkers describe the 
acetylation of terminal alkynes using n-BuLi, zinc (II) chloride and acetyl chloride.138 Unfortunately, in 
our hands this protocol failed to give any product, possibly attributable to acetic acid being present in 
the acetyl chloride, quenching out the anion intermediate (Scheme 85). 
 
Scheme 85: Synthesis of acetylenic ketone 304 
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Furthermore, reaction of the pre-formed anion with acetic anhydride failed to give any product. At this 
point, a two-step procedure was considered, wherein the anion would be trapped out with 
acetaldehyde, giving propargylic alcohol 308, and was subsequently subjected to Swern oxidation 
conditions, to afford the desired ketone. Pleasingly, this delivered 304 in 93% yield over both steps.  
Propargylic alcohol 308 was also synthesised in 85% yield from but-3-yl-1-ol, via a double deprotonation, 
silyl protection and silyl ether deprotection procedure, as precedented on propargyl alcohol in section 
3.3.2. 
With ketone 304 in hand, attention turned to an asymmetric reduction to install the C22 stereocentre 
(Scheme 86). Ruthenium complex 299 was kindly donated by Adam Yip. On small (25 mg) scale, the 
reaction proceeded smoothly, providing the enantioenriched alcohol in 86% yield. 19F NMR analysis 
carried out on the Mosher esters of the corresponding TIPS alkyne determined an excellent 97% e.e, in 
line with literature values.136 
In our hands however, the reaction had disappointing scalability. The reaction repeatedly stalled, 
although even with the re-isolated ketone, mass recovery was poor. Attempts made to alleviate this by 
portionwise addition of the catalyst, were only modestly successful.  
Hampered by the volatility of alcohol 309, the silyl deprotection proved challenging. Due to the scale 
issues with the previous step, the product was never obtained in significant enough quantities to 
facilitate distillation. Deprotection under standard conditions with TBAF in THF gave the product in 45% 
yield. Unfortunately, switching to the more volatile Et2O failed to give any product and potassium 
carbonate in methanol also only delivered the terminal alkyne in 52% yield (albeit on small scale). 
Mesylation of the resultant alcohol proceeded smoothly, providing mesylate 310 in 55% yield.  
 
 
Scheme 86: Noyori reduction of ketone 304 and subsequent elaboration into non-racemic mesylate 310 
 
  
 
 
 
 
 
 
Figure 29: Proposed reaction mechanism for the propargylation of aldehydes 
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Due to the low yield for the deprotection step, an alternative strategy was considered, wherein the silyl 
removal could take place post Marshall propargylation. Alcohol 306 was treated with mesyl chloride 
and triethylamine delivering mesylate 317 in 68% yield. Subjection of this to diethyl zinc and aldehyde 
258 in the presence of palladium (0) tetrakistriphenylphosphine gratifyingly gave homopropargylic 
alcohol 318 in 68% yield as a single product by NMR. The alkynyl silane could then be removed by 
treatment with potassium carbonate in methanol in 78% yield (Scheme 87). Although the overall yield 
for this sequence remained lower than for the racemic version, it represented a sufficient improvement 
on the previous route via mesylate 310, due to its better scalability.  
 
Scheme 87: Modified propargylation with delayed silyl deprotection 
 
The propargylation is proposed to proceed via the following mechanism (shown in Figure 29). Oxidative 
insertion of the palladium into the alkyne, with displacement of the mesylate gives allenyl intermediate 
312. Diethylzinc then carries out a ligand exchange on palladium to provide species 313, which can then 
undergo transmetallation forming diethyl palladium (II) and allenyl zinc species 314. The aldehyde then 
coordinates to this allenyl zinc species, promoting nucleophilic attack, affording the anti-propargylation 
product 316. The aldehyde reacts selectively from the lower face of the chiral allenyl species, to avoid 
β-hydride elimination and ligand dissociation of the diethyl palladium releases ethane and ethylene 
providing palladium (0) to re-enter the catalytic cycle.  
With propargylation product 319 in hand, it was envisaged that the desired fragment could be obtained 
via a straightforward silyl protection of the newly formed alcohol, followed by a Lindlar reduction of the 
terminal alkyne. Initial investigations were carried out on the diastereomeric mixture of 
homopropargylic alcohols 297. Disappointingly, the requisite silyl protection proved more challenging 
than expected. Treatment of the secondary alcohol with TESOTf and 2,6-lutidine led to significant levels 
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of deprotection of the primary TBS (Scheme 88). We attributed this to the putative presence of triflic 
acid, produced by small levels of aqueous quenching of the TESOTf. With this process seemingly 
occurring at a similar rate to the secondary alcohol protection, the resulting free primary alcohol could 
undergo TES protection, producing a product mixture of differentially protected primary alcohols.  
 
Scheme 88: Attempted protection of diastereomeric alcohol 297 
Numerous attempts were made to alleviate this issue. Addition of a large excess of 2,6-lutidine failed to 
prohibit the deprotection (Table 12, entry 2), indicating that the Lewis acidity of the TESOTf may be the 
contributing factor instead. Attempted protection with TESCl, imidazole and catalytic DMAP (entry 3) 
proved unreactive and failed to provide any product. Disappointingly, the same conditions with 
triethylamine and stoichiometric DMAP failed to provide any improvement. A fresh bottle of TESOTf 
(entry 5), provided a significant improvement in the product ratio, but with sufficient deprotection still 
observed, this was not deemed a reasonable solution. At this junction, the protecting group strategy 
was reconsidered and, since the C23 alcohol would need to be deprotected prior to the C24 or C25 
alcohols, a TMS at this position should both survive the intermediate reaction conditions and be easier 
to selectively deprotect. With the TMSCl significantly less Lewis acidic than TESOTf, but sufficiently more 
reactive than TESCl, the protection proceeded smoothly, giving TMS silyl ether 322 in 80% yield.3  
  
Table 12: Selected conditions attempted for the protection of alcohol 297 
 
                                                 
3 These conditions were later carried out on the single diastereomer 319, giving TMS ether 323 in 82% yield.  
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Using diastereomeric alkynes 320 and 321 (With P= 1.9:1 TES/TBS), a solvent screen was carried out to 
determine the optimum conditions for the Lindlar reduction (Scheme 89). Whilst ethyl acetate and 
toluene failed to give any product, methanol delivered the product alkenes (324 and 325) in good yield 
(75%). Frustratingly though, the reaction proved to be capricious, frequently stalling. Resubmission to 
the reaction conditions required purification of the crude material to be effective, but despite this, 
pushing the reaction to 100% completion was challenging.  
 
Scheme 89: Solvent screen for the Lindlar reduction of alkynes 320 and 321 
 
An alternative reduction procedure was explored, following a hydrozirconation protocol. Generation of 
the reactive zirconium hydride species (Schwarz reagent) in situ can be achieved by the pre-mixing of 
zirconocene dichloride and DIBAL. Although in this case the regiochemistry of the hydrozirconation 
product obtained is inconsequential, the major product predicted would be the terminal vinyl zirconium 
moiety. This species can be trapped out with a variety of nucleophiles, but quenching with water should 
afford the terminal unfunctionalized alkene. Although this reaction was only attempted on small scale, 
a similar result to the Lindlar reduction was obtained, with a 65% conversion observed (Scheme 91). 
 
 
Scheme 90: Attempted reduction of alkyne 322 via a hydrozirconation 
 
With the difficulties encountered with the scalability of the Noyori reduction and the conversion rates 
of the alkyne reduction, a new strategy to construct the C22-C23 bond was sought.   
  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Preferred transition states for benzoyl protected enolates 
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4.4 Revised Approach to C20-C25 Fragment via an Aldol Coupling Strategy 
4.4.1 Titanium Aldol Approach to Aldol Adduct 254 
With both the crotylation and propargylation routes failing to provide the final fragment in good yield, 
the alternative strategy detailed in section 4.1 was pursued, based on an aldol approach. It was 
envisaged that access to each of the eight different stereoisomers of the fragment could be made via 
either an Evans syn aldol or anti aldol using a lactate derived ketone.   
With lactate derived ketones, the enol borinate geometry is determined by the availability of the α’-
oxygen centre. In the benzoyl case, the α’-oxygen lone pair is delocalised as part of the ester, so is not 
available to coordinate to boron. A similar transition state to that described for the Roche ester derived 
ketones is observed. A favourable hydrogen bonding interaction between the α-proton on the ethyl 
group and the chloride, ensures that the boron preferentially lies on the side of the ethyl group. This 
interaction also increases the acidity of the other α–proton, leading to (E)-enolate formation (Figure 
31). 
 
Figure 31: Selective lactate-derived (E)-enolate geometry using a benzoyl protecting group 
 
It is proposed that the transition state for the aldol reaction adopts a boat conformation (Figure 30, TS-
328).92 The π-facial selectivity of the enolate is dictated by the minimisation of allylic strain, placing the 
α-proton eclipsing the enolate olefin. The excellent diastereoselectivity typically observed in these 
reactions can be attributed to the carbonyl of the benzoyl group having sufficient reach to chelate 
internally, forming a favourable formyl hydrogen bond to the aldehydic proton. This leads to the 1,3-
anti, 1,4-syn diastereomer as the major product.  
 
 
 
 
 Figure 32: Transition state for the Evans syn aldol 
 
 
Figure 33: Proposed access to all four possible C21-C22 diastereomers  
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The Evans auxiliary can be derived from phenylalanine (or valine for the isopropyl variant) in 3 steps. 
Since all eight stereoisomers will ultimately need synthesising, both enantiomers of the auxiliary are 
required. For initial studies to explore the route though, use of the natural enantiomer (L)-phenylalanine 
was chosen. For these studies, the auxiliary was kindly donated by Matthew Anketell. 
As discussed in section 2.3.1, the selective enolisation of carbonyl species has been well documented. 
The small ligands and good leaving group of dibutylboron triflate lead to the formation of the (Z)-enol 
borinate, as shown in Figure 34. Preliminary chelation of the Lewis acid between the two carbonyls 
affords intermediate 345. Deprotonation occurs from above to avoid steric clashing of the bulky base 
with the benzyl group, with the proton being removed, orientated perpendicular to the carbonyl to 
maximise overlap between the C-H σ and C=O π* orbitals. In one conformation, there is a destabilising 
interaction between the oxazolidinone ring and the methyl group, which is not present in the other, 
lower energy, conformer.  
 
Figure 34: Rationale for selective Evans auxiliary enolate formation 
 
The aldol reaction is known to take place via a Zimmerman-Traxler type transition state. The (Z)-enol 
borinate therefore leads to the two possible products being the respective 1,2-syn aldol adducts. The 
enantioselectivity is derived from the chiral auxiliary. With dipoles opposed, the lower energy transition 
state (Figure 32, TS-333) places the bulky benzyl group facing outwards, selectively delivering the syn 
product in which the alcohol and methyl group lie on the opposite face to the benzyl.    
Between the ‘lactate’ and Evans’ aldols shown and those for the epimeric lactate starting materials, all 
four product stereoisomers are obtainable (Figure 33). Both lactate and Evans ‘auxillaries’ can be readily 
converted to useful functional groups through a series of simple transformations. In the lactate case, 
  
 
 
 
 
 
 
 
Figure 35: Transition state for the Crimmins syn aldol 
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concomitant reduction of the benzoate ester and ketone, followed by a periodate cleavage should 
afford aldehyde precursors from which terminal alkenes 337 and 339 can be accessed. In the Evans 
auxiliary case, the oxazolidone derivative can be cleaved by reaction with lithium hydroxide, sodium 
methoxide or lithum borohydride, revealing the corresponding carboxylic acid, ester or alcohol 
respectively, from which the appropriate oxidation or reduction and Wittig olefination reactions, should 
provide alkene 341 or 344. 
Unfortunately, standard Evans aldol conditions of dibutylboron triflate and DIPEA furnished aldol adduct 
254 in only 45% yield (Scheme 91). This was attributed to poor reagent quality of the dibutylboron 
triflate, despite it being freshly distilled. The diastereoselectivity was an acceptable 10:1 d.r. 
 
Scheme 91: Dibutylboron triflate-mediated aldol with Evans auxilliary 340 
 
A search through the literature identified a paper,139 in which Crimmins describes an alternative 
procedure for the asymmetric addition of oxazolidinone propionates to aldehydes, mediated by 
titanium tetrachloride. Previous protocols had suffered from poorer diastereoselectivities with respect 
to the dibutyl enol borinates and required a significant excess (2-5 equiv.) of the aldehyde for the 
reaction to reach completion. In 1998,140 Crimmins reported an improved method using 1.0 equiv. of 
titanium tetrachloride and 2.2 equiv. of (  ̶)-sparteine to afford the titanium enolates. It was proposed 
that the second equivalent of sparteine was required as an additional ligand for titanium, ensuring that 
there were no free sites on the titanium for chelation of the auxiliary. The supply issues with sparteine 
however, necessitated the development of a second-generation protocol. In 2004,139 Crimmins 
described the use of 1.05 equiv. of titanium tetrachloride, 1.1 equiv. of DIPEA and 1.0 equiv. of NMP to 
form the requisite titanium enolate, reporting a 99% yield and 97:3 d.r. in the reaction between 
oxazolidinone 340 and isobutyraldehyde (Figure 35). 
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Pleasingly, this protocol afforded aldol adduct 254 in 78% yield and 11:1 d.r. (Scheme 92). A 
diastereoselectivity similar to the equivalent dibutylboron enolate was obtained, with a significant 
improvement in yield and reliability of the reaction. 
 
Scheme 92: Titanium-mediated aldol with Evans auxilliary 340 
 
4.4.2 Auxiliary Cleavage and Elaboration of C20 Terminus 
As with the propagylation product, aldol adduct 254 was protected as the C23 TMS ether with TMSCl and 
imidazole, affording the product in good yield (89%, Scheme 93). Auxiliary cleavage with sodium bis-
(methoxyethoxy)aluminium hydride to give the corresponding aldehyde in a single step, as precedented 
by Shin and coworkers in their synthesis of Dictyostatin141 was attempted, but without success. Reaction 
with sodium methoxide to give the corresponding methyl ester was also tried, but despite the addition 
of a large excess of reagent, the reaction proceeded very slowly. Fortunately, a reductive cleavage with 
lithium borohydride in the presence of methanol delivered alcohol 355 smoothly in 85% yield. Oxidation 
with Dess-Martin periodinane furnished the aldehyde (356) in 93% yield, which was then submitted to 
a Wittig olefination protocol, affording terminal alkene 341 in 86% yield.  
 
Scheme 93: Elaboration of aldol adduct 254 into completed C13-C19 fragment 341 (the Heck substrate) 
  
 
Scheme 94: Initial proposed fragment union strategy to form macrocycle 361 
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Chapter 5: Results and Discussion – Part IV 
Macrocycle endgame 
5.1 Formation of the C12—C13 Bond 
5.1.1 Initial Strategy via an Acetylide Addition Approach 
With three of the unknown stereocentres lying in the C20-C25 fragment, it was envisaged that the most 
concise route to the eight completed macrocycles would involve the formation of a C1-C19 fragment 
(206), which could be reacted in turn with the eight different C20-C25 fragment stereoisomers (e.g. 341). 
The diastereomeric C1-C25 linear fragments generated, could then be converted into the desired 
macrocycles in five steps (Scheme 94). 
To this end, a strategy was required in which the C12-C13 bond could be formed before the C19-C20 bond. 
After attempts to mask the C19 vinyl iodide as a vinyl silane had proved fruitless, an alternative strategy 
was devised. Of particular importance, any C12-C13 bond forming reaction would need to be compatible 
with the vinyl iodide, obviating the use of any palladium-catalysed methods.  
With this in mind, it was proposed that aldehyde 200 could be converted into terminal alkyne 358 via a 
Seyferth-Gilbert homologation,61,62 using the Ohira-Bestmann modification63 (or alternatively via a 
Corey-Fuchs olefination reaction).65 Deprotonation at the terminal position could form a nucleophile 
which could participate in an SN2 displacement of iodide 359 (in turn formed from alcohol 207). Lindlar 
reduction of the resultant alkyne, would give (Z)- alkene 206.  
To investigate this proposed strategy, a model system was synthesised (Scheme 95). The enantiomeric 
C13-C19 fragment ent-207 was converted into iodide ent-359 under Appel conditions142 (I2, PPh3 and 
imidazole) in good yield (87%) and TMS-protected acetylene was used as a model alkyne. 
 
Scheme 95: Synthesis of iodide ent-359 and attempted conversion to alkyne 362 
 
Disappointingly, none of the conditions attempted delivered the desired product. TMS-protected 
acetylene was lithiated with n-BuLi at   ̶78 °C before addition to the iodide. No reaction was observed at  
 Scheme 96: Proposed C12-C13 bond formation via an acetylide addition into aldehyde 363 
 
 
Scheme 97: Nicholas type deoxygenation by Clarke and coworkers. 
 
 
Scheme 98: Attempted deoxygenation via a Nicolas reaction  
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this temperature, or upon warming to 0 °C (Table 13, entry 1). Addition at   ̶ 78 °C and immediate 
warming to room temperature, followed by refluxing also only returned starting material. Considering 
that the lithiated acetylene might be too hard a nucleophile for the relatively soft alkyl iodide, addition 
of the corresponding cuprate was attempted (entry 3), but likewise without success.   
 
Table 13: Attempted displacement conditions to afford alkyne 362 
With attempts at a direct substitution proving fruitless, an alternative strategy encompassing fragment 
union via the addition of lithiated alkyne 358 into aldehyde 363 and subsequent removal of the resulting 
alcohol was proposed (Scheme 96). A Lindlar reduction should then afford the complete C1-C19 fragment 
206. As with the displacement studies, TMS-acetylene was used as a model for the C1-C12 fragment.  
Accordingly, alcohol ent-207 was oxidised with Dess-Martin periodinane in excellent yield to aldehyde 
ent-363. Deprotonation of TMS-acetylene as before, followed by addition into the aldehyde, afforded 
propargylic alcohol 368 as a 2.5:1 mixture of diastereomers (94% over two steps, Scheme 99) 
 
Scheme 99: Oxidation of alcohol ent-207 and subsequent acetylide addition. 
With propargylic alcohol in hand, attention turned to deoxygenation strategies. Since the vinyl iodide 
was deemed unlikely to survive Barton-McCombie deoxygenation conditions,143 due to its likely reaction 
under in radical mediated process, alternative deoxygenation protocols were sought. Considering the 
alcohol requiring displacement was propargylic, it seemed pertinent to attempt to utilise this 
functionality. A Nicholas type deoxygenation was therefore initially considered instead.144–146 In 2009, 
Clarke and co-workers147 described the deoxygenation of propargylic alcohol 366 under Nicholas 
conditions (Scheme 97). Co-ordination of the octacarbonyl dicobalt to the alkyne, with subsequent 
protonation of the alcohol and loss of water, gives a stabilised [(propargylium)Co2(CO)6]+ cation. 
Reduction out of the cation with sodium borohydride, followed by oxidative decomplexation of the 
cobalt  
  
 
 
 
 
 
Scheme 100: Revised fragment coupling strategy 
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with iron (III) nitrate gave alkyne 367 in 37% yield. Attempting to use the same methodology on our 
system however disappointingly delivered none of the desired product (Scheme 98).  
Alternatively, it was envisaged that the hydroxyl could be removed by conversion into a good leaving 
group and displacement by a hydride source. Encouraged by a paper from De Clercq,148 in which he 
describes the tosylation of propargylic alcohol 371 under standard conditions, followed by the addition 
of lithium triethylborohydride (Super Hydride®) to afford alkyne 372 (Scheme 101), we sought to 
replicate this result. Diastereomeric alcohols 368 were treated with tosyl choride and pyridine to afford 
tosylates 373 in 83% yield. Exposure of these tosylates to Super Hydride® unfortunately only returned 
starting material (Scheme 102). With three electron-donating groups, Super Hydride® is one of the 
strongest hydride sources commercially available. Considering the lack of reactivity from both these 
proposed methods, an alternative strategy was considered.  
 
Scheme 101: Reductive cleavage of propargylic alcohol 371 by De Clercq 
 
 
Scheme 102: Tosylation of alcohol 368 and attempted displacement with Super Hydride® 
 
5.1.2 Model Studies to Investigate C12-C13 Suzuki Coupling 
With the failure of acetylide based methods to form the C12-C13 bond, it became clear that the fragment 
union strategy would need to be revised. An initial coupling of the C13-C19 and C20-C25 fragments via a 
Heck coupling would allow for a coupling between the C1-C12 and C13-C25 fragments via a palladium-
catalysed cross coupling, no longer in the presence of the C19 vinyl iodide. 
Conversion of Heck product 369 into iodide 370 would allow for a similar lithiation-borylation-Suzuki 
coupling sequence to that used to form the C2-C3 bond, as described in Section 2.3.3. Successful 
formation of the C12-C13 bond would furnish the complete C1-C25 fragment 360, converging with the 
  
 
 
 
 
 
 
 
 
 
Scheme 104: Model Suzuki coupling to form C12-C13 bond 
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previous fragment union strategy and amenable to macrolactonisation after a further four steps 
(Scheme 100). 
To this end, a truncated fragment to model for the C13-C25 piece was synthesised to investigate a 
potential Suzuki cross coupling to construct the C12-C13 bond. Vinyl iodide ent-207 was treated with n-
BuLi at low temperature to produce the corresponding vinyl lithium species, which was then quenched 
with water, affording the terminal alkene. Appel conditions were then used to give iodide 374 in 73% 
yield over both steps (Scheme 103). As with other fragment coupling studies, this truncated fragment 
was synthesised in enantiomeric series to the natural product (in the C13-C19 region), due to greater 
availability of stocks of (S)-Roche ester in our laboratory. 
 
Scheme 103: Conversion of alcohol ent-207 into model iodide 374 
 
For the purposes of investigating this fragment union reaction, a slightly simplified C1-C12 fragment was 
also synthesised (as described in Section 2.3.4); functionalising the C12 terminus prior to dihydroxylation 
across the C1-C2 bond. Treatment of this truncated analogue (186) with t-BuLi at low temperature 
afforded the alkyl lithium species, which could be swiftly trapped with OMe-9-BBN. Submission of this 
alkyl boronate to Suzuki coupling conditions (Pd(dppf)Cl2, K3PO4, DMF) with vinyl iodide 186, furnished 
the truncated C1-C19 piece. Several attempts were required to afford the product in good yield. Whereas 
the C2-C3 bond formation typically reached completion at room temperature, this reaction repeatedly 
stalled (or slowed down) at around 60% completion after 16 hours at rt. Pleasingly though, warming the 
reaction mixture to 50 °C for an additional 3 hours proceeded to push the reaction to completion 
affording alkene 375 in 57% yield (Scheme 104). 
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This could be attributed to the reaction being hampered by the slightly greater steric bulk around both 
the boronate and the vinyl iodide or the use of a vinyl iodide in place of a vinyl bromide. Buchwald 
reports that whilst vinyl iodides typically undergo oxidative addition at a faster rate, this process is 
generally no longer the rate determining step in a Suzuki coupling mechanism.149 Improved ligands (such 
as the diphenylphosphineferrocene one used in this instance), have increased the rate of this process. 
Instead, the deprotonation step is typically rate-determining and this had been shown to be slower with 
the less acidic iodide species compared with the respective bromides or chlorides. Attempts with other 
ligand/base combinations, such as triphenylarsine and caesium carbonate failed to provide an 
improvement on the original results.  
It was proposed that a late-stage dihydroxylation across the C1-C2 alkene immediately prior to oxidation 
and macrolactonisation would decrease the step count of the longest linear sequence; obviating the 
requirement for diol protection. It was envisaged that the C1-C2 olefin should react preferentially (due 
to its slightly higher electron density), over the 1,2-disubstituted C11-C12 alkene and the C18-C19 alkene 
with an allylic methoxy group, although we expected the difference to the latter to be more prominent 
with the full diene in place. With triene 375 in hand, a regio- and stereoselective dihydroxylation could 
be attempted. For these initial studies (and operational simplicity), ADmixα was used as the reagent. We 
were encouraged by an initial result, affording the desired diol 376 in 58%, but unfortunately this result 
was unreproducible (Scheme 105). Given its unreliability, this somewhat adventurous transformation 
was not pursued. Instead, dihydroxylation immediately post C2-C3 bond formation was prioritised, 
followed by protection as the bis-TES ether.  
 
Scheme 105: Regioselective C1-C2 dihydroxylation of triene 375 
 
 
 
 
  
  
 
 
Scheme 106: Heck coupling between vinyl iodide ent-252 and model alkene 378 
 
 
 
Scheme 107: Heck coupling between vinyl iodide ent-207 and model alkene 379 
 
 
 
 
 
 
Table 14: Optimisation of the C19-C20 Heck coupling 
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5.2 Formation of the C19-C20 Bond 
5.2.1 Model Studies to Investigate C19-C20 Heck Coupling 
With a reliable method for C12-C13 bond formation in place, attention turned to exploring the C19-C20 
coupling. Taking inspiration from the Paterson synthesis of Leoidermatolide,150 a Heck coupling 
catalysed by Pd(OAc)2 was proposed.  With the C20-C25 fragment synthesis still in progress, a model 
system was employed to investigate the reaction, initially using alkene 377 (Scheme 106). 
Employing 1 mol% of Pd(OAc)2, and 1.0 equiv. of Ag2CO3 in DMF and using an equimolar ratio of the 
vinyl iodide ent-207 and alkene 379, the reaction failed to reach completion. Frustratingly, both starting 
materials, the product and a side product impurity co-ran by TLC (Table 14, entry 1). A similar result was 
obtained when the equivalents of the alkene coupling partner was increased to 1.5. Prolonging the 
reaction time to 18 hours (entry 3) resulted in the reaction reaching completion, although the product 
was still produced in a 2:1 ratio with the impurity. Unable to be separated from the product, the identity 
of this side-product remains unknown.  
Attempted PMB deprotection of this Heck product mixture with DDQ led to considerable amounts of 
decomposition, indicating that the methoxydiene moiety is incompatible with these reaction conditions. 
Considering the amenability of cross couple reactions to free hydroxyl groups, the obvious solution 
appeared to be a reversal of steps. PMB deprotection proceeded very smoothly (as described in section 
3.3.3), giving alcohol ent-207 in 90% yield.  
Drawing on the experience of these related studies, the proposed deprotection of the C9 PMB ether 
during the endgame under the same conditions may need to be reconsidered. Alternative conditions 
have been reported in the literature including the use CAN and LiDBB, so these can also be attempted. 
At this junction, it was considered that using a model alkene with greater similarity to the actual 
substrate would be sensible. To this end, the vinyl iodide was reacted with alkene 379 instead, under 
the same conditions (Scheme 107). Conversion was around 80%, but increasing the catalyst loading to 
10 mol% afforded the desired product in 62% yield, with no production of the side product.  
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5.2.2  C19-C20 Heck Coupling and C12-C13 Suzuki Coupling to give alkene 360 
With conditions for the C19-C20 Heck coupling optimised on a model system, attention turned to the real 
fragment. Treatment of vinyl iodide 207 (now being used in the natural enantiomeric series) and alkene 
341 with 10 mol% Pd(OAc)2 and Ag2CO3 afforded diene 369 in 65% yield (Scheme 108). Attempted 
conversion of the model Heck coupling product to the iodide under Appel conditions led to 
decomposition. Instead, generation of the corresponding tosylate (381) proceeded smoothly, in 75% 
yield. Displacement with lithium iodide then gave iodide 370 in 84% yield, in preparation for C12-C13 
bond coupling.  
 
Scheme 108: Heck coupling between 207 and 341 with subsequent elaboration to iodide 370 
 
With iodide 370 and vinyl iodide 196 in hand the Suzuki coupling to unite the C1-C12 and C13-C25 
fragments could be attempted. Using the conditions optimised on vinyl iodide 186 and iodide 384, 
alkene 360 was synthesised in 54% yield (Scheme 109). With limited material and a lack of time, this C1-
C25 fragment represents the endpoint of the research to date. Proposals for the elaboration of this 
intermediate (360) into the truncated macrocycle can be found in section 5.4.  
 
Scheme 109: Suzuki cross coupling between the C1-C12 and C13-C19 fragments 
  
 
 
 
 
 
 
Scheme 110: Successful route to the completed C1-C12 fragment 
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5.3 Conclusions 
All three macrocycle fragments have been synthesised. The successful route to the C1-C12 fragment is 
detailed in Scheme 110. Vinyl iodide 196 had been produced in 17 steps from diacid 124 in 4.5% overall 
yield. The C5 methyl stereocentre was installed in 96% ee using an enzymatic desymmetrisation. A 
boron-mediated anti aldol with in situ reduction has been used to install the C7-C10 stereotetrad as a 
single diastereomer. The C2-C3 bond was constructed via an in situ Suzuki cross coupling, which was 
subsequently subjected to a Sharpless asymmetric dihydroxylation to install the C2 stereocentre. 
The successful route to the C13-C19 fragment is detailed in Scheme 111. Vinyl iodide 207 was synthesised 
in 10 steps from (R)-Roche ester in 15% overall yield. The C14-C17 stereotriad was constructed using a 
boron-mediated anti aldol, affording the aldol adduct in greater than 20:1 d.r. The C15 stereocentre was 
then installed via a substrate controlled reduction of the C15 ketone.  
  
Scheme 111: Successful route to the completed C13-C19 fragment 
 
  
  
 
 
 
 
Scheme 112: Fragment union strategy to C1-C25 fragment 
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One possible stereoisomer of the C20-C25 fragment has been synthesised. Alkene 341 was produced in 
11 steps from isobutenol in 18% overall yield (Scheme 113). A Sharpless asymmetric epoxidation has 
been used to install the C24 stereocentre. An Evans aldol was then used to construct the syn 
stereochemistry of this stereoisomer. Importantly, with use of the enantiomeric tartrate catalyst for the 
epoxidation, the opposite enantiomer of the Evans oxazolidinone auxiliary and an anti aldol using a 
lactate derived ketone, all the other seven possible stereoisomers of this fragment are accessible.  
 
 
Scheme 113: Successful route to one stereoisomer of the C20-C25 fragment 
 
Investigations into an endgame strategy are well underway (Scheme 112). The C19-C20 bond has been 
constructed using a Heck coupling. Alcohol 369 has also been converted into the corresponding iodide 
370 over two steps. This iodide then underwent a lithiation, borylation, Suzuki coupling sequence with 
vinyl iodide 196 to give the fully elaborated C1-C25 fragment 360. In conclusion, whilst the synthesis has 
not progressed far enough to conduct structural determination studies, almost all the chemistry 
required to produce the truncated macrocycle has been developed. Proposed routes for the conversion 
of the C1-C25 fragment into the truncated macrocycle (36) for NMR studies are detailed in section 5.4. 
 
 
 
  
 
Scheme 114: Proposed route from TES ether 360 to the truncated macrocycle 36 
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5.4  Future Work 
The proposed route from C1-C25 fragment 360 will proceed via site-selective deprotection of the C1 TES 
ether, with PPTS in MeOH/CH2Cl2 (Scheme 114). Double oxidation of the ensuing primary alcohol under 
Swern (oxalyl chloride, DMSO, Triethylamine) and Pinnick (NaClO2, NaH2PO4, 2-methyl-but-2-ene) 
conditions should afford the corresponding carboxylic acid 382. We propose that the next most labile 
silyl ether, would be the TMS ether at C23. Deprotection with PPTS/MeOH or TBAF should afford the 
secondary alcohol in preparation for a Yamaguchi macrolactonisation to give macrolactone 361. In the 
instance that site selective deprotection of the C1 TES ether in the presence of the C23 TMS ether is not 
possible, numerous methods have been reported in the literature for the chemoselective oxidation of 
a primary alcohol in the presence of a secondary alcohol.151–153 Therefore simultaneous deprotection of 
both silyl ethers should not be problematic.  
Orthogonal protection of the C9 alcohol should allow for selective deprotection and oxidation to install 
the C9 ketone. As discussed in section 5.2.1 though, deprotection of the C9 PMB ether in the presence 
of the C18-C21 diene might be a challenging step. Oxidative cleavage of the PMB ether with DDQ or LiDBB 
should hopefully deliver the secondary alcohol smoothly. Oxidation of the C9 alcohol to the ketone could 
take place under Swern or Dess Martin oxidation conditions. A global deprotection of the remaining silyl 
protecting groups with HF/pyridine should then give the truncated macrocycle 36 in preparation for 
NMR comparison with the natural product.  
It is hoped that the two side chains will have only minimal effect on the NMR shifts and coupling 
constants of the macrocycle environments. Thus, comparison of the NMRs of truncate 36 to the natural 
product NMRs (provided by Moore and Yoshida) should provide a good indication of the most likely 
configuration of the three stereocentres lying within the macrocycle; specifically, those at C10, C22 and 
C23. With confidence in these stereocentres a partial synthesis of the C23-C32 side chain will be carried 
out to explore permutations of the C24 stereocentre. Analysis of both 1H and 13C chemical shifts as well 
as 1H-1H coupling constants should hopefully indicate the likely stereochemistry of the natural product. 
It is also proposed that the proximity of three of the unknown stereocentres to the C23 alcohol may aid 
the structural determination, with one or more of the stereoisomers proving too crowded for the 
macrocycle to form.  
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If NMR comparison at the macrocycle stage has provided confidence in a single stereoisomer of the C20-
C25 fragment, it is proposed that a modified strategy could be used to complete the natural product. A 
more convergent approach will incorporate the thiazole side chain prior to macrolactone fragment 
union, taking into account the number of steps required for the C1-C12 fragment. Deprotection of the 
C25 alcohol immediately post Evans or lactate-derived aldol and subsequent oxidation and submission 
to Corey-Fuchs olefination conditions should give vinyl dibromide 388. Installation of the C26 methyl 
group and conversion to the (Z)-vinyl iodide takes inspiration from work by Miyashita,154 in which Roche 
ester derived vinyl dibromide 384 is transformed into the requisite vinyl iodide 385 by the addition of 
Me2CuLi and trapping out of the ensuing vinyl copper species with iodide (Scheme 115) 
.  
Scheme 115: Precedent for the formation of a (Z)-vinyl iodide from vinyl dibromide 384 
 
With vinyl iodide 389 in place, we envisage a Negishi cross coupling to the thiazole side chain 390. The 
corresponding iodide has been synthesised by Bing Yuan Han155 in the Paterson lab, but was found to 
be light-sensitive, so a modification to the bromide should hopefully provide a solution to these issues. 
The sensitive epoxide moiety will be maintained as the protected diol until the final stages of the 
endgame. Coupled product 391 could then be converted into the completed C21-C32 fragment in 3 steps 
beginning with cleavage of the benzoate or Evans auxiliary (Scheme 116). 
 
Scheme 116: Proposed route to completed C20-C32 fragment incorporating the thiazole moiety prior to 
macrolactonisation  
 Scheme 117: Proposed endgame to patellazole B 
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With the C21-C32 fragment in hand, Heck coupling with the C13-C19 fragment under the previously 
optimised conditions should provide alcohol 393, which can then be converted into the corresponding 
iodide. Suzuki coupling with a modified C1-C12 fragment 394 (with the ester-linked side chain already in 
place) should then afford the complete C1-C32 linear fragment. At this point, the route converges with 
the route proposed to furnish the simplified macrocycle. Selective deprotection of the C1 primary TES, 
will precede double oxidation under Swern and Pinnick conditions, deprotection of the C23 TMS and a 
Yamaguchi macrolactonisation to give lactone 396.  
Deprotection of the C31-C32 diol and conversion of the secondary alcohol to the corresponding iodide 
under Appel conditions will proceed with inversion of configuration. Deprotonation of the tertiary 
alcohol should then displace the iodide, affording epoxide 397. Deprotection of the C9 PMB ether with 
DDQ or LiDBB and subsequent oxidation should reveal the ketone moiety. A final global deprotection of 
the remaining silyl groups with HF·py should then afford patellazole B (Scheme 117). 
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Chapter 6: Experimental 
6.1 General Comments  
Materials: All reagents, obtained from Acros, Aldrich, Alfa Aesar, Fluka, Fluorochem and Lancaster fine 
chemicals suppliers, were used directly as supplied or purified by the methods described by Armarego 
and Chai156 except where otherwise noted in the experimental text.  All non-aqueous reactions were 
performed in oven-dried apparatus under argon or nitrogen atmospheres, using distilled anhydrous 
solvents, at rt unless otherwise indicated. CH2Cl2, acetonitrile and methanol were distilled from calcium 
hydride and stored under an argon atmosphere. THF was distilled from potassium wire/benzophenone 
ketyl radical under an argon atmosphere. Et2O was distilled from sodium wire/benzophenone ketyl 
radical under an argon atmosphere. 
 
2,6-lutidine, Et3N, DIPA and DIPEA were distilled from calcium hydride or calcium chloride and stored 
under an argon atmosphere. DMSO and DMF were distilled from MgSO4 and stored over 4Å MS. DDQ 
was recrystallised from chloroform and proton sponge recrystallised from EtOH. TFA and oxalyl chloride 
were distilled. All solvents used in extraction and chromatography were distilled. The use of ammonium 
chloride (NH4Cl), sodium bicarbonate (NaHCO3), sodium thiosulfate (Na2S2O3), brine (NaCl) and sodium 
/ potassium (Na / K) tartrate refers to saturated aqueous solutions unless otherwise stated. 4Å MS were 
activated by heating under high vacuum or in a microwave. Ba(OH)2 was prepared by heating 
Ba(OH)2·8H2O at 150 °C overnight under high vacuum before being stored in a glove box.  
 
 
6.2 Analytical Procedures 
 
Flash column chromatography was performed according to the method described by Still, Kahn and 
Mitra,157 using a positive solvent pressure, with silica gel obtained from Merck Kieselgel 60 (230-400 
mesh). 
 
Reactions were monitored by TLC using pre-coated glass-backed plates (Merck Kieselgel 60 with 
fluorescent indicator UV254). Spots were visualised by quenching of UV fluorescence and staining with 
potassium permanganate or phosphomolybdic acid / Ce2(SO4)3, ninhydrin, anisaldehyde or vanillin dips.  
 
NMR spectra were recorded using an internal deuterium lock for the residual protons in CDCl3 (δH 7.26) 
at ambient probe temperatures on the following instruments: Bruker AVANCE BB 500, AVANCE TCI 
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cryoprobe (500 MHz) or AVANCE DRX 400 (400 MHz). Proton data are presented in the following way: 
chemical shift (in ppm on a δ-scale relative to δTMS = 0), integration, multiplicity (s = singlet, d = doublet, 
t = triplet, q = quartet, quint = quintet, br = broad, app = apparent), coupling constants (J / Hz) and 
assignment. Assignments were determined either on the basis of unambiguous chemical shift or 
coupling patterns, 2D NMR experiments, or by analogy to fully interpreted spectra for structurally 
related compounds. Protons of OH groups are missing in some spectra due to proton exchange. 13C 
spectra were recorded by broadband proton spin decoupling, at ambient probe temperatures on the 
following instruments: Bruker AVANCE BB 500 and AVANCE TCI 500 (125.7 MHz), using an internal 
deuterium lock for CDCl3 (δC 77.0). Chemical shifts are given in ppm on a δ-scale relative to δTMS = 0. 
Signals are assigned according to the numbering scheme for patellazole B (Figure 1), unless otherwise 
indicated. Signals for non-patellazole related compounds are denoted by a prime, e.g. H-1’. 
Optical rotations were recorded on a Perkin Elmer 241 polarimeter at the sodium D-line (589 nm) 
using a 10 cm path length cell and are reported as follows: [∝]𝐷20 concentration (c in g / 100 mL) and 
solvent.  
 
High and low resolution mass spectra were recorded by the EPSRC Mass Spectrometry facility (Swansea, 
UK), using chemical ionisation (CI), electron impact (EI) or electron spray ionisation (ESI) techniques. The 
parent ion [M]+, [M+H]+, [M-H]+, [M+NH4]+ or [M+Na]+ is quoted. High resolution values are calculated 
to 4 decimal places from the molecular formula. 
 
HPLC analysis was carried out on an Agilent 1200 series running in normal phase under UV detection 
using a ZO2RBAX RX-SIL (150 mm x 4.6 mm ID) as the analytical column. Chiral analysis was carried out 
using a DAICEL CHIRALPAK-IA, IB, IC (250 mm x 4.6 mm ID). 
 
Fourier transform IR spectra were recorded on a Perkin-Elmer Spectrum One FT-IR spectrometer with 
the sample being prepared as a thin film on a universal ATR sampling accessory. Wavelengths of 
maximum absorbance (νmax) are quoted in cm-1. Only selected, characteristic IR absorption data are 
provided for each compound. 
 
GC analysis was performed using a 6890N Network GC system (Agilent Technologies Inc., Palo Alto, CA, 
-1USA), equipped with a Varian CP7502, CHIRASIL DEX CB (25.0 m x 250 μm x 0.25 μL nominal) capilliary 
column. The GC analyses were carried out in split mode (ratio 50:1) using helium as a carrier gas at a 
flow rate of 134 mL min-1 25.00 psi. The injection port temperature was 250 °C, using H2 flow at 40.00 
mL min-1 , air at 450 mL min-1 and helium makeup flow at 45.0 mL min-1. 
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6.3 Preparation of Reagents 
Dicyclohexylboron chloride 
 
To a solution of freshly distilled cyclohexene (40.0 mL, 400 mmol, 2.0 equiv.) in Et2O (250 mL) at   ̶ 10 °C 
was added chloroborane dimethylsulfide complex (20.6 mL, 200 mmol, 1.0 equiv.) dropwise over 30 
mins. The rate of addition was limited to control the exotherm generated. The reaction mixture was 
allowed to warm to 0 °C and stirred for 1 hour, then warmed to rt and stirred for a further hour. The 
solvent was removed by distillation at atmospheric pressure and then distillation under reduced 
pressure gave the reagent as a colourless liquid, b.p. 96 °C @ 0.3 mmHg.  
 
Dibutylboron trifluoromethanesulfonate (n-Bu2BOTf) 
 
In a strictly moisture excluded environment, fresh trifluoromethanesulfonic acid (5.0 g, 33.3 mmol, 1.9 
equiv.) was added dropwise over 15 min to tributylborane (8.5 mL, 34.9 mmol, 1.05 equiv.) while 
vigorous stirring and a cold water bath were used to control the exotherm observed. Following the 
addition of the tributylborane, the mixture was stirred at 0 °C for 30 min then warmed to rt and stirred 
for a further 1 h. Direct distillation under reduced pressure (39 °C, 0.05 mmHg) yield dibutylboron 
trifluoromethanesulfonate as a colourless liquid.  
 
para-Methoxybenzyl trichloroacetimidate 
 
To a stirring solution of KOH (150 mg, 3.13 mol, 12.1 equiv.), para-methoxybenzyl alcohol (35.4 g, 256 
mmol, 1.0 equiv.) and tetra-n-butylammonium hydrogensulfate (870 mg, 2.56  
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mmol, 0.1 equiv.) in CH2Cl2 (300 mL) and H2O (300 mL) at   ̶10 °C was added trichloroacetonitrile (29.6 
mL, 294 mmol, 1.15 equiv.) dropwise over 30 mins. The reaction mixture was allowed to warm to rt over 
30 mins and then stirred for a further 90 mins. The layers were then separated and the aqueous layer 
was extracted with Et2O (3 x 300 mL). Combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The crude material was purified by flash column chromatography (Al2O3) to give 
the title compound as a colourless liquid (50.1 g, 77%).  
 
i-Propylmagnesium chloride solution 
 
To a suspension of magnesium turnings (12.5 g, 520 mmol, 1.1 equiv.) and iodine (5 pellets) in Et2O (155 
mL) was added 2-chloropropane (40.1 mL, 473 mmol, 1.0 equiv.) dropwise. When the addition was 
complete, the reaction mixture was refluxed for a further 45 min before cooling to rt to give the i-
propylmagnesium chloride as a dark grey solution (approx. 3 M in Et2O, 473 mmol). 
 
Ethylmagnesium bromide solution 
To a suspension of magnesium turnings (1.11 g, 46.2 mmol, 1.1 equiv.) and iodine (1 pellet) in Et2O (42 
mL) was added bromoethane (3.14 mL, 42.0 mmol, 1.0 equiv.) dropwise. When the addition was 
complete, the reaction mixture was refluxed for a further 45 min before cooling to rt to give the 
ethylmagnesium bromide as a dark grey solution (approx. 1 M in Et2O, 42 mmol). 
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6.4 Experimental Procedures 
 
6.4.1 Preparation of the C1-C12 Vinyl Iodide 
 
3-Methylbut-3-en-1-yl benzoate (51) 
 
 
To a solution of 3-methyl-but-3-en-1-ol (2.54 mL, 25.0 mmol, 1.0 equiv.) in CH2Cl2 (35 mL) at 0 °C were 
added benzoic anhydride (7.90 g, 35.0 mmol, 1.4 equiv.) and Et3N (7.04 mL, 50.0 mmol, 2.0 equiv.) The 
reaction mixture was stirred at rt for 4 h. Further CH2Cl2 (10 mL) was added and the reaction quenched 
with HCl (10% aq, 2 x 30 mL). The layers were separated and the aqueous extracted with CH2Cl2 (2 x 10 
mL). The combined organic layers were washed with NaHCO3 (30 mL) and brine (30 mL), dried over 
MgSO4 and concentrated in vacuo. The crude material was purified by flash column chromatography 
(9:1 PE/EtOAc) to give the title compound as a colourless oil (3.90 g, 82 %). 
 
Rf 0.35 (8:1 PE/EtOAc); 
1H NMR (400 MHz, CDCl3): δH 8.06 (2H, d, J = 7.3 Hz, H-Ar), 7.57 (1H, t, J = 7.3 Hz, 
H-Ar), 7.45 (2H, t, J = 7.3 Hz, H-Ar), 4.84 (1H, s, H-1a), 4.81 (1H, s, H-1b), 4.44 (2H, t, J = 6.7 Hz, H-4), 2.48 
(2H, t, J = 6.7 Hz, H-3), 1.40 (3H, s, Me-2); 13C NMR (100 MHz, CDCl3) δC 116.6, 141.7, 132.9, 130.3, 129.6, 
128.4, 112.5, 63.1, 36.8, 22.6.  
Data in agreement with literature values.158 
 
 
(R)-3,4-Dihydroxy-3-methylbutyl benzoate (56) 
 
 
To a stirred solution of K2OsO2(OH)4, (0.2 mg, 0.00052 mmol, 0.002 equiv.), (DHQ)2AQN (2.2 mg, 0.0026 
mmol, 0.01 equiv.), K2CO3 (107 mg, 0.78 mmol, 3.0 equiv.) and K3Fe(CN)6 (255 mg, 0.78 mmol, 3.0 equiv.) 
in tBuOH/water (1:1, 3 mL) was added alkene 51 (50.0 mg, 0.26 mmol, 1.0 equiv.) and the reaction 
mixture stirred at   ̶̶ 7 °C for 16 h. The reaction was quenched with Na2S2O3 (5 mL) and the layers 
separated. The aqueous layer was extracted with EtOAc (3 x 5 mL). Combined organic layers were 
washed with NaOH (2 M, 2 x 10 mL), dried over MgSO4 and the solvent removed in vacuo. The crude 
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material was purified by flash column chromatography (4:1 → 1:2 PE/EtOAc) to give the title compound 
as a pale-yellow oil (55 mg, 93% yield, 86 ee%)  
 
Rf 0.16 (1:2 PE/EtOAc); 1H NMR (400 MHz, CDCl3): δH 8.00 (2H, dd, J = 8.3 Hz, 1.2 Hz, H-Ar), 7.53 (1H, tt, 
J = 7.3, 1.2 Hz, H-Ar), 7.41 (2H, t, J = 7.9 Hz, H-Ar), 4.49 (2H, t, J = 7.05 Hz, H-4), 3.54 (1H, dd, J = 11.2, 5.1 
Hz, H-1a), 3.48 (1H, dd, J = 11.2, 5.1 Hz, H-1b), 2.96 (1H, t, J = 5.1 Hz, H-3a), 2.93 (1H, s, OH), 2.07 - 2.01 
(1H, m, H-3b), 1.26 (3H, s, Me-2). 13C NMR (100 MHz, CDCl3) δC 166.8, 133.1, 130.1, 129.5, 128.5, 72.1, 
69.9, 61.6, 37.0, 23.7; (CHIRALPAK IA, 14 mL/min, 10% IPA/hexanes, Rt 13.18 min, 13.86 min (major). 
Data in agreement with literature values.159 
 
(S)-2-(2,2,4-Trimethyl-1,3-dioxolan-4-yl)ethyl benzoate (49) 
 
 
To a solution of  56 (73.0 mg, 0.45 mmol, 1.0 equiv.) in CH2Cl2 (5 mL) was added 2,2-dimethoxypropane  
(1.09 mL, 8.93 mmol, 20 equiv.) and PPTS (22.6 mg, 0.09 mmol, 0.2 equiv.) and the reaction stirred at rt 
for 60 min. The reaction mixture was quenched with NaHCO3 (5 mL),  the layers separated and aqueous 
layer extracted with CH2Cl2 (3 x 5 mL). Combined organic layers were dried over MgSO4 and the solvent 
removed in vacuo. The crude product was purified by flash column chromatography (4:1 PE/EtOAc) to 
give the title compound as a pale yellow oil (78.1 mg, 99%) 
 
Rf 0.28 (3:1 PE/EtOAc); [𝛼]𝐷20 + 3.48 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 2984, 1720, 1602, 1453, 
1379, 1316, 1275, 1115, 1071, 1029, 972, 820, 716, 680; 1H NMR (400 MHz, CDCl3): δH 8.01 (2H, d, J = 
7.5 Hz, H-Ar), 7.53 (1H, t, J = 7.5 Hz, H-Ar), 7.41 (2H, t, J = 7.5 Hz, H-Ar), 4.51-4.38 (2H, m, H-4), 3.90 (1H, 
d, J = 8.4 Hz, H-1a), 3.75 (1H, d, J = 8.4 Hz, H-1b), 2.06-2.02 (2H, m, H-3), 1.39 (6H, s, H-5a, H-5b), 1.36 
(3H, s, Me-2); 13C NMR (100 MHz, CDCl3): δC 166.3, 132.3, 130.2, 129.4, 128.3, 109.2, 79.6, 74.3, 61.5, 
38.3, 27.0, 24.9; HRMS (ES+): calc. for C15H21O4 [M+H]+ 265.1434, found 265.1435. 
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 (R)-2-(2,2,4-Trimethyl-1,3-dioxolan-4-yl)ethan-1-ol (61) 
 
 
To a solution of 49 (200 mg, 0.76 mmol, 1.0 equiv.) in MeOH (8 mL) was added K2CO3 (261 mg, 1.89 
mmol, 2.5 equiv.) and stirred at rt for 2 h. The reaction mixture was quenched with NaHCO3 (10 mL), 
the layers separated and the aqueous layer extracted with CH2Cl2 (3 x 6 mL). Combined organic layers 
were dried over MgSO4 and the solvent removed in vacuo. The crude material was purified by flash 
column chromatography (3:1 PE30-40 /Et2O) to give the title compound as a colourless oil (106 mg, 88 %) 
 
Rf 0.21 (3:1 PE/EtOAc);  1H NMR (500 MHz, CDCl3): δH  3.91-3.86 (1H, m, H-4a), 3.84 (1H, d, J = 8.5 Hz, H-
1), 3.78-3.73 (1H, m, H-4b), 3.77 (1H, d, J = 8.5 Hz, H-1), 1.94-1.89 (1H, m, H-3a), 1.76-1.71 (1H, m, H-
3b), 1.42 (3H, s, H-5a), 1.41 (3H, s, H-5b), 1.34 (3H, s, Me-2); 13C NMR (125 MHz, CDCl3): δC 109.4, 81.2, 
74.5, 59.3, 41.0, 27.0, 26.8, 24.9.  
Data in agreement with literature values.160 
 
(11bS)-N,N-Bis((S)-1-phenylethyl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine (58) 
 
To a stirred mixture of Et3Npph3 (0.31 mL, 2.22 mmol, 5.0 equiv.) and PCl3 (39 µL, 0.44 mmol, 1.0 equiv.) 
at 0 °C was added a solution of Bis-[(S)-1-phenylethyl]amine (100 µL, 0.44 mmol, 1.0 equiv.) in THF (0.5 
mL). The reaction mixture was stirred at rt for 3 h, cooled to 0 °C and a solution of (R)-2,2´-binapthol 
(127 mg, 0.44 mmol, 1.0 equiv.) in THF (1.2 mL) slowly added. The reaction mixture was then stirred for 
16 h at rt, before being diluted with toluene (5 mL), filtered through a short pad of alumina and the 
solvent removed in vacuo. The crude material was purified by flash column chromatography (Al2O3, 
Toluene) to give the title compound as an off-white solid (136 mg, 57%). 
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Rf 0.85 (Al2O3, Toluene); 1H NMR (500 MHz, CDCl3): δH 7.94 (2H, d, J = 8.9 Hz, H-Ar), 7.92-7.88 (2H, m, H-
Ar), 7.59 (1H, d, J = 8.9 Hz, H-Ar), 7.43 (1H, d, J = 8.9 Hz, H-Ar), 7.41-7.39 (2H, m, H-Ar), 7.30-7.24 (4H, 
m, H-Ar), 7.14-7.09 (1H, m, H-Ar), 4.54 – 4.45 (2H, m, CH(Ph)CH3, 1.74 (6H, d, J = 7.1 Hz, CH3); 13C NMR 
(125 MHz, CDCl3): δC  150.3, 149.8, 142.9, 132.6, 131.3, 130.5, 129.3, 128.3, 128.0, 127.9, 127.8, 127.2, 
126.7, 126.1, 124.7, 122.3, 52.4, 21.7.  
Data in agreement with literature values.161 
 
3-Methyl-4-oxononanal (60) 
 
 
To a solution of acid-washed magnesium (232 mg, 9.60 mmol, 2.0 equiv.) and iodine (2 crystals) in Et2O 
(0.5 mL) was added hexyl iodide (0.72 mL, 4.80 mmol, 1.0 equiv.) in Et2O (4.5 mL) and gently heated to 
initiate Grignard reagent formation. The reaction mixture was refluxed at 45 °C for 2 h to produce a 
solution of hexyl magnesium iodide (0.96 M in Et2O). To a solution of copper thiophene carboxylate (9.5 
mg, 0.05 mmol, 0.05 equiv.) in CH2Cl2 (4 mL) was added phosphoramidite ligand 58 (23.0 mg, 0.055 
mmol, 0.055 equiv.) and the solution stirred at rt for 30 min. Concurrently, crotonaldehyde (82 µL, 1.00 
mmol, 1.0 equiv.), freshly distilled from CaCl2, was added dropwise to a solution of acetyl chloride (76 
µL, 1.00 mmol, 1.0 equiv.) and freshly fused ZnCl2 (2.0 mg, 0.015 mmol, 0.015 equiv.) in CH2Cl2 (2 mL) at 
  ̶  10 °C. The resulting solution was then added to the catalyst solution, at   ̶78 °C. After stirring for 5 min 
at   ̶78 °C, the Grignard solution (1.15 mL, 1.20 mmol, 1.2 equiv., diluted with CH2Cl2 (1.4 mL)) was added 
dropwise over 6 h via syringe pump. Upon completion of the addition, the reaction mixture was stirred 
for a further 4 h at   ̶78 °C before being quenched with NH4Cl (4 mL) and warmed to rt. The solution was 
then diluted with Et2O and the layers separated. The aqueous layer was extracted with Et2O (3 x 10 mL), 
combined organic layers dried over Na2SO4 and the solvent removed in vacuo. The crude material, 
isolated as the enol acetate, was purified by flash column chromatography (80:1 PE/EtOAc). The clean 
enol acetate was dissolved in MeOH (10 mL) and K2CO3 (256 mg, 1.85 mmol, 5.0 equiv.) at rt for 1 h. The 
solvent was removed in vacuo, water (5 mL) added and the mixture extracted with Et2O (3 x 5 mL). 
Combined organic layers were dried over MgSO4 and concentrated in vacuo to give the title compound 
as a colourless oil (39.0 mg, 25%).  
 
Rf 0.32 (60:1 PE/EtOAc); 1H NMR (400 MHz, CDCl3): δH 9.77 (1H, t, J = 2.4 Hz, CHO), 2.40 (1H, ddd, J = 
15.9, 5.8, 2.2 Hz, H-2’), 2.23 (1H, ddd, J = 15.9, 7.9, 2.6 Hz, H-2’), 2.09-2.02 (1H, m, H-3’), 1.31-1.24 (10H, 
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m, H4’-8’), 0.97 (3H, d, J = 6.8 Hz, Me-3’), 0.89 (3H, t, J = 1.85 Hz, H-9’); 13C NMR (125 MHz, CDCl3): δC 
203.0, 51.0, 36.8, 31.7, 29.3, 28.1, 26.8, 22.5, 19.9, 14.0.  
Data in agreement with literature values.162  
 
 
4-Bromo-2-methylbut-1-ene (62) 
 
To a solution of 3-methyl-3-butene-1-ol (1.18 mL, 11.6 mmol, 1.0 equiv.) in CH2Cl2 (30 mL) at 0 °C was 
added PPh3 (3.36 g, 12.8 mmol, 1.1 equiv.) followed by NBS (2.28 g, 12.8 mmol, 1.1 equiv.) in 10 portions. 
The reaction mixture warmed to rt and stirred for 4 h, before addition of PE (8 mL). The suspension was 
filtered through a short plug of silica, washed with further PE (20 mL) and the solvent removed in vacuo. 
The crude material was purified by flash column chromatography (8:1 PE/EtOAc) to give the title 
compound as a colourless oil (533 mg, 57%). 
 
Rf 0.28 (8:1 PE/EtOAc); 1H NMR (400 MHz, CDCl3): δH 4.87 (1H, s, H-1a), 4.78 (1H, s, H-1b), 3.48 (2H, t, J 
= 7.4 Hz, H-4), 2.59 (2H, t, J = 7.4 Hz, H-3), 1.76 (3H, s, Me-2); 13C NMR (125 MHz, CDCl3): δC 142.3, 112.6, 
40.8, 30.7, 21.9. 
Data in agreement with literature values.163  
 
 
(S)-tert-Butyldimethyl((2-methyloxiran-2-yl)methoxy)silane (66) 
 
To activated powdered 3Å MS (1.50 g), were added CH2Cl2 (50 mL), D-(  ̶)-diisopropyltartrate (0.13 mL, 
0.60 mmol, 0.06 equiv.) and methallyl alcohol (0.84 mL, 10.0 mmol, 1.0 equiv.) at    ̶ 20 °C. After stirring 
for 5 min, Ti(OiPr)4 (0.15 mL, 0.50 mmol, 0.05 equiv.) was added and the reaction mixture stirred for a 
further 30 min. Cumene hydroperoxide (80% in cumeme, 3.60 mL, 20.0 mmol, 2.0 equiv.) was then 
added and the reaction flask placed in a freezer at   ̶ 20 °C for 16 h. The excess peroxide was quenched 
with the dropwise addition of P(OEt)3 (2.56 mL, 15.0 mmol, 1.5 equiv.) at   ̶20 °C over 1 h, before Et3N 
(2.14 mL, 15.0 mmol, 1.5 equiv.), DMAP (60.5 mg, 0.50 mmol, 0.05 equiv.) and TBSCl  (2.26 g, 15.0 mmol, 
1.5 equiv.) were added and the reaction stirred for a further h at 0 °C. Upon completion, the reaction 
mixture was filtered through Celite®. The filtrate was then washed with tartaric acid (10% aq, 20 mL). 
The layers were separated and the organic layer further washed with NaHCO3 (2 x 10 mL) and brine (2 
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 x 10 mL), before being dried over Na2SO4 and the solvent removed in vacuo. The crude material was 
purified by flash column chromatography (20:1 PE30-40 / Et2O) to give the title compound as a colourless 
oil (1.42 g, 70%).   
 
Rf 0.25 (9:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 3.68 (1H, d, J = 11.2 Hz, H-1a), 3.62 (1H, d, J = 11.2 
Hz, H-1b), 2.77 (1H, d, J = 5.0 Hz, H-3a), 2.62 (1H, d,  J = 5.0 Hz, H-3b), 1.37 (3H, s, Me-2), 0.92 (9H, s, 
SiC(CH3)3, 0.09 (3H, s, Si(CHa3)(CHb3)), 0.08 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC  66.4, 
57.0, 51.4, 25.7, 18.2, 17.9,   ̶ 5.5.  
Data in agreement with literature values.164 
 
 
 (R)-(2-Methyloxiran-2-yl)methanol (77)  
 
 
To a suspension of activated 4Å MS (22.0 mg, 30 wt%) in CH2Cl2 (3.5 mL) at   ̶ 30  °C were added Ti(OiPr)4 
(0.29 mL, 1.00 mmol, 1.0 equiv.) and D (  ̶ )-Diethyltartrate (246 mg, 1.20 mmol, 1.2 equiv.) and the 
reaction mixture stirred for 30 min. Methallyl alcohol (84 µL, 1.00 mmol, 1.0 equiv.) was then added and 
the reaction stirred for a further 30 min. tert-Butylhydroperoxide (5.5 M in decane, 0.55 mL, 3.00 mmol, 
3.0 equiv.) was then added, stirred for 5 min and the reaction flask placed in a freezer at   ̶ 20 °C for 16 
h. The reaction mixture was recooled to   ̶  30 °C and quenched with a solution of FeSO4 (2.46 g, 9.00 
mmol, 9.0 equiv.) and tartaric acid (432 mg, 3.00 mmol, 3.0 equiv.) in water (2 mL) and slowly warmed 
to rt. The layers were separated and the organic layer washed with Na2S2O3 (2 x 4 mL). The organic layer 
was dried over Na2SO4 and the solvent removed carefully in vacuo. The crude material was purified by 
flash column chromatography (2:1 PE30-40 /Et2O o 100% Et2O) to give the title compound as a colourless 
oil (10 mg, 11%) 
 
Rf 0.35 (2:1 PE/EtOAc); 1H NMR (400 MHz, CDCl3): δH 3.73 (1H, d, J = 12.3 Hz, H-1a), 3.61 (1H, d, J = 12.3 
Hz, H-1b), 2.92 (1H, d, J = 4.8 Hz, H-3a), 2.65 (1H, d, J = 4.8 Hz, H-3b), 1.36 (3H, s, Me-2).  
Data in agreement with literature values.165 
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(S)-(2-Methyloxiran-2-yl)methyl benzoate   
 
Procedure A:  
To a solution of alcohol 77 (88.0 mg, 1.00 mmol, 1.0 equiv.) in CH2Cl2 (8 mL) under argon at 0 °C was 
added benzoic anhydride (316 mg, 1.40 mmol, 1.4 equiv.) and Et3N (0.39 mL, 2.00 mmol, 2.0 equiv.) The 
reaction mixture was stirred at rt for 4 h and then quenched with HCl (6 mL, 1 M aq). The layers were 
separated and the aqueous extracted with CH2Cl2 (2 x 5 mL). Combined organic layers were washed with 
NaHCO3 (10 mL) and brine (10 mL) before being dried over MgSO4 and concentrated in vacuo. The crude 
material was purified by flash column chromatography (6:1 PE/EtOAc) to give the title compound as a 
colourless oil (159 mg, 84 %)  
 
Procedure B:  
To activated powdered 3Å MS (0.80 g), was added CH2Cl2 (25 mL), D ( )̶ diisopropyl tartrate (60 µL, 0.297 
mmol, 0.0595 equiv.) and methallyl alcohol (0.42 mL, 5.00 mmol, 1.0 equiv.) at    ̶ 20 °C. After stirring for 
5 min, Ti(OiPr)4 (74 µL, 0.25 mmol, 0.05 equiv.) was added and the reaction stirred for a further 30 min. 
Cumene hydroperoxide (80% in cumene, 1.8 mL, 10.0 mmol, 2.0 equiv.) was then added and the 
reaction placed in a freezer at   ̶ 20 °C for 16 h. The excess peroxide was quenched with the portionwise 
addition of P(OEt)3 (1.28 mL, 7.50 mmol, 1.5 equiv.) at   ̶ 20 °C over 1 h, before Et3N (1.04 mL, 7.50 mmol, 
1.5 equiv.) and benzoyl chloride (0.87 mL, 7.50 mmol, 1.5 equiv.) were added and the reaction mixture 
stirred for a further 1 h at 0 °C. The reaction mixture was then filtered through Celite® and the filtrate 
washed with tartaric acid (10% aq, 20 mL). The layers were separated and the organic layer washed with 
NaHCO3 (2 x 10 mL) and brine (2 x 10 mL), before being dried over Na2SO4 and the solvent removed in 
vacuo. The crude material was purified by flash column chromatography (20:1 PE/ EtOAc) to give the 
title compound (710 mg, 74% yield, 95% ee (CHIRALPAK IA, 14 mL/min, 0.5% IPA/hexanes, Rt 9.30 min 
(major), 10.06 min). 
 
Rf 0.35 (2:1 PE/Et2O); [𝛼]𝐷20 + 18.4 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 2989, 1720, 1602, 1451, 1270, 
1115, 1071, 1027, 979, 815, 710, 687; HRMS (ES+): calc. for C11H12O3 [M+H]+ 193.0859, found 193.0856; 
1H NMR (500 MHz, CDCl3): δH 8.01 (2H, dd, J = 8.3, 1.5 Hz, H-Ar), 7.55 (1H, tt, J = 7.5, 1.5 Hz, H-Ar), 7.43 
(2H, dd, J = 8.3, 7.5 Hz, H-Ar), 4.52 (1H, d, J = 12.0 Hz, H-1a), 4.24 (1H, d, J = 12.0 Hz, H-1b), 2.89 (1H, d, 
J = 4.8 Hz, H-3a), 2.75 (1H, d, J = 4.8 Hz, H-3b), 1.50 (3H, s, Me-2); 13C NMR (125 MHz, CDCl3): δC 165.9, 
133.1, 129.5, 128.8, 128.3, 67.5, 54.8, 51.7, 18.4.           
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 (S)-4-(But-3-en-1-yl)-2,2,4,7,7,8,8-heptamethyl-3,6-dioxa-2,7-disilanonane (67) 
 
 
To a solution of secondary alcohol 86 (1.00 g, 4.34 mmol, 1.0 equiv.) in CH2Cl2 (40 mL) were added 
imidazole (443 mg, 6.51 mmol, 1.5 equiv.), DMAP (23.9 mg, 0.22 mmol, 0.05 equiv.) and 
chlorotrimethylsilane (0.66 mL, 5.21 mmol, 1.2 equiv.). The reaction mixture was stirred at rt for 2 h 
before being quenched with NH4Cl (20 mL). The layers were separated, the aqueous layer extracted with 
Et2O (3 x 10 mL) and combined organic layers dried over MgSO4. The solvent was removed in vacuo. The 
crude material was purified by flash column chromatography (25:1 PE/EtOAc) to give the title compound 
as a colourless oil (830 mg, 64%) 
 
Rf 0.45 (10:1 PE/EtOAc); [𝛼]𝐷20 + 13.2 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 2956, 2931, 1642, 1472, 
1250, 1100, 1026, 908, 825, 774, 752, 666; 1H NMR (400 MHz, CDCl3): δH  5.90-5.80 (1H, m, H-5), 5.04-
4.91 (2H, m, H-6), 3.42 (1H, d, J = 9.7 Hz, H-1a), 3.33 (1H, d, J = 9.7 Hz, H-1b), 2.12-2.06 (2H, m, H-4), 
1.63-1.57 (1H, m, H-3a), 1.53-1.45 (1H, m, H-3b), 1.19 (3H, s, Me-2), 0.90 (9H, s, SiC(CH3)3), 0.11 (9H, s, 
Si(CH3)3), 0.05 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC  139.4, 113.6, 76.1, 70.0, 38.3, 27.9, 25.8, 
25.0, 18.2, 2.5, - 5.6; HRMS (ES+): calc. for C16H36O2Si2 [M+H]+ 317.2327, found 317.2328. 
 
 
 
(S)-5-((tert-Butyldimethylsilyl)oxy)-4-methyl-4-((trimethylsilyl)oxy)pentanal (85) 
 
 
To a solution of alkene 67 (35.0 mg, 0.11 mmol, 1.0 equiv.) in CH2Cl2 (2 mL) at    ̶78 °C was bubbled ozone 
until the solution turned blue. The ozone stream was then replaced with oxygen until the solution 
returned to colourless. The reaction mixture was quenched with PPh3 (43.5 mg, 0.16 mmol, 1.5 equiv.) 
and slowly warmed to rt. The solvent was them removed in vacuo to give the crude product, which was 
purified by flash column chromatography (25:1 PE/ EtOAc) to give the title compound as a colourless oil 
(33.6 mg, 95%). 
Rf 0.45 (10:1 PE/EtOAc); [𝛼]𝐷20 + 18.5 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 2955, 1727, 1472, 1250, 
1099, 1058, 832, 775, 666, 542; 1H NMR (400 MHz, CDCl3): δH  9.75 (1H, t, J = 2.0 Hz, H-5), 3.41 (1H, d, J 
= 9.6 Hz, H-1a), 3.35 (1H, d, J = 9.6 Hz, H-1b), 2.47-2.42 (2H, m, H-4), 1.89 (1H, dt, J = 14.1, 7.2 Hz, H- 
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3a), 1.76 (1H, dt, J = 14.1, 7.5 Hz, H-3b), 1.22 (3H, s, Me-2), 0.90 (9H, s, SiMe2C(CH3)3, 0.10 (9H, s, 
Si(CH3)3), 0.05 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC 203.0, 75.6, 69.7, 38.7, 31.9, 25.7, 24.9, 
18.1, 2.3,   ̶ 5.6; HRMS (ES+): calc. for C15H34O3Si2 [M+Na]+ 341.1939, found 341.1937.  
 
 
Ethyl (S,E)-7-((tert-butyldimethylsilyl)oxy)-6-methyl-6-((trimethylsilyl)oxy)hept-2-enoate (68) 
 
 
To a slurry of Ba(OH)2 (31.9 mg, 0.19 mmol, 1.8 equiv.) in THF (0.5 mL) at rt was added 
triethylphosphonoacetate (31 µL, 0.16 mmol, 1.5 equiv.) and the mixture stirred at rt for 45 min. A 
solution of aldehyde 85 (33.0 mg, 0.10 mmol, 1.0 equiv.) in THF: H2O (40:1, 0.5 mL) was then added and 
the reaction mixture stirred at rt for 16 h before being quenched with NH4Cl (1 mL). The aqueous layer 
was extracted with Et2O (3 x 2 mL) and the combined organic layers were dried with MgSO4 before the 
solvent was removed in vacuo. The crude material was purified by flash column chromatography (20:1 
PE/EtOAc) to give the title compound as a colourless oil (32.3 mg, 80%). 
 
Rf 0.51 (4:1 PE/EtOAc); [𝛼]𝐷20 + 9.3 (c 1.00, CHCl3; IR (thin film, νmax/cm-1): 2956, 2859, 1723, 1654, 1473, 
1367, 1252, 1101, 1044, 978, 820, 776; 1H NMR (400 MHz, CDCl3): δH  7.01 (1H, dt, J = 15.7, 6.9 Hz, H-5), 
5.82 (1H, d, J = 15.7 Hz, H-6), 4.19 (2H, q, J = 7.1 Hz, OCH2CH3), 3.41 (1H, d, J = 9.6 Hz, H-1a), 3.32 (1H, d, 
J = 9.6 Hz, H-1b), 2.31-2.19 (2H, m, H-4), 1.70-1.62 (1H, m, H-3a), 1.55-1.49 (1H, m, H-3b), 1.29 (3H, t, J 
= 7.1 Hz, OCH2CH3), 1.20 (3H, s, Me-2), 0.90 (9H, s, SiC(CH3)3), 0.11 (9H, s, Si(CH3)3), 0.05 (6H, s, Si(CH3)2); 
13C NMR (125 MHz, CDCl3): δC 166.7, 150.0, 120.7, 75.8, 69.7, 60.0, 37.3, 26.6, 25.8, 25.1, 18.2, 14.2, 2.4, 
  ̶ 5.6; HRMS (ES+): calc. for C19H40O4Si2 [M+H]+ 411.2357, found 411.2352 
 
 (S)-1-((tert-Butyldimethylsilyl)oxy)-2-methylhex-5-en-2-ol (86) 
 
 
To a solution of CuI (140 mg, 0.74 mmol, 0.1 equiv.) in THF (80 mL) at 0 °C was added allyl magnesium 
chloride (1.7 M in THF, 17.5 mL, 29.7 mmol, 4.0 equiv.) dropwise. A solution of epoxide 66 (1.49 g, 7.40 
mmol, 1.0 equiv.) in Et2O (1 mL) was then added and the reaction mixture stirred for 2 h. The reaction 
mixture was quenched with NH4Cl (50 mL), the layers separated and the aqueous layer extracted with 
Et2O (3 x 15 mL). Combined organic layers were dried over MgSO4 and the solvent removed in vacuo.   
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The crude material was purified by flash column chromatography (10:1 PE30-40/Et2O) to give the title 
compound as a colourless oil (1.47 g, 81%) 
 
Rf 0.25 (8:1 PE/EtOAc); [𝛼]𝐷20 + 19.4 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 3747, 2960, 2331, 1275, 
1115, 935, 836, 770; 1H NMR (500 MHz, CDCl3): δH  5.92-5.82 (1H, m, H-5), 5.03 (1H, ddt, J = 17.1, 1.9, 
1.7 Hz, H-6a), 4.94 (1H, ddt, J = 10.3, 1.9, 1.4 Hz, H-6b), 3.44 (1H, d, J = 9.5 Hz, H-1a), 3.38 (1H, d, J = 9.5 
Hz, H-1b), 2.33 (1H, s, O-H), 2.19-2.05 (2H, m, H-4), 1.63-1.47 (2H, m, H-3), 1.13 (3H, s, Me-2), 0.91 (9H, 
s, SiC(CH3)3), 0.07 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC 139.0, 114.1, 72.0, 70.0, 37.6, 28.1, 
25.8, 23.0, 18.2,   ̶5.6; HRMS (ES+): calc. for C13H28O2Si [M+H]+ 267.1751, found 267.1751. 
 
1-(Benzyloxy)-2-methylhex-5-en-2-ol (91) 
 
  
To a suspension of magnesium (240 mg, 10.0 mmol, 2.0 equiv.) and iodine (2 crystals) in Et2O (2 mL) was 
added allyl chloride (0.41 mL, 5.00 mmol, 1.0 equiv.) in Et2O (13 mL) and gently heated to initiate 
Grignard formation. The reaction mixture was refluxed at 45 °C for 2 h to produce a solution of allyl 
magnesium chloride (0.25 M). To a solution of epoxide 80 (50.0 mg, 0.28 mmol, 1.0 equiv.) in THF (3 mL) 
at 0 °C was added CuI (5.7 mg, 0.03 mmol, 0.1 equiv.) and the preformed allyl magnesium chloride (0.25 
M, 4.50 mL, 1.12 mmol, 4.0 equiv.). The reaction mixture was stirred for 3 h before being quenched with 
NH4Cl (5 mL). The layers were separated and the aqueous layer extracted with Et2O (3 x 5 mL). Combined 
organic layers were dried with MgSO4 and the solvent removed in vacuo. The crude material was 
purified by flash column chromatography (8:1 PE/EtOAc) to give a 5:1 inseparable mixture of the title 
alcohol and chloride 83 as a colourless oil (55.0 mg, 4.50 mmol, 90 %).  
 
Rf 0.33 (4:1 PE/EtOAc); IR (thin film, νmax/cm-1): 3260, 2856, 1976, 1640, 1454, 1369, 1102, 910, 737, 
698; 1H NMR (500 MHz, CDCl3): δH 7.38-7.31 (5H, m, H-Ar), 5.88-5.80 (1H, m, H-5), 5.03 (1H, dq, J = 17.2, 
1.8 Hz, H-6a), 4.95 (1H, ddt, J = 10.3, 2.0, 1.2 Hz, H-6b), 4.58 (2H, s, OCH2Ar), 3.36 (1H, d, J = 9.0 Hz, H-
1a), 3.31 (1H, d, J = 9.0 Hz, H-1b), 2.24 (1H, s, O-H), 2.18-2.06 (2H, m, H-4), 1.69-1.57 (2H, m, H-3), 1.19 
(3H, s, Me-2); 13C NMR (125 MHz, CDCl3): δC  138.8, 138.0, 128.4, 128.3, 127.6, 114.2, 77.0, 73.3, 71.9, 
38.0, 28.0, 23.6. 
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3-(Benzyloxy)-2-chloro-2-methylpropan-1-ol (83) 
 
Rf 0.23 (4:1 PE/EtOAc); IR (thin film, νmax/cm-1): 3447, 2860, 1454, 1371, 1093, 1027, 911, 793, 735, 698, 
611; 1H NMR (400 MHz, CDCl3): δH 7.39-7.31 (5H, m, H-Ar), 4.59 (2H, s, CH2Ar), 3.61 (1H, d, J = 10.7 Hz, 
H-3a), 3.55 (1H, d, J = 10.7 Hz, H-3b), 3.54 (1H, d, J = 9.2 Hz, H-1a), 3.39 (1H, d, J = 9.2 Hz, H-1b), 2.54 
(1H, br s, O-H), 1.29 (3H, s, Me-2); 13C NMR (125 MHz, CDCl3): δC  137.7, 128.4, 127.8, 127.6, 73.7, 73.4, 
72.0, 50.0, 21.9; HRMS (ES+): calc. for C11H1935ClO2N [M+NH4]+ 232.1099, found 232.1100.   
 
 
 ((1-(Benzyloxy)-2-methylhex-5-en-2-yl)oxy)trimethylsilane (91b) 
 
 
To a solution of alcohol 91 (314 mg, as mixture with 83, 1.43 mmol, 1.0 equiv.) in CH2Cl2 (14 mL) at 0 °C 
was added imidazole (167 mg, 2.57 mmol, 1.8 equiv.) and chlorotrimethylsilane (0.27 mL, 2.14 mmol, 
1.5 equiv.). The reaction mixture was stirred at rt for 2 h before being quenched with NH4Cl (10 mL). 
The layers were separated and the aqueous layer extracted with Et2O (3 x 5 mL). Combined organic 
layers were dried over MgSO4 and the solvent removed in vacuo. The crude material was purified by 
flash column chromatography (10:1 PE/EtOAc) to give the title compound as a colourless oil (355 mg, 
1.22 mmol, 85%) 
 
Rf 0.34 (9:1 PE/EtOAc); IR (thin film, νmax/cm-1): 2956, 1453, 1249, 1100, 1039, 838, 751, 697, 611; 1H 
NMR (500 MHz, CDCl3): δH  7.32-7.28 (5H, m, H-Ar), 5.88-5.80 (1H, m, H-5), 5.01 (1H, dq, J = 17.2, 1.8 Hz, 
H-6a), 4.95-4.92 (1H, m, H-6b), 4.55 (2H, s, CH2Ar), 3.33 (1H, d, J = 9.0 Hz, H-1a), 3.27 (1H, d, J = 9.0 Hz, 
H-1b), 2.13-2.03 (2H, m, H-4), 1.69-1.63 (1H, m, H-3a), 1.59-1.52 (1H, m, H-3b), 1.26 (3H, s, Me-2), 0.11 
(9H, s, Si(CH3)3); 13C NMR (125 MHz, CDCl3): δC 139.3, 138.5, 128.2, 127.6, 127.5, 113.8, 77.3, 75.3, 73.3, 
38.9, 27.9, 24.0, 2.4. 
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5-(Benzyloxy)-4-methyl-4-((trimethylsilyl)oxy)pentanal (91c) 
 
 
To a solution of alkene 91b (386 mg, 1.32 mmol, 1.0 equiv.) in CH2Cl2 (30 mL) at  ̶ 78 °C was bubbled 
ozone until the solution turned blue. The ozone stream was then replaced with oxygen until the solution 
returned to colourless. The reaction mixture was quenched with PPh3 (380 mg, 1.45 mmol, 1.1 equiv.) 
and slowly warmed to rt. The solvent was removed in vacuo and the residue purified by flash column 
chromatography (15:1 PE/ EtOAc) to give the title compound as a colourless oil (70 % over 3 steps from 
80). 
 
Rf 0.23 (10:1 PE/EtOAc);  IR (thin film, νmax/cm-1): 3052, 1721, 1584, 1477, 1433, 1249, 1089, 1026, 839, 
740, 692, 541, 499; 1H NMR (400 MHz, CDCl3): δH  9.73 (1H, t, J = 2.0 Hz, H-5), 7.37 – 7.28 (5H, m, H-Ar), 
4.53 (1H, d, J = 12.1 Hz, CHaHbAr), 4.50 (1H, d, J = 12.1 Hz, CHaHbAr), 3.32 (1H, d, J = 9.0 Hz, H-1a), 3.26 
(1H, d, J = 9.0 Hz, H-1b), 2.44 (2H, td, J = 7.5, 2.0 Hz, H-4), 1.99-195 (1H, m, H-3a), 1.80 (1H, m, H-3b), 
1.27 (3H, s, Me-2), 0.09 (9H, s, Si(CH3)3; 13C NMR (125 MHz, CDCl3): δC  203.1, 149.8, 138.3, 128.4, 127.6, 
77.0, 74.9, 73.3, 38.8, 32.6, 25.5, 2.4. 
 
Ethyl (E)-7-(benzyloxy)-6-methyl-6-((trimethylsilyl)oxy)hept-2-enoate (92) 
 
 
To a slurry of Ba(OH)2 (280 mg, 1.64 mmol, 1.8 equiv.) in THF (5 mL) at rt was added 
triethylphosphonoacetate (307 mg, 1.37 mmol, 1.5 equiv.) and the mixture stirred at rt for 45 min. A 
solution of aldehyde 91c (268 mg, 0.91 mmol, 1.0 equiv.) in THF: H2O (40:1, 5 mL) was then added and 
the reaction mixture stirred at rt for 16 h before being quenched with NH4Cl (8 mL). The aqueous layer 
was extracted with Et2O (3 x 5 mL) and combined organic layers dried with MgSO4 before the solvent 
was removed in vacuo. The crude material was purified by flash column chromatography (10:1 
PE/EtOAc) to give the title compound as a colourless oil (291 mg, 0.79 mmol, 87%). 
Rf 0.51 (4:1 PE/EtOAc); IR (thin film, νmax/cm-1): 2954, 1719, 1654, 1455, 1368, 1250, 1132, 1098, 1041, 
830, 751, 698; 1H NMR (400 MHz, CDCl3): δH  7.34-7.28 (5H, m, H-Ar), 7.01 (1H, dt, J = 15.7, 6.8 Hz, H-5), 
5.82 (1H, d, J = 15.7 Hz, H-6), 4.54 (1H, d, J = 12.2 Hz, CHaHbAr), 4.51 (1H, d, J = 12.2 Hz, CHaHbAr), 4.19 
(2H, q, J = 7.20, OCH2CH3), 3.32 (1H, d, J = 9.1 Hz, H-1a), 3.25 (1H, d, J = 9.1 Hz, H-1b),  2.30-2.17  
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(2H, m, H-4), 1.77-1.71 (1H, m, H-3a), 1.62-1.56 (1H, m, H-3b), 1.29 (3H, t, J = 7.20 Hz, OCH2CH3), 1.26 
(3H, s, Me-2), 0.10 (9H, s, Si(CH3)3); 13C NMR (125 MHz, CDCl3): δC  166.6, 149.8, 138.3, 129.2, 127.5, 
127.4, 120.8, 77.0, 75.1, 73.2, 60.0, 37.9, 26.6, 25.5, 14.2, 2.4; HRMS (ES+): calc. for C20H32O4SiNa 
[M+Na]+ 387.1962, found 387.1965. 
 
Ethyl (3S)-7-(benzyloxy)-3,6-dimethyl-6-((trimethylsilyl)oxy)heptanoate (93) 
 
 
A solution of (S)-Tol-BINAP (2.8 mg, 0. 0041 mmol, 0.03 equiv.) and CuI (0.5 mg, 0.0027 mmol, 0.02 
equiv.) in TBME (0.5 mL) was stirred at rt for 10 min until a yellow suspension formed. The reaction was 
the cooled to   ̶ 20 °C and MeMgBr (3 M in Et2O, 0.23 mL, 0.69 mmol, 5.0 equiv.) was added dropwise. 
After stirring for 15 min, a solution of unsaturated ester 92 (50.0 mg, 0.14 mmol, 1.0 equiv.) in TBME 
(0.3 mL) was added dropwise over 1 h via syringe pump. The reaction mixture was then stirred for a 
further 1.5 h at   ̶20 °C before being quenched with MeOH (0.25 mL) then NH4Cl (1 mL). Once warmed 
to rt, the layers were separated and the aqueous layer extracted with Et2O (3 x 2 mL). Combined organic 
layers were dried over MgSO4 and the solvent removed in vacuo. The crude material was purified by 
flash column chromatography (8:1 PE/EtOAc) to give the title compound as a colourless oil (16.5 mg, 
0.04 mmol, 35%) along with ketone 94 (12.0 mg, 0.03 mmol, 23 %) 
 
Rf 0.34 (6:1 PE/EtOAc);  IR (thin film, νmax/cm-1): 2962, 1736, 1456, 1371, 1250, 1102, 1036, 830, 751, 
698; 1H NMR (500 MHz, CDCl3): δH  7.37-7.28 (5H, m, H-Ar), 4.53 (2H, s, CH2Ar), 4.13 (2H, q, J = 7.1 Hz, 
OCH2CH3), 3.29 (1H, d, J = 9.1 Hz, H-1a), 3.23 (1H, dd, J = 9.1, 1.6 Hz, H-1b), 2.30 (1H, ddd, J = 14.6, 5.9, 
1.5 Hz, H-6a), 2.12-2.05 (1H, m, H-6b), 1.97-1.85 (1H, m, H-5), 1.56 (3H, s, Me-2), 1.51-1.43 (4H, m, H-3, 
H-4), 1.26 (3H, t, J = 7.1 Hz, OCH2CH3), 1.22 (3H, d, J = 2.6 Hz, Me-5), 0.10 (9H, s, Si(CH3)3); 13C NMR (125 
MHz, CDCl3): δC  169.0, 138.5, 128.2, 127.4, 127.3, 75.5, 73.1, 61.0, 60.0, 37.1, 33.1, 30.4, 28.8, 25.3, 
19.7, 14.1, 2.4. 
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(4R)-8-(Benzyloxy)-4,7-dimethyl-7-((trimethylsilyl)oxy)octan-2-one (94) 
 
Rf 0.31 (6:1 PE/EtOAc); IR (thin film, νmax/cm-1): 2955, 1715, 1454, 1367, 1249, 1099, 1037, 838, 751, 
698; 1H NMR (400 MHz, CDCl3): δH  7.36-7.29 (5H, m, H-Ar), 4.53 (2H, s, H-CH2Ar), 3.29 (1H, d, J = 9.1 Hz, 
H-1a), 3.23 (1H, dd, J = 9.1, 1.6 Hz, H-1b), 2.42 (1H, dd, J = 16.0, 5.6 Hz, H-6a), 2.21 (1H, dd, J = 16.0, 8.3 
Hz, H-6b), 2.12 (3H, s, H-8), 1.99-1.90 (1H, m, H-5), 1.55-1.38 (2H, m, H-4), 1.34-1.13 (2H, m, H-3), 1.22 
(3H, d, J = 2.1 Hz, Me-2), 0.90 (3H, d, J = 6.7 Hz, Me-5), 0.10 (9H, s, Si(CH3)3); 13C NMR (125 MHz, CDCl3): 
δC  209.0, 138.5, 128.2, 127.4, 127.3, 75.5, 73.1, 51.1, 37.1, 30.5, 30.2, 29.6, 25.3, 19.8, 2.4; HRMS (ES+): 
calc. for C20H34O3Si [M+H]+ 373.2169, found 373.2165. 
 
S-Phenyl 2-(diethoxyphosphoryl)ethanethioate (88) 
 
 
To a solution of diethylphosphonoacetic acid (0.50 mL, 3.00 mmol, 1.0 equiv.) in CH2Cl2 (6 mL) at 0 °C 
was added thiophenol (0.31 mL, 3.00 mmol, 1.0 equiv.) and DMAP (37.0 mg, 0.30 mmol, 0.1 equiv.). 
DCC (0.63 g, 3.0 mmol, 1.0 equiv.) was then added portionwise and the reaction mixture stirred for 16 
h whilst slowly warming to rt. On completion, the reaction mixture was filtered through Celite®, which 
was then washed with further CH2Cl2 (10 mL). The organic filtrate was washed sequentially with Na2CO3 
(3 x 5 mL), water (2 x 5 mL) and brine (2 x 5 mL) before being dried over MgSO4 and the solvent removed 
in vacuo. The crude material was purified by flash column chromatography (3:1 PE/EtOAc → EtOAc) to 
give the title compound as a colourless oil (697 mg, 2.43 mmol, 81%) 
 
Rf 0.59 (9:1 PE/EtOAc); IR (thin film, νmax/cm-1): 1701, 1255, 1018, 994, 956, 748, 690, 582, 537, 474; 1H 
NMR (500 MHz, CDCl3): δH 7.43 (5H, s, H-Ar), 4.20 (4H, app quint., J = 7.2 Hz, CH2CH3), 3.31 (2H, d, JH-P = 
21.2 Hz, H-1’), 1.37 (6H, t, J = 7.2 Hz, CH2CH3);  13C NMR (125 MHz, CDCl3) δC 188.5, 134.3, 129.7, 129.3, 
127.2, 62.9,  42.8, 16.3; HRMS (ES+): calc. for C12H17O4PS [M+H]+ 289.0658, found 289.0658. 
 
 
 
 
 
  
  
Chapter 6: Experimental 
104 
 
S-Phenyl-(6S)-7-((tert-butyldimethylsilyl)oxy)-6-methyl-3-(phenylthio)-6-
((trimethylsilyl)oxy)heptanethioate (90) 
 
 
To a slurry of Ba(OH)2 (95.4 mg, 0.56 mmol, 1.8 equiv.) in THF (1.0 mL) at rt was added a solution of 
phosphonate 88 (135 mg, 0.47 mmol, 1.5 equiv.) in THF (0.5 mL) and the mixture stirred for 45 min. A 
solution of aldehyde 85 (100 mg, 0.31 mmol, 1.0 equiv.) in THF: H2O (40:1, 1.5 mL) was added dropwise 
and the reaction mixture stirred for a further 16 h. The reaction was quenched with NH4Cl (2 mL) and 
the organic layer extracted with Et2O (3 x 5 mL). Combined organic layers were dried over MgSO4 and 
the solvent removed in vacuo. The crude material was purified by flash column chromatography (25:1 
PE/EtOAc) to give an inseparable diastereomeric mixture of 90 and 89 in a 1:1 ratio (135 mg, 0.29 mmol, 
95%). 
 
Rf 0.59 (9:1 PE/EtOAc); IR (combined, thin film, νmax/cm-1): 2954, 1692, 1633, 1472, 1250, 1099, 1024, 
966, 834, 776, 744, 688; 1H NMR (500 MHz, CDCl3): δH 7.50-7.27 (10H, m, H-Ar), 3.65-3.59 (1H, m, H-5), 
3.42 (1H, d, J = 9.8 Hz, H-1a), 3.35 (1H, d, J = 9.6 Hz, H-1b), 2.96 (1H, dd, J = 15.4, 6.3 Hz, H-6a), 2.89 (1H, 
dd, J = 15.4, 7.6Hz, H-6b), 1.82-1.72 (2H, m, H-4), 1.67-1.62 (1H, m, H-3a), 1.59-1.53 (1H, m, H-3b), 1.21 
(3H, s, Me-2), 0.93 (9H, s, SiC(CH3)3), 0.12 (9H, s, Si(CH3)3), 0.08 (6H, s, Si(CH3)2); 13C NMR (combined, 125 
MHz, CDCl3): δC 195.4, 188.1, 147.8, 134.7, 134.0, 123.7, 129.4, 129.3, 129.2, 129.1,129.0, 127.8, 127.6, 
127.4, 127.3, 76.1, 75.9, 70.1, 70.0, 69.9, 49.1, 45.7, 37.4, 36.5, 28.5, 26.9, 26.0, 25.2, 25.0, 18.3, 2.62,   ̶ 
5.3,   ̶ 5.4; HRMS (ES+): calc. for C29H46O3Si2S2 [M+H]+ 563.2500, found 563.2489.  
 
S-Phenyl-(S,E)-7-((tert-butyldimethylsilyl)oxy)-6-methyl-6-((trimethylsilyl)oxy)hept-2-enethioate (89) 
 
 
Rf 0.37 (10:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 7.43 (5H, s, H-Ar), 7.07 (1H, dt, J = 15.5, 6.8 Hz, H-
5), 6.22 (1H, dt, J = 15.5, 1.5 Hz, H-6), 3.46 (1H, d, J = 9.6 Hz, H-1a), 3.38 (1H, d, J = 9.6 Hz, H-1b), 2.39-
2.27 (2H, m, H-4), 1.72-1.70 (1H, m, H-3a), 1.62-1.59 (1H, m, H-3b), 1.25 (3H, s, Me-2), 0.94 (9H,  
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s, SiC(CH3)3), 0.16 (9H, s, Si(CH3)3), 0.09 (6H, s, Si(CH3)2); HRMS (ES+): calc. for C23H40O3Si2S [M+H]+ 
453.2309, found 453.2301. 
 
S-Ethyl 2-(diethoxyphosphoryl)ethanethioate (91) 
 
 
To a solution of diethylphosphonoacetic acid (0.5 mL, 3.00 mmol, 1.0 equiv.) in CH2Cl2 (6 mL) at 0 °C was 
added ethanethiol (0.22 mL, 3.00 mmol, 1.0 equiv.) and DMAP (37.0 mg, 0.30 mmol, 0.1 equiv.) and 
stirred for 5 min. DCC (0.63 g, 3.00 mmol, 1.0 equiv.) was then added in 5 portions. The reaction mixture 
was slowly warmed to rt and stirred for 16 h before being filtered through Celite®, which was then 
washed with CH2Cl2 (10 mL). The filtrate was then washed with NaHCO3 (2 x 8 mL), H2O (8 mL) and brine 
(8 mL), dried over MgSO4 and concentrated in vacuo. The crude material was purified by flash column 
chromatography (2:1 PE/Et2O o Et2O). Remaining 1,3 dicyclohexyl urea was filtered off to give the title 
compound as a colourless oil (563 mg, 78%) 
Rf 0.17 (2:1 PE/EtOAc ); IR (thin film, νmax/cm-1): 2982, 2933, 1681, 1452, 1393, 1256, 1164, 1008, 966, 
823, 703, 668; 1H NMR (500 MHz, CDCl3): δH 4.18 (2H, qd, J = 6.9, 1.8 Hz, 2 x OCHaHbCH3), 4.16 (2H, qd, 
J = 6.9, 1.3 Hz, 2 x OCHaHbCH3), 3.21 (2H, d, J = 21.3 Hz, H-1), 2.92 (2H, q, J = 7.4 Hz, SCH2CH3), 1.34 (6H, 
t, J = 6.9 Hz, OCH2CH3)2, 1.27 (3H, t, J = 7.4 Hz, SCH2CH3); 13C NMR (125 MHz, CDCl3) δC 190.1, 62.6, 43.2, 
42.1, 24.0, 16.2, 16.1, 14.3; HRMS (ES+): calc. for C8H18O4PS [M+H]+ calc. 241.0658, found 241.0656. 
 
S-Ethyl(S,E)-7-((tert-butyldimethylsilyl)oxy)-6-methyl-6-((trimethylsilyl)oxy)hept-2-enethioate (69) 
 
To a suspension of dry LiCl (11.9 mg, 0.28 mmol, 1.8 equiv.) in THF (0.75 mL) at   ̶  35 °C was added a 
solution of phosphonate 91 (68.0 mg, 0.28 mmol, 1.8 equiv.) in THF (0.3 mL) and the reaction mixture 
stirred for 10 min. Et3N (39 μL, 0.28 mmol, 1.8 equiv.) was then added and the reaction mixture stirred 
for a further 10 min. A solution of aldehyde 85 (50.0 mg, 0.16 mmol, 1.0 equiv.) in THF (0.75 mL) was 
subsequently added and the resulting suspension stirred for 16 h, maintaining a temperature of   ̶35 °C. 
The reaction was then quenched with NH4Cl (3 mL), the layers separated and the aqueous layer 
  
  
Chapter 6: Experimental 
106 
 
extracted with Et2O (3 x 3 mL). Combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The crude material was purified by flash column chromatography (40:1 PE/EtOAc) to give the 
title compound as a colourless oil (52.3 mg, 80%, 94% brsm).  
Rf 0.38 (20:1 PE/EtOAc); [𝛼]𝐷20 + 16.5 (c 0.45, CHCl3); IR (thin film, νmax/cm-1): 2955, 2930, 2858, 1677, 
1634, 1463, 1251, 1102, 1024, 830, 776, 668; 1H NMR (500 MHz, CDCl3): δH 6.95 (1H, dt, J = 15.5, 6.8 Hz, 
H-5), 6.12 (1H, dt, J = 15.5, 1.5 Hz, H-6), 3.42 (1H, d, J = 9.6 Hz, H-1a), 3.35 (1H, d, J = 9.6 Hz, H-1b), 2.96 
(2H, q, J = 7.5 Hz, SCH2CH3), 2.33-2.20 (2H, m, H-4), 1.68 (1H, ddd, J = 13.5, 10.3, 6.1 Hz, H-3a), 1.55 (1H, 
ddd, J = 13.5, 10.3, 5.6 Hz, H-3b), 1.30 (3H, t, J = 7.5 Hz, SCH2CH3), 1.22 (3H, s, Me-2), 0.92 (9H, s, 
SiC(CH3)3), 0.13 (9H, s, Si(CH3)3), 0.07 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 190.1, 146.1, 128.2, 
75.8, 69.8, 37.3, 26.6, 25.8, 25.1, 22.9, 18.2, 14.7, 2.5,   ̶5.5; HRMS (ES+): calc. for C19H41O3SSi2 [M+H]+ 
calc. 405.2309, found 405.2310. 
 
S-Ethyl (3S,6S)-7-((tert-butyldimethylsilyl)oxy)-3,6-dimethyl-6-((trimethylsilyl)oxy) heptanethioate 
(71) 
 
 
CuI (0.9 mg, 4.75 µmol, 0.05 equiv) and (S)-Tol-BINAP (3.5 mg, 5.23 µmol, 0.055 equiv.) were stirred in 
Et2O (1.0 mL) at rt under a yellow suspension was observed, at which point the reaction mixture was 
cooled to   ̶ 78 °C. A solution of methyl magnesium bromide (3 M in Et2O, 0.13 mL, 0.38 mmol, 7.0 equiv.) 
was added dropwise and the reaction mixture stirred for 10 min. A solution of thioester 69 (23 mg, 0.06 
mmol, 1.0 equiv.) in CH2Cl2 (0.3 mL) was then added over 5 min and the reaction mixture stirred for 16 
h. The reaction was then quenched with MeOH (1 mL) and NH4Cl (2 mL) and warmed to rt. The layers 
were then separated and the aqueous layer extracted with Et2O (3 x 3 mL). Combined organic layers 
were then dried over MgSO4 and concentrated in vacuo. The crude material was purified by flash column 
chromatography (40:1 PE/EtOAc) to give the title compound as a colourless oil (9.5 mg, 40%, 1.5:1 d.r.) 
and methyl ketone 100 (11.7 mg, 54%).  
Rf 0.63 (2:1 PE/EtOAc); [𝛼]𝐷20 + 12.3 (c 0.82, CHCl3); IR (thin film, νmax/cm-1): 2959, 1691, 1394, 1250, 
1077, 828, 776, 668; 1H NMR (major diastereomer) (500 MHz, CDCl3): δH  3.38 (1H, d, J = 9.6 Hz, H-1a), 
3.29 (1H, dd, J = 9.6, 6.1 Hz, H-1b), 2.87 (2H, q, J = 7.5 Hz, SCH2CH3), 2.54 (1H, ddd, J = 14.7, 5.9. 3.2 Hz, 
H-3a), 2.34 (1H, dt, J = 14.7, 8.0 Hz, H-3a), 2.00-1.93 (1H, m, H-5), 1.56-1.28 (4H, m, H-3, H-4), 1.24 (3H, 
  
  
Chapter 6: Experimental 
107 
 
t, J = 7.5 Hz, SCH2CH3), 1.16 (3H, s, Me-2), 0.93 (3H, d, J = 6.7 Hz, Me-5), 0.89 (9H, s, SiC(CH3)3), 0.09 (9H, 
s, Si(CH3)3), 0.04 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 199.2, 76.3, 69.8, 51.6, 36.4, 31.6, 30.3, 
25.3, 23.3, 19.6, 18.3, 15.3, 14.8, 2.6,   ̶5.4,   ̶5.5; HRMS (ES+): calc. for C20H48NO3SSi2 [M+NH4]+ calc. 
438.2888, found 438.2883. 
 
(4S,7S)-8-((tert-Butyldimethylsilyl)oxy)-4,7-dimethyl-7-((trimethylsilyl)oxy)octan-2-one (100) 
 
1H NMR (major diastereomer) (500 MHz, CDCl3): δH  3.38 (1H, d, J = 9.5 Hz, H-1a), 3.29 (1H, dd, J = 9.5, 
3.6 Hz, H-1b), 2.42 (1H, dd, J = 16.0, 5.5 Hz, H-6a), 2.21 (1H, ddd, J = 16.0, 7.2, 2.0 Hz, H-6b), 2.12 (3H, s, 
COCH3), 1.97-1.90 (1H, m, H-5), 1.33-1.22 (4H, m, H-4, H-3), 1.16 (3H, s, Me-2), 0.89 (9H, s, SiC(CH3)3), 
0.87 (3H, d, J =6.5 Hz, Me-5), 0.09 (9H, s, Si(CH3)3), 0.03 (6H, s, Si(CH3)2); 
 
(S)-tert-Butyl((3,7-dimethyloct-6-en-1-yl)oxy)dimethylsilane (106) 
 
To a solution of β-citronellol (1.16 mL, 6.40 mmol, 1.0 equiv.) in CH2Cl2 (40 mL) were added imidazole 
(653 mg, 9.60 mmol, 1.5 equiv.) and DMAP (39.0 mg, 0.32 mmol, 0.05 equiv.). TBSCl (1.25 g, 8.32 mmol, 
1.2 equiv.) was then added in 5 portions and the reaction mixture stirred at rt for 90 min before being 
quenched with NH4Cl (30 mL). The layers were separated and the aqueous layer extracted with CH2Cl2 
(3 x 25 mL). Combined organic layers were dried over MgSO4 and the solvent removed in vacuo. The 
crude material was purified by flash column chromatography (20:1 PE/EtOAc) to give the title compound 
as a colourless oil (1.56 g, 90 %).  
1H NMR (500 MHz, CDCl3): δH 5.09 (1H, t, J = 7.2 Hz, H-8), 3.67-3.58 (2H, m, H-3), 2.03-1.90 (2H, m, H-7), 
1.67 (3H, s, Me-9a), 1.59 (3H, s, Me-9b), 1.58-1.51 (2H, m, H-4), 1.35-1.29 (2H, m, H-6), 1.17-1.10 (1H, 
m, H-5), 0.88 (9H, s, SiC(CH3)3), 0.87 (3H, d, J = 6.6 Hz, Me-5); HRMS (ES+): calc. for C16H35OSi [M+H]+ 
calc. 271.2452, found 271.2449. 
Data in agreement with literature values166 
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 (S)-6-((tert-Butyldimethylsilyl)oxy)-4-methylhexanal (107) 
 
Alkene 106 (615 mg, 2.27 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (23 mL) and cooled to   ̶ 78 °C. Ozone 
was then bubbled through until a persistent blue colour was observed. At this point the gas inlet was 
replaced with oxygen until the blue colour dissipated. PPh3 (894 mg, 3.41 mmol, 1.5 equiv.) was then 
added and the reaction mixture stirred for 1 h. After the addition of PE (30 mL), the precipitate was 
filtered through Celite® and the filtrate concentrated in vacuo. The crude material was purified by flash 
column chromatography (PE o 20:1 PE/EtOAc) to give the title compound as a colourless oil (405 mg, 
74%).  
IR (thin film, νmax/cm-1): 1727, 1472, 1388, 1255, 1094, 834, 775; 1H NMR (500 MHz, CDCl3): δH 9.77 (1H, 
t, J = 1.8 Hz, H-8), 3.69-3.60 (2H, m, H-3), 2.50-2.38 (2H, m, H-7), 1.71-1.43 (5H, m, H-4, H-5, H-6), 0.89 
(9H, s, SiC(CH3)3), 0.86 (3H, d, J = 6.6 Hz, Me-5), 0.04 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC 202.7, 
60.9, 41.6, 39.4, 29.1, 28.8, 25.8, 19.2, 18.2,   ̶5.4,   ̶5.4; HRMS (ES+): calc. for C13H29OSi [M+H]+ calc. 
245.1931, found 245.1935. 
Data in agreement with literature values.166 
 
 (S,E)-1-(6-((tert-Butyldimethylsilyl)oxy)-4-methylhex-1-en-1-yl)pyrrolidine (113) 
 
To a solution of aldehyde 107 (50.0 mg, 0.21 mmol, 1.0 equiv.) in CH2Cl2 (1.0 mL) were added pyrrolidine 
(34 μL, 0.42 mmol, 2.0 equiv.) and 4Å MS (25 mg, 50 wt%) and stirred for 2 h. With only starting material 
observed by TLC, K2CO3 (43.0 mg, 0.31 mmol, 1.5 equiv.) was added and the reaction mixture stirred for 
a further h, before being quenched with NaHCO3 (1 mL). The layers were separated and the aqueous 
layer extracted with Et2O (3 x 1 mL). Combined organic layers were dried over Na2SO4 and concentrated 
in vacuo to give the crude enamine (52 mg, 85%), which was used in the following reaction without 
further purification.  
Rf 0.32 (15:1 PE/EtOAc); IR (thin film, νmax/cm-1): 2928, 1644, 1462, 1254, 1093, 823, 775, 663; 1H NMR 
(500 MHz, CDCl3): δH 6.13 (1H, d, J = 13.6 Hz, H-8), 4.08 (1H, dt, J = 13.6, 7.3 Hz, H-7), 3.66-3.59 (2H, m,  
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H-3), 3.13-3.00 (4H, m, H-1’), 1.87-1.78 (4H, m, H-2’), 1.65-1.25 (5H, m, H-4, H-5, H-6), 0.89 (9H, s, SiC(CH-
3)3), 0.86 (3H, d, J = 6.8 Hz, Me-5), 0.04 (6H, s, Si(CH3)2). 
 
(R)-5-((tert-Butyldimethylsilyl)oxy)-3-methylpentanal (111) 
 
Procedure A:  
To a stirred solution of ester 128 (2.0 g, 7.69 mmol, 1.0 equiv.) in (80 mL) at   ̶ 78 °C was added DIBAL (1 
M in hexanes, 8.08 mL, 8.08 mmol, 1.05 equiv.) dropwise. The reaction mixture was maintained at this 
temperature for 1 h, before being quenched with NaK tartrate (60 mL) and stirred for a further h whilst 
warming to rt. The layers were separated and the aqueous layer extracted with CH2Cl2 (3 x 40 mL). 
Combined organic extracts were dried over MgSO4 and the solvent removed in vacuo. The crude 
material was purified by flash column chromatography (19:1 PE/EtOAc) to give the title compound as a 
colourless oil (1.63 g, 92%) 
 
Procedure B:  
To a stirred solution of aldehyde 107 (250 mg, 1.02 mmol, 1.0 equiv.) in DMF (0.3 mL) were added TMSCl 
(0.18 mL, 1.43 mmol, 1.4 equiv.) and Et3N (0.37 mL, 2.66 mmol, 2.6 equiv.) The reaction mixture was 
then heated to 140 °C for 2 h. After cooling to rt, the reaction was quenched with NaHCO3 (0.5 mL) and 
extracted with PE (3 x 1 mL). Combined organic layers were dried over MgSO4 and concentrated in 
vacuo.  
 
The crude residue was then redissolved in CH2Cl2 (3 mL), cooled to   ̶78 °C and a stream of ozone bubbled 
through. Once the solution had turned blue, the stream was replaced with oxygen until the solution 
became colourless. PPh3 (393 mg, 1.53 mmol, 1.5 equiv.) was then added and the reaction mixture 
warmed to rt before stirring for a further h. PE (5 mL) was then added to precipitate out the 
triphenylphosphine oxide, which was removed by filtration. The filtrated was concentrated in vacuo and 
the crude residue purified by flash column chromatography (PE o 20:1 PE/EtOAc) to give the title 
compound as a colourless oil (67 mg, 30% over both steps). 
 
Rf 0.37 (9:1 PE/EtOAc); IR (thin film, νmax/cm-1): 1727, 1256, 1095, 913, 836, 774, 743; 1H NMR (400 MHz, 
CDCl3): δH 9.75 (1H, t, J = 2.3 Hz, H-7), 3.67 (1H, t, J = 6.4, 2.6 Hz, H-3), 2.46 (1H, ddd, J = 10.4, 8.6, 2.3 Hz, 
H-6a), 2.26 (1H, ddd, J = 10.4, 7.8, 2.3 Hz, H-6b), 1.61-1.43 (3H, m, H-5, H-4), 0.99 (3H, d, J = 6.5  
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Hz, Me-5), 0.90 (9H, s, SiC(CH3)3), 0.05 (6H, s, Si(CH3)2)  ; 13C NMR (125 MHz, CDCl3): δC 202.8, 60.7, 50.9, 
39.5, 25.9, 25.1, 20.0, 18.3,   ̶  5.4; HRMS (ES+): calc. for C12H27O2Si [M+H]+ 231.1775, found 231.1776. 
Data in accordance with literature values.167 
 
(S)-5-((tert-Butyldimethylsilyl)oxy)-3-methylpentan-1-ol 
 
Rf 0.24 (9:1 PE/EtOAc); 1H NMR (400 MHz, CDCl3): δH 3.75-3.62 (4H, m, H-7, H-3), 1.78-1.37 (5H, m, H-6, 
H-5, H-4), 0.93 (3H, d, J = 6.7 Hz, Me-5), 0.90 (9H, s, SiC(CH3)3), 0.06 (6H, s, Si(CH3)2. 
Data in agreement with literature values.168  
 
(S)-6-((tert-Butyldimethylsilyl)oxy)-4-methylhexan-1-ol (116) 
 
Procedure A:  
To a solution of aldehyde 107 (300 mg, 1.25 mmol, 1.0 equiv.) in MeOH (10 mL) at 0 °C was added NaBH4 
(35.0 mg, 0.94 mmol, 0.75 equiv.) and stirred for 20 min. The reaction was then quenched with NH4Cl 
(8 mL) and Et2O (5 mL), the layers extracted and the aqueous layer extracted with Et2O (3 x 5 mL). 
Combined organic layers were dried over MgSO4 and concentrated in vacuo. The crude material was 
purified by flash column chromatography (9:1 PE/EtOAc) to give the title compound as a colourless 
liquid (180 mg, 60%).  
Procedure B:  
Alkene 106 (1.70 g, 6.30 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (40 mL) and cooled to    ̶78 °C. A 
stream of ozone was bubbled through the solution until a blue colour was observed, at which point 
oxygen was bubbled through until the blue colour dissipated. NaBH4 (177 mg, 4.73 mmol, 0.75 equiv.) 
was then added, the reaction mixture warmed to rt and stirred for 1 h. The solvent was then removed 
in vacuo and the residue purified by flash column chromatography (10:1 o 6:1 PE/EtOAc) to give the 
title compound as a colourless liquid (1.29 g, 79%).  
Rf 0.18 (10:1 PE/EtOAc); IR (thin film, νmax/cm-1): 3363, 1472, 1255, 1096, 823, 775; 1H NMR (500 MHz, 
CDCl3): δH 3.71-3.60 (4H, m, H-8, H-3), 1.65-1.17 (7H, m, H-7, H-6, H-5, H-4), 0.90 (3H, d, J = 6.8 Hz, Me- 
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5), 0.89 (9H, s, SiC(CH3)3), 0.05 (6H, s, Si(CH3)2); HRMS (ES+): calc. for C13H31O2Si [M+H]+ 247.2088, found 
247.2089.  
Data in agreement with literature values169 
 
 (S)-6-((tert-Butyldimethylsilyl)oxy)-4-methylhexyl 4-methylbenzenesulfonate (123) 
 
To a solution of alcohol 116 (180 mg, 0.83 mmol, 1.0 equiv.) in CH2Cl2 (8 mL) at rt was added tosyl 
chloride (471 mg, 2.48 mmol, 3.0 equiv.) and Et3N (0.58 mL, 4.15 mmol, 5.0 equiv.) and stirred for 3 h. 
The reaction was then quenched with NaHCO3 (8 mL) and the layers separated. The aqueous layer was 
extracted with EtOAc (3 x 5 mL), combined organic layers dried over MgSO4 and concentrated in vacuo. 
The crude material was purified by flash column chromatography (10:1 PE/EtOAc) to give the title 
compound as a colourless oil (275 mg, 94%).   
Rf 0.44 (9:1 PE/EtOAc); [𝛼]𝐷20 + 6.7 (c 0.85, CHCl3); IR (thin film, νmax/cm-1): 3104, 1520, 1474, 1083, 984, 
839, 770; 1H NMR (500 MHz, CDCl3): δH 7.79 (2H, d, J = 8.3 Hz, H-Ar), 7.34 (2H, d, J = 8.3 Hz, H-Ar), 4.02 
(2H, t, J = 6.4 Hz, H-8), 3.64-3.56 (2H, m, H-3), 2.45 (3H, s, Ar-Me), 1.71-1.46 (6H, m, H-7, H-6, H-4), 1.33-
1.30 (1H, m, H-5), 0.88 (9H, s, SiC(CH3)3), 0.87 (3H, d, J = 6.8 Hz, Me-5), 0.03 (6H, s, Si(CH3)2); 13C NMR 
(125 MHz, CDCl3): δC 144.7, 133.2, 129.8, 127.9, 70.8, 62.7, 39.3, 35.2, 26.3, 25.7, 21.6, 19.3, 19.2, 18.1, 
  ̶ 2.9; HRMS (ES+): calc. for C20H37O4SSi [M+H]+ 401.2176, found 401.2179. 
 
(S)-tert-Butyldimethyl((3-methylhex-5-en-1-yl)oxy)silane (119) 
 
To a solution of alcohol 116 (30.0 mg, 0.12 mmol, 1.0 equiv.) in THF (1.5 mL) was added 2-nitrophenyl 
selenocyanate (36.0 mg, 0.16 mmol, 1.3 equiv.) and then tributylphosphine (40 μL, 0.16 mmol, 1.3 
equiv.) before being stirred for 1 h. H2O2 (30% aq, 0.2 mL, 1.60 mmol, 13.0 equiv.) was then added and 
the reaction mixture stirred for 20 h, before being quenched with NaHCO3 (2 mL). The layers were 
separated and the aqueous layer extracted with Et2O (3 x 2 mL). Combined organic layers were washed 
with brine (3 mL), dried over MgSO4 and concentrated in vacuo. The crude material was purified by flash 
column chromatography (20:1 PE/EtOAc) to give the title compound as a colourless oil (17 mg, 60%).  
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Rf 0.35 (20:1 PE/EtOAc); IR (thin film, νmax/cm-1): 1599, 1472, 1362, 1180, 1097, 835, 776, 664; 1H NMR 
(500 MHz, CDCl3): δH 5.80-5.74 (1H, m, H-7), 5.02-4.96 (2H, m, H-8), 3.69-3.59 (2H, m, H-3), 2.07 (1H, 
dddd, J = 13.5, 6.2, 6.2, 1.1 Hz, H-6a),  1.90 (1H, ddd, J = 13.5, 7.3. 7.2 Hz, H-6b), 1.69-1.52 (2H, m, H-4), 
1.37-1.29 (1H, m, H-5), 0.88 (9H, s, SiC(CH3)3), 0.87 (3H, d, J = 6.1 Hz, Me-5), 0.03 (6H, s, Si(CH3)2). 
Data in agreement with literature values170 
 
Dimethyl 3-methylpentanedioate (120) 
 
 
 
To a stirred solution of 3-methylglutaric acid (19.0 g, 13.0 mmol, 1.0 equiv.) in MeOH (250 mL) at 0 °C 
was added acetyl chloride (37.1 mL, 52.0 mmol, 4.0 equiv.) dropwise. The reaction mixture was heated 
to reflux for 3 h. The solvent was removed in vacuo and the residue redissolved in NaHCO3 (100 mL) to 
neutralise. Once gas evolution had ceased, the product was extracted with CH2Cl2 (4 x 80 mL). Combined 
organic layers were dried over MgSO4 and concentrated in vacuo to give the product as a yellow oil (20.2 
g, 89%), which was used without further purification.  
 
Rf 0.61 (2:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 3.68 (6H, s, CO2Me), 2.52-2.42 (1H, m, H-5), 2.40 
(2H, dd, J = 15.0, 6.0 Hz, H-4a, H-6a), 2.25 (2H, dd, J = 15.0, 7.3, Hz, H-4b, H-6b), 1.03 (3H, d, J =6.5 Hz, 
Me-5); HRMS (ES+): calc. for C8H15O4 [M+H]+ 175.0965, found 175.0962. 
Data in agreement with literature values.171  
 
(R)-5-Methoxy-3-methyl-5-oxopentanoic acid (121) 
 
 
A solution of diester 120 (10.0 g, 57.1 mmol, 1.0 equiv.) in MeOH (44.5 mL) and pH 7 buffer 
(KH2PO4/Na2HPO4, 0.1 M, 220 mL) was cooled to    ̶ 10 °C and pig liver esterase (550 mg, 9900 U) added. 
A solution of NaOH (1.0 M aq, 57.1 mL, 57.1 mmol, 1.0 equiv.) was added dropwise over 54 h, at such a 
rate as to maintain a pH between 6.5 and 8.0. After the addition was completed, the light brown 
suspension was filtered through Celite® and the residue rinsed with H2O (150 mL). The pH of the 
combined filtrates was adjusted to 3 with HCl (3M aq) and the mixture extracted with Et2O (8 x 250 
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 mL). Combined organic extracts were dried over Na2SO4 and concentrated in vacuo to give the title 
compound (8.92 g, 55.3 mmol, 97%) as a colourless liquid. 
 
Enantioenriched monoester 121 was dissolved in acetone (180 mL) and cinchonidine (16.8 g 57.1 mmol, 
1.0 equiv.) added. The white suspension was heated to 40 °C and stirred rapidly. H2O (23 mL) was added 
dropwise until a pale-yellow solution formed. The solution was cooled to rt and then left to stand at   ̶ 5 
°C for 16 h to give off-white, needle like crystals. The solid was collected by filtration, washed with ice-
cold acetone (35 mL) and dried in vacuo. The mother liquor was recooled to   ̶ 10 °C, left to stand for 16 
h, filtered and the solids washed (acetone, 20 mL) and collected, to isolate a second crop of the crystals. 
Combined collected solids were dissolved in HCl (2M, 120 mL) and extracted with Et2O (5 x 150 mL). The 
organic extracts were dried over Na2SO4 and concentrated in vacuo to yield the title compound as a 
colourless oil (5.53 g, 34.3 mmol, 62%, 96% ee).  
 
Rf 0.24 (1:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 3.70 (3H, s, OCH3), 2.53-2.42 (3H, m, H-4a, H-5, H-
6a), 2.35-2.27 (2H, m, H-4b, H-6b), 1.08 (3H, d, J = 6.5 Hz, Me-5); HRMS (ES+): calc. for C7H10O [M-H]- 
159.0663, found 159.0665. RT (R) 165.6 min, RT (S) 172.0 min, total run time 240 min.  
 
Data in agreement with literature values.88 
 
Methyl (R)-5-hydroxy-3-methylpentanoate (127) 
 
 
To a stirred solution of carboxylic acid 121 (2.00 g, 12.5 mmol, 10.0 equiv.) In THF (200 mL) at 0 °C was 
added BH3·DMS (6.8 mL, 13.75 mL, 1.1 equiv.) dropwise. The reaction mixture stirred for 1 h. NaHCO3 
(150 mL) was then added and the layers separated. The aqueous layer was extracted with Et2O (3 x 100 
mL) and combined organic extracts dried over MgSO4 before the solvent was carefully removed in 
vacuo. The crude material was used directly in the following reaction without further purification.  
 
Rf 0.45 (1:1 PE/EtOAc); 1H NMR (400 MHz, CDCl3): δH 3.70-3.67 (2H, m, H-3), 3.68 (3H, s, OMe), 2.34 (1H, 
dd, J = 14.7, 6.5 Hz, H-6a), 2.21 (1H, dd, J = 14.7, 7.1 Hz, H-6b), 2.20 -2.10 (1H, m, H-5), 1.65 (1H, br s, O-
H), 1.61-1.49 (2H, m, H-4), 0.99 (3H, d, J = 6.7 Hz, Me-5); IR (thin film, νmax/cm-1): 3452, 2958, 1733, 1437, 
1292, 1212, 1165, 1059, 1014, 846; HRMS (ES+): calc. for C7H15O3 [M+H]+ 147.1016, found 147.1012.  
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Data in agreement with literature values172 
 
Methyl (R)-5-((tert-butyldimethylsilyl)oxy)-3-methylpentanoate (128) 
 
 
To a stirred solution of crude alcohol 127 (1.82 g, 12.5 mmol, 1.0 equiv.) in CH2Cl2 (125 mL) was added 
imidazole (1.02 g, 15 mmol, 1.2 equiv.), then TBSCl (2.07 g, 13.75 mmol, 1.2 equiv.) The reaction mixture 
was stirred for 90 min before being quenched with NH4Cl (80 mL). The layers were separated and the 
aqueous layer extracted with further CH2Cl2 (3 x 50 mL). Combined organic extracts were dried over 
MgSO4 and the solvent removed in vacuo. The crude material was purified by flash column 
chromatography (9:1 PE/EtOAc) to give the title compound as a colourless oil (2.98 g, 92% over two 
steps).  
1H NMR (500 MHz, CDCl3): δH 3.69-3.61 (2H, m, H-3), 3.66 (3H, s, OMe), 2.36 (1H, dd, J = 12.9, 5.0 Hz, H-
6), 2.17-2.04 (2H, m, H-6, H-5), 1.60-1.52 (1H, m,) 1.46-1.38 (1H, m), 0.96 (3H, d, J = 6.5 Hz, Me-5), 0.89 
(9H, s, SiC(CH3)3), 0.04 (9H, s, Si(CH3)2); HRMS (ES+): calc. for C14H31O3Si [M+H]+ 275.2037, found 
275.2038. 
Data in agreement with literature values173 
 
(R)-4-Methyltetrahydro-2H-pyran-2-one (125) 
 
1H NMR (400 MHz, CDCl3): δH 4.43 (1H, dt, J = 11.3, 4.4 Hz, H-3a), 4.27 (1H, ddd, J = 11.3, 10.7, 3.8 Hz, 
H-3b), 2.68 (1H, dd, J = 11.7, 1.3 Hz, H-6a), 2.28-2.05 (2H, m, H-4), 1.93 (1H, dd, J = 11.7, 4.0 Hz, H-6b), 
1.58-1.50 (1H, m,  H-5), 1.08 (3H, d, J = 6.4 Hz, Me-5). 
Data in agreement with literature values174 
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Methyl (S)-3-((4-methoxybenzyl)oxy)-2-methylpropanoate (133) 
 
 
To a stirred solution of (S)-Roche ester (15.6 g, 132 mmol, 1.0 equiv.) in CH2Cl2 (300 mL) were 
sequentially added PMBTCA (50.0 g, 198 mmol, 1.5 equiv.) and PPTS (3.31 g, 13.2 mmol, 0.1 equiv.) The 
reaction mixture was stirred for 16 h before being quenched with NaHCO3 (200 mL). The layers were 
separated and the aqueous layer extracted with further CH2Cl2 (3 x 100 mL).  Combined organic layers 
were washed with brine (100 mL) and dried over MgSO4. The crude material was purified by flash 
column chromatography (9:1 o 6:1 PE/EtOAc) to give the title compound as a colourless oil (25 g, 81%). 
  
Rf 0.38 (4:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 7.23 (2H, d, J = 8.7, H-Ar), 6.87 (2H, d, J = 8.7 Hz), 
4.46 (1H, d, J = 11.9 Hz, OCHaHbAr), 4.44 (1H, d, J = 11.9 Hz, OCHaHbAr), 3.80 (3H, s, ArOCH3), 3.69 (3H, 
s, CO2CH3), 3.63 (1H, dd, J = 9.2, 7.4 Hz, H-11a), 3.46 (1H, dd, J = 9.2, 6.0 Hz, H-11b), 2.77 (1H, dtd, J = 
7.4, 7.1, 6.0 Hz, H-10), 1.16 (3H, d, J = 7.1 Hz, Me-10).  
Data in agreement with literature values.175 
 
(S)-N-Methoxy-3-((4-methoxybenzyl)oxy)3-N,2-dimethylpropanamide (129) 
 
 
To a slurry of N, O- dimethylhydroxylamine hydrochloride (15.7 g, 158 mmol, 1.5 equiv.) and methyl 
ester 133 (25.0 g, 105 mmol, 1.0 equiv.) in THF (180 mL) was added i-PrMgCl (3 M in Et2O, 155 mL, 473 
mmol, 4.5 equiv.) over 30 min, maintaining a temperature of   ̶  20 °C. The reaction mixture was then 
stirred at    ̶10 °C for a further 3 h before quenching with NH4Cl (200 mL). The layers were separated and 
the aqueous layer extracted with EtOAc (5 x 50 mL). The crude material was purified by flash column 
chromatography (4:1 o 1:1 PE/EtOAc) to give the title compound as an orange liquid (23.8 g, 85%). 
 
Rf 0.18 (3:1 PE/EtOAc); 1H NMR (400 MHz, CDCl3): δH 7.23 (2H, d, J = 8.6 Hz, H-Ar), 6.86 (2H, d, J = 8.6 
Hz, H-Ar), 4.48 (1H, d, J = 11.7 Hz, OCHaHbAr), 4.40 (1H, d, J = 11.7 Hz, OCHaHbAr), 3.79 (3H, s, ArOCH3), 
3.69 (1H, app t, J  = 8.8 Hz, H-11a), 3.68 (3H, s, N(CH3)OCH3), 3.39 (1H, dd, J = 8.8, 5.9 Hz, H-11b), 3.28 -
3.22 (1H, m, H-10), 3.20 (3H, s, N(CH3)OMe), 1.10 (3H, d, J = 6.8 Hz, Me-10).  
Data in agreement with literature values.176  
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(S)-1-((4-Methoxybenzyl)oxy)-2-methylpentan-3-one (45) 
 
 
To a stirred solution of Weinreb amide 129 (4.5 g, 16.9 mmol, 1.0 equiv.) in THF (80 mL) at 0 °C was 
added EtMgBr (1M in Et2O, 42 mL, 42 mmol, 2.5 equiv.). The reaction mixture was stirred for 2 h before 
quenching with NH4Cl (70 mL). The layers were separated and the aqueous layer extracted with Et2O (3 
x 40 mL). Combined organic layers were dried over MgSO4 and concentrated in vacuo. The crude 
material was purified by flash column chromatography (9:1 PE/EtOAc) to give the title compound as a 
pale-yellow liquid (3.50 g, 88%). 
 
Rf 0.32 (9:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 7.21 (2H, d, J = 8.6 Hz, H-Ar), 6.87 (2H, d, J = 8.6 
Hz, H-Ar), 4.43 (1H, d, J = 11.6 Hz, OCHaHbAr), 4.39 (1H, d, J = 11.6 Hz, OCHaHbAr), 3.80 (3H, s, ArOMe), 
3.59 (1H, dd, J = 9.2, 7.9 Hz, H-11a), 3.42 (1H, dd, J = 9.2, 5.5 Hz, H-11b), 2.86 (1H, dtd, J = 7.9, 7.1, 5.5 
Hz, H-10), 2.50 (2H, q, J = 7.3 Hz, H-8), 1.06 (3H, d, J = 7.1 Hz, Me-10), 1.04 (3H, t, J = 7.3 Hz, CH2CH3).  
Data in agreement with literature values.90 
 
 (2S,3R,4S,5S,7R)-9-((tert-Butyldimethylsilyl)oxy)-1-((4-methoxybenzyl)oxy)-2,4,7-trimethylnonane-
3,5-diol (110) 
 
 
Dicyclohexylboron chloride (6.86 mL, 31.7 mmol, 1.9 equiv.) and Et3N (4.88 mL, 35.1 mmol, 2.1 equiv.) 
were sequentially added to Et2O (60 mL) and cooled to 0 °C before stirring for 10 min. A solution of 
ketone 45 (7.57 g, 33.5 mmol, 2.0 equiv.) in Et2O (30 mL) was then added via cannula and the reaction 
mixture stirred for 90 min before cooling to   ̶78 °C. A solution of aldehyde 111 (3.85 g, 16.7 mmol, 1.0 
equiv.) in Et2O (30 mL) was then added via cannula and the reaction mixture stirred at this temperature 
for a further 4 h before being place in a freezer at    ̶ 20 °C for 16 h. The reaction mixture was then re-
cooled to   ̶ 78 °C before the dropwise addition of LiBH4 (4 M in THF, 16.7 mL, 66.8 mmol, 4.0 equiv.). 
After 2.5 h, the reaction was quenched with NH4Cl (80 mL) and warmed to rt. The layers  
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were separated and the aqueous layer extracted with Et2O (3 x 50 mL). Combined organic extracts were 
dried over MgSO4 and the solvent removed in vacuo. The crude boronate was purified by flash column 
chromatography (9:1 o 4:1 PE/EtOAc) to remove excess reduce ketone before being redissolved in 
MeOH (75 mL). NaOH (10% aq, 45 mL) and H2O2 (30% aq, 22.5 mL) were sequentially added and the 
solution stirred for an h before the product was extracted with Et2O (3 x 50 mL) and EtOAc (50 mL). 
Combined organic layers were dried over Na2SO4 and the solvent removed in vacuo. The crude diol was 
then repurified by flash column chromatography (9:1 o 4:1 PE/EtOAc) to give the title compound as a 
colourless oil (6.73 g, 86%).  
Rf 0.23 (4:1 PE/EtOAc); [𝛼]𝐷20   ̶  16.7 (c 1.55, CHCl3); IR (thin film, νmax/cm-1): 3425, 1612, 1513, 1463, 
1248, 1090, 1038, 980, 835, 775; 1H NMR (500 MHz, CDCl3): δH 7.27 (2H, d, J = 8.7 Hz, H-Ar), 6.88 (2H, d, 
J = 8.7 Hz, H-Ar), 4.48 (1H, d, J = 11.6 Hz, OCHaHbAr), 4.45 (1H, d, J = 11.6 Hz, OCHaHbAr), 3.81 (3H, s, 
ArOCH3), 3.78 (1H, dd, J =  10.3, 1.8 Hz, H-7), 3.67 (1H, dd, J = 6.5, 1.4 Hz, H-11a), 3.66 (1H, dd, J = 6.5, 
1.9 Hz, H-11b), 3.61-3.58 (2H, m, H-2), 3.34 (1H, dd, J = 9.0, 6.2 Hz, H-9), 2.09-1.98 (2H, m, H-8, H-10), 
1.52-1.30 (5H, m, H-4, H-5, H-6), 0.90 (3H, d, J = 6.8 Hz, Me-10), 0.89 (9H, s, SiC(CH3)3), 0.80 (3H, d, J = 
6.6 Hz, Me-8), 0.76  (3H, d, J = 6.9 Hz, Me-5), 0.05 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC 159.3, 
130.0, 129.3, 113.9, 79.1 75.4, 74.0, 73.2, 61.6, 55.3, 42.1, 41.6, 40.9, 35.1, 26.2, 26.0, 19.4, 18.4, 12.9, 
9.4,   ̶5.3; HRMS (ES+): calc. for C26H47O5Si [M  ̶H] ̶  467.3187, found 467.3183. 
 
 
(2S,4S,5S,8S)-10-((tert-Butyldimethylsilyl)oxy)-1-((4-methoxybenzyl)oxy)-2,4,8-trimethyl-3-
oxodecan-5-yl (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (154) 
 
 
To a solution of alcohol 153 (5.0 mg, 10.4 μmol, 1.0 equiv.) in CH2Cl2 (0.5 mL) were added (R)-3,3,3-
trifluoro-2-methoxy-2-phenylpropanoic acid (12.2 mg, 0.05 mmol, 5.0 equiv.), DCC (10.7 mg, 0.05 mmol, 
5.0 equiv.) and DMAP (6.4 mg, 0.05 mmol, 5.0 equiv.). The reaction mixture was stirred for 5 h before 
being filtered through Celite® and washed with PE (1.0 mL). The filtrate was concentrated in vacuo and 
the residue passed through a short plug of silica to remove excess (R)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoic acid.  
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1H NMR (500 MHz, CDCl3): δH 7.49-7.35 (5H, m, H-Ar), 7.19 (2H, d, J = 8.7 Hz, H-Ar), 6.86 (2H, d, J = 8.7 
Hz, H-Ar), 5.38 (1H, q, J = 5.9 Hz, H-7), 4.40 (1H, d, J = 11.6 Hz, OCHaHbAr), 4.36 (1H, d, J = 11.6 Hz,  
OCHaHbAr), 3.80 (3H, s, ArOCH3), 3.66-3.55 (3H, m, H-11a, H-2’), 3.52 (3H, s, OCH3), 3.35 (1H, dd, J = 9.1, 
5.2 Hz, H-11b), 3.05 (1H, app quint, J = 7.1 Hz, H-8), 2.92 (1H, qdd, J = 7.0, 5.2, 3.2 Hz, H-10), 1.67-1.62 
(2H, m, H-6’), 1.53-1.47 (1H, m, H-4’), 1.28-1.24 (2H, m, H-5’), 1.21 (2H, td, J = 7.0, 4.6 Hz, H-3’), 0.98 
(3H, d, J = 7.2 Hz, H-8), 0.88 (9H, s, SiC(CH3)3), 0.84 (3H, d, J = 6.4 Hz, Me-4’), 0.82 (3H, d, J = 7.1 Hz, Me-
10), 0.03 (6H, s, Si(CH3)2).  
 
 
(2S,4S,5S,8S)-10-((tert-Butyldimethylsilyl)oxy)-1-((4-methoxybenzyl)oxy)-2,4,8-trimethyl-3-
oxodecan-5-yl (S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (155) 
 
To a solution of alcohol 153 (5.0 mg, 10.4 μmol, 1.0 equiv.) in CH2Cl2 (0.5 mL) were added (S)-3,3,3-
trifluoro-2-methoxy-2-phenylpropanoic acid (12.2 mg, 0.05 mmol, 5.0 equiv.), DCC (10.7 mg, 0.05 mmol, 
5.0 equiv.) and DMAP (6.4 mg, 0.05 mmol, 5.0 equiv.). The reaction mixture was stirred for 5 h before 
being filtered through Celite® and washed with PE (1.0 mL). The filtrate was concentrated in vacuo and 
the residue passed through a short plug of silica to remove excess MTPA. 
1H NMR (500 MHz, CDCl3): δH 7.57-7.37 (5H, m, H-Ar), 7.19 (2H, d, J = 8.6 Hz, H-Ar), 6.85 (2H, d, J = 8.6 
Hz, H-Ar), 5.37 (1H, td, J =7.1, 3.2 Hz, H-7), 4.41 (1H, d, J = 11.6 Hz, CHaHbAr), 4.37 (1H, d, J = 11.6 Hz, 
CHaHbAr), 3.80 (3H, s, ArOCH3), 3.61-3.56 (2H, m, H-2’), 3.57 (1H, dd, J = 9.1, 3.2 Hz, H-11a), 3.46 (3H, s, 
OCH3), 3.39 (1H, dd, J = 9.1, 5.2 Hz, H-11b),  3.06 (1H, app quint, J = 7.3 Hz, H-8), 2.94 (1H, qdd, J = 6.8, 
5.2, 3.2 Hz, H-10), 1.63-1.59 (2H, m, H-6’), 1.48-1.42 (1H, m, H-4’), 1.27-1.23 (2H, m, 5’), 1.22-1.17 (2H, 
m, 3’), 1.04 (3H, d, J = 7.2 Hz, Me-8), 0.88 (9H, s, SiC(CH3)3), 0.88 (3H, d, J = 6.8 Hz, Me-10), 0.79 (3H, d, 
J = 6.4 Hz, Me-4’), 0.04 (6H, s, Si(CH3)2).  
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tert-Butyl((R)-4-((4S,5S,6R)-6-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-2,2,5-trimethyl-1,3-dioxan-
4-yl)-3-methylbutoxy)dimethylsilane (151) 
 
To a solution of diol 110 (10 mg, 0.02 mmol, 1.0 equiv.) in CH2Cl2 (0.2 mL) were added 2,2-
dimethoxypropane (53 μL, 0.43 mmol, 20 equiv.) and PPTS (1 crystal). The reaction mixture was stirred 
for 2.5 h before being concentrated in vacuo. The residue was purified by flash column chromatography 
(9:1 PE/EtOAc) to give the title compound as a colourless oil (9.3 mg, 86%) 
Rf 0.41 (4:1 PE/EtOAc); IR (thin film, νmax/cm-1): 3670, 2987, 1407, 1394, 1249, 1080, 869; 1H NMR (500 
MHz, CDCl3): δH 7.25 (2H, d, J = 8.7 Hz, H-Ar), 6.86 (2H, d, J = 8.7 Hz, H-Ar), 4.43 (1H, d, J = 11.8 Hz, 
CHaHbAr), 4.39 (1H, d, J = 11.8 Hz, CHaHbAr), 3.79 (3H, s, ArOCH3), 3.66 (1H, dd, J = 10.1, 1.7 Hz, H-7), 
3.65-3.61 (2H, m, H-11), 3.48 (1H, td, J = 9.5, 3.3 Hz, H-9), 3.43 (1H, t, J = 8.7 Hz, H-3a), 3.26 (1H, dd, J = 
8.7, 6.3 Hz, H-3b), 2.06-2.00 (1H, m, H-10), 1.86-1.77 (1H, m, H-8), 1.54-1.32 (5H, m, H-4, H-5, H-6), 1.36 
(3H, s, H-1’), 1.29 (3H, s, H-2’), 0.88 (9H, s, SiC(CH3)3), 0.84 (3H, d, J = 6.1 Hz, Me-), 0.83 (3H, d, J = 6.4 Hz, 
Me-), 0.70 (3H, d, J = 6.7 Hz, Me-), 0.03 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC 159.1, 131.0, 
129.2, 113.7, 97.6, 77.2, 73.2, 73.0, 72.8, 71.9, 61.5, 5.3, 41.0, 40.8, 35.7, 34.0, 30.1, 26.0, 25.4, 19.5, 
18.9, 18.3, 11.7, 9.6,   ̶ 5.2,   ̶ 5.3. 
 
(5S,7R)-5-((1R)-1-((4R,5S)-2-(4-Methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)ethyl)-
2,2,3,3,7,11,11,12,12-nonamethyl-4,10-dioxa-3,11-disilatridecane (156) 
 
 
To a solution of aldol adduct 110 (4.6 g, 10.0 mmol, 1.0 equiv.) in CH2Cl2 (100 mL) at    ̶78 °C was added 
2,6-lutidine (1.4 mL, 12.1 mmol, 1.2 equiv.) and TBSOTf (2.46 mL, 10.6 mmol, 1.05 equiv.) and stirred 
for 3 h before quenching with NH4Cl (50 mL). The layers were separated and the aqueous layer extracted 
with CH2Cl2 (3 x 30 mL). Combined organic layers were dried over MgSO4 and the solvent removed in 
vacuo. The crude product was purified by flash column chromatography (9:1 PE/EtOAc) to give the title 
compound as a colourless oil (4.93 g, 88%) 
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Rf 0.24 (9:1 PE/EtOAc); [𝛼]𝐷20   ̶  17.4 (c 1.25, CHCl3); IR (thin film, νmax/cm-1): 3691, 1514, 1463, 1250, 
1088, 835, 773; 1H NMR (500 MHz, CDCl3): δH; 7.24 (2H, d, J = 8.6 Hz, H-Ar), 6.87 (2H, d, J = 8.6 Hz, H-Ar), 
4.47 (1H, d, J = 11.7 Hz, OCHaHbAr), 4.40 (1H, d, J = 11.7 Hz, OCHaHbAr), 4.10 (1H, ddd, J = 9.7, 4.1, 2.4 
Hz, H-7), 3.80 (3H, s, ArOCH3), 3.67-3.63 (2H, m, H-3a, H-3b), 3.55 (1H, dd, J = 10.5, 2.5 Hz, H-9), 3.53 
(1H, dd, J = 9.0, 4.4 Hz, H-11a), 3.51 (1H, dd, J = 9.0, 5.1 Hz, H-11b), 2.71 (1H, d, J = 2.6 Hz, O-H), 1.87-
1.81 (1H, m, H-10), 1.80-1.70 (2H, m, H-8, H-5), 1.56-1.49 (1H, m, H-4a), 1.43-1.34 (2H, m, H-6a, H-4b), 
1.10 (1H, ddd, J = 12.9, 10.6, 2.2 Hz, H-6b), 0.93 (3H, d, J = 7.1 Hz, Me-10), 0.89 (9H, s, SiC(CH3)3), 0.88 
(9H, s, SiC(CH3)3), 0.88 (3H, d, J = 7.0 Hz, Me-8), 0.75 (3H, d, J = 7.0 Hz, Me-5), 0.06 (3H, s, Si(CHa3)(CHb3), 
0.05 (3H, s, Si(CHa3)(CHb3), 0.05 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC 159.2, 130.3, 129.2, 
113.8, 75.3, 75.2, 73.1, 70.5, 61.5, 55.3, 41.8, 41.4, 39.1, 34.9, 26.0, 26.0, 25.7, 19.1, 18.4, 18.1, 10.3, 
9.1,  ̶ 4.2,  ̶ 4.5,  ̶ 5.3; HRMS (ES+): calc. for C32H62O5Si2 [M+H]+ 583.4209, found 583.4195. 
 
 
(5S,7R)-5-((1R)-1-((4R,5S)-2-(4-Methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)ethyl)-
2,2,3,3,7,11,11,12,12-nonamethyl-4,10-dioxa-3,11-disilatridecane (109) 
 
 
Procedure A:  
To a solution of alcohol 156 (20 mg, 0.054 mmol, 1.0 equiv.) in CH2Cl2 (0.5 mL) at   ̶ 78 °C were added 
2,6-lutidine (29 μL, 0.27 mmol, 5.0 equiv.) and TBSOTf (37 μL, 0.16 mmol, 3.0 equiv.) The reaction 
mixture was stirred for 30 min at this temperature before being warmed to rt and stirred for a further 
1 h. The reaction was then quenched with NH4Cl (1 mL) and the layers separated. The aqueous layer 
was extracted with CH2Cl2 (3 x 1 mL), combined organic layers dried over MgSO4 and concentrated in 
vacuo. The crude material was purified by flash column chromatography (6:1 PE/EtOAc) to give the title 
compound as a colourless oil (17.0 mg, 68%) 
 
Procedure B:  
To a slurry of DDQ (754 mg, 3.31 mmol, 1.1 equiv.) and 4Å MS (525 mg), in CH2Cl2 (20 mL) at 0 °C was 
added a solution of PMB ether 157 (1.75 g, 3.01 mmol, 1.0 equiv.) in CH2Cl2 (10 mL). The reaction mixture 
was stirred for 1 h before being filtered through Celite® and washed with CH2Cl2 (15 mL). The filtrate 
was washed with NaHCO3 (2 x 20 mL) and back extracted with CH2Cl2 (3 x 30 mL). Combined 
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 organic layers were dried over MgSO4 and concentrated in vacuo. The crude material was purified by 
flash column chromatography (15:1 o 9:1 PE/EtOAc) to give the title compound as a colourless oil (1.40 
g, 80%).  
 
Rf 0.38 (6:1 PE/EtOAc); [𝛼]𝐷20   ̶  21.6 (c 0.31, CHCl3); IR (thin film, νmax/cm-1): 1618, 1518, 1463, 1388, 
1249, 1103, 833, 773; 1H NMR (500 MHz, CDCl3): δH 7.38 (2H, d, J = 8.7 Hz, H-Ar), 6.87 (2H, d, J = 8.7 Hz, 
H-Ar), 5.37 (1H, s, CHAr), 4.19 (1H, ddd, J = 10.1 3.1, 1.7 Hz, H-7), 4.05 (1H, dd, J = 11.1, 2.2 Hz, H-11a), 
4.01 (1H, dd, J = 11.1, 1.1 Hz, H-11b), 3.81 (3H, s, ArOCH3), 3.65-3.61 (2H, m, H-3), 3.58 (1H, dd, J = 10.7, 
2.1 Hz, H-9), 1.95 (1H, dqd, J = 10.7, 7.0, 3.1 Hz, H-8), 1.71 (1H, qddd, J = 6.8, 2.2, 2.1, 1.1 Hz, H-10), 1.6-
1.26 (5H, m, H-4-6), 1.15 (3H, d, J = 6.8 Hz, Me-5), 0.89 (9H, s, SiC(CH3)3), 0.88 (9H, s, SiC(CH3)3), 0.79 (3H, 
d, J = 7.0 Hz, Me-8), 0.76 (3H, d, J = 6.6 Hz, Me-10), 0.04 (3H, s, Si(CHa3)(CHb3)), 0.04 (6H, s, Si(CH3)2), 
0.02 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 159.7, 131.7, 127.1, 113.4, 101.2, 81.2, 74.1, 
68.6, 61.5, 55.3, 41.4, 40.4, 38.3, 29.9, 26.0, 26.0, 25.9, 19.0, 18.4, 18.1, 10.9, 7.9,   ̶4.2,   ̶ 4.6,    ̶ 5.3,   ̶ 
5.3; HRMS (ES+): calc. for C32H60O5Si2 [M+H]+ 581.4052, found 581.4044. 
 
(2S,3S,5R)-7-((tert-Butyldimethylsilyl)oxy)-2-((4R,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-
yl)-5-methylheptan-3-ol (157) 
 
 
DDQ (24.4 mg, 0.107 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (0.5 mL) and stirred over 4Å MS for 20 
min before cooling to 0 °C. A solution of diol 110 (50 mg, 0.107 mmol, 1.0 equiv.) in CH2Cl2 (0.5 mL) was 
then added and the reaction mixture stirred for 1 h. The reaction was quenched by filtration through 
Celite®, which was washed with CH2Cl2 (3 mL). The filtrate was washed with NaHCO3 (3 x 3 mL), dried 
over MgSO4 and concentrated in vacuo. The crude material was purified by flash column 
chromatography (9:1 PE/EtOAc) to give the title compound as a colourless oil (31.5 mg, 63%)  
 
Rf 0.38 (9:1 PE/EtOAc); [𝛼]𝐷20   ̶ 20.7 (c 1.20, CHCl3); IR (thin film, νmax/cm-1  :3671, 2960, 2902, 1616, 1518, 
1463, 1394, 1249, 1162, 1070, 893, 832, 775; 1H NMR (500 MHz, CDCl3): δH 7.38 (2H, d, J = 8.6 Hz, H-Ar), 
6.87 (2H, d, J = 8.6 Hz, H-Ar), 5.47 (1H, s, CHAr), 4.08 (1H, d, J = 11.2 Hz, H-11a), 4.03 (1H, d, J = 11.2 Hz, 
H-11b), 3.84 (1H, d, J = 6.4 Hz, H-3a), 3.80 (1H, d, J = 6.4 Hz, H-3b), 3.79 (3H, s, ArOCH3), 3.65 (2H, td, J = 
Hz, H-7), 3.36 (1H, dd, J = 9.0, 6.7 Hz, H-9), 1.88-1.78 (2H, m, H-10, H-8), 1.72-1.66 (1H, m, H-6a), 1.57-
1.24 (4H, m, H-4, H-5, H-6b), 1.21 (3H, d, J = 6.9 Hz, Me-5), 0.89 (3H, d, J = 6.0 Hz, Me- 
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8), 0.88 (9H, s, SiC(CH3)3), 0.78 (3H, d, J = 6.7 Hz, Me-10), 0.04 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3): 
δC 159.7, 131.6, 128.0, 113.6, 102.3, 75.1, 73.8, 68.8, 61.4, 55.2, 42.3, 41.5, 41.1, 38.1, 34.8, 26.1, 25.5, 
19.6, 12.7, 8.9,   ̶ 5.3. 
 
 (3R,5S,6R)-5-((tert-Butyldimethylsilyl)oxy)-6-((4R,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-
yl)-3-methylheptan-1-ol (183) 
 
 
To a solution of silyl ether 109 (3.70 g, 6.38 mmol, 1.0 equiv.) in THF (100 mL) at rt was added TBAF (1M 
in THF, 6.4 mL, 6.38 mmol, 1.0 equiv.) dropwise. The reaction mixture was stirred for 1 h before the 
addition of an extra 0.5 equiv. of TBAF. After a further h, the reaction was quenched with NH4Cl (50 mL) 
and the layers separated. The aqueous layer was extracted with Et2O (3 x 30 mL). Combined organic 
layers were dried over MgSO4 and concentrated in vacuo. The crude material was purified by flash 
column chromatography (6:1 PE/EtOAc) to give the title compound (2.52 g, 85%), plus silyl ether 109 
(390 mg, 11%) 
 
Rf 0.16 (6:1 PE/EtOAc); [𝛼]𝐷20   ̶ 22.2 (c 0.6, CHCl3); IR (thin film, νmax/cm-1): 3363, 1380, 1086, 1045, 880, 
772; 1H NMR (500 MHz, CDCl3): δH 7.38 (2H, d, J = 8.6 Hz, H-Ar), 6.88 (2H, d, J = 8.6 Hz, H-Ar), 5.38 (1H, 
s, CHAr), 4.19 (1H, ddd, J = 10.2, 3.6, 1.8 Hz, H-7), 4.06 (1H, dd, J = 11.0, 2.3 Hz, H-11a), 4.02 (1H, dd, J = 
11.1, 1.3 Hz, H-11b), 3.81 (3H, s, OCH3), 3.71-3.64 (2H, m, H-3), 3.58 (1H, dd, J = 10.6, 2.1 Hz, H-9), 1.97 
(1H, dqd, J = 10.6, 7.0, 3.6 Hz, H-8), 1.70 (1H, qddd, J = 6.8, 2.3, 2.1, 1.3 Hz, H-10), 1.61-1.47 (2H, m, H-
5, H-4a), 1.43 (1H, ddd, J = 12.8, 10.2, 2.6 Hz, H-6a), 1.28-1.24 (1H, m, H-4b), 1.15 (3H, d, J = 6.9 Hz, Me-
5), 1.05 (1H, ddd, J = 12.8, 10.2, 1.8 Hz, H-6b), 0.89 (9H, s, SiC(CH3)3), 0.80 (3H, d, J = 6.8 Hz, Me-10), 0.79 
(3H, d, J = 7.0 Hz, Me-8), 0.05 (3H, s, Si(CHa3)(CHb3)), 0.03 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, 
CDCl3): δC 159.7, 131.6, 127.1, 113.4, 101.2, 81.2, 74.1, 68.9, 61.2, 55.3, 41.0, 40.4, 37.8, 29.9, 26.0, 25.9, 
19.6, 18.1, 10.9, 7.9,   ̶4.2,   ̶4.6; HRMS (ES+): calc. for C26H47O4Si [M+H]+ 467.3187, found 467.3184. 
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(3R,5S,6R)-5-((tert-Butyldimethylsilyl)oxy)-6-((4R,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-
yl)-3-methylheptyl 4-methylbenzenesulfonate (184) 
 
 
To a solution of alcohol 183 (420 mg, 0.91 mmol, 1.0 equiv.) in CH2Cl2/pyridine (1:1, 10 mL), was added 
tosyl chloride (516 mg, 2.72 mmol 3.0 equiv.) and stirred for 6 h. The reaction was then quenched with 
NaHCO3 (12 mL) and the layers separated. The aqueous layer was extracted with CH2Cl2 (3 x 8 mL), 
combined organic layers dried over MgSO4 and concentrated in vacuo. The crude material was purified 
by flash column chromatography (15:1 PE/EtOAc) to give the title compound as a colourless oil (510 mg, 
91%). 
 
Major diastereomer:  
Rf 0.28 (6:1 PE/EtOAc); [𝛼]𝐷20    ̶ 7.0 (c 0.1, CHCl3); IR (thin film, νmax/cm-1): 2927, 2339, 2012, 1613, 1360, 
1249, 1177, 1073, 942, 828, 773; 1H NMR (500 MHz, CDCl3): δH 7.78 (2H, d, J = 8.3 Hz, H-Ar), 7.36 (2H, d, 
J = 8.8 Hz, H-Ar), 7.32 (2H, d, J = 8.3 Hz, H-Ar), 6.87 (2H, d, J = 8.8 Hz, H-Ar), 5.35 (1H, CHAr), 4.14 (1H, 
ddd, J = 9.8, 3.4, 1.8 Hz, H-7), 4.09-4.02 (4H, m, H-11, H-3), 3.80 (3H, s, ArOCH3), 3.53 (1H, dd, J = 10.7, 
2.1 Hz, H-9), 2.44 (3H, s, ArCH3), 1.98-1.91 (1H, m, H-10), 1.69-1.62 (1H, m, H-8), 1.60-1.24 (5H, m, H-4-
6), 1.14 (3H, d, J = 6.8 Hz, Me-8), 0.86 (9H, s, SiC(CH3)3), 0.76 (3H, d, J = 7.1 Hz, Me-10), 0.71 (3H, d, J = 
6.4 Hz, Me-5), 0.03 (3H, s, Si(CHa3)(CHb3)),   ̶ 0.01 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 
159.7, 144.6, 133.3, 131.6, 129.8, 127.9, 127.0, 113.4, 101.2, 81.2, 74.1, 69.0, 68.4, 55.3, 40.3, 37.7, 
36.9, 29.8, 25.9, 25.8, 21.6, 18.7, 18.1, 10.9, 7.9,   ̶4.2,   ̶4.7; HRMS (ES+): calc. for C33H53O7SSi [M+H]+ 
621.3281, found 621.3269. 
 
Minor diastereomer:  
 1H NMR (500 MHz, CDCl3): δH 7.79 (2H, d, 8.1 Hz, H-Ar), 7.36 (2H, d, J =8.8 Hz, H-Ar), 7.33 (2H, d, J = 8.1 
Hz, H-Ar), 6.87 (2H, d, J = 8.8 Hz, H-Ar), 5.99 (1H, s, CHAr), 4.27 (1H, dt, J = 11.4, 2.7 Hz, H-7), 4.09-4.02 
(2H, m, H-3), 4.01 (1H, dd, J = 11.1, 1,2 Hz, H-11a, 3.82 (3H, s, ArOCH3), 3.62 (1H, dd, J = 11.1, 2.4 Hz, H-
11b), 3.40 (1H, dd, J = 10.6, 2.2 Hz, H-9), 2.44 (3H, s, ArCH3), 1.98-1.91 (1H, m, H-10), 1.69-1.62 (1H, m, 
H-8), 1.60-1.24 (5H, m, H-4-6), 1.16 (3H, d, J = 7.1 Hz, Me-8), 0.88 (9H, s, SiC(CH3)3), 0.95 (3H,  
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d, J = 6.7 Hz, Me-5), 0.66 (3H, d, J = 7.1 Hz, Me-10), 0.10 (3H, s, Si(CHa3)(CHb3)), 0.07 (3H, s, Si(CHa3-
)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 159.4, 144.6, 133.3, 131.6, 130.2, 128.2, 127.9, 113.8, 96.5, 81.1, 
72.3, 68.1, 67.1, 55.3,  40.9, 37.1, 36.7, 30.7, 25.9, 25.7, 21.6, 18.5, 18.1, 10.9, 8.1,  ̶  4.1,   ̶ 4.6. 
 
 
tert-Butyl(((2R,3S,5S)-7-iodo-2-((4R,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-5-
methylheptan-3-yl)oxy)dimethylsilane (108) 
 
 
To a stirred solution of tosylate 184 (500 mg, 0.808 mmol, 1.0 equiv.) in MeCN (20 mL) was added LiI 
(650 mg, 4.84 mmol, 6.0 equiv.) and heated to 60 °C for 4 h. Upon completion, the reaction mixture was 
cooled to rt and diluted with Et2O (15 mL) and quenched with NaHCO3 (20 mL). The layers were 
separated and the aqueous layer extracted with Et2O (3 x 20 mL). Combined organic layers were dried 
over MgSO4 and concentrated in vacuo. The crude material was purified by flash column 
chromatography (10:1 PE/EtOAc) to give the title compound as a colourless oil (425 mg, 91%).  
 
Major diastereomer: 
Rf 0.48 (6:1 PE/EtOAc); [𝛼]𝐷20   ̶  22.8 (c 0.82, CHCl3); IR (thin film, νmax/cm-1): 1616, 1518, 1463, 1380, 
1249, 1164, 1036, 834, 774; 1H NMR (500 MHz, CDCl3): δH 7.38 (2H, d, J = 8.7 Hz, H-Ar), 6.88 (2H, d, J = 
8.7 Hz, H-Ar), 5.37 (1H, s, CHAr), 4.18 (1H, ddd, J =10.1, 3.2, 1.6 Hz, H-7), 4.07-4.00 (2H, m, H-11), 3.81 
(3H, s, ArOCH3), 3.56 (1H, dd, J = 10.7, 2.0 Hz, H-9), 3.27-3.14 (2H, m, H-3), 2.00-1.93 (1H, m, H-10), 1.89-
1.80 (1H, m, H-8), 1.74-1.26 (5H, m, H-4, H-5, H-6), 1.15 (3H, d, J = 6.9 Hz, Me-5), 0.88 (9H, s, SiC(CH3)3), 
0.79 (3H, d, J = 7.1 Hz, Me-10), 0.76 (3H, d, J = 6.1 Hz, Me-8), 0.05 (3H, s, Si(CHa3)(CHb3)), 0.05 (3H, s, 
Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 159.7, 131.6, 127.1, 113.5, 101.2, 81.2, 74.1, 68.5, 55.3, 
42.3, 40.4, 37.4, 30.4, 29.9, 26.0, 18.3, 18.1, 10.9, 7.9, 4.9,   ̶ 4.2,   ̶ 4.5; HRMS (ES+): calc. for C26H46IO4Si 
[M+H]+ 577.2205, found 577.2196. 
 
Minor diastereomer:  
1H NMR (500 MHz, CDCl3): δH 7.35 (2H, d, J = 8.7 Hz, H-Ar), 6.89 (2H, d, J = 8.7 Hz, H-Ar), 6.01 (1H, s, 
CHAr), 4.31 (1H, ddd, J = 11.5, 2.8, 2.0 Hz, H-7), 4.07-4.00 (2H, m, H-11a), 3.83 (3H, s, ArOCH3), 3.62 (1H, 
dd, J = 11.2, 2.3 Hz, H-9), 3.44 (1H, dd, J = 10.7, 2.4 Hz, H-11b), 3.27-3.14 (2H, m, H-3), 2.00-1.93 (1H, m, 
H-10), 1.89-1.80 (1H, m, H-8), 1.74-1.26 (5H, m, H-4, H-5, H-6), 1.17 (3H, d, J = 6.9 Hz, Me-5),   
  
  
Chapter 6: Experimental 
125 
 
1.00 (3H, d, J = 6.6 Hz, Me-8), 0.88 (9H, s, SiC(CH3)3), 0.71 (3H, d, J = 7.0 Hz, Me-10), 0.12 (6H, s, Si(CH3)2); 
13C NMR (125 MHz, CDCl3): δC 159.4, 130.3, 128.3, 113.8, 96.5, 72.3, 68.1, 67.1, 55.3, 42.5, 41.0, 36.3, 
30.7, 30.3, 26.0, 22.6, 20.5, 18.2, 17.9, 11.5,   ̶4.0 
 
 
tert-Butyl(((2R,3S,5R)-2-((4R,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-5,8-dimethylnon-8-
en-3-yl)oxy)dimethylsilane (104) 
 
 
A solution of iodide 108 (400 mg, 0.69 mmol, 1.0 equiv.) in Et2O (7 mL) was cooled to   ̶ 78 °C and t-BuLi 
(1.7 M in pentane, 1.6 mL, 2.78 mmol, 4.0 equiv.) added in a single portion. The reaction mixture was 
stirred for 3 min before the addition of B-Methoxy-9-BBN (1 M in hexanes, 4.27 mL, 4.27 mmol, 6.0 
equiv.). After a further 5 min, the THF (7 mL) was added and the resulting solution slowly warmed to rt 
and stirred for a further h. K3PO4 (3M, 0.7 mL, 2.01 mmol, 3.0 equiv.), Pd(dppf)Cl2 (51 mg, 0.069 mmol, 
0.1 equiv.) and DMF (7 mL) were then added, followed by 2-bromopropene (0.18 mL, 2.07 mmol, 3.0 
equiv.) The resulting solution was stirred for 16 h before being quenched with H2O (20 mL). The layers 
were separated and the aqueous layer extracted with Et2O (3 x 15 mL). Combined organic layers were 
washed with brine (10 mL), dried over MgSO4 and concentrated in vacuo. The crude material was 
purified by flash column chromatography (PE o 20:1 PE/EtOAc) to give the title compound as pale-
yellow oil (231 mg, 67%) in an inseparable 3:1 mixture with alkane 185.  
 
Major diastereomer: 
Rf 0.58 (9:1 PE/EtOAc); [𝛼]𝐷20   ̶  41.6 (c 0.37, CHCl3); IR (thin film, νmax/cm-1): 2336, 1616, 1518, 1463, 
1249, 1072, 833, 773;  1H NMR (500 MHz, CDCl3): δH 7.37 (2H, d, J = 8.6 Hz, H-Ar), 6.86 (2H, d, J =8.6 Hz, 
H-Ar), 5.36 (1H, s, CHAr), 4.66-4.63 (2H, m, H-2), 4.17 (1H, ddd, J = 10.1, 3.2, 1.7 Hz, H-7), 4.04 (1H, dd, J 
= 11.2, 2.4 Hz, H-11a), 4.00 (1H, dd, J = 11.2, 1.2 Hz, H-11b), 3.79 (3H, s, ArOCH3), 3.57 (1H, dd, J = 10.8, 
2.0 Hz, H-9), 1.96-1.91 (1H, m, H-8), 1.84-1.78 (1H, m, H-10), 1.69 (3H, s, Me-2), 1.64-1.25 (7H, m, H-3, 
H-4, H-5, H-6), 1.13 (3H, d, J =6.9 Hz, Me-5), 0.87 (9H, s, SiC(CH3)3), 0.78 (3H, d, J = 7.0 Hz, Me-8), 0.76 
(3H, d, J = 6.6 Hz, Me-10), 0.03 (3H, s, Si(CHa3)(CHb3)), 0.00 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, 
CDCl3): δC 159.7, 146.5, 131.7, 127.1, 113.4, 109.5, 101.2, 81.2, 74.1, 68.7, 55.3, 40.5, 38.0, 36.4, 35.4, 
29.9, 28.7, 25.9, 22.5, 19.1, 18.1, 10.9, 7.9,   ̶4.2,   ̶4.7; HRMS (ES+): calc. for C29H51O4Si [M+H]+ 491.3551, 
found 491.3542. 
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Minor diastereomer: 
 1H NMR (500 MHz, CDCl3): δH 7.35 (2H, d, J= 8.7 Hz, H-Ar), 6.88 (2H, d, J = 8.7 Hz, H-Ar), 6.00 (1H, s, 
CHAr), 4.67-4.65 (2H, m, H-1), 4.30 (1H, ddd, J = 11.6, 2.7, 2.1 Hz, H-7), 4.00 (1H, dd, J = 11.2, 1.2 Hz, H-
11a), 3.81 (3H, s, ArOCH3), 3.61 (1H, dd, J = 11.2, 2.2 Hz, H-11b), 3.44 (1H, dd, J = 10.6, 2.5 Hz, H-9), 1.96-
1.91 (1H, m, H-8), 1.84-1.78 (1H, m, H-10), 1.70 (3H, s, Me-2), 1.64-1.25 (7H, m, H3, H-4, H-5, H-6), 1.16 
(3H, d, J = 6.9 Hz, Me-5), 1.00 (3H, d, J = 6.8 Hz, Me-10), 0.89 (9H, s, SiC(CH3)3), 0.70 (3H, d, J = 7.1 Hz, 
Me-8), 0.10 (3H, s, Si(CHa3)(CHb3)), 0.08 (3H, s, Si(CHa3)(CHb3)). 
 
 
tert-Butyl(((2R,3S,5R)-2-((4R,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-5-methylheptan-3-
yl)oxy)dimethylsilane (185) 
 
Major diastereomer: 
Rf 0.58 (9:1 PE/EtOAc); [𝛼]𝐷20   ̶ 2.8 (c 0.12, CHCl3); IR (thin film, νmax/cm-1): 1380, 1258, 1169, 1023, 834, 
776; 1H NMR (400 MHz, CDCl3): δH 7.39 (2H, d, J = 8.8 Hz, H-Ar), 6.88 (2H, d, J = 8.8 Hz, H-Ar), 5.38 (1H, 
s, CHAr), 4.18 (1H, ddd, J = 9.9, 3.3, 1.9 Hz, H-7), 4.07-4.00 (2H, m, H-11), 3.81 (3H, s, ArOCH3), 3.59 (1H, 
dd, J = 10.7, 2.1 Hz, H-9), 2.00-1.91 (1H, m, H-10), 1.63-1.57 (1H, m, H-8), 1.48-1.22 (8H, m, H-3, H-4, H-
5, H-6), 1.16 (3H, d, J = 7.0 Hz, Me-8), 0.89 (9H, s, SiC(CH3)3), 0.80 (3H, d J = 6.4 Hz, Me-5), 0.75 (3H, d, J 
= 7.0 Hz, Me-10), 0.05 (3H, s, Si(CHa3)(CHb3)), 0.03 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 
159.5, 131.6, 126.9, 113.3, 101.1, 81.1, 74.0, 68.7, 55.1, 40.4, 37.5, 30.8, 30.6, 29.8, 25.8, 18.7, 18.0, 
11.5, 10.8, 7.8,   ̶4.3,   ̶4.7; HRMS (ES+): calc. for C26H47O4Si [M+H]+ 451.3233, found 451.3238. 
 
Minor diastereomer: 
 1H NMR (400 MHz, CDCl3): δH 7.37 (2H, d, J = 8.8 Hz, H-Ar), 6.90 (2H, d, J = 8.8 Hz, H-Ar), 6.02 (1H, s, 
CHAr), 4.32 (1H, dt, J = 11.1, 2.6 Hz, H-7), 4.07-4.00 (2H, m H-11), 3.82 (3H, s, ArOCH3), 3.62 (1H, dd, J = 
11.2, 2.3 Hz, H-9), 2.00-1.91 (1H, m, H-10), 1.63-1.57 (1H, m, H-8), 1.48-1.22 (7H, m, H-3, H-4, H-5, H-6), 
1.18 (3H, d, J = 7.0 Hz, Me-8), 0.91 (9H, s, SiC(CH3)3), 0.71 (3H, d, J = 7.1 Hz, Me-10), 0.13 (3H, s, Si(CHa3-
)(CHb3)), 0.11 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 159.2, 130.1, 128.2, 113.7, 96.4, 
72.3, 58.3, 66.9, 55.2, 41.0, 36.4, 31.0, 30.6, 30.2, 25.9, 18.3, 18.1, 11.4, 10.8, 8.0,   ̶4.2,   ̶ 4.7. 
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 (2S,3R,4R,5S,7R)-5-((tert-Butyldimethylsilyl)oxy)-3-((4-methoxybenzyl)oxy)-2,4,7,10-
tetramethylundec-10-en-1-ol (193) 
 
 
To a solution of PMP acetal 104 (170 mg, 0.347 mmol, 1.0 equiv.) in CH2Cl2 (3.5 mL) at    ̶ 78 °C was added 
DIBAL (1 M in hexanes, 1.7 mL, 1.735 mmol, 5.0 equiv.) dropwise. The reaction mixture was stirred for 
1 h at this temperature and then warmed to rt over another h. Upon completion, the reaction was 
quenched with NaK tartrate (5 mL) and stirred for 2 h before the layers were separated. The aqueous 
layer was extracted with CH2Cl2 (3 x 5 mL), combined organic layers dried over MgSO4 and concentrated 
in vacuo. The crude material was purified by flash column chromatography (9:1 PE/EtOAc), to give the 
title compound as a colourless oil (140 mg, 82%).  
 
Rf 0.14 (9:1 PE/EtOAc); [𝛼]𝐷20   ̶  23.6 (c 2.50, CHCl3); IR (thin film, νmax/cm-1): 3377, 1614, 1514, 1462, 
1378, 1240, 1037, 834, 773; 1H NMR (500 MHz, CDCl3): δH 7.25 (2H, d, J = 8.9 Hz, H-Ar), 6.87 (2H, d, J = 
8.9 Hz, H-Ar), 4.68 (1H, app s, H-1), 4.67 (1H, app s, H-1), 4.53 (1H, d, J = 10.9 Hz, CHaCHbAr), 4.49 (1H, 
d, J = 10.9 Hz, CHaHbAr), 4.18 (1H, dt, J = 11.0, 2.5 Hz, H-7), 3.80 (3H, s, ArOCH3), 3.65-3.59 (2H, m, H-
11), 3.42 (1H, dd, J = 10.2, 1.8 Hz, H-9), 2.03-1.98 (1H, m, H-10), 1.95-1.89 (1H, m, H-8), 1.72 (3H, s, Me-
2), 1.66-1.10 (8H, m, H-3-6, O-H), 0.88 (9H, s, SiC(CH3)3), 0.88 (3H, d, J = 6.8 Hz, Me-10), 0.85 (3H, d, J = 
6.6 Hz, Me-8), 0.82 (3H, d, J = 7.0 Hz, Me-5), 0.05 (3H, s, Si(CHa3)(CHb3)), 0.02 (3H, s, Si(CHa3)(CHb3)); 13C 
NMR (125 MHz, CDCl3): δC 158.9, 146.4, 131.2, 128.6, 113.7, 109.6, 80.6, 73.6, 69.6, 66.1, 55.3, 42.6, 
38.3, 37.8, 36.4, 35.3, 31.0, 28.6, 25.9, 22.6, 19.1, 18.1, 9.9,   ̶ 4.1,   ̶ 4.6. 
 
 (2R,3S,4R,5S,7R)-5-((tert-Butyldimethylsilyl)oxy)-3-((4-methoxybenzyl)oxy)-2,4,7,10-
tetramethylundec-10-enal (194) 
 
To a solution of alcohol 193 (130 mg, 0.26 mmol, 1.0 equiv.) in CH2Cl2 (2.6 mL) were added 
triacetoxyiodobenzene (568 mg, 1.32 mmol, 5.0 equiv.) and anhydrous NaHCO3 (178 mg, 2.11 mmol, 
8.0 equiv.) and stirred for 20 min. The reaction was then quenched with NaHCO3 (2 mL) and Na2S2O3 (2 
mL) and stirred for a further 10 min before the layers were separated. The aqueous layer was  
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extracted with CH2Cl2 (3 x 4 mL), combined organic layers dried over MgSO4 and concentrated in vacuo. 
The crude material (95 mg, 73%), was used without further purification.  
 
Rf 0.39 (9:1 PE/EtOAc); 1H NMR (400 MHz, CDCl3): δH 9.84 (1H, d, J = 1.6 Hz, H-11),  7.17 (2H, d, J = 8.7 
Hz, H-Ar), 6.84 (2H, d, J = 8.7 Hz, H-Ar), 4.69-4.66 (2H, m, H-1), 4.26 (2H, s, CH2Ar), 4.17 (1H, ddd, J = 
11.2, 3.1, 2.3 Hz, H-7), 3.83-3.79 (4H, m, ArOCH3, H-10), 2.52 (1H, qd, J = 7.2, 1.6 Hz, H-10), 2.02-1.96 
(1H, m, H-8), 1.72 (3H, s, Me-2), 1.64-1.28 (7H, m, H-3, H-4, H-5, H-6), 1.18 (3H, d, J = 7.1 Hz, Me-10), 
0.88 (9H, s, SiC(CH3)3), 0.87 (3H, d, J = 6.7 Hz, Me-8), 0.82 (3H, d, J = 6.6 Hz, Me-5),  0.03 (3H, s, Si(CHa3-
)(CHb3)), 0.01 (3H, s, Si(CHa3)(CHb3)). 
 
tert-Butyl(((3S,4R,5R,6S,8R,Z)-1-iodo-4-((4-methoxybenzyl)oxy)-3,5,8,11-tetramethyldodeca-1,11-
dien-6-yl)oxy)dimethylsilane (186) 
 
 
To a suspension of (iodomethane)triphenylphosphonium iodide (288 mg, 0.55 mmol, 3.0 equiv.) in THF 
(1.3 mL) at 0 °C was added NaHMDS (1 M in THF, 0.55 mL, 0.55 mmol, 3.0 equiv.) and stirred for 30 min 
before being cooled to    ̶78 °C. A solution of aldehyde 194 (90 mg, 0.18 mmol, 1.0 equiv.) in THF (0.5 
mL) was added via cannula and the reaction mixture stirred for a further 90 min before being quenched 
with PE (3 mL) and filtered through Celite®. The filtrate was then dried over MgSO4 and concentrated in 
vacuo. The crude material was purified by flash column chromatography (19:1 PE/EtOAc) to give the 
title compound as a colourless oil (99 mg, 88%).  
 
Rf 0.64 (9:1 PE/EtOAc); [𝛼]𝐷20 + 55.4 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 1514, 1462, 1248, 1065, 834, 
773; 1H NMR (500 MHz, CDCl3): δH 7.22 (2H, d, J = 8.6 Hz, H-Ar), 6.86 (2H, d, J  =8.6 Hz, H-Ar), 6.22 (1H, 
dd, J = 8.6, 7.3 Hz, H-11), 6.16 (1H, dd, J = 7.3, 1.5 Hz, H-12), 4.68-4.66 (2H, m, H-1), 4.46 (1H, d, J = 11.0 
Hz, CHaCHbAr), 4.42 (1H, d, J = 11.0 Hz, CHaCHbAr), 4.11 (1H, ddd, J = 10.4, 3.2, 1.8 Hz, H-), 3.80 (3H, s, 
ArOCH3), 3.25 (1H, dd, J = 9.6, 2.9 Hz, H-), 2.72 (1H, dqd, J = 8.6, 6.8, 2.9 Hz, H-10), 1.98-1.91 (1H, m, H-
8), 1.71 (3H, s, Me-2), 1.63-1.06 (7H, m, H-3, H-4, H-5, H-6), 1.04 (3H, d, J = 6.8 Hz, Me-10), 0.92 (3H, d, 
J = 7.1 Hz, Me-8), 0.88 (9H, s, SiC(CH3)3), 0.83 (3H, d, J = 6.6 Hz, Me-5), 0.03 (3H, s, Si(CHa3)(CHb3)), 0.01 
(3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 158.9, 146.4, 145.4, 131.2, 128.4, 113.6, 109.5, 
83.4, 80.9, 74.1, 69.5, 55.3, 55.3, 42.8, 41.8, 38.6, 36.4, 35.3, 28.6, 26.0, 22.5, 19.1, 18.1, 12.4, 10.4,   ̶ 
4.1,   ̶ 4.6; HRMS (ES+): calc. for C30H52IO3Si [M+H]+ 615.2721, found 615.2725. 
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(2S,5R,7S,8R)-7-((tert-Butyldimethylsilyl)oxy)-8-((4R,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-
4-yl)-2,5-dimethylnonane-1,2-diol (197) 
 
To a solution of alkene 104 (50 mg, 0.102 mmol, 1.0 equiv.) (as a 3:1 mixture with alkane 185), in t-
BuOH/H2O (1:1, 1 mL), were added K2OsO2(OH)4 (0.74 mg, 2 μmol, 2.0 mol%), (DHQ)2AQN (2.3 mg, 3 
μmol, 3.0 mol%), K2CO3 (42.5 mg, 0.306 mmol, 3.0 equiv.) and K3Fe(CN)6 (101 mg, 0.306 mg, 3.0 equiv.) 
and stirred for 16 h. The reaction was quenched with Na2S2O3 (2 mL) and Et2O (2 mL) before the layers 
were separated. The aqueous layer was extracted with Et2O (3 x 3 mL) and EtOAc (2 x 3 mL). Combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. The crude material was purified by 
flash column chromatography (3:1 PE/EtOAc) to give the title compound as a viscous colourless oil (25 
mg, 63%, 2.3:1 ratio of PMP acetal diastereomers) and alkane 185 (12 mg).  
 
Major diastereomer:  
Rf 0.18 (3:1 PE/EtOAc); [𝛼]𝐷20   ̶  33.2 (c 1.80, CHCl3); IR (thin film, νmax/cm-1): 3466, 3416, 1517, 1463, 
1379, 1249, 1166, 1038, 834, 774; 1H NMR (500 MHz, CDCl3): δH 7.39 (2H, d, J = 8.8 Hz, H-Ar), 6.88 (2H, 
d, J = 8.8 Hz, H-Ar), 5.37 (1H, s, CHAr), 4.20 (1H, ddd, J = 10.0, 3.1, 1.5 Hz, H-7), 4.04-4.01 (2H, m, H-11), 
3.81 (3H, s, ArOCH3), 3.58 (1H, dd, J = 10.3, 2.0 Hz, H-9), 3.45 (1H, d, J = 10.7 Hz, H-1a), 3.39 (1H, d, J = 
10.7 Hz, H-1b), 2.04 (1H, br s, O-H), 2.00-1.93 (1H, m, H-10), 1.86 (1H, br s, O-H), 1.61-1.57 (1H, m, H-8), 
1.55 -1.22 (7H, m, H-3-6), 1.16 (3H, d, J = 7.0 Hz, Me-8), 1.15 (3H, s, Me-2), 0.89 (9H, s, SiC(CH3)3), 0.79 
(3H, d J = 6.4 Hz, Me-5), 0.80 (3H, d, J = 7.0 Hz, Me-10), 0.05 (3H, s, Si(CHa3)(CHb3)), 0.03 (3H, s, Si(CHa3-
)(CHb3)) ; 13C NMR (125 MHz, CDCl3): δC 159.7, 131.6, 127.1, 113.5, 101.2, 81.3, 74.1, 73.0, 69.9, 68.7, 
55.3, 40.5, 37.7, 36.2, 32.1, 29.9, 29.4, 25.9, 23.3, 19.2, 18.1, 10.9, 7.9,   ̶ 4.2,   ̶ 4.6; HRMS (ES+): calc. for 
C29H53O6Si [M+H]+ 525.3611, found 525.3612. 
 
Minor diastereomer:  
1H NMR (500 MHz, CDCl3): δH 7.39 (2H, d, J = 8.8 Hz, H-Ar), 6.90 (2H, d, J = 8.8 Hz, H-Ar), 6.02 (1H, s, 
CHAr), 4.32 (1H, dt, J = 11.5, 2.1 Hz, H-7), 4.04-4.01 (2H, m, H-11), 3.83 (3H, s, ArOCH3), 3.63 (1H, dd, J = 
11.3, 2.1 Hz, H-9), 3.45 (1H, d, J = 10.7 Hz, H-1a), 3.39 (1H, d, J = 10.7 Hz, H-1b), 2.04 (1H, br s, O-H), 
2.00-1.93 (1H, m, H-10), 1.88 (1H, br s, O-H), 1.18 (3H, d, J = 7.0 Hz, Me-8), 1.55-1.22 (7H, m, H-3-6), 1.15 
(3H, s, Me-2), 0.91 (9H, s, SiC(CH3)3), 0.71 (3H, d, J = 7.1 Hz, Me-10), 0.13 (3H, s, Si(CHa3)(CHb3)), 0.11 
(3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 159.3, 130.3, 128.3, 113.9, 96.6, 81.2, 72.4, 68.2, 
67.1, 65.9, 55.3, 41.1, 37.8, 36.1, 32.4, 30.7, 30.3, 23.3, 18.9, 18.2, 15.3, 10.9, 8.1,   ̶ 4.1,   ̶ 4.6.  
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 (5S,7R,10S)-13,13-Diethyl-5-((1R)-1-((4R,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)ethyl)-
2,2,3,3,7,10-hexamethyl-10-((triethylsilyl)oxy)-4,12-dioxa-3,13-disilapentadecane (198) 
 
 
To a solution of diol 197 (22 mg, 0.038 mmol, 1.0 equiv.) in CH2Cl2 (0.5 mL) at    ̶78 °C were added 2,6-
lutidine (49 μL, 0.478 mmol, 12.5 equiv.) and TESOTf (53 μL, 0.288 mmol, 7.5 equiv.) and stirred for 1 h 
before being warmed up to rt. After stirring for a further 30 min, the reaction was quenched with NH4Cl 
(1 mL) and the layers separated. The aqueous layer was extracted with CH2Cl2 (4 x 1 mL), combined 
organic layers were dried over MgSO4 and concentrated in vacuo. The crude material was purified by 
flash column chromatography (PE o 10:1 PE/EtOAc) to give the title compound as a colourless oil (31 
mg, 99%).  
 
Rf 0.61 (3:1 PE/EtOAc); [𝛼]𝐷20   ̶12.7 (c 0.85, CHCl3); IR (thin film, νmax/cm-1): 1517, 1461, 1249, 1166, 1106, 
1014, 833, 740; 1H NMR (500 MHz, CDCl3): δH 7.39 (2H, d, J = 8.7 Hz, H-Ar), 6.88 (2H, d, J = 8.7 Hz, H-Ar), 
5.38 (1H, s, CHAr), 4.17 (1H, br d, J = 9.8 Hz, H-7), 4.06 (1H, dd, J = 11.3, 2.2, Hz, H-11a), 4.02 (1H, dd, J = 
11.3, 1.1 Hz, H-11b), 3.81 (3H, s, ArOCH3), 3.58 (1H, dd, J = 10.5, 2.0 Hz, H-9), 3.39 (1H, d, J = 9.4 Hz, H-
1a), 3.30 (1H, dd, J = 9.4, 2.0 Hz, H-1b), 1.95 (1H, qddd, J = 7.0, 2.2, 2.0, 1.1 Hz, H-10), 1.61-1.56 (1H, m, 
H-8), 1.50-1.19 (7H, m, H-3-6), 1.15 (3H, d, J = 6.8 Hz, Me-8), 1.14 (3H, s, Me-2), 0.95 (9H, t, J = 8.0 Hz, 
Si(CH2CH3)3), 0.93 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.88 (9H, s, SiC(CH3)3), 0.79 (3H, d, J = 7.0 Hz, Me-10), 
0.75 (3H, d, J = 6.5 Hz, Me-5), 0.58 (6H, q, J = 7.9 Hz, Si(CH2CH3)3), 0.56 (6H, q, J = 7.8 Hz, Si(CH2CH3)3), 
0.04 (3H, s, Si(CHa3)(CHb3)), 0.02 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 159.7, 131.7, 
127.1, 113.4, 101.2, 81.2, 75.9, 74.1, 69.9, 68.7, 55.3, 40.4, 38.1, 37.1, 31.9, 29.9, 29.5, 25.9, 25.3, 22.6, 
19.3, 18.1, 10.9, 7.8, 7.2, 6.8, 4.4,   ̶ 4.2,   ̶ 4.7; HRMS (ES+): calc. for C41H81O6Si3 [M+H]+ 753.5341, found 
753.5349. 
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(2S,3R,4R,5S,7R,10S)-5-((tert-Butyldimethylsilyl)oxy)-3-((4-methoxybenzyl)oxy)-2,4,7,10-
tetramethyl-10,11-bis((triethylsilyl)oxy)undecan-1-ol (195) 
 
 
Procedure A:  
To a stirred solution of PMP acetal 198 (87 mg, 0.116 mmol, 1.0 equiv.) in CH2Cl2 (1.2 mL) at   ̶ 30 °C was 
added DIBAL (1 M in hexanes, 0.58 mL, 0.58 mmol, 5.0 equiv.) over 10 min. The reaction mixture was 
maintained at this temperature for 3 h before being quenched with NaK tartrate (3 mL) and stirred for 
a further 1 h. The layers were then separated and the aqueous layer extracted with CH2Cl2 (3 x 3 mL). 
Combined organic layers were dried over MgSO4 and concentrated in vacuo. The crude material was 
purified by flash column chromatography (9:1 PE/EtOAc) to give the title compound as a colourless oil, 
(48 mg 58%). 
 
Procedure B: 
To a stirred solution of PMP acetal 198 (30.0 mg, 0.039 mmol, 1.0 equiv.) in CH2Cl2 (0.6 mL) at   ̶78 °C 
was added DIBAL (1 M in hexanes, 0.20 mL, 0.20 mmol, 5.0 equiv.) over 10 min. The reaction mixture 
was maintained at this temperature for 30 min before being warmed to 0 °C over 30 min and stirred for 
a further 1 h. The reaction was then quenched with NaK tartrate (1 mL) and stirred for 1 h. The layers 
were then separated and the aqueous layer extracted with CH2Cl2 (3 x 3 mL). Combined organic layers 
were dried over MgSO4 and concentrated in vacuo. The crude material was purified by flash column 
chromatography (9:1 PE/EtOAc) to give the title compound as a colourless oil, (11.7 mg, 40%) and diol 
199 (10.3 mg, 41 %).  
 
Rf 0.18 (9:1 PE/EtOAc); [𝛼]𝐷20   ̶28.7 (c 1.30, CHCl3); IR (thin film, νmax/cm-1): 3443, 1614, 1514, 1461, 1248, 
1087, 1038, 822, 741; 1H NMR (500 MHz, CDCl3): δH 7.26 (2H, d, J = 8.8 Hz, H-Ar), 6.87 (2H, d, J = 8.8 Hz, 
H-Ar), 4.53 (1H, d, J = 11.0 Hz, CHaHbAr), 4.48 (1H, d, J = 11.0 Hz, CHaHbAr), 4.17 (1H, d, J = 10.7 Hz, H-
7), 3.80 (3H, s, ArOCH3),  3.66-3.58 (2H, m, H-11), 3.42 1H, dd, J = 10.1, 2.2 Hz, H-9), 3.40 (1H, d, J = 10.0 
Hz, H-1a), 3.31 (1H, dd, J = 9.5, 2.6 Hz, H-1b),  2.04-1.97 (1H, m, H-8), 1.94-1.89 (1H, m, H-10), 1.60 (1H, 
t, J = 5.2 Hz, O-H), 1.53-1.19 (7H, m, H-3, H-4, H-5, H-6), 1.16 (3H, s, Me-2), 0.96 (9H, t, J = 8.0 Hz, Si(CH-
2CH3)3), 0.94 (9H, t, J = 7.8 Hz, Si(CH2CH3)3), 0.89 (3H, d, J = 7.0 Hz, Me-10), 0.88 (9H, s, SiC(CH3)3), 0.85 
(3H, d, J = 7.4 Hz, Me-5), 0.82 (3H, d, J = 7.0 Hz, Me-8), 0.59 (6H, q, J = 8.0 Hz,  
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Si(CH2CH3)3), 0.57 (6H, q, J = 7.8 Hz, Si(CH2CH3)3), 0.05 (3H, s, Si(CHa3)(CHb3)), 0.02 (3H, s, Si(CHa3)(CHb3)); 
13C NMR (125 MHz, CDCl3): δC 158.9, 131.2, 128.6, 113.7, 80.7, 75.9, 73.5, 69.9, 69.6, 66.2, 55.3, 42.6, 
38.4, 37.8, 37.1, 31.9, 29.4, 25.9, 25.3, 19.4, 18.1, 15.3, 10.2, 9.9, 7.2, 6.8, 4.4,   ̶ 4.2,  ̶ 4.7; HRMS (ES+): 
calc. for C41H80O6Si3Na [M+Na]+ 777.5317, found 777.5315. 
 
 
 (2S,5R,7S,8R,9R,10S)-7-((tert-Butyldimethylsilyl)oxy)-9-((4-methoxybenzyl)oxy)-2,5,8,10-
tetramethyl-2-((triethylsilyl)oxy)undecane-1,11-diol (199) 
 
 
Rf 0.12 (3:1 PE/EtOAc); [𝛼]𝐷20   ̶25.9 ° (c 0.46, CHCl3); IR (thin film, νmax/cm-1): 3551, 3443, 1614, 1510, 
1462, 1248, 1052, 822, 741; 1H NMR (500 MHz, CDCl3): δH 7.25 (2H, d, J = 8.7 Hz, H-Ar), 6.87 (2H, d, J = 
8.7 Hz, H-Ar), 4.52 (1H, d, J = 11.2 Hz, CHaCHbAr), 4.48 (1H, d, J = 11.2 Hz, CHaHbAr), 4.17 (1H, dt, J = 
10.9, 2.2 Hz, H-7), 3.80 (3H, s, ArOCH3), 3.64-3.60 (2H, m, H-11), 3.41 (1H, dd, J = 9.8, 1.9 Hz, H-9), 3.38 
(1H, dd, J = 10.7, 6.9 Hz, H-1a), 3.31 (1H, dd, J = 10.7, 5.6 Hz, H-1b), 2.03-1.97 (2H, m, H-8, O-H), 1.95-
1.89 (1H, m, H-10), 1.59 (1H, br s, O-H), 1.54-1.21 (7H, m, H-3, H-4, H-5, H-6), 1.19 (3H, s, Me-2), 0.98-
0.95 (9H, m, Si(CH2CH3)3)). 0.89-0.81 (18H, m, Me-5, Me-8, Me-10, SiC(CH3)3), 0.64-0.58 (6H, m, Si(CH2-
CH3)3), 0.05 (3H, s, Si(CHa3)(CHb3)), 0.02 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 158.8, 
131.1, 128.4, 113.6, 80.5, 76.2, 73.4, 69.8, 69.4, 66.0, 55.2, 42.5, 38.0, 37.7, 37.3, 29.0, 27.6, 25.8, 22.5,  
19.3, 18.0, 10.1, 9.7, 7.0, 4.3,   ̶ 4.3,   ̶ 4.7; HRMS (ES+): calc. for C35H69O6Si2 [M+H]+ 641.4633, found 
641.4641. 
 
 
 (2R,3S,4R,5S,7R,10S)-5-((tert-Butyldimethylsilyl)oxy)-3-((4-methoxybenzyl)oxy)-2,4,7,10-
tetramethyl-10,11-bis((triethylsilyl)oxy)undecanal (200) 
 
 
To a solution of alcohol 195 (32 mg, 0.042 mmol, 1.0 equiv.) in CH2Cl2 (0.5 mL) were added 
triacetoxyiodobenzene (36 mg, 0.085, 2.0 equiv.) and NaHCO3 (10.6 mg, 0.126 mmol, 3.0 equiv.) and 
stirred for 20 min. Upon completion, Na2S2O3 (0.5 mL) and NaHCO3 (0.5 mL) were added and stirred  
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for a further 10 min, before the layers were separated and the aqueous layer was extracted with CH2Cl2 
(3 x 1 mL). Combined organic layers were dried over MgSO4 and concentrated in vacuo. The crude 
material (31 mg, 97%) was used directly in the following reaction without further purification.  
 
Rf 0.34 (9:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 9.83 (1H, s, H-11), 7.17 (2H, d, J = 8.7 Hz, H-Ar), 
6.83 (2H, d, J = 8.7 Hz, H-Ar), 4.28 (1H, d, J = 10.8 Hz, CHaHbAr), 4.24 (1H, d, J = 10.8 Hz, CHaHbAr), 4.15 
(1H, dt, J = 9.9, 2.9 Hz, H-7), 3.81 (1H, dt, J = 9.4, 2.1 Hz, H-9), 3.79 (3H, ArOCH3), 3.39 (1H, d, J =  9.6 Hz, 
H-1a), 3.31 (1H, dd, J = 9.6, 2.9 Hz, H-1b), 2.52 (1H, q, J = 7.1 Hz, H-10), 2.01-1.96 (1H, m, H-8), 1.54-1.23 
(7H, m, H-3, H-4, H-5, H-6), 1.17 (3H, d, J = 7.1 Hz, Me-10), 1.15 (3H, s, Me-2), 0.95 (9H, t, J = 7.9 Hz, 
Si(CH2CH3)3), 0.93 (9H, t, J = 8.1 Hz, Si(CH2CH3)3), 0.87 (9H, s, SiC(CH3)3), 0.85 (3H, d, J = 7.1 Hz, Me-8), 
0.80 (3H, d J = 6.8 Hz, Me-5), 0.59 (6H, q, J = 7.9 Hz, Si(CH2CH3)3), 0.56 (6H, q, J = 8.1 Hz, Si(CH2CH3)3), 
0.02 (3H, s, Si(CHa3)(CHb3)), 0.01 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 205.1, 159.1, 
130.4, 129.3, 113.6, 79.2, 75.9, 72.6, 69.8, 69.5, 55.2, 55.2, 49.4, 42.2, 38.5, 37.1, 31.8, 29.4, 25.9, 25.3, 
25.3, 19.5, 19.4, 18.1, 10.5, 7.2, 6.8, 4.4,    ̶ 4.2,   ̶ 4.7. 
   
(5S,7R,10S)-13,13-Diethyl-5-((2R,3R,4S,Z)-6-iodo-3-((4-methoxybenzyl)oxy)-4-methylhex-5-en-2-yl)-
2,2,3,3,7,10-hexamethyl-10-((triethylsilyl)oxy)-4,12-dioxa-3,13-disilapentadecane (196) 
 
 
To a stirred suspension of (iodomethyl)triphenylphosphonium iodide (89 mg, 0.170 mmol, 4.0 equiv.) in 
THF (0.3 mL) at 0 °C was added NaHMDS (1M in THF, 0.14 mL, 0.144 mmol, 3.5 equiv.) and stirred for 
30 min. The reaction mixture was then cooled to    ̶ 78 °C and a solution of aldehyde 200 (31 mg, 0.041 
mmol, 1.0 equiv.) in THF (0.3 mL) added via cannula, before stirring for a further h. The reaction was 
then quenched by addition of PE and filtered through a short plug of Celite®, before being concentrated 
in vacuo. The crude material was purified by flash column chromatography (19:1 PE/EtOAc) to give the 
title compound as a colourless oil (23 mg, 64%).  
 
Rf 0.17 (19:1 PE/EtOAc); [𝛼]𝐷20 + 14.5 ° (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 1514, 1462, 1248, 1065, 
836, 771; 1H NMR (500 MHz, CDCl3): δH 7.23 (2H, d, J = 8.5 Hz, H-Ar), 6.86 (2H, d, J 8.5 Hz, H-Ar), 6.23 
(1H, dd, J =8.8, 7.2 Hz, H-11), 6.16 (1H, d, J = 7.3 Hz, H-12), 4.47 (1H, d, J = 11.0 Hz, CHaHbAr), 4.42 (1H, 
d, J = 11.0 Hz, CHaHbAr), 4.11 (1H, d, J= 10.1 Hz, H-7), 3.81 (3H, s, ArOCH3), 3.40 (1H, d, J = 9.4 Hz, H-1a), 
3.31 (1H, d, J = 9,4 Hz, H-1b), 3.26 (1H, dd, J = 9.6, 2.6 Hz, H-9), 2.76-2.70 (1H, m, H-10), 1.99-1.93  
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(1H, m, H-8), 1.55-1.26 (7H, m, H-3, H-4, H-5, H-6), 1.16 (3H, s, Me-2), 0.96 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 
0.94 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.92 (3H, d, J  7.2 Hz, Me-8), 0.82 (3H, d, J  = 6.5 Hz, Me-5), 0.59 (6H, 
q, J = 8.0 Hz, Si(CH2CH3)3), 0.57 (6H, q, J = 8.0 Hz, Si(CH2CH3)3), 0.04 (6H, s, SiC(CH3)3), 0.02 (6H, s, SiC(CH-
3)3); 13C NMR (125 MHz, CDCl3): δC 158.9, 145.5, 131.2, 128.4, 113.6, 83.3, 80.8, 75.9, 74.0, 69.9, 69.5, 
55.3, 42.8, 41.8, 38.6, 37.1, 32.0, 29.4, 25.9, 25.3, 22.6, 19.4, 18.1, 12.2, 10.3, 7.2, 6.8, 4.4,   ̶ 4.1,   ̶ 4.6 ; 
HRMS (ES+): calc. for C42H81IO5Si3 [M+H]+ 899.4334, found 899.4336 
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6.4.2 Preparation of the C13-C19 Vinyl Iodide 
 
(R)-N-Methoxy-3-((4-methoxybenzyl)oxy)-N,2-dimethylpropanamide (218) 
 
To a slurry of N, O- dimethylhydroxylamine hydrochloride (16.6 g, 167 mmol, 1.5 equiv.) and methyl 
ester 223 (26.4 g, 111 mmol, 1.0 equiv.) in THF (150 mL) was added i-PrMgCl (3 M in THF, 167 mL, 473 
mmol, 4.5 equiv.) over 30 min, maintaining a temperature of   ̶ 20 °C. The reaction mixture was then left 
to stir at    ̶ 10 °C for a further 3 h before quenching with NH4Cl (200 mL). The layers were separated and 
the aqueous layer extracted with EtOAc (5 x 80 mL). Combined organic layers were dried over MgSO4 
and concentrated in vacuo. The crude material was purified by flash column chromatography (4:1 o 
0:1 PE/EtOAc) to give the title compound as an orange liquid (23.7 g, 80%). 
 
Rf 0.18 (3:1 PE/EtOAc); 1H NMR (400 MHz, CDCl3): δH 7.23 (2H, d, J = 8.6 Hz, H-Ar), 6.86 (2H, d, J = 8.6 
Hz, H-Ar), 4.48 (1H, d, J = 11.7 Hz, OCHaHbAr), 4.40 (1H, d, J = 11.7 Hz, OCHaHbAr), 3.79 (3H, s, ArOMe), 
3.69 (1H, app t, J  = 8.8 Hz, H-13a), 3.68 (3H, s, N(Me)OMe), 3.39 (1H, dd, J = 8.8, 5.9 Hz, H-13b), 3.28 -
3.22 (1H, m, H-14), 3.20 (3H, s, N(Me)OMe), 1.10 (3H, d, J = 6.8 Hz, Me-14).  
Data in agreement with literature values176 
 
(R)-4-((4-Methoxybenzyl)oxy)-3-methylbutan-2-one (220) 
 
To a solution of Weinreb amide 218 (900 mg, 3.36 mmol, 1.0 equiv.) in THF (24 mL) at 0 °C was added 
MeMgBr (3 M in Et2O, 1.68 mL, 5.04 mmol, 1.5 equiv.) dropwise over 10 min and the reaction mixture 
stirred for 90 min. Upon completion by TLC, the reaction was quenched with NH4Cl (15 mL) and the 
layers separated. The aqueous layer was extracted with Et2O (3 x 10 mL). Combined organic layers were 
dried over MgSO4 and concentrated in vacuo. The crude material was purified by flash column 
chromatography (9:1 o 7:1 PE/EtOAc) to give the title compound as a pale-yellow oil (669 mg, 81%).  
Rf 0.18 (3:1 PE/EtOAc); 1H NMR (400 MHz, CDCl3): δH 7.23 (2H, d, J = 8.6 Hz, H-Ar), 6.86 (2H, d, J = 8.6 
Hz, H-Ar), 4.48 (1H, d, J = 11.7 Hz, OCHaHbAr), 4.40 (1H, d, J = 11.7 Hz, OCHaHbAr), 3.79 (3H, s, ArOMe), 
3.60 (1H, dd, J = 9.1, 7.7 Hz, H-13a), 3.43 (1H, dd, J = 9.1, 5.5 Hz, H-13b), 2.87 (1H, dqd, J = 9.1, 7.0, 5.5 
Hz, H-14), 2.17 (3H, s, H-16), 1.07 (3H, d, J = 7.0 Hz, Me-14). 
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Data in agreement with literature values177 
 
(R)-1-Hydroxy-4-((4-methoxybenzyl)oxy)-3-methylbutan-2-one (222) 
 
To a stirred solution of methyl ketone 220 (1.00 g, 4.08 mmol, 1.0 equiv.) in THF (13 mL) at   ̶ 78 °C was 
added LDA (1 M in THF, 5.70 mL, 5.70 mmol, 1.4 equiv.) via cannula. After 1 h at this temperature, TMSCl 
(0.9 mL, 6.53 mmol, 1.6 equiv.) was added and the solution stirred for another 1 h at this temperature 
before being allowed to warm to rt over the following h. The reaction mixture was then concentrated 
in vacuo and pentane (10 mL) added. The precipitate formed was filtered through Celite® and the filtrate 
concentrated in vacuo.  The crude silyl enol ether was then redissolved in t-BuOH/H2O/THF (1:1:1, 20 
mL) and OsO4 (4 wt% in H2O, 1.4 mL, 0.22 mmol, 0.05 equiv.) and NMO (50 wt% in H2O, 2.13 mL, 9.10 
mmol, 2.2 equiv.) added. The reaction mixture was left to stir for 16 h before being quenched with 
Na2S2O3 (15 mL) and Et2O (20 mL). The layers were separated and the aqueous layer extracted with Et2O 
(3 x 20 mL) and EtOAc (20 mL). Combined organic layers were dried over MgSO4 and the solvent removed 
in vacuo. The crude material was purified by flash column chromatography (9:1 o 4:1 PE/EtOAc) to give 
the title compound as a colourless oil (880 mg, 82%). 
Rf 0.14 (3:1 PE/EtOAc); [𝛼]𝐷20   ̶  27.3 (c 1.15, CHCl3); IR (thin film, νmax/cm-1): 3484, 1717, 1612, 1513, 
1456, 1302, 1246, 1094, 1031, 819; 1H NMR (500 MHz, CDCl3): δH 7.20 (2H, d, J = 8.7 Hz, H-Ar), 6.87 (2H, 
d, J = 8.7 Hz, H-Ar), 4.42 (1H, d, J = 11.6 Hz, CHaHbAr), 4.39 (1H, d, J = 11.6 Hz, CHaHbAr), 4.35 (1H, dd, 
J = 18.6, 4.9 Hz, H-16a), 4.29 (1H, dd, J = 18.6, 4.8 Hz, H-16b), 3.81 (3H, s, ArOCH3), 3.55 (1H, dd, J = 8.8, 
8.7 Hz, H-13a), 3.48 (1H, dd, J = 8.8, 5.1 Hz, H-13b), 3.13 (1H, dd, J = 4.9, 4.8 Hz, O-H), 2.91-2.84 (1H, m, 
H-14), 1.10 (3H, d, J = 7.0 Hz, Me-14); 13C NMR (125 MHz, CDCl3): δC 212.4, 159.3, 129.7, 129.3, 73.1, 
71.7, 68.2, 55.3, 43.0, 13.0; HRMS (ES+) calc. for C13H18O4Na [M+Na]+ 261.1103, found 261.1114. 
 
(R)-1-((tert-Butyldimethylsilyl)oxy)-4-((4-methoxybenzyl)oxy)-3-methylbutan-2-one (216) 
 
 
To a solution of alcohol 222 (256 mg, 0.59 mmol, 1.0 equiv.) in CH2Cl2 (5 mL) were added imidazole (60.5 
mg, 0.89 mmol, 1.5 equiv.) and TBSCl (107 mg, 0.71 mmol, 1.2 equiv.). The reaction mixture was stirred  
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for 1 h before being quenched with NH4Cl (5 mL) and the layers separated. The aqueous layer was 
extracted with CH2Cl2 (3 x 4 mL) and combined organic layers dried over MgSO4 before being 
concentrated in vacuo. The crude material was purified by flash column chromatography (9:1 o 5:1 
PE/EtOAc) to give the title compound as a colourless oil (310 mg, 85%).  
Rf 0.49 (3:1 PE/EtOAc); [𝛼]𝐷20   ̶  11.8 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 2930, 1732, 1613, 1587, 
1513, 1463, 1361, 1302, 1246, 1172, 1093, 1033, 939, 836, 779, 668; 1H NMR (500 MHz, CDCl3): δH 7.21 
(2H, d, J = 8.3 Hz, H-Ar), 6.86 (2H, d, J = 8.3 Hz, H-Ar), 4.43 (1H, d, J = 11.5 Hz, CHaHbAr), 4.37 (1H, d, J = 
11.5 Hz, CHaHbAr), 4.33 (1H, d, J = 19.2 Hz, H-16a), 4.26 (1H, d, J = 19.2 Hz, H-16b), 3.80 (3H, s, ArOCH3), 
3.58 (1H, t, J = 8.5 Hz, H-13a), 3.43 (1H, dd, J = 8.5, 5.4 Hz, H-13b), 3.07-2.99 (1H, m, H-14), 1.06 (3H, d, 
J = 7.1 Hz, Me-14), 0.91 (9H, s, SiC(CH3)3), 0.07 (3H, s, Si(CHa3)(CHb3)), 0.06 (3H, s, Si(CHa3)(CHb3)); 13C 
NMR (125 MHz, CDCl3): δC 211.8, 159.2, 130.1, 129.2, 113.7, 72.9, 71.8, 69.5, 55.2, 41.9, 25.6, 18.3, 13.2, 
  ̶ 3.6,   ̶ 5.6; HRMS (ES+) calc. for C19H32O4SiNa [M+Na]+ 375.1968, found 375.2008. 
 
 
3-(Trimethylsilyl)prop-2-yn-1-ol (224) 
 
A solution of freshly distilled propargyl alcohol (1.00 mL, 17.3 mmol, 1.0 equiv.) in THF (65 mL) was 
cooled to    ̶  78 °C and n-BuLi (1.6 M, 23.2 mL, 38.0 mmol, 2.2 equiv.) added over 15 min. The reaction 
mixture was stirred for 40 min. TMSCl (4.80 mL, 38.0 mmol, 2.2 equiv.) was then added dropwise and 
the solution slowly warmed to rt. After stirring for a further 2 h, the reaction mixture was re-cooled to 
0 °C and HCl (1 M, 34.6 mL, 34.6 mmol, 2.0 equiv.) added. After stirring vigorously for 1 h, the layers 
were separated and the aqueous layer extracted with Et2O (3 x 30 mL). Combined organic layers were 
dried over MgSO4 and concentrated in vacuo. The crude material was purified by flash column 
chromatography (9:1 PE/EtOAc) to give the title compound as a colourless liquid (1.86 g, 84%) 
Rf 0.41 (9:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 4.27 (2H, d, J = 6.2 Hz, H-17), 1.56 (1H, t, J = 6.2 Hz, 
O-H), 0.18 (9H, s, Si(CH3)3). 
Data in agreement with literature values178 
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(E)-2-Methyl-3-(trimethylsilyl)prop-2-en-1-ol (225) 
 
To a stirred suspension of copper (I) iodide (148 mg, 0.78 mmol, 0.2 equiv.) in THF (6 mL) was added a 
solution of alkyne 224 (500 mg, 3.90 mmol, 1.0 equiv.) in THF (4 mL) and stirred for 5 min. MeMgBr (3 
M in Et2O, 3.25 mL, 9.75 mmol, 2.5 equiv.) was then added dropwise over 5 min and the reaction mixture 
heated to reflux for 16 h. After cooling to 0 °C, the reaction was quenched with NH4Cl/NH4OH (9:1, 10 
mL). The layers were separated and the aqueous layer extracted with Et2O (3 x 8 mL). Combined organic 
layers were dried over MgSO4 and concentrated in vacuo. Purification by flash column chromatography 
(15:1 PE/EtOAc) gave an inseparable 3:2 mixture of the title compound and starting material.   
Rf 0.40 (9:1 PE/EtOAc); 1H NMR (400 MHz, CDCl3): δH 5.50 (1H, s, H-19), 4.00 (2H, d, J = 4.2 Hz, H-17), 
1.76 (3H, s, Me-18), 1.69 (1H, t, J = 4.2 Hz, O-H), 0.12 (9H, s, Si(CH3)3). 
Data in agreement with literature values179 
 (E)-2-Methyl-3-(trimethylsilyl)acrylaldehyde (215) 
 
To a solution of allylic alcohol 225 (220 mg, 1.53 mmol, 1.0 equiv.) in Et2O (8 mL) was added MnO2 (1.33 
g, 15.3 mmol, 10 equiv.) and stirred for 16 h. The reaction mixture was then filtered through Celite®, 
which was washed with Et2O (3 mL). The filtrate was concentrated carefully in vacuo and then dried 
over 4Å MS before being used directly in the following reaction, without further purification.  
 
 (E)-3-Iodo-2-methylacrylic acid (227) 
 
To a suspension of NaH (60% in mineral oil, 2.23 g, 55.5 mmol, 1.2 equiv.) in Et2O (70 mL) was added 
diethylmethylmalonate (8.0 mL, 46.4 mmol, 1.0 equiv.) slowly and then heated to reflux for 2 h. 
Iodoform (18.3 g, 46.4 mmol, 1.0 equiv.) was then added and the reaction mixture refluxed for a further 
15 h, before cooling to 0 °C. Et2O (50 mL) and HCl (3 M, 75 mL) were then added and the solution stirred 
for 10 min before the layers were separated and the aqueous layer extracted with Et2O (3 x 40 mL). The 
product was concentrated in vacuo before being redissolved in EtOH (35mL) and KOH (4 M, 35 mL, 140 
mmol, 3.0 equiv.). The solution was then heated to reflux for 16 h before being cooled to rt and 
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concentrated in vacuo. The residue was redissolved in K2CO3 (10% aq, 100 mL) and the precipitate 
filtered, washing with CH2Cl2 (2 x 30 mL). The filtrate was acidified to pH 1 with conc. HCl and the product 
extracted with CH2Cl2 (8 x 40 mL). Combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The crude product was isolated as a yellow-brown solid (6.4 g, 65%) and used without further 
purification.  
1H NMR (500 MHz, CDCl3): δH 8.04 (1H, s, H-19), 2.05 (3H, Me-18).  
Data in agreement with literature values112 
 
 (E)-3-Iodo-2-methylprop-2-en-1-ol (228) 
 
To a solution of carboxylic acid 227 (300 mg, 1.42 mmol, 1.0 equiv.) in Et2O (6 mL) at 0 °C was added 
LiAlH4 (62 mg, 1.62 mmol, 1.15 equiv.) in 4 portions. The reaction mixture was slowly warmed to rt and 
stirred for 2 h before being quenched with Na2SO4 (4 mL) and then H2SO4 (1.5 M aq, 4 mL). The layers 
were separated and the aqueous layer extracted with CH2Cl2 (3 x 8 mL). Combined organic layers were 
washed with K2CO3 (10% aq, 10 mL), dried over MgSO4, and concentrated in vacuo. The crude material 
was purified by flash column chromatography (4:1 PE/EtOAc) to give the title compound as a colourless 
liquid (269 mg, 96%).  
IR (thin film, νmax/cm-1): 3292, 1619, 1377, 1276, 1068, 1011, 774; 1H NMR (500 MHz, CDCl3): δH 6.29 (1H, 
sextet, J = 1.3 Hz, H-19), 4.13 (2H, br d, J = 3.7 Hz, H-17), 1.85 (3H, d, J = 1.3 Hz, Me-18), 1.6 (1H, t, J = 
3.7 Hz, O-H); HRMS (ES+) calc. for C4H6IO [M-H]- 196.9458, found 196.9458. 
Data in agreement with literature values.180 
 
 (E)-3-Iodo-2-methylacrylaldehyde (214) 
 
To a solution of allylic alcohol 228 (1.7 g, 8.58 mmol, 1.0 equiv.) in Et2O (40 mL) was added MnO2 (7.47 
g, 85.8 mmol, 10 equiv.) and stirred for 16 h. The reaction mixture was then filtered through Celite®, 
which was washed with Et2O (20 mL). The filtrate was concentrated carefully in vacuo and then dried 
over 4Å MS before being used directly in the following reaction, without further purification.  
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 (2R,4R,5R,E)-4-((tert-Butyldimethylsilyl)oxy)-5-hydroxy-7-iodo-1-((4-methoxybenzyl)oxy)-2,6-
dimethylhept-6-en-3-one (212) 
 
To a solution of Cy2BCl (1.01 mL, 5.48 mmol, 1.5 equiv.) in Et2O (8 mL) at 0 °C was added Et3N (0.86 mL, 
6.21 mmol, 1.7 equiv.) and stirred for 10 min before the addition of a solution of ketone 216 (1.25 g, 
3.65 mmol, 1.0 equiv.) in Et2O (8 mL). The reaction mixture was stirred for a further 75 min before 
cooling to   ̶78 °C. A solution of aldehyde 214 (2.5 g, 14.6 mmol, 3.5 equiv.) in Et2O (8 mL) was then 
added via cannula and the reaction mixture allowed to stir at this temperature for 5 h before quenching 
with MeOH (4 mL), pH 7 buffer (4 mL) and H2O2 (30 wt% aq, 2.5 mL) and warming to rt, stirring for a 
further 30 min. The layers were then separated and the aqueous layer extracted with Et2O (3 x 8 mL). 
Combined organic layers were dried over MgSO4 and concentrated in vacuo. The crude material was 
purified by flash column chromatography (9:1 PE/EtOAc) to give the title compound as a pale-yellow oil 
(1.61 g, 82%).   
 
Rf 0.26 (9:1 PE/EtOAc); [𝛼]𝐷20 + 51.3 (c 2.49, CHCl3); IR (thin film, νmax/cm-1): 3409, 1719, 1613, 1513, 
1249, 1075, 838, 778; 1H NMR (500 MHz, CDCl3): δH 7.18 (2H, d, J = 8.7 Hz, H-Ar), 6.88 (2H, d, J = 8.7 Hz, 
H-Ar), 6.26 (1H, s, H-19), 4.43 (1H, d, J = 11.7 Hz, OCHaHbAr), 4.37 (1H, d, J = 11.7 Hz, OCHaHbAr), 4.29 
(1H, dd, J = 7.8, 4.9 Hz, H-17), 3.89 (1H, d, J = 7.8 Hz, H-16), 3.81 (3H, s, ArOCH3), 3.73 (1H, d, J = 4.9 Hz, 
O-H), 3.62 (1H, dd, J = 10.2, 8.1 Hz, H-13a),  4.49-4.41 (1H, m, H-14), 3.38 (1H, dd, J = 8.1, 4.2 Hz, H-13b), 
1.82 (3H, s, Me-18), 1.00 (3H, d, J = 6.7 Hz, Me-14), 0.89 (9H, s, SiC(CH3)3),   ̶ 0.02 (3H, s, Si(CHa3)(CHb3)), 
  ̶  0.03 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 213.3, 159.6, 145.3, 129.7, 128.6, 114.0, 
81.4, 79.9, 77.1, 73.3, 73.2, 55.3, 40.0, 30.1, 25.7, 23.7, 19.4, 17.9, 14.6,   ̶4.8,   ̶ 5.1; HRMS (ES+) calc. for 
C23H37IO5SiNa [M+Na]+ 571.1353, found 571.1365. 
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(2S,4S,5S,E)-4-((tert-Butyldimethylsilyl)oxy)-5-hydroxy-1-((4-methoxybenzyl)oxy)-2,6-dimethyl-7-
(trimethylsilyl)hept-6-en-3-one (ent-213) 
 
To a solution of Cy2BCl (0.13 mL, 0.72 mmol, 1.56 equiv.) in Et2O (2.5 mL) at 0 °C was added Et3N (0.11 
mL, 0.81 mmol, 1.76 equiv.) and stirred for 10 min before the addition of a solution of ketone 216 (162 
mg, 0.46 mmol, 1.0 equiv.) in Et2O (3 mL). The reaction mixture was stirred for a further 75 min before 
cooling to   ̶78 °C. A solution of aldehyde 215 (261 mg, 1.84 mmol, 4.0 equiv.) in Et2O (2.5 mL) was then 
added via cannula and the reaction mixture allowed to stir at this temperature for 5 h. The solution was 
then warmed to 0 °C and stirred for 90 min before quenching with MeOH (4 mL), pH 7 buffer (4 mL) and 
H2O2 (30 wt% aq, 2.5 mL) and warming to rt, stirring for a further 30 min. The layers were then separated 
and the aqueous layer extracted with Et2O (3 x 8 mL). Combined organic layers were dried over MgSO4 
and concentrated in vacuo. The crude material was purified by flash column chromatography (9:1 
PE/EtOAc) to give the title compound as a pale-yellow oil (183 mg, 81%). 
 
Rf 0.31 (9:1 PE/EtOAc); [𝛼]𝐷20   ̶  12.9 (c 0.10, CHCl3); IR (thin film, νmax/cm-1): 3424, 1718, 1614, 1514, 
1463, 1302, 1247, 1173, 1074, 836, 777, 690; 1H NMR (500 MHz, CDCl3): δH 7.20 (2H, d, J = 8.6 Hz, H-Ar), 
6.87 (2H, d, J = 8.6 Hz, H-Ar), 5.56 (1H, s, H-19), 4.45 (1H, d, J = 11.9 Hz, CHaCHbAr), 4.37 (1H, d, J = 11.9 
Hz, CHaCHbAr), 4.29 (1H, d, J = 5.1 Hz, O-H), 4.18 (1H, dd, J = 7.2, 5.1 Hz, H-17), 4.04 (1H, d, J = 7.2 Hz, 
H-16), 3.80 (3H, s, ArOCH3), 3.59-3.55 (1H, m, H-13a), 3.41-3.33 (2H, m, H-13b, H-14), 1.82 (3H, s, Me-
18), 1.00 (3H, d, J = 6.7 Hz, Me-14), 0.89 (9H, s, SiC(CH3)3), 0.11 (9H, s, Si(CH3)3), 0.06 (3H, s, Si(CHa3Hb3), 
  ̶ 0.01 (3H, s, Si(CHa3Hb3); 13C NMR (125 MHz, CDCl3): δC 213.3, 159.4, 151.2, 129.5, 121.0, 127.6, 113.9, 
80.8, 79.4, 73.0, 72.9, 55.2, 40.5, 25.7, 18.0, 17.3, 14.4,   ̶ 0.1,   ̶4.6,   ̶5.1; HRMS (ES+) calc. for C26H46O5-
Si2Na [M+Na]+ 517.2781, found 517.2786. 
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 (2R,4R,5R,E)-4-((tert-Butyldimethylsilyl)oxy)-7-iodo-5-methoxy-1-((4-methoxybenzyl)oxy)-2,6-
dimethylhept-6-en-3-one (210) 
 
To a solution of aldol adduct 212 (1.60 g, 2.97 mmol, 1.0 equiv.) in CH2Cl2 (30 mL) was added 
trimethyloxonium tetrafluoroborate (3.52 g, 23.8 mmol, 8.0 equiv.) and 1,8-Bis(dimethylamino)-
naphthalene (6.36 g, 29.7 mmol, 10.0 equiv.) and stirred for 16 h before being quenched with NaHCO3 
(20 mL). The layers were separated and the aqueous layer extracted with CH2Cl2 (2 x 10 mL). Combined 
organic layers were then washed with citric acid (10% aq, 3 x 10 mL) to remove excess 1,8-bis-
(dimethylamino)-naphthalene, dried over MgSO4 and concentrated in vacuo. The crude material was 
purified by flash column chromatography (9:1 PE/EtOAc) to give the title compound as a colourless oil 
(1.32 g, 82%).  
 
Rf 0.37 (9:1 PE/EtOAc); [𝛼]𝐷20 + 11.8 (c 0.51, CHCl3); IR (thin film, νmax/cm-1): 2360, 1723, 1613, 1513, 
1462, 1248, 1109, 839; 1H NMR (500 MHz, CDCl3): δH 7.24 (2H, d, J = 8.8 Hz, H-Ar), 6.87 (2H, d, J = 8.8 
Hz, H-Ar),  6.28 (1H, br s, H-19), 4.43 (1H, d, J = 11.8 Hz, OCHaHbAr), 4.39 (1H, d, J = 11.8 Hz, OCHaHbAr), 
4.11 (1H, d, J = 8.0 Hz, H-17), 3.80 (3H, s, ArOCH3), 3.76 (1H, d, J = 8.0 Hz, H-16), 3.54 (1H, dd, J = 8.7, 
6.8, Hz, H-13a), 3.37-3.29 (2H, m, H-13b, H-14), 3.07 (3H, s, OCH3), 1.76 (3H, d, J = 1.1 Hz, Me-18), 1.06 
(3H, d, J = 6.5 Hz, Me-14), 0.86 (9H, s, SiC(CH3)3),   ̶  0.04 (3H, s, Si(CHa3)(CHb3)),   ̶  0.06 (3H, s, Si(CHa3-
)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 212.9, 159.2, 144.6, 130.1, 129.4, 113.8, 87.2, 82.6, 77.8, 72.9, 
72.4, 56.4, 55.3, 42.6, 25.7, 18.9, 18.0, 14.1,   ̶  4.8,   ̶ 5.1; HRMS (ES+) calc. for C24H43I O5NSi [M+NH4]+ 
580.1950, found 580.1940. 
 
 
 (2R,3R,4S,5R,E)-4-((tert-Butyldimethylsilyl)oxy)-7-iodo-5-methoxy-1-((4-methoxybenzyl)oxy)-2,6-
dimethylhept-6-en-3-ol (208) 
 
A solution of ketone 210 (930 mg, 1.68 mmol, 1.0 equiv.) in CH2Cl2 (20 mL) was cooled to   ̶78 °C and 
DIBAL (1 M in hexanes, 8.40 mL, 8.42 mmol, 5.0 equiv.) added. The reaction mixture was stirred for 2 h 
before being quenched with NH4Cl (10 mL) and NaK tartrate (15 mL) and stirred for a further 2 h.  
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The layers were then separated and the aqueous layer extracted with CH2Cl2 (4 x 20 mL). Combined 
organic layers were dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
flash column chromatography (8:1 PE/EtOAc) to give the title compound as a colourless oil (838 mg, 
90%). 
Rf 0.29 (9:1 PE/EtOAc); [𝛼]𝐷20 + 2.3 (c 0.40, CHCl3); IR (thin film, νmax/cm-1): 3230, 1613, 1513, 1462, 1248, 
1109, 839; 1H NMR (500 MHz, CDCl3): δH 7.26 (2H, d, J = 8.6 Hz, H-Ar), 6.87 (2H, d, J = 8.6 Hz, H-Ar), 6.27 
(1H, s, H-19), 4.47 (1H, d, J = 12.0 Hz, OCHaHbAr), 4.43 (1H, d, J = 12.0 Hz, OCHaHbAr), 3.80 (3H, s, 
ArOCH3), 3.81-3.75 (2H, m, H-17, H-13a), 3.68 (1H, dd, J = 9.0, 4.5 Hz, H-13b), 3.49 (1H, ddd, J = 9.2, 8.6, 
1.8 Hz, H-15), 3.40 (1H, dd, J = 9.2, 6.6 Hz, H-16), 3.17 (3H, s, OCH3), 2.76 (1H, d, J = 8.6 Hz, O-H), 1.94-
1.86 (1H, m, H-14), 1.76 (3H, s, Me-18), 0.97 (3H, d, J = 6.8 Hz, Me-14), 0.87 (9H, s, SiC(CH3)3), 0.07 (3H, 
s, Si(CHa3)(CHb3)), 0.03 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 159.0, 145.2, 130.8, 129.1, 
113.7, 86.8, 82.3, 73.8, 73.1, 72.8, 72.1, 56.5, 55.3, 36.2, 26.1, 19.7, 18.3, 14.8,    ̶ 3.7,    ̶ 4.1; HRMS (ES+) 
calc. for C24H42IO5Si [M+H]+ 565.1841, found 565.1832. 
 
 
 (4R,5S)-4-((S,E)-3-Iodo-1-methoxy-2-methylallyl)-5-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-2,2-
dimethyl-1,3-dioxolane (242) 
 
To a solution of silyl ether 208 (10 mg, 0.018 mmol, 1.0 equiv.) in THF (0.5 mL) was added TBAF (1.0 M, 
27 μL, 0.027 mmol, 1.5 equiv.) and stirred for 3 h. The reaction was then quenched with NH4Cl (1 mL) 
and the layers separated. The aqueous layer was extracted with Et2O (3 x 1 mL). Combined organic layers 
were dried over MgSO4 and concentrated in vacuo. The residue was redissolved in PE/EtOAc (3:1) and 
filtered through a short plug of silica, before being used directly in the following reaction.  
 
To a solution of diol 241 (7 mg, 0.016 mmol, 1.0 equiv.) in CH2Cl2 (0.4 mL) were added 2,2-
methoxypropane (0.3 mL, 2.44 mmol, 150 equiv.) and PPTS (1 crystal). The reaction mixture was stirred 
for 2 h before being concentrated in vacuo. The crude material was purified by flash column 
chromatography (4:1 PE/EtOAc) to give the title compound as a colourless oil (6.5 mg, 75% over 2 steps).  
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Rf 0.57 (4:1 PE/EtOAc); IR (thin film, νmax/cm-1): 1613, 1513, 1463, 1368, 1247, 1095, 1038, 821; 1H NMR 
(500 MHz, CDCl3): δH 7.26 (2H, d, J = 8.7 Hz, H-Ar), 6.87 (2H, d, J = 8.7 Hz, H-Ar), 6.22 (1H, s, H-19), 4.44 
(2H, s, OCH2Ar), 4.01 (1H, dd, J = 6.8, 6.0 Hz, H-16), 3.88 (1H, app t, J = 6.0 Hz, H-17), 3.81 (3H, s, ArOCH3), 
3.63 (1H, d, J = 6.8 Hz, H-15), 3.61 (1H, dd, J = 9.3, 5.2 Hz, H-13a), 3.36 (1H, dd, J = 9.3, 6.7 Hz, H-13b), 
3.19 (3H, s, OCH3), 2.05 (1H, qdd, J = 7.0, 6.7, 5.2 Hz, H-14), 1.81 (3H, d, J = 1.0 Hz, Me-18), 1.35 (3H, s, 
H-1’), 1.33 (3H, s, H-2’), 1.00 (3H, d, J = 7.0 Hz, Me-14); HRMS (ES+) calc. for C21H35INO5 [M+NH4]+ 
508.1554, found 508.1543. 
 
(5R,6R)-5-((R,E)-3-Iodo-1-methoxy-2-methylallyl)-6-((R)-1-((4-methoxybenzyl)oxy)propan-2-yl)-
2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane (252) 
 
To a solution of alcohol 208 (646 mg, 1.17 mmol, 1.0 equiv.) in CH2Cl2 (12 mL) at    ̶78 °C were added 
TBSOTf (0.32 mL, 1.40 mmol, 1.2 equiv.) and 2,6-lutidine (0.20 mL, 1.75 mmol, 1.5 equiv.) and stirred 
for 1 h before the addition of NH4Cl (10 mL). Upon warming to rt, the layers were separated and the 
aqueous layer extracted with CH2Cl2 (3 x 10 mL). Combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude material was purified by flash column chromatography (19:1 
PE/EtOAc) to give the title compound as a pale-yellow oil (746 mg, 96%) 
 
Rf 0.23 (19:1 PE/EtOAc); [𝛼]𝐷20   ̶  9.8 (c 1.90, CHCl3); IR (thin film, νmax/cm-1): 1611, 1512, 1462, 1248, 
1107, 837, 775; 1H NMR (500 MHz, CDCl3): δH 7.26 (2H, d, J = 8.6 Hz, H-Ar), 6.87 (2H, d, J = 8.6 Hz, H-Ar), 
6.19 (1H, s, H-19), 4.45 (1H, d, J = 11.9 Hz, OCHaHbAr), 4.39 (1H, d, J = 11.9 Hz, OCHaHbAr), 3.81 (3H, s, 
ArOCH3), 3.74 (1H, app t, J = 7.7 Hz, H-17), 3.72 (1H, dd, J = 7.7, 2.3 Hz, H-16), 3.68 (1H, dd, J = 8.1, 2.3 
Hz, H-15), 3.56 (1H, dd, J = 9.1, 3.4 Hz, H-13a), 3.24 (1H, dd, J = 9.1, 8.0 Hz, H-13b), 3.07 (3H, s, OCH3), 
2.06 (1H, dqdd, J = 8.0, 6.8, 3.4, 2.3 Hz, H-14), 1.74 (3H, s, Me-18), 1.02 (3H, d, J = 6.8 Hz, Me-14), 0.88 
(9H, s, SiC(CH3)3), 0.85 (9H, s, SiC(CH3)3), 0.07 (3H, s, Si(CHa3)(CHb3)), 0.06 (3H, s, Si(CHa3)(CHb3)), 0.02 
(3H, s, Si(CHa3)(CHb3)), 0.00 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 159.0, 146.4, 131.0, 
129.1, 113.7, 85.5, 82.0, 75.2, 73.9, 72.9, 72.6, 55.6, 55.3, 35.8, 26.1, 26.0, 19.4, 18.4, 18.3, 16.1,   ̶ 3.6,   ̶ 
3.7,   ̶ 4.1,   ̶4.4; HRMS (ES+) calc. for C30H56IO5Si2 [M+H]+ 679.2705, found 679.2698 
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(2R,3R,4R,5R,E)-3,4-bis((tert-Butyldimethylsilyl)oxy)-7-iodo-5-methoxy-2,6-dimethylhept-6-en-1-ol 
(207) 
 
To a solution of PMB ether 252 (720 mg, 1.08 mmol, 1.0 equiv.) in CH2Cl2/pH 7 buffer (9:1, 10 mL) at 0 
°C was added DDQ (515 mg, 2.27 mmol, 2.1 equiv.) and stirred for 1 h. The reaction was then quenched 
with NaHCO3 (10 mL) and the layers separated. The aqueous layer was extracted with CH2Cl2 (3 x 8 mL) 
and combined organic layers dried over MgSO4 before being concentrated in vacuo.  
 
The crude material was then subjected to Pinnick oxidation conditions to separate the product from the 
anisaldehyde by-product. The crude mixture was redissolved in t-BuOH (5 mL) and a solution of NaClO2 
(360 mg, 4.0 mmol, 3.7 equiv.) and Na2H2PO4 (620 mg, 4.0 mmol, 3.7 equiv.) in H2O (2 mL) added, 
followed by 2-methyl-but-2-ene (0.4 mL). The reaction mixture was stirred for 1 h, before being 
quenched with NaHCO3 (5 mL) and Et2O (5 mL). The layers were separated and the aqueous layer 
extracted with Et2O (3 x 5 mL). Combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The crude material was purified by flash column chromatography (9:1 o 4:1 PE/EtOAc) to give 
the title compound as a colourless oil (542 mg, 90%). 
Rf 0.34 (6:1 PE/EtOAc); [𝛼]𝐷20 + 26.1 (c 0.15, CHCl3); IR (thin film, νmax/cm-1): 3448, 1472, 1361, 1254, 
1094, 834, 774; 1H NMR (500 MHz, CDCl3): δH 6.23 (1H, s, H-19), 3.84 (1H, d, J = 8.1 Hz, H-17), 3.73 (1H, 
dd, J = 6.2, 3.1 Hz, H-15), 3.69 (1H, dd, J = 8.1, 3.1 Hz, H-16), 3.61 (1H, ddd, J = 11.0, 7.1, 3.8 Hz, H-13a), 
3.52 (1H, ddd, J = 11.0, 8.2, 4.2 Hz, H-13b),  3.10 (3H, s, OCH3), 2.76 (1H, br s, O-H), 2.14 – 2.06 (1H, m, 
H-14), 1.74 (3H, s, Me-18), 0.96 (3H, d, J = 7.1 Hz, Me-14), 0.92 (9H, s, SiC(CH3)3), 0.85 (9H, s, SiC(CH3)3), 
0.13 (3H, s, Si(CHa3)(CHb3)), 0.11 (3H, s, Si(CHa3)(CHb3)), 0.07 (3H, s, Si(CHa3)(CHb3)), 0.00 (3H, s, Si(CHa-
3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 145.9, 86.2, 82.3, 73.6, 66.6, 60.4, 55.6, 36.0, 26.0, 25.9, 19.4, 
18.2, 18.1, 16.7,   ̶  3.5,   ̶  3.9,   ̶  4.5,   ̶  4.6; HRMS (ES+) calc. for C22H48IO4Si2 [M+H]+ 559.2130, found 
559.2123. 
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6.4.3 Preparation of the C20-C25 alkene 
 
(R)-tert-Butyldimethyl((2-methyloxiran-2-yl)methoxy)silane (258) 
 
To activated powdered 3Å MS (1.50 g), were added CH2Cl2 (50 mL), L-(+)-diisopropyltartrate (0.13 mL, 
0.60 mmol, 0.06 equiv.) and methallyl alcohol (0.84 mL, 10.0 mmol, 1.0 equiv.) at    ̶ 20 °C. After stirring 
for 5 min, Ti(OiPr)4 (0.15 mL, 0.50 mmol, 0.05 equiv.) was added and the reaction mixture stirred for a 
further 30 min. Cumene hydroperoxide (80%, 3.60 mL, 20.0 mmol, 2.0 equiv.) was then added and the 
reaction flask placed in a freezer at   ̶  20 °C for 16 h. The excess peroxide was quenched with the 
dropwise addition of P(OEt)3 (2.56 mL, 15.0 mmol, 1.5 equiv.) at   ̶20 °C over 1 h, before Et3N (2.14 mL, 
15.0 mmol, 1.5 equiv.), DMAP (60.5 mg, 0.50 mmol, 0.05 equiv.) and TBSCl  (2.26 g, 15.0 mmol, 1.5 
equiv.) were added and the reaction stirred for a further h at 0 °C. Upon completion, the reaction 
mixture was filtered through Celite®. The filtrate was then washed with tartaric acid (10% aq, 20 mL). 
The layers were separated and the organic layer further washed with NaHCO3 (2 x 10 mL) and brine (2 
x 10 mL), before being dried over Na2SO4 and the solvent removed in vacuo. The crude material was 
purified by flash column chromatography (20:1 PE30-40 / Et2O) to give the title compound as a colourless 
oil (1.42 g, 70%).   
 
Rf 0.25 (9:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 3.68 (1H, d, J = 11.2 Hz, H-25a), 3.62 (1H, d, J = 11.2 
Hz, H-25b), 2.77 (1H, d, J = 5.0 Hz, H-23a), 2.62 (1H, d,  J = 5.0 Hz, H-23b), 1.37 (3H, s, Me-24), 0.92 (9H, 
s, SiC(CH3)3, 0.09 (3H, s, Si(CHa3)(CHb3)), 0.08 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC  66.4, 
57.0, 51.4, 25.7, 18.2, 17.9,   ̶ 5.5.  
Data in agreement with literature values.164 
 
 
 (S)-1-((tert-Butyldimethylsilyl)oxy)-2-methyl-3-(phenylthio)propan-2-ol (260) 
 
To a stirred solution of epoxide 258 (2.5 g, 12.38 mmol, 1.0 equiv.) in MeOH (70 mL) were added 
thiophenol (2.52 mL, 24.8 mmol, 2.0 equiv.) and Et3N (5.17 mL, 37.1 mmol, 3.0 equiv.). The reaction 
mixture was left to stir for 75 minutes before being quenched with NH4Cl (50 mL) and the product 
extracted with CH2Cl2 (3 x 40 mL). Combined organic layers were dried over MgSO4 and the solvent 
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removed in vacuo. The crude material was purified by flash column chromatography (9:1 PE/EtOAc) to 
yield the title compound as a colourless oil (3.48 g, 90%) 
 
Rf 0.28 (9:1 PE/EtOAc); [𝛼]𝐷20   ̶ 3.9 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 3506, 1472, 1253, 1090, 837, 
777, 738, 690; 1H NMR (500 MHz, CDCl3): δH 7.37 – 7.09 (5H, m, H-Ar), 3.64 (1H, d, J = 9.4 Hz, H-25a), 
3.41 (1H, d, J = 9.4 Hz, H-25b), 3.17 (1H, d, J = 12.7 Hz, H-23a), 3.11 (1H, d, J = 12.7 Hz, H-23b), 1.29 (3H, 
s, Me-24), 0.88 (9H, s, SiC(CH3)3), 0.04 (3H, Si(CHa3)(CHb3)), 0.03 (3H, Si(CHa3)(CHb3)); 13C NMR (125 MHz, 
CDCl3): δC 137.3, 129.3, 128.9, 126.0, 72.9, 68.6, 42.6, 25.9, 23.2, 18.3,   ̶ 5.5; HRMS (ES+) calc. for C16H-
28O2SSiNa [M+Na]+ 335.1471, found 335.1470. 
 
 (S)-8,8-Diethyl-2,2,3,3,6-pentamethyl-6-((phenylthio)methyl)-4,7-dioxa-3,8-disiladecane (261) 
 
A solution of alcohol 260 (1.08 g, 3.46 mmol, 1.0 equiv.) in CH2Cl2 (33 mL) was cooled to   ̶ 78 °C and 2,6-
lutidine (0.60 mL, 5.19 mmol, 1.5 equiv.) and TESOTf (0.94 mL, 4.15 mmol, 1.2 equiv.) added. The 
reaction mixture was stirred for 15 min at this temperature, before being stirred for a further h whilst 
gradually warming to rt. The reaction was then quenched with NH4Cl (15 mL) and the layers separated. 
The aqueous layer was extracted with CH2Cl2 (3 x 10 mL), combined organic layers dried over MgSO4 
and concentrated in vacuo. The crude material was purified by flash column chromatography (15:1 
PE/EtOAc) to give the title compound as a colourless oil (1.40 g, 96%).  
 
Rf 0.44 (9:1 PE/EtOAc); [𝛼]𝐷20 + 4.9 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 1492, 1478, 1100, 1032, 838, 
777, 735, 663; 1H NMR (400 MHz, CDCl3): δH 7.37-7.35 (2H, m, H-Ar), 7.25-7.10 (3H, m, H-Ar), 3.64 (1H, 
d, J = 9.5 Hz, H-25a), 3.41 (1H, d, J = 9.5 Hz, H-25b), 3.17 (1H, d, J = 12.7 Hz, H-23a), 3.11 (1H, d, J = 12.7 
Hz, H-23b), 1.29 (3H, s, Me-24), 0.94 (9H, t, J = 8.0 Hz, Si(CH2CH3)3, 0.88 (9H, s, SiC(CH3)3), 0.58 (6H, q, J 
= 8.0 Hz, Si(CH2CH3)3), 0.43 (3H, s, Si(CHa3)(CHb)), 0.42 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): 
δC 138.6, 128.7, 128.6, 125.2, 76.2, 69.1, 43.7, 25.9, 18.3, 7.1, 6.7,   ̶  5.4,   ̶  5.5; HRMS (ES+) calc. for 
C22H42O2SSi2Na [M+Na]+ 449.2336, found 449.2330. 
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 (6R)-8,8-Diethyl-2,2,3,3,6-pentamethyl-6-((phenylsulfinyl)methyl)-4,7-dioxa-3,8-disiladecane (262) 
 
To a stirred solution of sulphide 261 (500 mg, 1.17 mmol, 1.0 equiv.) in CH2Cl2 (12 mL) at – 5 °C was 
added meta-chloroperbenzoic acid (technical grade <77%, 263 mg, 1.17 mmol, 1.0 equiv.) in 5 portions. 
The reaction mixture was left to stir for 2 h before being quenched with NaHCO3 (10 mL). The layers 
were separated and the aqueous layer extracted with CH2Cl2 (3 x 6 mL). Combined organic layers were 
dried over MgSO4 and the solvent removed in vacuo. The crude material was purified by flash column 
chromatography (3:1 PE/EtOAc) to give the diastereomeric sulfoxides as a colourless oil (451 mg, 88%, 
95% brsm).  
 
Rf 0.30 (2:1 PE/EtOAc); IR (thin film, νmax/cm-1): 1472, 1253, 1190, 1096, 1048, 837, 778, 745; 1H NMR 
(500 MHz, CDCl3): δH  7.64-7.45 (5H, m, H-Ar), 3.81 (0.45H, d, J = 9.90 Hz, H-25a), 3.69 (0.45H, d, J = 9.90 
Hz, H-25b), 3.54 (0.55H, d, J = 9.7 Hz, H-25a*), 3.42 (0.55H, d, J = 9.7 Hz, H-25b*), 3.05-2.89 (2H, m, H-
23), 1.50 (1.65H, s, Me-24*), 1.37 (1.35H, s, Me-24), 1.02-0.94 (9H, m, Si(CH2CH3)3), 0.91 (4H, s, 
Si*C(CH3)3), SiC(CH3)3), 0.86 (5H, s, SiC(CH3)3)), 0.71-0.59 (6H, m, Si(CH2CH3)3), 0.11 (1.3H, m,  
Si*(CHa3)(CHb3)), 0.10 (1.3H, m,  Si*(CHa3)(CHb3)), 0.03 (3.4H, Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC  
146.1, 146.0*, 130.5*, 130.3, 129.1, 129.1*, 123.9, 123.9*, 75.3*, 75.1, 71.0, 70.7*, 69.6*, 69.1, 25.9, 
25.9*, 18.3, 18.3*, 7.1, 7.1*, 6.8, 6.7*,   ̶ 5.3*,   ̶ 5.4,   ̶ 5.4*,   ̶ 5.5; HRMS (ES+) calc. for C22H42O3SSi2Na 
[M+Na]+ 465.291, found 465.2298. * refers to the major diastereomer.  
 
 (2R)-3-((tert-Butyldimethylsilyl)oxy)-2-methyl-1-(phenylthio)-2-((triethylsilyl)oxy)propyl acetate 
(266) 
 
To a stirred solution of sulfoxide 262 (2.67 g, 6.04 mmol, 1.0 equiv.) in acetic anhydride (30 mL) was 
added NaOAc (2.97 g, 36.2 mmol, 6.0 equiv.) and the reaction mixture heated to reflux for 16 h. After 
cooling to rt, the solution was diluted with CH2Cl2 (100 mL) and NaOH (1 M, aq, 100 mL) added slowly. 
After stirring for a further 30 min, the layers were separated and the aqueous layer extracted with 
further CH2Cl2 (3 x 50 mL). Combined organic layers were dried over MgSO4 and the solvent removed  
in vacuo. The crude material was purified by flash column chromatography (PE o 5:1 PE/EtOAc) to 
give the diastereomeric acetoxysulfides as a colourless oil (2.26 g, 79%).   
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Rf 0.41 (10:1 PE/EtOAc); IR (thin film, νmax/cm-1): 1753, 1369, 1222, 1104, 1018, 838, 776, 742 ; 1H NMR 
(500 MHz, CDCl3): δH  7.55-7.50 (2H, m, H-Ar), 7.31-7.22 (3H, m, H-Ar), 6.46 (0.5H, s, H23), 6.29 (0.5H, s, 
H23*), 3.92 (0.5H, d, J = 9.6 Hz, H-25a), 3.66 (0.5H, d, J = 9.7 Hz, H-25a*), 3.58 (0.5H, d, J = 9.7 Hz, H-
25b*), 3.43 (0.5H, d, J = 9.6 Hz, H-25b), 2.05 (1.5H, s, COCH3*), 2.03 (1.5H, s, COCH3), 1.39 (1.5H, s, Me-
24*), 1.32 (1.5H, s, Me-24), 1.01 (9H, q, J = 8.0 Hz, Si(CH2CH3)3), 0.91 (4.5H, s, Si*C(CH3)3), 0.90 (4.5H, s, 
SiC(CH3)3), 0.70-0.63 (6H, m, Si(CH2CH3)3), 0.07 (1.5H, s, Si*(CHa3)2), 0.06 (1.5H, s, Si*(CHb3)2), 0.05 (3H, 
s, Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC  169.7, 169.3*, 134.5, 133.9*, 132.5*, 132.0, 128.8*, 128.7, 
127.5*, 127.2, 87.3, 86.3*, 78.6*, 78.4, 68.9, 68.0*, 25.9*, 25.8, 21.1*, 21.0 18.3*, 18.2, 7.1*, 7.0, 6.7, 
6.7*,   ̶ 5.4,   ̶ 5.4*,   ̶ 5.5,   ̶ 5.5*; HRMS (ES+) calc. for C24H44O4SSi2Na [M+Na]+ 507.2397, found 507.2456. 
 
 (R)-3-((tert-Butyldimethylsilyl)oxy)-2-methyl-2-((triethylsilyl)oxy)propanal (257) 
 
To a solution of α-acetoxy sulphides 266 (2.3 g, 4.85 mmol, 1.0 equiv.) in CH2Cl2 (50 mL) at   ̶ 78 °C was 
added DIBAL (1 M in hexanes, 7.30 mL, 1.5 equiv.) dropwise and the reaction mixture stirred for 90 min 
at this temperature. Na2CO3 (30 mL) and NaK tartrate (30 mL) were then added and the mixture left to 
stir for 30 min while warming to rt. The layers were then separated and the aqueous layer extracted 
with CH2Cl2 (3 x 30 mL). Combined organic layers were dried over MgSO4 and concentrated in vacuo. 
The crude product was purified by flash column chromatography (19:1 PE/EtOAc) to give the title 
compound as a colourless oil (1.47 g, 92%).  
 
Rf 0.21 (19:1 PE/EtOAc); [𝛼]𝐷20 + 8.1 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 1739, 1463, 1253, 1156, 
1107, 1006; 1H NMR (500 MHz, CDCl3): δH 9.60 (1H, s, H-23), 3.65 (1H, d, J = 10.2 Hz, H-25a), 3.59 (1H, d, 
J = 10.2 Hz, H-25b), 1.26 (3H, s, Me-24), 0.96 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.87 (9H, s, SiC(CH3)3), 0.62 
(6H, q, J = 8.0 Hz, Si(CH2CH3)3), 0.04 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC 204.3, 80.4, 68.5, 
25.8, 20.0, 18.3, 6.9, 6.4,   ̶ 5.5,   ̶ 5.6; HRMS (ES+) calc. for C16H37O3Si2 [M+H]+ 333.2276, found 333.2283. 
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 (1R,2R)-N1,N2-bis(4-Bromobenzyl)cyclohexane-1,2-diamine (267) 
 
To a solution of (R,R)-1,2-diaminocyclohexane (L)-tartrate salt (500 mg, 1.89 mmol, 1.0 equiv.) in H2O 
(10 mL), was added K2CO3 (522 mg, 3.78 mmol, 2.0 equiv.) then EtOH (5 mL). A solution of 
methanesulfonic acid (21 mg, 0.22 mmol, 0.12 equiv.) and 4-bromobenzaldehyde (654 mg, 3.78 mmol, 
2.0 equiv.) in CH2Cl2 (10 mL) was then added and the reaction mixture stirred for 16 h before being 
heated to reflux for a further h. After cooling to rt, the reaction mixture was concentrated in vacuo, H2O 
(10 mL) added and the precipitate collected by filtration. The solid was suspended in MeOH (15 mL) and 
cooled to 0 °C. NaBH4 (158 mg, 4.26 mg, 2.26 equiv.) was added and the reaction mixture stirred for 10 
min (until gas evolution was complete) and then heated to reflux for 1 h. The reaction mixture was then 
cooled to rt and concentrated in vacuo. To the residue was added NaOH (1 M, 10 mL), EtOAc (10 mL) 
and PE (10 mL). The layers were separated and the aqueous later extracted with EtOAc/PE (1:1, 2 x 10 
mL). Combined organic layers were washed with brine (8 mL), dried over MgSO4 and concentrated in 
vacuo. The crude material was purified by flash column chromatography (4:1 PE/EtOAc) to give the title 
compound as a pale-yellow amorphous solid (605 mg, 72%).  
 
Rf 0.33 (4:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 7.42 (4H, dt, J = 8.3, 1.9 Hz, H-Ar), 7.17 (4H, d, J = 
8.3 Hz, H-Ar), 3.83 (2H, d, J = 13.4 Hz, NCHaHbAr x 2), 3.59 (2H, d, J = 13.4 Hz, NHaHbAr x 2), 2.23-2.11 
(4H, m, H-1’, H-2’a), 1.79-1.69 (4H, m, NH x 2, H-2’b), 1.23-0.98 (4H, m, H-3’).  
Data in agreement with literature values.129  
 
 
 (E)-But-2-en-1-yltrichlorosilane (268) 
 
 
Copper (I) chloride (20.2 mg, 0.20 mmol, 0.02 equiv.) and Et3N (1.53 mL, 11.0 mmol, 1.1 equiv.) were 
dissolved in Et2O (6 mL) and cooled to 0 °C. A solution of trans-crotyl bromide (0.98 mL, 10.0 mmol, 1.0 
equiv.) and trichlorosilane (1.10 mL, 11.0 mmol, 1.1 equiv.) in Et2O (3 mL) was then added dropwise 
over 30 min maintaining the reaction temperature at 0 °C. The resulting solution was stirred for a  
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further 30 min before warming to rt and stirring for another h. Et2O and Et3N were removed by 
distillation, before the residue was transferred to a separate flask and distilled (bp ~ 140 °C @ 760 
mmHg) to give the title compound (968 mg, 51%) as a colourless liquid.  
 
1H NMR (500 MHz, CDCl3): δH 5.63-5.57 (1H, m, H-2’), 5.41-5.34 (1H, m, H-3’), 2.26 (2H, dt, J = 7.6, 1.1 
Hz, H-1’), 1.73-1.70 (3H, m, H-4’).  
Data in agreement with literature values.129  
 
 
Di-tert-butyl ((1R,2R)-cyclohexane-1,2-diyl)dicarbamate (280) 
 
To a solution of (R,R)-1,2-diaminocyclohexane (L)-tartrate salt (100 mg, 0.38 mmol, 1.0 equiv.) in CH2Cl2 
(5 mL) were added di-tert-butyl dicarbonate (87 μL, 0.38 mmol, 1.0 equiv.) and Na2CO3 (sat. aq., 2.5 mL, 
1.9 mmol, 5.0 equiv.). The reaction mixture was stirred for 2 h before being quenched with H2O (5 mL) 
and the layers separated. The aqueous layer was extracted with CH2Cl2 (2 x 3 mL), combined organic 
layers dried over Na2SO4 and concentrated in vacuo to give the title compound an off-white solid (45 
mg, 38%)  
 
1H NMR (500 MHz, CDCl3): δH 4.89 (2H, br s, N-H), 3.32-3.25 (2H, m, H-1’), 2.04-2.01 (2H, m, H-2’a), 1.73-
1.71 (2H, m, H2’b), 1.43 (18H s, C(CH3)3), 1.30-1.14 (4H, m, H-3’); 13C NMR (125 MHz, CDCl3): δC 156.5, 
79.1, 55.0, 33.0, 28.4, 24.9. 
Data in agreement with literature values181 
 
 
tert-Butyl (2-aminocyclohexyl)carbamate (282) 
 
 To a stirred solution of conc. HCl (0.35 mL, 4.39 mmol, 1.0 equiv.) in MeOH (1.4 mL) at 0 °C was added 
racemic diaminocyclohexane (0.53 mL, 4.39 mmol, 1.0 equiv.). The reaction mixture was then warmed 
to rt and stirred for 15 min before the addition of H2O (0.4 mL). After a further 30 min, a solution of di-
tert-butyl dicarbonate (957 mg, 4.39 mmol, 1.0 equiv.) in MeOH (0.5 mL) was added slowly and the  
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reaction stirred for 16 h. The solution was then concentrated in vacuo and the residue treated with 3 M 
NaOH (3 mL) and extracted with CH2Cl2 (3 x 4 mL). Combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude material (680 mg, 72%) was isolated as a beige solid, which was used 
without further purification.  
 
1H NMR (500 MHz, CDCl3): δH 4.43 (1H, br s, N-H), 3.16-3.09 (1H, m, H-Cy), 2.31 (1H, td, 10.6, 4.2 Hz, H-
Cy), 2.01-1.93 (2H, m, H-Cy), 1.72-1.68 (2H, m, H-Cy), 1.45 (9H, s, CO2C(CH3)3), 1.38 (2H, br s, N-H), 1.28-
1.07 (4H, m, H-Cy). 
Data in agreement with literature values130  
 
3-(tert-Butyl)-2-hydroxybenzaldehyde (284) 
 
To a stirred solution of 2-tert-butylphenol (1.53 mL, 10.0 mmol, 1.0 equiv.) in MeCN (20 mL) were added 
paraformaldehyde (2.02 g, 67.5 mmol, 6.75 equiv.), MgCl2 (1.43 g, 15.0 mmol, 1.5 equiv.), and Et3N (5.15 
mL, 37.0 mmol, 3.7 equiv.) and heated to reflux for 5 h. After cooling to rt, HCl (5% aq., 10 mL) was 
added to quench and the mixture was extracted with CH2Cl2 (3 x 20 mL). Combined organic layers were 
concentrated in vacuo and the residue partitioned between Et2O (50 mL) and H2O (50 mL). The layers 
were separated and the organic layer washed with brine (15 mL), dried over Na2SO4 and concentrated 
in vacuo. The crude material was vacuum distilled (bp 72-75 °C @ 5 mm Hg) to give the title compound 
as a pale-yellow oil (1.10 g, 62%).  
 
1H NMR (500 MHz, CDCl3): δH 11.81 (1H, s, O-H), 9.88 (1H, s, CHO), 7.53 (1H, d, J = 7.6 Hz, H-Ar), 7.42 
(1H, d, J = 7.6 Hz, H-Ar), 6.96 (1H, t, J = 7.6 Hz, H-Ar), 1.42 (9H, s, ArC(CH3)3); HRMS (ES+) calc. for C11H15O2 
[M+H]+ 179.1072, found 179.1070. 
Data in agreement with literature values130 
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tert-Butyl ((1R,2R)-2-(((E)-3-(tert-butyl)-2-hydroxybenzylidene)amino)cyclohexyl)carbamate (278a) 
 
A solution of amine 282 (680 mg, 3.18 mmol, 1.0 equiv.) and aldehyde 284 (566 mg, 3.18 mmol, 1.0 
equiv.) in EtOH (30 mL) was heated to reflux and stirred for 3 h. Upon completion, the reaction mixture 
was cooled to rt and concentrated in vacuo. The crude material was purified by recrystallisation from 
boiling EtOH to give the title compound as yellow crystals (180 mg, 75%) 
 
1H NMR (500 MHz, CDCl3): δH 8.31 (1H, s, H-7’), 7.29 (1H, dd, J = 7.7, 1.7 Hz, H-Ar), 7.08 (1H, dd, J = 7.7, 
1.7 Hz, H-Ar), 6.78 (1H, t, J =7.7 Hz, H-Ar), 4.37 (1H, br s, N-H), 3.62-3.57 (1H, m, H-Cy), 3.01 (1H, br s, H-
Cy), 2.11-2.05 (1H, m, H-Cy), 1.98-1.87 (1H, m, H-Cy), 1.92- 1.60 (3H, m, H-Cy), 1.49-1.35 (3H, m, H-Cy) 
1.48 (9H, s, CO2C(CH3)3), 1.35 (9H, s, ArC(CH3)3).  
Data in agreement with literature values130  
 
 
2-(tert-Butyl)-6-((((1R,2R)-2-(methylamino)cyclohexyl)amino)methyl)phenol (278b) 
 
A suspension of LiAlH4 (54.9 mg, 1.44 mmol, 3.0 equiv.) in THF (3 mL) was cooled to 0 °C and a solution 
of imine 278a (180 mg, 0.48 mmol, 1.0 equiv.) in THF (2 mL) added dropwise. The reaction mixture was 
then heated to reflux for 4 h. After recooling to 0 °C, the reaction was quenched by the dropwise 
addition of H2O (5 mL) and the layers separated. The aqueous layer was extracted with Et2O (3 x 5 mL), 
combined organic layers dried over MgSO4 and concentrated in vacuo. The crude product was purified 
by recrystalisation from hexanes to give the title compound as white crystals (100 mg, 72%).  
 
1H NMR (500 MHz, CDCl3): δH 7.17 (1H, dd, J = 7.6, 1.7 Hz, H-Ar), 6.86 (1H, app d, J = 7.6 Hz, H-Ar), 6.70 
(1H, t, J = 7.6 Hz, H-Ar), 4.01 (1H, d, J = 13.4 Hz, H-7’a), 3.83 (1H, d, J = 13.4 Hz, H-7’b), 2.39 (3H, s,  
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NCH3), 2.21-2.12 (4H, m, H-1’, H-2’, H-3’a, H-6’a), 1.77-1.69 (2H, m, H-3’b, H-6’b), 1.42 (9H, s, ArC(CH3)3), 
1.29-1.14 (3H, m, H-5’, H-4’a), 0.99-0.94 (1H, m, H-4’b); 13C NMR (125 MHz, CDCl3): δC 157.3, 136.7, 
126.1, 125.6, 124.3, 118.0, 62.3, 62.1, 50.9, 34.7, 33.4, 31.1, 31.0, 29.5, 25.1, 24.6. 
Data in agreement with literature values130 
 
 
But-3-yn-2-yl methanesulfonate (296) 
 
A solution of freshly distilled but-3-yn-2-ol (0.11 mL, 1.43 mmol, 1.0 equiv.) in CH2Cl2 (1.2 mL) was cooled 
to   ̶ 78 °C and Et3N (0.8 mL, 5.71 mmol, 4.0 equiv.) and MsCl (0.33 mL, 4.28 mmol, 3.0 equiv.) added. 
The reaction mixture was stirred for 30 min before being quenched with NaHCO3 (2 mL). The layers were 
separated and the aqueous layer extracted with CH2Cl2 (3 x 2 mL). Combined organic layers were dried 
over MgSO4 and concentrated in vacuo. The crude material was purified by flash column 
chromatography (4:1 PE/Et2O) to give the title compound as a colourless liquid (175 mg, 83%).  
Rf 0.43 (3.1 PE/Et2O); 1H NMR (500 MHz, CDCl3): δH 5.29 (1H, qd, J = 6.7, 2.1 Hz, H-22), 3.12 (3H, s, 
SO2CH3), 2.70 (1H, d, J = 2.1 Hz, H-20), 1.66 (3H, d, J = 6.7 Hz, Me-22).  
Data in agreement with literature values182 
 
 
4-(Trimethylsilyl)but-3-yn-2-ol (308) 
 
Procedure A: 
 To a solution of butyn-1-ol (1.00 mL, 12.7 mmol, 1.0 equiv.) in THF (25 mL) at    ̶ 78 °C was added n-BuLi 
(1.6 M in hexanes, 17.5 mL, 27.9 mmol, 2.2 equiv.) and stirred for 30 min. TMSCl (4.02 mL, 31.8 mmol, 
2.5 equiv.) was then added and the reaction mixture stirred for 20 min at this temperature, before being 
warmed up to rt and stirred for a further 30 min. H2O (8 mL) and HCl (1 M, aq, 25 mL) were then added 
and the reaction stirred vigorously for an hour, at which point the layers were separated and the 
aqueous layer extracted with Et2O (3 x 20 mL). Combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude material was purified by flash column chromatography (6:1 PE/EtOAc) 
to give the title compound as a colourless oil (1.53 g, 85%).  
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Procedure B: 
 A solution of ethynyltrimethylsilane (0.1 mL, 0.67 mmol, 1.0 equiv.) in THF (1.2 mL) was cooled to   ̶ 78 
°C and n-BuLi (1.4 M in hexanes, 0.7 mL, 1.0 mmol, 1.5 equiv.) added dropwise. The reaction mixture 
was stirred for 30 min before the addition of acetaldehyde (0.19 mL, 3.35 mmol, 5.0 equiv.). The reaction 
mixture was then slowly warmed to rt over a further 30 min before being quenched with NH4Cl (1.5 mL) 
and the layers separated. The aqueous layer was extracted with Et2O (3 x 1 mL). Combined organic layers 
were dried over MgSO4 and concentrated in vacuo. The crude material was purified by flash column 
chromatography (6:1 PE/EtOAc) to give the title compound as a colourless oil (136 mg, 99%).  
Rf 0.27 (9:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 4.52 (1H, dq, J = 6.7, 5.4 Hz, H-22), 1.80 (1H, d, J = 
5.4 Hz, O-H), 1.46 (3H, d, J = 6.7 Hz, Me-22), 0.18 (9H, s, Si(CH3)3).   
 
Data in agreement with literature values183  
 
 
4-(Trimethylsilyl)but-3-yn-2-one (304) 
 
To a solution of oxalyl chloride (1.35 mL, 15.8 mmol, 1.5 equiv.) in CH2Cl2 (30 mL) at    ̶78 °C was added 
DMSO (1.49 mL, 21.1 mmol, 2.0 equiv.) and stirred for 15 min. A solution of alcohol 308 (1.5 g, 10.6 
mmol, 1.0 equiv.) in CH2Cl2 (30 mL) was then added via cannula at the reaction mixture stirred for a 
further 15 min before the dropwise addition of Et3N (4.41 mL, 31.7 mmol, 3.0 equiv.) The reaction 
mixture was stirred for 5 min before being slowly warmed to rt over 30 min. NH4Cl (40 mL) was then 
added and the layers separated. The aqueous layer was extracted with CH2Cl2 (3 x 10 mL), combined 
organic layers dried over MgSO4 and concentrated in vacuo. The crude material was purified by flash 
column chromatography (9:1 PE/EtOAc) to give the title compound as a colourless oil (1.44 g, 97%).  
 
Rf 0.37 (9:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 2.34 (3H, s, Me-22), 0.24 (9H, s, Si(CH3)3).  
Data in agreement with literature values183 
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 (S)-4-(Trimethylsilyl)but-3-yn-2-ol (306) 
 
To a solution of ketone 304 (140 mg, 1.0 mmol, 1.0 equiv.) in IPA (5 mL) was added a solution of Ru[(R,R)-
p-TsNCH(C6H5)CH(C6H5)NH](η6-p-cymene) (11.1 mg, 0.05 mmol, 0.05 equiv.) in IPA (3 mL) in 3 portions 
over 8 h before being stirred for a further 40 h. Further catalyst (5.5 mg, 0.025 mmol, 0.025 equiv.) was 
added at this point and the reaction mixture stirred for another 24 h. The solution was then diluted with 
Et2O (10 mL) and washed with H2O (3 x 8 mL) to remove IPA. Combined aqueous layers were then back-
extracted with CH2Cl2 (3 x 5 mL) and combined organic layers dried over MgSO4 and concentrated in 
vacuo. The crude material was then purified by flash column chromatography (5:1 PE/EtOAc) to give the 
title compound as a colourless oil (110 mg, 77%). Mosher ester analysis (using 19F NMR) on the 
corresponding TIPS alkyne gave an ee of 97.8%)   
Rf 0.28 (9:1 PE/EtOAc); [𝛼]𝐷20 = + 22.3 (c 0.13, CHCl3); 1H NMR (500 MHz, CDCl3): δH 4.52 (1H, dq, J = 6.7, 
5.4 Hz, H-22), 1.80 (1H, d, J = 5.4 Hz, O-H), 1.46 (3H, d, J = 6.7 Hz, Me-22), 0.18 (9H, s, Si(CH3)3).   
Data in agreement with literature values136 
 (S)-4-(Triisopropylsilyl)but-3-yn-2-yl (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate 
 
To a solution of alcohol (2.0 mg, 8.0 μmol, 1.0 equiv.) in CH2Cl2 (0.2 mL) were added (R)-3,3,3-trifluoro-
2-methoxy-2-phenylpropanoic acid (10.3 mg, 0.04 mmol, 5.0 equiv.), DCC (9.1 mg, 0.04 mmol, 5.0 
equiv.) and DMAP (5.6 mg, 0.04 mmol, 5.0 equiv.). The reaction mixture was stirred for 16 h before 
being filtered through Celite® and washed with PE (1.0 mL). The filtrate was concentrated in vacuo and 
the residue passed through a short plug of silica to remove excess (S)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoic acid. 
1H NMR (500 MHz, CDCl3): δH 7.54 (2H, d, J = 7.6 Hz, H-Ar), 7.43-7.36 (3H, m, H-Ar), 5.65 (1H, q, J = 6.8 
Hz, H-22), 3.55 (3H, s, OCH3), 1.60 (3H, d, J = 6.8 Hz, Me-22), 1.03 (18H, app s, Si(CH(CH3)2)3), 0.89-0.86 
(3H, m, Si(CH(CH3)2)3).; 19F NMR (500 MHz, CDCl3): δF    ̶ 71.9. 
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(S)-4-(Triisopropylsilyl)but-3-yn-2-yl (S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate 
 
To a solution of propargyl alcohol (2.0 mg, 8.0 μmol, 1.0 equiv.) in CH2Cl2 (0.2 mL) were added (S)-3,3,3-
trifluoro-2-methoxy-2-phenylpropanoic acid (10.3 mg, 0.04 mmol, 5.0 equiv.), DCC (9.1 mg, 0.04 mmol, 
5.0 equiv.) and DMAP (5.6 mg, 0.04 mmol, 5.0 equiv.). The reaction mixture was stirred for 16 h before 
being filtered through Celite® and washed with PE (1.0 mL). The filtrate was concentrated in vacuo and 
the residue passed through a short plug of silica to remove excess (S)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoic acid. 
1H NMR (500 MHz, CDCl3): δH 7.56 (2H, d, J = 7.6 Hz, H-Ar), 7.42-7.36 (3H, m, H-Ar), 5.67 (1H, q, J = 6.8 
Hz, H-22), 3.59 (3H, s, OCH3), 1.53 (3H, d, J = 6.8 Hz, Me-22), 1.06 (18H, app s, Si(CH(CH3)2)3), 0.92-0.81 
(3H, m, Si(CH(CH3)2)3); 19F NMR (500 MHz, CDCl3): δF    ̶ 72.2. 
 
(S)-But-3-yn-2-ol (309) 
 
To a solution of silane 306 (50.0 mg, 0.35 mmol, 1.0 equiv.) in THF (3 mL) was added TBAF (1 M, 0.7 mL, 
0.7 mmol, 2.0 equiv.) and the reaction mixture stirred for 1 h at rt. The reaction was then quenched 
with NH4Cl (1 mL) and Et2O (1 mL). The layers were separated and the aqueous layer extracted with Et2O 
(2 x 1 mL). Combined organic layers were washed with brine (2 mL), dried over MgSO4 and carefully 
concentrated in vacuo. The crude material was purified by flash column chromatography (6:1 PE30-40/Et-
2O) to give the title compound as a colourless liquid (11.0 mg, 45%). 
 
Rf 0.28 (9:1 PE/EtOAc); 1H NMR (500 MHz, CDCl3): δH 4.57-4.51 (1H, m, H-22), 2.46 (1H, d, J = 1.9 Hz, H-
20), 1.87 (1H, d, J = 5.4 Hz, O-H), 1.48 (3H, d, J = 6.7 Hz, Me-22). 
Data in agreement with literature values.184 
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(S)-4-(Trimethylsilyl)but-3-yn-2-yl methanesulfonate (317) 
 
To a solution of alcohol 306 (80.0 mg, 0.56 mmol, 1.0 equiv.) in CH2Cl2 (5 mL) at    ̶78 °C was added Et3N 
(0.31 mL, 2.25 mmol, 4.0 equiv.) and MsCl (0.13 mL, 1.69 mmol, 3.0 equiv.) and stirred for 1 h before 
being quenched with NH4Cl (5 mL). The layers were separated and the aqueous layer extracted with 
CH2Cl2 (3 x 4 mL). Combined organic layers were dried over MgSO4 and concentrated in vacuo. The crude 
material was purified by flash column chromatography (6:1 o 4:1 PE/EtOAc) to give the title compound 
as a colourless oil (79 mg, 64%).  
 
1H NMR (500 MHz, CDCl3): δH 5.25 (1H, q, J = 6.7 Hz, H-22), 3.11 (3H, s, SO2CH3), 1.62 (3H, d, J = 6.7 Hz, 
Me-22), 0.18 (9H, Si(CH3)3); 13C NMR (125 MHz, CDCl3): δC 101.3, 93.7, 68.6, 39.1, 22.5,   ̶0.5. 
Data in agreement with literature values.185 
 
(2S,3R,4R)-1-((tert-Butyldimethylsilyl)oxy)-2,4-dimethyl-2-((triethylsilyl)oxy)-6-(trimethylsilyl)hex-5-
yn-3-ol (318) 
 
To a stirred solution of Pd(PPh3)4 (13.9 mg, 0.012 mmol, 0.05 equiv.) in THF (2 mL) at 0 °C were added 
mesylate 317 (85.0 mg, 0.39 mmol, 1.6 equiv.) and aldehyde 258 (80.1 mg, 0.24 mmol, 1.0 equiv.) Et2Zn 
(1.1 M in toluene, 0.66 mL, 0.72 mmol, 3.0 equiv.) was then added over 10 min and the reaction mixture 
stirred for 8 h, before being quenched with NH4Cl (2 mL). The layers were separated and the aqueous 
layer extracted with Et2O (3 x 2 mL). Combined organic layers were dried over MgSO4 and concentrated 
in vacuo. The crude material was purified by flash column chromatography (9:1 PE/EtOAc) to give the 
title compound as a pale-yellow oil (74 mg, 68%) 
 
Rf 0.45 (9:1 PE/EtOAc); [𝛼]𝐷20   ̶ 11.9 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 3355, 2240, 1260, 962, 857, 
690; 1H NMR (500 MHz, CDCl3): δH 3.54 (2H, s, H-25), 3.31 (1H, dd, J = 7.8, 1.6 Hz, H-23), 3.00 (1H, qd, J 
= 7.8, 1.6 Hz, H-22), 2.69 (1H, d, J = 7.8 Hz, O-H), 1.28 (3H, d, J = 7.8 Hz, Me-22), 1.28 (3H, s, Me-24), 0.94 
(9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.90 (9H, s, SiC(CH3)3), 0.61 (6H, q, J = 7.9 Hz, Si(CH2CH3)3), 0.14 (9H, s, 
SiCCH3)3), 0.07 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC 108.5, 88.2, 77.8, 77.4, 70.5, 28.1,  
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25.9, 20.9, 20.2, 18.3, 7.1, 6.7, 0.1,   ̶ 5.5,   ̶5.6; HRMS (ES+) calc. for C23H51O3Si3 [M+H]+ 459.3141, found 
459.3138. 
 
 
(2S,3R,4R)-1-((tert-Butyldimethylsilyl)oxy)-2,4-dimethyl-2-((triethylsilyl)oxy)-hex-5-yn-3-ol (319) 
 
Procedure A:   
To a stirred solution of Pd(PPh3)4 (17.0 mg, 0.015 mmol, 0.05 equiv.) in THF (1 mL) at 0 °C were added a 
solution of mesylate 296 (80.0 mg, 0.54 mmol, 1.8 equiv.) in THF (2 mL) and a solution of aldehyde 258 
(100 mg, 0.30 mmol, 1.0 equiv.) in THF (2 mL). After stirring for 5 min Et2Zn (15 wt% in toluene, 0.60 mL, 
0.66 mmol, 2.2 equiv.) was added dropwise over 20 min. The reaction mixture was then stirred for 16 h 
at 0 °C and a further 2 h at rt. After re-cooling to 0 °C the NH4Cl (4 mL) was added to quench and the 
layers were separated. The aqueous layer was extracted with Et2O (3 x 3 mL), combined organic layers 
dried over MgSO4 and concentrated in vacuo. The crude material was purified by flash column 
chromatography (PE o 9:1 PE/EtOAc) to give the title compound as a 1.4:1 mixture of C22/C23 anti 
diastereomers (95 mg, 82%).  
 
Procedure B: 
 To a solution of silane 318 (50 mg, 0.11 mmol, 1.0 equiv.) in MeOH (1.5 mL) was added K2CO3 (76 mg, 
0.55 mmol, 5.0 equiv.) and stirred for 90 min. The reaction was quenched with H2O (2 mL) and extracted 
with Et2O (3 x 1 mL). Combined organic layers were dried over MgSO4 and concentrated in vacuo. The 
crude material was purified by flash column chromatography (PE o 10:1 PE/EtOAc) to give the title 
compound as a colourless oil (33 mg, 78%). 
 
Rf 0.38 (9:1 PE/EtOAc); [𝛼]𝐷20 + 1.9 (c 0.32, CHCl3); IR (thin film, νmax/cm-1): 3340, 2150, 1260, 981, 832, 
765; 1H NMR (500 MHz, CDCl3): δH 3.65 (1H, d, J = 9.6 Hz, H-25a), 3.57 (1H, d, J = 2.0 Hz, H-23), 3.53 (1H, 
d, J = 9.6 Hz, H-25b), 2.95 (1H, qt, J = 6.9, 2.2 Hz, H-22), 2.07 (1H, d, J = 2.2 Hz, H-20), 1.31 (3H, d, J = 6.9 
Hz, Me-22), 1.22 (3H, s, Me-24), 1.02 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.93 (9H, s, SiC(CH3)3), 0.70 (6H, q, J 
= 7.9 Hz, Si(CH2CH3)3), 0.10 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC 86.6, 78.0, 74.8, 70.4, 67.8, 
27.8, 25.8, 20.5, 20.3, 18.1, 6.9, 5.4,   ̶5.5,   ̶5.6; HRMS (ES+) calc. for C20H43O3Si2 [M+H]+ 387.2745, found 
387.2747. 
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(6S)-7-(But-3-yn-2-yl)-9,9-diethyl-2,2,3,3,6-pentamethyl-6-((triethylsilyl)oxy)-4,8-dioxa-3,9-
disilaundecane (320) 
 
 
 
To a solution of diastereomeric alcohols 297 (1.9:1 d.r., 10 mg, 0.026 mmol, 1.0 equiv.) in CH2Cl2 (0.3 
mL) at   ̶78 °C were added 2,6-lut. (6 μL, 0.052 mmol, 2.0 equiv.) and TESOTf (9 μL, 0.039 mmol, 1.5 
equiv.) sequentially. The reaction mixture was stirred at this temperature for 2 h before being quenched 
with NH4Cl (1 mL) and warmed to rt. The layers were separated and the aqueous layer extracted with 
CH2Cl2 (3 x 1 mL). Combined organic layers were dried over MgSO4 and concentrated in vacuo. The crude 
material was purified by flash column chromatography (PE o 15:1 PE/EtOAc) to give the title compound 
as a mixture of colourless oils with tris TES ether 321 (1.9:1 d.r., 10.2 mg, 86%) 
 
Rf 0.35 (15:1 PE/EtOAc); IR (thin film, νmax/cm-1): 2124, 1048, 989, 834, 765; 1H NMR (500 MHz, CDCl3): 
δH 3.63 (1H, d, J = 10.2 Hz, H-25a), 3.38 (1H, d, J = 10.2 Hz, H-25b), 3.38 (1H, s, H-23), 3.07 (1H, qt, J = 
7.2, 2.0 Hz, H-22), 2.00 (1H, d, J = 2.0 Hz, H-20), 1.26 (3H, s, Me-24), 1.22 (3H, s, Me-24), 1.01-0.84 (30H, 
m, Me-22, 2 x Si(CH2CH3)3, SiC(CH3)3), 0.69-0.58 (12H, m, 2 x Si(CH2CH3)3), 0.07 (3H, s, Si(CHa3)(CHb3), 
0.06 (3H, s, Si(CHa3)(CHb3); HRMS (TOF MS) calc. for C26H58O3Si3 [M+H]+ 501.3615, found 501.3612. 
 
 
(6S)-5-(But-3-yn-2-yl)-3,3,9,9-tetraethyl-6-methyl-6-((triethylsilyl)oxy)-4,8-dioxa-3,9-disilaundecane 
(321) 
 
 
Rf 0.35 (15:1 PE/EtOAc); IR (thin film, νmax/cm-1): 2124, 1048, 989, 834, 765; 1H NMR (500 MHz, CDCl3): 
δH 3.88 (1H, d, J = 10.8 Hz, H-25a), 3.72 (1H, d, J = 10.8 Hz, H-25b), 3.34 (1H, s, H-23), 3.17-3.11 (1H, m, 
H-22), 1.99 (1H, d, J = 2.4 Hz, H-20), 1.25 (3H, s, Me-24), 1.01-0.84 (30H, m, Me-22, 3 x Si(CH2CH3)3), 
0.69-0.58 (18H, m, 3 x Si(CH2CH3)3); HRMS (TOF MS) calc. for C26H58O3Si3 [M+H]+ 501.3615, found 
501.3612. 
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(4R,5S)-4-((R)-But-3-yn-2-yl)-2,2,5,8,8,9,9-heptamethyl-5-((triethylsilyl)oxy)-3,7-dioxa-2,8-
disiladecane (326) 
 
 
To a solution of alcohol 323 (26.0 mg, 0.067 mmol, 1.0 equiv.) in CH2Cl2 (1.0 equiv.) were added TMSCl 
(13 μL, 0.10 mmol, 1.5 equiv.) and imidazole (11.3 mg, 0.16 mmol, 2.5 equiv.). The reaction mixture was 
stirred for 3 h before being quenched with NH4Cl (1 mL) and the layers separated. The aqueous layer 
was extracted with CH2Cl2 (3 x 1 mL). Combined organic layers were dried over MgSO4 and concentrated 
in vacuo. The crude material was purified by flash column chromatography (PE o 19:1 PE/EtOAc) to 
give the title compound as a colourless oil (25 mg, 82%) 
 
Rf 0.28 (19:1 PE/EtOAc); [𝛼]𝐷20    ̶6.7 (c 0.75, CHCl3); IR (thin film, νmax/cm-1): 2124, 1048, 989, 834, 765; 
1H NMR (500 MHz, CDCl3): δH 3.66 (1H, d, J = 10.2 Hz, H-25a), 3.47 (1H, d, J = 10.2 Hz, H-25a), 3.46 (1H, 
d, J = 1.6 Hz, H-23), 2.98 (1H, qdd, J = 7.2, 2.5, 1.6 Hz, H-22), 2.03 (1H, d, J = 2.5 Hz, H-20), 1.29 (3H, s, 
Me-24), 1.22 (3H, d, J = 7.2 Me-22), 1.01 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.93 (9H, s, SiC(CH3)3), 0.69 (6H, 
q, J = 8.0 Hz, Si(CH2CH3)3), 0.09 (3H, s, Si(CHa3)(CHb3)), 0.08 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, 
CDCl3): δC 109.8, 86.1, 82.6, 79.6, 67.0, 27.9, 26.1, 23.2, 21.7, 18.5, 7.2, 6.6, 0.8,   ̶5.4,   ̶5.4; HRMS (ES+) 
calc. for C23H51O3Si3 [M+H]+ 459.3141, found 459.3138. 
 
 
(6S)-7-(But-3-en-2-yl)-9,9-diethyl-2,2,3,3,6-pentamethyl-6-((triethylsilyl)oxy)-4,8-dioxa-3,9-
disilaundecane (324) 
 
 
 
To a solution of alkynes 320 and 321 (41.0 mg, 0.08 mmol, 1.0 equiv.) in MeOH (1 mL) were added 
Lindlar’s catalyst (5% Pd on CaCO3, 20.0 mg, 0.002 mmol, 0.025 equiv.) and quinoline (18 μL, 0.16 mmol, 
2.0 equiv.). After 5 min, the argon line was replaced with an H2 balloon and the reaction mixture stirred 
for 16 h. The suspension was then filtered through Celite® and the residue washed with CH2Cl2 (2 mL). 
The filtrate was collected and concentrated in vacuo. The crude material was purified by flash column 
  
  
Chapter 6: Experimental 
162 
 
chromatography (PE o 15:1 PE/EtOAc) to give the title compound as a mixture of colourless oil with tris 
TES ether 325 (31 mg, 75%). 
 
Rf 0.35 (15:1 PE/EtOAc); IR (thin film, νmax/cm-1): 1642, 1221, 1084, 953, 771, 687; 1H NMR (500 MHz, 
CDCl3): δH 6.31-5.94 (1H, m, H-21), 4.96-4.88 (2H, m, H-20), 3.64 (1H, d, J = 10.2 Hz, H-25a), 3.61-3.47 
(2H, m, H-23, H-25b), 2.81-2.69 (1H, m, H-22), 1.18 (3H, s, Me-24), 1.06 (3H, d, J = 7.2 Hz, Me-22), 1.00-
0.89 (27H, m, 2 x Si(CH2CH3)3, SiC(CH3)3), 0.68-0.57 (12H, m, 2 x Si(CH2CH3)3), 0.05 (3H, s, Si(CHa3)(CHb3)), 
0.04 (3H, s, Si(CHa3)(CHb3)); HRMS (TOF MS) calc. for C26H58O3Si3 [M  ̶H] ̶  501.3612, found 501.3612. 
 
 
(6S)-5-(But-3-en-2-yl)-3,3,9,9-tetraethyl-6-methyl-6-((triethylsilyl)oxy)-4,8-dioxa-3,9-
disilaundecane (325) 
 
 
Rf 0.35 (15:1 PE/EtOAc); IR (thin film, νmax/cm-1): 1642, 1221, 1084, 953, 771, 687; 1H NMR (500 MHz, 
CDCl3): δH 6.31-5.94 (1H, m, H-21), 4.96-4.88 (2H, m, H-20), 3.61-3.47 (2H, m, H-23, H-25a), 3.34 (1H, d, 
J = 9.9 Hz, H-25b), 2.81-2.69 (1H, m, H-22), 1.14 (3H, s, Me-24), 1.07 (3H, d, J = 7.2 Hz, Me-22), 1.00-0.89 
(27H, m, 3 x Si(CH2CH3)3), 0.69-0.57 (18H, m, 3 x Si(CH2CH3)3); HRMS (TOF MS) calc. for C26H58O3Si3 [M  ̶
H] ̶  501.3612, found 501.3612. 
 
 
 (S)-4-(Benzyloxy)-3-((2S,3S,4R)-5-((tert-butyldimethylsilyl)oxy)-3-hydroxy-2,4-dimethyl-4-
((triethylsilyl)oxy)pentanoyl)oxazolidin-2-one (254) 
 
 
Oxazoline 340 (211 mg, 0.90 mmol, 2.0 equiv.) was dissolved in CH2Cl2 (2 mL) and cooled to 0 °C. TiCl4 
(105 μL, 0.95 mmol, 2.1 equiv.) was then added and the reaction mixture stirred for 65 mins with 
additions of DIPEA (173 μL, 1.00 mmol, 2.2 equiv.) and NMP (87 μL, 0.90 mmol, 2.0 equiv.) after 15 mins 
and 55 mins respectively. At this point, the reaction mixture was cooled to    ̶78 °C and a solution of 
aldehyde 258 (150 mg, 0.45 mmol, 1.0 equiv.) in CH2Cl2 (1 mL) added via cannula. After stirring at this 
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temperature for a further 2 hours, the reaction mixture was quenched with NH4Cl (3 mL) and the layers 
separated. The aqueous layer was extracted with CH2Cl2 (3 x 3 mL) and combined organic layers dried 
over MgSO4, with the solvent removed in vacuo. The crude product was purified by flash column 
chromatography (6:1 PE/EtOAc) to give the title compound as a colourless oil (198 mg, 78%, 11:1 d.r.) 
Rf 0.33 (6:1 PE/EtOAc); [𝛼]𝐷20 = + 15.5 (c 1.00, CHCl3); IR: (thin film, νmax/cm-1): 3500(br), 1783, 1692, 1451, 
1208, 1008, 838, 743; 1H NMR (500 MHz, CDCl3): δH 7.35-7.21 (5H, m, H-Ar), 4.66 (1H, qd, J = Hz, H-2’), 
4.16-4.10 (3H, m, H-1’, H-22), 3.95 (1H, dd, J = 10.0, 5.6 Hz, H-23), 3.79 (1H, d, J = 9.7 Hz, H-25a), 3.34 
(1H, d, J = 9.7 Hz, H-25b), 3.30 (1H, dd, J = 13.3, 3.2 Hz, CHaHbAr), 3.02 (1H, d, J = 10.0 Hz, O-H), 2.74 (1H, 
13.3, 9.8 Hz, CHaHbAr), 1.38 (3H, s, Me-24), 1.29 (3H, d, J = 7.0 Hz, Me-22), 0.94 (9H, t, J = 8.0 Hz, 
Si(CH2CH3)3), 0.89 (9H, s, Si(CH3)3), 0.59 (6H, q, J = 8.0 Hz, Si(CH2CH3)3), 0.08 (3H, s, Si(CHa3CHb3)), 0.07 
(3H, s, Si(CHa3CHb3)); 13C NMR (125 MHz, CDCl3): δC 176.0, 153.1, 135.5 ,129.5, 128.9, 127.3, 75.0, 68.9, 
65.9, 55.6, 39.2, 37.8, 25.8, 23.2, 18.2, 12.9, 7.0, 6.7, -5.6, -5.6 ; HRMS (ES+) calc. for C29H51NO6Si2Na  
[M+Na]+ 588.3153, found 588.3158. 
 
(S)-4-Benzyl-3-((2R,3R,4R)-5-((tert-butyldimethylsilyl)oxy)-3-hydroxy-2,4-dimethyl-4-
((triethylsilyl)oxy)pentanoyl)oxazolidin-2-one (343) 
 
Rf 0.38 (6:1 PE/EtOAc); [𝛼]𝐷20 = + 40.2 (c 1.00, CHCl3); IR: (thin film, νmax/cm-1): 3500(br), 1783, 1692, 1451, 
1208, 1008, 838, 743; 1H NMR (500 MHz, CDCl3): δH 7.36-7.21 (5H, m, H-Ar), 4.71-4.66 (1H, m, H-2’), 
4.32 (1H, d, J = 9.6 Hz, O-H), 4.22 (1H, qd, J = 7.2, 2.5 Hz, H-22), 4.19-4.14 (2H, m, CH2Ar), 3.68 (1H, dd, J 
= 9.6, 2.4 Hz, H-23), 3.58 (1H, d, J = 9.8 Hz, H-25a), 3.36 (1H, d, J = 9.8 Hz, H-25b), 3.23 (1H, dd, J = 13.5, 
2.8 Hz, H-1’a), 2.73 (1H, dd, J = 13.5, 9.8 Hz, H-1’b),  
1.40 (3H, d, J = 7.1 Hz, Me-22), 1.36 (3H, s, Me-24), 0.92 (9H, t, J = 7.8 Hz, Si(CH2CH3)3), 0.88 (9H, s, 
Si(CH3)3), 0.56 (6H, q, J = 7.8 Hz, Si(CH2CH3)3), 0.07 (3H, s, Si(CHa3CHb3)), 0.05 (3H, s, Si(CHa3CHb3)); 13C 
NMR (125 MHz, CDCl3): δC 178.2, 152.8, 135.2,129.5, 129.0, 127.4, 79.3, 78.7, 69.1, 65.8, 55.1, 37.7, 
34.6, 25.8, 22.2, 18.1, 17.6, 7.0, 6.6,   ̶5.6,   ̶5.7 ; HRMS (ES+) calc. for C29H51NO6Si2Na  [M+Na]+ 588.3153, 
found 588.3158. 
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(S)-4-Benzyl-3-((2S,3S,4R)-5-((tert-butyldimethylsilyl)oxy)-2,4-dimethyl-4-((triethylsilyl)oxy)-3-
((trimethylsilyl)oxy)pentanoyl)oxazolidin-2-one (354) 
 
A solution of alcohol 254 (217 mg, 0.38 mmol, 1.0 equiv.) in CH2Cl2 (4 mL) was cooled to 0 °C and 
imidazole (47.0 mg, 0.69 mmol, 1.8 equiv.) and TMSCl (65 μL, 0.5 mmol, 1.3 equiv.) added. The reaction 
mixture was left to stir for 1 h before being quenched with NH4Cl (3 mL) and the layers separated. The 
aqueous layer was extracted with CH2Cl2 (3 x 2 mL) and combined organic layers were dried over MgSO4, 
before the solvent was removed in vacuo. The crude material was purified by flash column 
chromatography (9:1 PE/EtOAc) to give the title compound as a colourless oil (217 mg, 89%).  
 
Rf 0.35 (9:1 PE/EtOAc); [𝛼]𝐷20 + 9.6 (c 0.97, CHCl3); IR (thin film, νmax/cm-1): 1788, 1701, 1458, 1387, 1209, 
1107, 1009, 838, 741; 1H NMR (500 MHz, CDCl3): δH 7.37-7.24 (5H, m, H-Ar), 4.71-4.67 (1H, m, H-2’), 
4.24- 4.16 (4H, m, H-1’, H-22, H-23), 3.69 (1H, d, J = 10.1 Hz, H-25a), 3.58 (1H, d, J = 10.1 Hz, H-25b), 3.28 
(1H, dd, J = 13.4, 3.2 Hz, CHaHbAr), 2.75 (1H, dd, J = 13.2, 9.6 Hz, CHaHbAr), 1.22 (3H, s, Me-24), 1.20 (3H, 
d, J = 6.8 Hz, Me-22), 0.94 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.94 (9H, s, Si(CH3)3), 0.63-0.55 (6H, m, 
Si(CH2CH3)3), 0.21 (9H, s, Si(CH3)3), 0.09 (3H, s, Si(CHa3CHb3), 0.08 (3H,s, Si(CHa3CHb3)3); 13C NMR (125 
MHz, CDCl3): δC 176.6, 152.9, 135.8, 129.4, 128.9, 127.2, 79.3, 74.7, 69.1, 65.8, 55.7, 38.4, 38.1, 26.0, 
20.8, 18.4, 14.1, 7.1, 6.7, 0.59,   ̶5.3,   ̶5.5; HRMS (ES+) calc. for C32H60NO6Si3 [M+H]+ 638.3723, found 
638.3722. 
 
 (2R,3S,4R)-5-((tert-butyldimethylsilyl)oxy)-2,4-dimethyl-4-((triethylsilyl)oxy)-3-
((trimethylsilyl)oxy)pentan-1-ol (355) 
 
To a stirred solution of amide 354 (210 mg, 0.33 mmol, 1.0 equiv.) in THF (3.5 mL) at 0 °C was added 
LiBH4 (4 M in THF, 0.21 mL, 0.83 mmol, 2.5 equiv.) and MeOH (54 μL, 1.23 mmol, 4.0 equiv.) The reaction 
mixture was stirred for 100 min before being quenched with NH4Cl (4 mL). The layers were separated 
and the aqueous layer extracted with Et2O (3 x 3 mL). The crude material was purified by column 
chromatography (9:1 PE/EtOAc) to give the title compound as a colourless oil (129 mg, 85%).  
 
Rf 0.33 (9:1 PE/EtOAc); [𝛼]𝐷20 + 14.7 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 3494, 1413, 1251, 1089, 
1036, 884, 837, 775, 743, 668; 1H NMR (500 MHz, CDCl3): δH 3.65 (1H, d, J = 2.3 Hz, H-23), 3.61 (1H, d, J 
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= 10.1 Hz, H-25a), 3.52-3.38 (2H, m, H-21), 3.34 (1H, d, J = 10.1 Hz, H-25b),  2.17-2.09 (1H, m, H-22), 1.81 
(1H, t, J = 5.7 Hz, O-H), 1.19 (3H, s, Me-24), 0.94 (9H, t, J = 7.7 Hz, Si(CH2CH3)3), 0.90 (9H, s, Si(CH3)3), 0.89 
(3H, d, J = 7.1 Hz, Me-22), 0.62 (6H, q, J = 7.7 Hz, Si(CH2CH3)3), 0.11 (9H, s, Si(CH3)3), 0.06 (3H, s, Si(CHa3-
)(CHb3)), 0.06 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 79.7, 77.9, 67.3, 36.8, 25.9, 23.6, 
18.4, 12.9, 11.4, 7.0, 6.6, 6.5, 0.60, 0.56,   ̶  5.5,   ̶  5.6; HRMS (ES+) calc. for C22H52O4Si3Na [M+Na]+ 
487.3066, found 487.3059.  
 
 (2S,3S,4S)-5-((tert-Butyldimethylsilyl)oxy)-2,4-dimethyl-4-((triethylsilyl)oxy)-3-
((trimethylsilyl)oxy)pentanal (356) 
 
To a solution of alcohol 355 (125 mg, 0.27 mmol, 1.0 equiv.) in CH2Cl2 (3 mL) was added 
triacetoxyiodobenzene (232 mg, 0.54 mmol, 2.0 equiv.) and anhydrous NaHCO3 (68.0 mg, 0.81 mmol, 
3.0 equiv.) and stirred for 20 min before being quenched with NaHCO3 (1 mL), and Na2S2O3 (1 mL) and 
stirred for a further 10 min. The layers were then separated and the aqueous layer extracted with CH2Cl2 
(3 x 2 mL). Combined organic layers were dried over MgSO4 and the solvent removed in vacuo to give 
the crude title compound as a colourless oil (120 mg, 96%), which was then used directly in the following 
reaction without further purification.  
 
Rf 0.28 (15:1 PE/EtOAc); [𝛼]𝐷20 + 17.3 (c 1.86, CHCl3);  IR (thin film, νmax/cm-1): 1728, 1410, 1280, 838, 780, 
667; 1H NMR (500 MHz, CDCl3): δH 9.56 (1H, d, J =1.8 Hz, H-21), 3.89 (1H, d, J = 5.7 Hz, H-23), 3.62 (1H, 
d, J = 10.2 Hz, H-25a), 3.53 (1H, d, J = 10.2 Hz, H-25b), 2.72 (1H, qdd, J = 7.1, 5.7, 1.8 Hz, H-22), 1.19 (3H, 
s, Me-24), 1.06 (3H, d, J = 7.1 Hz, Me-22), 0.93-0.90 (18H, m, Si(CH2CH3)3, SiC(CH3)3), 0.66-0.56 (6H, m, 
Si(CH2CH3)3), 0.10 (9H, s, Si(CH3)3), 0.05 (3H, Si(CHa3)(CHb3)), 0.05 (3H, Si(CHa3)(CHb3)); 13C NMR (125 
MHz, CDCl3): δC 202.9, 78.9, 77.4, 67.0, 48.0, 25.9, 23.5, 18.4,  11.0, 6.9, 6.3, 0.5,   ̶ 5.6 ; HRMS (ES+) calc. 
for C22H51O4Si3 [M+H]+ 463.3095, found 463.3087. 
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 (4S,5S)-4-((R)-But-3-en-2-yl)-2,2,5,8,8,9,9-heptamethyl-5-((triethylsilyl)oxy)-3,7-dioxa-2,8-
disiladecane (341) 
 
To a stirred solution of (bromomethyl)triphenylphosphonium bromide (326 mg, 0.91 mmol, 3.5 equiv.) 
in THF (1.5 mL) at 0 °C was added n-BuLi (1.6 M in hexanes, 0.49 mL, 0.78 mmol, 3.0 equiv.) After 20 
min, a solution of aldehyde 356 (115 mg, 0.26 mmol, 1.0 equiv.) in THF (1.5 mL) was added and the 
reaction mixture left to stir for a further hour before being quenched with PE. The precipitate was 
filtered through Celite® and the solvent removed in vacuo. The crude material was purified by flash 
column chromatography (PE o 20:1 PE/EtOAc) to give the title compound as a colourless oil (100 mg, 
87%). 
 
Rf 0.36 (20:1 PE/EtOAc); [𝛼]𝐷20 + 19.7 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 1461, 1364, 1250, 1216, 
1091, 885, 836, 742; 1H NMR (500 MHz, CDCl3): δH 5.84 (1H, ddd, J = 17.3, 10.4, 7.0, H-21), 4.94 (1H, dt, 
J = 17.3, 1.6 Hz, H-20a), 4.92 (1H, ddd, J = 10.4, 1.6, 1.3 Hz, H-20b), 3.62 (1H, d, J = 9.7 Hz, H-25a), 3.49 
(1H, d, J = 2.2 Hz, H-23), 3.46 (1H, d, J = 9.7 Hz, H-25b), 2.70-2.63 (1H, m, H-22), 1.17 (3H, s, Me-24), 
0.96-0.92 (12H, m, Me-22, Si(CH2CH3)3), 0.91 (9H, s, SiC(CH3)3), 0.64-0.56 (6H, Si(CH2CH3)3), 0.09 (9H, 
Si(CH3)3), 0.05 (3H, Si(CHa3)(CHb3)), 0.05 (3H, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC  145.3, 
112.3, 81.0, 79.7, 67.6, 37.5, 26.0, 23.7, 18.5, 14.4, 7.1, 6.8, 0.7,   ̶ 5.4,   ̶ 5.4; HRMS (ES+) calc. for C23H-
52O3Si3Na [M+Na]+ 483.3116, found 483.3113. 
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6.4.4 Preparation of Compounds for Model Coupling Studies 
 
(5S,6S)-5-((S,E)-3-Iodo-1-methoxy-2-methylallyl)-6-((R)-1-iodopropan-2-yl)-2,2,3,3,8,8,9,9-
octamethyl-4,7-dioxa-3,8-disiladecane (ent-359) 
 
PPh3 (21.7 mg, 0.083 mmol, 1.5 equiv.) and imidazole (5.6 mg, 0.083 mmol, 1.5 equiv.) were dissolved 
in CH2Cl2 (0.5 mL) and stirred for 5 min before the addition of I2 (21.2 mg, 0.083 mmol, 1.5 equiv.), upon 
which the solution turned yellow. After a further 5 min, a solution of alcohol ent-207 (31.0 mg, 0.056 
mmol, 1.0 equiv.) in CH2Cl2 (0.5 mL) was added and the reaction mixture stirred for 2 h. The reaction 
was then quenched with NH4Cl (2 mL) and CH2Cl2 (2 mL) and the layers separated. The aqueous layer 
was extracted with further CH2Cl2 (3 x 1 mL). Combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude material was then purified by flash column chromatography (15:1 
PE/EtOAc) to give the title compound as a colourless oil (32 mg, 87%) 
Rf 0.28 (9:1 PE/EtOAc); [𝛼]𝐷20 + 32.5 (c 0.91, CHCl3); IR (thin film, νmax/cm-1): 1472, 1361, 1254, 1094, 834, 
774; 1H NMR (500 MHz, CDCl3): δH 6.24 (1H, s, H-19), 3.78-3.74 (2H, m, H-16, H-17), 3.58 (1H, dd, J =  8.2, 
1.4 Hz, H-15), 3.45 (1H, dd, J = 6.8, 2.6 Hz, H-13a), 3.23 (1H, dd, J = 9.5, 6.8 Hz, H-13b), 3.12 (3H, s, OCH3), 
1.75 (3H, s, Me-18), 1.72-1.64 (1H, m, H-14), 1.03 (3H, d, J = 6.6 Hz, Me-14), 0.91 (9H, s, SiC(CH3)3), 0.86 
(9H, s, SiC(CH3)3), 0.14 (3H, s Si(CHa3)(CHb3)), 0.13 (3H, s, Si(CHa3)(CHb3)), 0.08 (3H, s Si(CHa3)(CHb3)), 
0.01 (3H, s, Si(CHa3)(CHb3)3); 13C NMR (125 MHz, CDCl3): δC 146.3, 85.8, 82.4, 74.2, 55.8, 37.1, 26.0, 26.0, 
22.6, 19.4, 19.0, 18.4, 18.2, 18.1,   ̶3.6,   ̶3.6,   ̶3.9,   ̶4.3; HRMS (TOF MS) calc. for C22H46I2O3Si2 [M+H]+ 
669.1153, found 669.1160. 
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 (2R,3S,4S,5S,E)-3,4-bis((tert-Butyldimethylsilyl)oxy)-7-iodo-5-methoxy-2,6-dimethylhept-6-enal 
(ent-363) 
 
To a solution of alcohol ent-207 (40.0 mg, 0.07 mmol, 1.0 equiv.) in CH2Cl2 (1 mL) was cooled to 0 °C and 
Dess-Martin periodinane (90.8 mg, 0.22 mmol, 3.0 equiv.) and anhydrous NaHCO3 (36.2 mg, 0.44 mmol, 
6.0 equiv.) added. The reaction mixture was warmed to rt and stirred for 30 min before being quenched 
with NaHCO3 (1 mL) and Na2S2O3 (1 mL). After stirring for a further 5 min, the layers were separated and 
the aqueous layer extracted with CH2Cl2 (3 x 2 mL). Combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude material was used without further purification.  
Rf 0.48 (6:1 PE/EtOAc); [𝛼]𝐷20 + 18.4 (c 1.23, CHCl3); IR (thin film, νmax/cm-1): 1713, 1472, 1361, 1254, 
1094, 834, 774; 1H NMR (500 MHz, CDCl3): δH 9.69 (1H, d, J = 4.0 Hz, H-13), 6.24 (1H, s, H-19), 3.89 (1H, 
dd, J = 4.2, 2.6 Hz, H-15), 3.69 (1H, dd, J = 8.2, 2.6 Hz, H-16), 3.65 (1H, d, J = 8.2 Hz, H-17), 3.01 (3H, s, 
OCH3), 2.70 (1H, qdd, J = 7.2, 4.2, 4.0 Hz, H-14), 1.73 (3H, s, Me-18), 1.12 (3H, d, J = 7.2 Hz, Me-14), 0.89 
(9H, s, SiC(CH3)3), 0.85 (9H, s, SiC(CH3)3), 0.11 (3H, s Si(CHa3)(CHb3)), 0.07 (3H, s, Si(CHa3)(CHb3)), 0.05 
(3H, s Si(CHa3)(CHb3)),   ̶ 0.01 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 205.3, 145.6, 85.9, 
82.6, 73.4, 55.2, 46.7, 25.8, 25.8, 22.6, 19.1, 18.2, 18.0, 13.9,   ̶3.7,   ̶4.0,   ̶4.3,   ̶4.7; HRMS (ES+) calc. for 
C22H46IO4Si2 [M+H]+ 557.1974, found 557.1971 
 
(4S,5S,6S,7S,E)-5,6-bis((tert-Butyldimethylsilyl)oxy)-9-iodo-7-methoxy-4,8-dimethyl-1-
(trimethylsilyl)non-8-en-1-yn-3-ol (368) 
 
A solution of ethynyl trimethylsilane (42 μL, 0.30 mmol, 4.2 equiv.) in THF (1 mL) was cooled to    ̶78 °C 
and n-BuLi (1.6 M in hexanes, 0.19 mL, 0.30 mmol, 4.2 equiv.) added. The solution was then stirred for 
40 min at this temperature before being warmed to rt for 10 min. Aldehyde ent-363 (~40 mg, 0.072 
mmol, 1.0 equiv.) was dissolved in THF (0.5 mL) and cooled to   ̶ 78 °C and the lithium acetylide solution 
added via cannula. The reaction mixture was then stirred for 30 min at this temperature and for a further 
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30 min at rt before being quenched with NH4Cl (2 mL) and the layers separated. The aqueous layer was 
extracted with Et2O (3 x 1 mL), combined organic layers dried over MgSO4 and concentrated in vacuo. 
The crude material was purified by flash column chromatography (9:1 PE/EtOAc) to give the title 
compound as a 2.5:1 mixture of C13 diastereomers (42 mg, 94% over two steps) 
Major diastereomer: 
Rf 0.42 (6:1 PE/EtOAc);  IR (thin film, νmax/cm-1): 3435, 2152, 1472, 1361, 1254, 1094, 834, 774; 1H NMR 
(500 MHz, CDCl3): δH 6.26 (1H, s, H-19), 4.52 (1H, dd, J = 7.3, 2.4 Hz, H-13), 3.99 (1H, dd, J = 8.7, 1.9 Hz, 
H-17), 3.81-3.77 (2H, m, H-15, H-16), 3.12 (3H, s, OCH3), 2.18-2.11 (1H, m, H-14), 1.76 (3H, s, Me-18), 
1.07 (3H, d, J = 7.1 Hz, Me-14), 0.92 (9H, s, SiC(CH3)3), 0.89 (9H, s, SiC(CH3)3), 0.19 (3H, s, Si(CHa3)(CHb3)), 
0.18 (9H, s, Si(CH3)3), 0.18 (3H, s, Si(CHa3)(CHb3)), 0.09 (3H, s, Si(CHa3)(CHb3)), 0.02 (3H, s, Si(CHa3)(CHb-
3)); 13C NMR (125 MHz, CDCl3): δC 146.0, 106.0, 89.9, 85.8, 82.4, 78.6, 73.9, 69.4, 55.7, 41.2, 26.0, 26.0, 
19.6, 18.3, 18.2, 13.4, 0.0,   ̶3.4,   ̶3.5,   ̶4.1,   ̶4.5; HRMS (ES+) calc. for C27H56IO4Si3 [M+H]+ 655.2526, 
found 655.2521. 
Minor diastereomer 
1H NMR (500 MHz, CDCl3): δH 6.24 (1H, s, H-19), 4.59 (1H, dd, J = 6.1, 4.5 Hz, H-13), 3.85 (1H, d, J = 7.8 
Hz, H-17), 3.75 (1H, dd, J = 8.1, 2.7 Hz, H-15), 3.72 (1H, dd, J = 7.8, 2.7 Hz, H-16), 3.10 (3H, s, OCH3), 2.70 
(1H, br s, O-H), 2.18-2.11 (1H, m, H-14), 1.74 (3H, s, Me-18), 1.05 (3H, d, J = 6.9 Hz, Me-14), 0.91 (9H, s, 
SiC(CH3)3), 0.86 (9H, s, SiC(CH3)3), 0.17 (9H, s, Si(CH3)3), 0.13 (3H, s, Si(CHa3)(CHb3)), 0.12 (3H, s, Si(CHa3-
)(CHb3)), 0.09 (3H, s Si(CHa3)(CHb3)), 0.01 (3H, s, Si(CHa3)(CHb3)). 
 
(4R,5S,6S,7S,E)-5,6-bis((tert-Butyldimethylsilyl)oxy)-9-iodo-7-methoxy-4,8-dimethyl-1-
(trimethylsilyl)non-8-en-1-yn-3-yl 4-methylbenzenesulfonate (373) 
 
To a solution of diastereomeric alcohols 368 (48.0 mg, 0.073 mmol, 1.0 equiv.) in CH2Cl2/pyridine (1:1, 
1.0 mL) was added tosyl chloride (41.6 mg, 0.22 mmol, 3.0 equiv.) and stirred at rt for 2.5 h. The reaction 
mixture was then quenched with NaHCO3 (2 mL), the layers separated and the aqueous layer extracted 
with CH2Cl2 (3 x 1 mL). Combined organic layers were dried over MgSO4 and concentrated in vacuo. The 
crude material was purified by flash column chromatography (12:1 PE/EtOAc) to give an inseparable 
2.5:1 ratio of diastereomeric tosylates as a pale-yellow oil (44 mg, 73%). 
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Rf 0.28 (12:1 PE/EtOAc); IR (thin film, νmax/cm-1): 3025, 2152, 1580 1472, 1361, 1254, 1094, 834, 774; 1H 
NMR (major diastereomer, 500 MHz, CDCl3): δH 7.93 (2H, d, J = 8.2 Hz, H-Ar), 7.41 (2H, d, J = 8.2 Hz, H-
Ar), 6.24 (1H, s, H-19), 4.59 (1H, dd, J = 5.9, 4.3 Hz, H-13), 3.85 (1H, d, J = 7.8 Hz, H-17), 3.81-3.72 (2H, 
m, H-15, H-16), 3.11 (3H, s, OCH3), 2.49 (3H, s, ArCH3), 2.19-2.12 (1H, m, H-14), 1.75 (3H, s, Me-18), 1.05 
(3H, d, J = 6.8 Hz, Me-14), 0.91 (9H, s, SiC(CH3)3), 0.84 (9H, s, SiC(CH3)3), 0.18 (9H, s, Si(CH3)3), 0.13 (3H, 
s, Si(CHa3)(CHb3)), 0.13 (3H, s, Si(CHa3)(CHb3)), 0.09 (3H, s, Si(CHa3)(CHb3)), 0.01 (3H, s, Si(CHa3)(CHb3)); 
HRMS (ES+) calc. for C34H62IO6SSi3 [M+H]+ 808.2541, found 808.2547. 
 
 (5S,6S)-5-((R)-1-Iodopropan-2-yl)-6-((S)-1-methoxy-2-methylallyl)-2,2,3,3,8,8,9,9-octamethyl-4,7-
dioxa-3,8-disiladecane (374) 
 
To a solution of vinyl iodide ent-207 (150 mg, 0.27 mmol, 1.0 equiv.) in THF (2.7 mL) at   ̶78 °C was added 
n-BuLi (1.6 M in hexanes, 0.57 mL, 1.08 mmol, 4.0 equiv.) and stirred for 10 min before being warmed 
up to rt over 1 h. The reaction mixture was then quenched with water (3 mL) and the layers separated. 
The aqueous layer was extracted with Et2O (3 x 3 mL) and the combined organic layers dried over MgSO4 
before removal of the solvent in vacuo. The crude product was purified by filtration though a short plug 
of silica gel. 
PPh3 (90.1 mg, 0.34 mmol, 1.5 equiv.) and imidazole (23.1 mg, 0.34 mmol, equiv.) were dissolved in 
Et2O/MeCN (1:1, 2 mL), and stirred for 5 min before the addition of I2 (87.3 mg, 0.34 mmol, 1.5 equiv.). 
The reaction mixture was then stirred for a further 10 min before a solution of the alcohol (95 mg, 0.23 
mmol, 1.0 equiv.) in Et2O/MeCN (1:1, 1 mL) was added. The suspension was then stirred for a further 1 
h before being quenched with NH4Cl (3 mL). The layers were separated and the aqueous layer extracted 
with Et2O (3 x 3 mL). Combined organic layers were dried over MgSO4 and concentrated in vacuo. The 
crude material was purified by flash column chromatography (15:1 PE/EtOAc) to give the title compound 
as a colourless oil (98 mg, 67% over both steps).  
Rf 0.36 (9:1 PE/EtOAc); [𝛼]𝐷20   ̶8.3 (c 0.52, CHCl3); IR (thin film, νmax/cm-1): 1463, 1253, 1101, 874, 834, 
774; 1H NMR (400 MHz, CDCl3): δH 5.05-5.03 (1H, m, H-19a), 4.99-4.98 (1H, m, H-19b), 3.76 (1H, dd, J = 
7.2, 2.4 Hz, H-16), 3.63 (1H, d, J = 7.2 Hz, H-17), 3.59 (1H, dd, J = 8.1, 2.4 Hz, H-15), 3.48 (1H, dd, J = 9.3, 
2.8 Hz, H-13a), 3.23 (1H, d, J = 9.3, 6.7 Hz, H-13b), 3.14 (3H, s, OCH3), 1.80-1.71 (1H, m, H-14), 1,68 (3H, 
s, Me-18), 1.04 (3H, d, J = 6.7 Hz, Me-14), 0.92 (9H, s, SiC(CH3)3), 0.86 (9H, s, SiC(CH3)3), 0.14 (6H, s, 
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Si(CH3)2), 0.08 (3H, s, Si(CHa3)(CHb3)), 0.04 (3H, s, Si(CHa3)(CHb3)); 13C NMR (125 MHz, CDCl3): δC 142.6, 
117.3, 85.1, 77.1, 55.3, 37.2, 26.1, 26.0, 19.0, 18.5, 18.3, 17.6,    ̶3.6,   ̶3.7,   ̶4.0,   ̶4.6; HRMS (ES+) calc. 
for C22H48IO3Si2 [M+H]+ 543.2187, found 543.2190. 
 
 (5S,6R,7R,8S,12S,13S,14S,Z)-13-((tert-Butyldimethylsilyl)oxy)-5-((R)-2,5-dimethylhex-5-en-1-yl)-14-
((S)-1-methoxy-2-methylallyl)-7-((4-methoxybenzyl)oxy)-2,2,3,3,6,8,12,16,16,17,17-undecamethyl-
4,15-dioxa-3,16-disilaoctadec-9-ene (375) 
  
To a solution of iodide 374 (10 mg, 0.018 mmol, 1.0 equiv.) in Et2O (0.2 mL) at    ̶78 °C was added t-BuLi 
(1.6 M in pentane, 70 μL, 0.11 mmol, 6.0 equiv.) and stirred for 3 min. OMe-9-BBN (1 M in hexanes, 0.18 
mL, 0.18 mmol, 10.0 equiv.) was then added, followed by THF (0.2 mL). The reaction mixture was then 
left to stir for 5 min at this temperature, before being warmed to rt and stirred for a further 1 h. K3PO4 
(3 M aq, 60 μL, 0.18 mmol, 10.0 equiv.), Pd(dppf)Cl2 (0.89 mg, 1.35 μmol, 0.075 equiv.) and DMF (0.2 
mL) were then added, followed by vinyl iodide 186 (11.5 mg, 0.018 mmol, 1.0 equiv.) The resulting 
solution was stirred for 16 h before being heated to 50 °C for a further 3 h. The reaction was then 
quenched with H2O (0.5 mL). The layers were separated and the aqueous layer extracted with Et2O (4 x 
0.5 mL). Combined organic layers were washed with brine (1 mL), dried over MgSO4 and concentrated 
in vacuo. The crude material was purified by flash column chromatography (PE o 20:1 PE/EtOAc) to 
give the title compound as pale-yellow oil (9.2 mg, 57 %) 
Rf 0.26 (19:1 PE/EtOAc); [𝛼]𝐷20    ̶14.7 (c 0.45, CHCl3); IR (thin film, νmax/cm-1): 1469, 1451, 1411, 1391, 
1301, 1168, 1008, 978, 877, 731; 1H NMR (500 MHz, CDCl3): δH 7.25 (2H, d, J = 8.6 Hz, H-Ar), 6.86 (2H, d, 
J = 8.6 Hz, H-Ar), 5.54 (1H, t, J = 10.4 Hz, H-11), 5.29-5.23 (1H, m, H-12), 5.03-4.96 (2H, m, H-19), 4.67 
(1H, s, H-1a), 4.66 (1H, s, H-1b), 4.56 (1H, d, J = 10.9 Hz, OCHaHbAr), 4.39 (1H, d, J = 10.9 Hz, OCHaCHbAr), 
4.15 (1H, dt, J = 10.5, 2.4 Hz, H-7), 3.80 (3H, s, ArOCH3), 3.75 (1H, dd, J = 7.6, 2.8 Hz, H-16), 3.63 (1H, d, 
J = 7.2 Hz, H-17), 3.59 (1H, dd, J = 9.3, 6.4 Hz, H-15), 3.15 (3H, s, OCH3), 3.10 (1H, dd, J = 10.1, 2.0 Hz, H-
9), 2.71-2.65 (1H, m, H-10), 2.41 (1H, dd, J = 12.1, 5.7 Hz, H-13a), 2.01 (2H, t, J = 8.0 Hz, H-3), 1.93 (1H, 
qt, J = 7.0, 2.8 Hz, H-8), 1.84-1.78 (2H, m, H-14, H-13b), 1.71 (3H, s, Me-2), 1.67 (3H, s, Me-18), 1.41-1.14 
(5H, m, H-6, H-5, H-4), 0.97 (3H, d, J = 7.1 Hz, Me-10), 0.94-0.85 (33H, m, 3 x SiC(CH3)3, Me-14, Me-8), 
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0.80 (3H, d, J = 6.5 Hz, Me-5), 0.11-0.01 (18H, m, 3 x Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC 158.8, 146.4, 
142.6, 135.5, 131.6, 128.4, 128.0, 117.0, 113.6, 109.5, 85.0, 74.0, 69.4, 55.4, 55.3, 43.0, 38.3, 36.6, 35.9, 
35.4, 33.9, 31.6, 30.5, 28.6, 26.2, 26.2, 26.0, 26.0, 22.5, 20.6, 19.1, 18.6, 18.5, 18.1, 17.7, 17.2, 13.4, 10.1, 
  ̶3.6,   ̶3.6,   ̶3.8,   ̶4.1,   ̶4.2,   ̶4.6; HRMS (ES+) calc. for C52H99O6Si3 [M+H]+ 903.6749, found 903.6733. 
 
(2S,5R,7S,8R,9R,10S,14S,15S,16S,17S,Z)-7,15,16-tris((tert-Butyldimethylsilyl)oxy)-17-methoxy-9-((4-
methoxybenzyl)oxy)-2,5,8,10,14,18-hexamethylnonadeca-11,18-diene-1,2-diol (376) 
 
To a solution of alkene 375 (2.0 mg, 2.2 μmol, 1.0 equiv.) in t-BuOH/H2O/THF (1:1:1, 0.1 mL) was added 
ADmixα (5.1 mg, 0.022 mmol, 10 equiv.) and stirred for 16 h. At this point further K2OsO2(OH)4 (1.6 mg, 
4.4 μmol, 2.0 equiv.) and (DHQ)2PHAL (5.1 mg, 6.6 μmol, 3.0 equiv.) were added and the reaction 
mixture stirred for a further 4 h. Upon completion, the reaction was diluted with Et2O (0.3 mL) and 
quenched with Na2S2O3 (0.2 mL) and NaHCO3 (0.2 mL). The layers were separated and the aqueous layer 
extracted with Et2O (3 x 0.3 mL). Combined organic layers were dried over Na2SO4 and concentrated in 
vacuo. The crude material was purified by flash column chromatography (9:1 PE/EtOAc) to give the title 
compound as a colourless oil (1.2 mg, 58%). 
Rf 0.24 (9:1 PE/EtOAc); [𝛼]𝐷20   ̶19.2 (c 0.11, CHCl3); IR (thin film, νmax/cm-1): 3452, 3381, 1469, 1411, 1301, 
1168, 1008, 978, 877, 731; 1H NMR (500 MHz, CDCl3): δH 7.24 (2H, d, J = 8.6 Hz, H-Ar), 6.86 (2H, d, J = 
8.6 Hz, H-Ar), 5.53 (1H, t, J = 10.6 Hz, H-11), 5.28-5.23 (1H, m, H-12), 5.02 (1H, s, H-19a), 4.98 (1H, s, H-
19b), 4.56 (1H, d, J = 10.9 Hz, OCHaHbAr), 4.39 (1H, d, J = 10.9 Hz, OCHaHbAr), 4.15 (1H, dt, J = 10.8, 2.2 
Hz, H-7), 3.80 (3H, s, ArOCH3), 3.76-3.73 (2H, m, H-1a, H-17), 3.63 (1H, d, J = 7.7 Hz, H-1b), 3.58 (1H, dd, 
J = 8.0, 1.4 Hz, H-16), 3.46-3.44 (1H, m, H-15), 3.15 (3H, s, OCH3), 3.09 (1H, dd, J = 10.0, 2.4 Hz, H-9), 
2.70-2.64 (1H, m, H-10), 2.40 (1H, ddd, J = 11.7, 4.4, 1.5 Hz, H-13a), 1.93 (1H, ddq, J = 10.8, 10.0, 6.9 Hz, 
H-8), 1.86-1.84 (1H, m, H-14), 1.82-1.78 (2H, m, H-13b, O-H), 1.69 (1H, d, J = 4.3 Hz, H-6a), 1.67 (3H, s, 
Me-18), 1.50 (3H, s, Me-2), 1.36-1.22 (6H, m, H-6b, H-5, H-4, H-3), 0.97 (3H, d, J = 6.8 Hz, Me-10), 0.93-
0.80 (36H, m, 3 x SiC(CH3)3, Me-14, Me-8, Me-5), 0.11-0.00 (18H, 3 x Si(CH3)2); 13C NMR (125 MHz, CDCl3): 
δC 158.8, 145.7, 142.6, 135.5, 131.5, 128.4, 117.0, 113.6, 84.9, 76.8, 74.1, 69.6, 65.0, 62.1, 58.7, 55.4, 
55.3, 53.4, 41.4, 36.4, 36.1, 33.7, 29.7, 29.0, 28.9, 27.7, 26.2, 26.1, 25.8, 22.6, 20.5, 19.4, 18.8, 18.1, 14.3, 
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11.4, 8.9,   ̶3.6,   ̶3.6,   ̶4.1,   ̶4.2,  ̶4.2,   ̶4.6; HRMS (ES+) calc. for C52H101O8Si3 [M+H]+ 937.6804, found 
937.6813. 
 
(5S,6S,7S,8E,10E)-6-((tert-Butyldimethylsilyl)oxy)-7-methoxy-5-((S)-1-((4-
methoxybenzyl)oxy)propan-2-yl)-2,2,3,3,8,16,16,17,17-nonamethyl-4,15-dioxa-3,16-disilaoctadeca-
8,10-diene (378) 
 
To a solution of vinyl iodide ent-252 (50.0 mg, 0.075 mmol, 1.0 equiv.) and alkene 377 (30.5 mg, 0.15 
mmol, 2.0 equiv.) in degassed DMF (1 mL) were added Pd(OAc)2 (1.4 mg, 7.5 μmol, 0.1 equiv.) and Ag2-
CO3 (20.5 mg, 0.075 mmol, 1.0 equiv.). The reaction mixture was heated to 80 °C for 16 h. After recooling 
to rt, H2O (2 mL) and Et2O (2 mL) were added and the layers separated. The aqueous layer was extracted 
with Et2O (3 x 2 mL), combined organic layers dried over MgSO4 and concentrated in vacuo. The crude 
material was purified by flash column chromatography (20:1 PE/EtOAc) to give the title compound as a 
yellow oil (24 mg, 43%).   
Rf 0.31 (20:1 PE/EtOAc); [𝛼]𝐷20   ̶5.6 (c 0.70, CHCl3); IR (thin film, νmax/cm-1): 2928, 2340, 1490, 1421, 1249, 
1095, 836, 774; 1H NMR (500 MHz, CDCl3): δH 7.25 (2H, d, J = 8.7 Hz, H-Ar), 6.86 (2H, d, J = 8.7 Hz, H-Ar), 
6.25 (1H, dd, J = 15.2, 10.9, Hz, H-1’), 5.93 (1H, d, J = 10.9 Hz, H-19), 5.64 (1H, dt, J = 15.2, 7.0 Hz, H-2’), 
4.44 (1H, d, J = 11.6 Hz, CHaHbAr), 4.39 (1H, d, J = 11.6 Hz, CHaHbAr), 3.80 (3H, s, ArOCH3), 3.72-3.67 
(2H, m, H-13), 3.61 (2H, t, J = 6.4 Hz, H-5’), 3.61-3.57 (1H, m, H-16), 3.53 (1H, d, J = 8.1 Hz, H-17), 3.23 
(1H, t, J = 8.6 Hz, H-15), 3.06 (3H, s, OCH3), 2.23-2.13 (2H, m, H-3’), 2.10-2.06 (1H, m, H-14), 1.65-1.59 
(2H, m, H-4’), 1.55 (3H, s, Me-18), 1.00 (3H, d, J = 6.7 Hz, Me-14), 0.90-0.81 (27H, m, 3 x  SiC(CH3)3), 0.07- 
  ̶0.05 (18H, m, 3 x Si(CH3)2); 13C NMR (125 MHz, CDCl3): δC 158.8, 134.1, 130.8, 130.2, 129.17, 129.1, 
126.8, 113.6, 86.4, 75.0, 73.8, 72.8, 71.8, 62.8, 55.3, 55.1, 36.0, 29.5, 29.0, 26.1, 26.0, 26.0, 18.0, 15.9, 
12.1, 11.6,   ̶3.7,   ̶4.0,   ̶4.2,   ̶4.4,   ̶4.5,   ̶5.2; HRMS (ES+) calc. for C41H79O6Si3 [M+H]+ 751.5179, found 
751.5177 
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(2S,3S,4S,5S,6E,8E,10R,11S)-3,4,13-tris((tert-Butyldimethylsilyl)oxy)-5,11-dimethoxy-2,6,10-
trimethyltrideca-6,8-dien-1-ol (380) 
 
 
Vinyl iodide ent-207 (40 mg, 0.09 mmol, 1.0 equiv.) and alkene 379 (35.2 mg, 0.14 mmol, 1.5 equiv.) 
were dissolved in degassed DMF (0.6 mL) and Pd(OAc)2 (2.0 mg, 9.0 μmol, 0.1 equiv.) and Ag2CO3 (24.7 
mg, 0.09 mmol, 1.0 equiv.) added. The reaction mixture was then heated to 80 °C and stirred for 16 h. 
After re-cooling to rt, the reaction was quenched with water (2 mL) and Et2O (2 mL). The layers were 
separated and the aqueous layer extracted with further Et2O (3 x 2 mL). Combined organic layers were 
washed with brine (2 mL), dried over MgSO4 and concentrated in vacuo. The crude material was purified 
by flash column chromatography (9:1 PE/EtOAc) to give the title compound as a colourless oil (32 mg, 
62%) 
 
Rf 0.37 (9:1 PE/EtOAc); [𝛼]𝐷20   ̶ 12.3 (c 0.65, CHCl3); IR (thin film, νmax/cm-1): 3628, 1490, 1256, 1098, 836, 
757; 1H NMR (500 MHz, CDCl3): δH 6.24 (1H, dd, J = 15.1, 11.0 Hz, H-1’), 5.98 (1H, d, J = 11.0 Hz, H-19), 
5.60 (1H, dd, J = 15.1, 7.8 Hz, H-2’), 3.76 (1H, dd, J = 6.1, 2.7 Hz, H-15), 3.68 (2H, t, J = 6.3 Hz, H-6’), 3.67 
(1H, dd, J = 8.1, 2.7 Hz, H-16), 3.63 (1H, d, J = 8.1 Hz, H-17), 3.63-3.59 (1H, m, 13a), 3.55 (1H, ddd, J = 
10.7, 8.5, 4.2 Hz, H-13b), 3.37 (3H, s, OCH3), 3.25 (1H, dt, J = 7.8, 4.4 Hz, H-4’), 3.08 (3H, s, OCH3), 2.94-
2.85 (1H, m, O-H), 2.54 (1H, quint d, J = 7.8, 7.0 Hz, H-3’), 2.14-2.08 (1H, m, H-14), 1.66 (3H, s, Me-18), 
1.59 (2H, dt, J = 6.3, 4.4 Hz, H-5’), 1.02 (3H, d, J = 7.0 Hz, Me-14), 0.95 (3H, d, J = 7.0 Hz, Me-3’), 0.93 (9H, 
s, SiC(CH3)3), 0.89 (9H, s, SiC(CH3)3), 0.81 (9H, s, SiC(CH3)3), 0.13-   ̶ 0.06 (18H, m, 3 x Si(CH3)2); 13C NMR 
(125 MHz, CDCl3): δC 136.7, 132.8, 131.1, 126.0, 87.2, 81.5, 73.5, 66.7, 66.6, 59.9, 57.9, 55.1, 39.5, 34.0, 
26.0, 25.9, 18.3, 18.2, 18.2, 16.7, 15.2, 12.0, 11.6, 10.6,   ̶ 3.5,   ̶ 3.8,   ̶ 4.6,   ̶ 4.6,   ̶ 5.3,   ̶ 5.3; HRMS (ES+) 
calc. for C36H80NO6Si3 [M+NH4]+ 706.5288, found 706.5281. 
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(2R,3R,4R,5R,6E,8E,10R,11S,12S)-3,4,13-tris((tert-Butyldimethylsilyl)oxy)-5-methoxy-2,6,10,12-
tetramethyl-12-((triethylsilyl)oxy)-11-((trimethylsilyl)oxy)trideca-6,8-dien-1-ol (369) 
 
To a solution of alkene 341 (55 mg, 0.12 mmol, 1.0 equiv.) and vinyl iodide 207 (100.5 mg, 0.18 mmol, 
1.5 equiv.) in DMF (1.0 mL) were added Pd(OAc)2 (5.38 mg, 0.024 mmol, 0.2 equiv.) and Ag2CO3 (48.4 
mg, 0.144 mmol, 1.2 equiv.). The reaction mixture was heated to 80 °C and stirred for 16 h. After 
cooling to rt, Et2O (4 mL) was added and the suspension filtered through a plug of Celite®, washing 
with further Et2O. The filtrate was then washed with brine (2 x 3 mL) and dried over MgSO4, before 
being concentrated in vacuo. The crude material was purified by flash column chromatography (PE o 
12:1 PE/EtOAc) to give the title compound as a colourless oil (65.9 mg, 65%).  
 
Rf 0.42 (9:1 PE/EtOAc); [𝛼]𝐷20 + 16.3 (c 0.84, CHCl3); IR (thin film, νmax/cm-1): 3471, 1470, 1463, 1361, 
1251, 1091, 834, 774; 1H NMR (500 MHz, CDCl3): δH 6.18 (1H, dd, J = 15.0, 10.9 Hz, H-20), 5.97 (1H, d, J 
= 10.9 Hz, H-19), 5.68 (1H, dd, J = 15.0, 7.9 Hz, H-21), 3.76 (1H, dd, J = 6.2, 2.8 Hz, H-15), 3.70 (1H, dd, J 
= 8.1, 2.8 Hz, H-16), 3.65-3.59 (2H, m, H-13a, H-17), 3.63 (1H, d, J = 9.6 Hz, H-25a), 3.55 (1H, dd, J = 8.4, 
4.0 Hz, H-13b), 3.49 (1H, d, J = 1.7 Hz, H-23), 3.43 (1H, d, J = 9.6 Hz, H-25b), 3.08 (3H, s, OCH3), 2.88 (1H, 
br s, O-H), 2.77 (1H, dqd, J = 7.9, 6.8, 1.7 Hz, H-22), 2.17-2.10 (1H, m, H-14), 1.65 (3H, s, Me-18), 1.16 
(3H, s, Me-24), 0.98 (3H, d, J  =6.8 Hz, Me-22), 0.97-0.82 (39H, m, Me-14, 3 x SiC(CH3)3, Si(CH2CH3)3), 
0.62-0.57 (6H, m, Si(CH2CH3)3), 0.14-   ̶0.05 (27H, 3 x Si(CH3)2, Si(CH3)3); 13C NMR (125 MHz, CDCl3): δC 
141.4 (C-21), 132.2 (C-18), 131.4 (C-19), 123.9 (C-20), 87.3, 80.7, 79.6, 78.8, 73.4, 67.6, 66.6, 54.9, 36.8, 
25.9, 25.8, 25.8, 25.7, 25.6, 23.7, 18.1, 18.0, 14.8, 11.7, 7.1, 6.7, 0.6,   ̶3.7,   ̶4.0,   ̶4.7,   ̶4.7,   ̶5.4,   ̶5.5; 
HRMS (ES+) calc. for C48H108NO7Si5 [M+NH4]+ 950.6966, found 950.6967. 
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(2R,3R,4R,5R,6E,8E,10R,11R,12S)-3,4,13-tris((tert-Butyldimethylsilyl)oxy)-5-methoxy-2,6,10,12-
tetramethyl-12-((triethylsilyl)oxy)-11-((trimethylsilyl)oxy)trideca-6,8-dien-1-yl 4-
methylbenzenesulfonate (381) 
 
To a stirred solution of alcohol 369 (25.0 mg, 0.029 mmol, 1.0 equiv.) in CH2Cl2/Py (1:1, 0.5 mL) was 
added tosyl chloride (16.9 mg, 0.089 mmol, 3.0 equiv.). After 4 h the reaction was quenched with 
NaHCO3 (1 mL) and the layers separated. The aqueous layer was extracted with CH2Cl2 (3 x 1 mL), 
combined organic layers dried over MgSO4 and concentrated in vacuo. The crude material was purified 
by flash column chromatography (19:1 PE/EtOAc) to give the title compound as a colourless oil (22 mg, 
75%).  
Rf 0.36 (19:1 PE/EtOAc); [𝛼]𝐷20 + 19.2 (c 0.54, CHCl3); IR (thin film, νmax/cm-1): 2927, 2339, 2012, 1470, 
1463, 1361, 1251, 1091, 834, 774; 1H NMR (500 MHz, CDCl3): δH 7.78 (2H, d, J = 8.2 Hz, H-Ar), 7.32 (2H, 
d, J = 8.2 Hz, H-Ar), 6.16 (1H, dd, J = 15.0, 10.3 Hz, H-20), 5.91 (1H, d, J = 10.3 Hz, H-19), 5.68 (1H, dd, J = 
15.0, 7.8 Hz, H-21), 4.18 (1H, dd, J = 9.5, 3.3 Hz, H-13a), 3.85 (1H, t, J = 9.3 Hz, H-13b), 3.66-3.62 (3H, m, 
H-15, H-17, H-25a), 3.49 (1H, d, J =  Hz, H-23), 3.47 (1H, d, J = 8.4 Hz, H-16), 3.42 (1H, d, J = 9.7 Hz, H-
25b),  3.01 (3H, s, OCH3), 2.78-2.72 (1H, m, H-22), 2.44 (3H, s, ArCH3), 2.19-2.10 (1H, m, H-14), 1.61 (3H, 
s, Me-18), 1.54 (3H, s, Me-24), 0.99-0.78 (42H, m, Me-14, Me-22, 3 x SiC(CH3)3), Si(CH2CH3)3), 0.62-0.57 
(6H, m, Si(CH2CH3)3), 0.08-   ̶ 0.09 (27H, 3 x Si(CH3)2, Si(CH3)3); 13C NMR (125 MHz, CDCl3): δC 144.5 (C-Ar), 
142.2 (C-Ar), 141.6 (C-21), 133.2 (C-18), 132.4 (C-Ar), 131.6 (C-19), 129.7 (C-Ar), 124.0 (C-20), 86.6, 80.8, 
79.6, 74.2, 74.1, 67.7, 62.4, 54.9, 37.0, 35.2, 29.7, 26.0, 25.9, 25.9, 23.7, 18.5, 18.3, 18.2, 14.9, 14.1, 11.7, 
7.1, 6.8, 0.7,   ̶3.7,  ̶3.9,   ̶4.2,   ̶4.6,   ̶5.3,   ̶5.4; HRMS (ES+) calc. for C52H108NO9SSi5 [M+NH4]+ 1062.6586, 
found 1062.6587. 
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(5R,6R,7R,8E,10E,12R,13S,14S)-6-((tert-Butyldimethylsilyl)oxy)-5-((S)-1-iodopropan-2-yl)-7-methoxy-
2,2,3,3,8,12,14,17,17,18,18-undecamethyl-14-((triethylsilyl)oxy)-13-((trimethylsilyl)oxy)-4,16-dioxa-
3,17-disilanonadeca-8,10-diene (370) 
 
 
 
To a stirred solution of tosylate 381 (6.0 mg, 5.7 μmol, 1.0 equiv.) in MeCN (0.15 mL) was added LiI (9.2 
mg, 69 μmol, 12 equiv.) and heated to 60 °C. After 3 h a further 12 equivalents of LiI was added and the 
temperature raised to 70 °C before stirring for a further 2.5 h. Upon completion, the reaction mixture 
was cooled to rt and quenched with NaHCO3 (1 mL) and diluted with Et2O (1 mL). The layers were 
separated and the aqueous layer extracted with Et2O (5 x 1.5 mL) before combined organic layers were 
dried over MgSO4 and concentrated in vacuo. The crude material was purified by flash column 
chromatography (PE) to give the title compound as colourless oil (4.8 mg, 84%).  
 
Rf 0.35 (19:1 PE/EtOAc); [𝛼]𝐷20 + 8.9 (c 1.00, CHCl3); IR (thin film, νmax/cm-1): 2956, 2369, 2162, 1420, 
1251, 1102, 836, 774; 1H NMR (500 MHz, CDCl3): δH 6.18 (1H, dd, J = 15.1, 10.8 Hz, H-20), 5.95 (1H, d J = 
10.8 Hz, H-19), 5.68 (1H, dd, J =15.1, 7.9 Hz, H-21), 3.77 (1H, dd, J = 7.5, 2.1 Hz, H-13a), 3.63 (1H, d, J = 
9.6 Hz, H-25a), 3.61-3.57 (2H, m, H-13b, H-17), 3.49 (1H, d, J = 2.2 Hz, H-23), 3.47 (1H, dd, J = 9.2, 2.7 Hz, 
H-16), 3.42 (1H, d, J = 9.6 Hz, H-25b), 3.24 (1H, dd, J = 9.2, 6.6 Hz, H-15), 3.09 (3H, s, OCH3), 2.75 (1H, 
app quint, J = 7.9 Hz, H-22), 1.74-1.70 (1H, m, H-14), 1.66 (3H, s, Me-18), 1.54 (3H, s, Me-24), 1.03-0.83 
(42H, m, Me-14, Me-22, 3 x SiC(CH3)3), Si(CH2CH3)3), 0.62-0.57 (6H, m, Si(CH2CH3)3), 0.14-   ̶0.03 (27H, 3 
x Si(CH3)2, Si(CH3)3); 13C NMR (125 MHz, CDCl3): δC 141.5 (C-21), 132.8 (C-18), 131.6 (C-19), 124.1 (C-20), 
86.8, 80.9, 79.7, 76.8, 74.8, 67.7, 55.2, 41.4, 37.0, 26.1, 26.0, 26.0, 23.8, 22.6, 18.5, 18.5, 18.3, 14.9, 14.3, 
12.0, 7.2, 6.8, 0.7,   ̶ 3.6,   ̶ 3.8,   ̶ 3.9,   ̶ 4.3,   ̶ 5.3,   ̶ 5.4; HRMS (ES+) calc. for C45H97IO6Si5Na [M+Na]+ 
1023.5068, found 1023.5069. 
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(6S,7S,8R,9E,11E,13R,14R,15R,16R,18Z,20S,21S,22R,23S,25R,28R)-14,15,23-tris((tert-
Butyldimethylsilyl)oxy)-31,31-diethyl-13-methoxy-21-((4-methoxybenzyl)oxy)-
2,2,3,3,6,8,12,16,20,24,25,28-dodecamethyl-6,28-bis((triethylsilyl)oxy)-7-((trimethylsilyl)oxy)-4,30-
dioxa-3,31-disilatritriaconta-9,11,18-triene (360) 
 
A solution of iodide 370 (20.0 mg, 0.021 mmol, 1.25 equiv.) in Et2O (0.3 mL) was stirred over crushed 
CaH2 for 30 min. After cooling to   ̶78 °C, t-BuLi (1.7 M in pentane, 74 μL, 0.127 mmol, 7.5 equiv.) was 
then added and the reaction mixture stirred for 3 min. OMe-9-BBN (1 M in hexanes, 0.21 mL, 0.212 
mmol, 12.5 equiv.) was then added, followed by THF (0.3 mL). The reaction mixture was then stirred for 
5 min at   ̶78 °C before being warmed to rt and stirred for 1 h. Pd(dppf)Cl2 (1.7 mg, 16.8 μmol, 0.1 equiv.), 
K3PO4 (3 M aq, 17 μL, 0.050 mmol, 3.0 equiv.), vinyl iodide 196 (14.7 mg, 0.017 mmol, 1.0 equiv.) and 
degassed DMF (0.3 mL) were then added. The reaction mixture was then stirred for 3 h and quenched 
with H2O (1 mL). The layers were separated and the organic layer extracted with Et2O (4 x 1 mL). The 
combined organic layers were washed with brine (2 mL), dried over MgSO4 and concentrated in vacuo. 
The crude material was purified by flash column chromatography (40:1 PE/Et2O) to give the title 
compound as a pale-yellow oil (15.1 mg, 54%).  
Rf 0.69 (9:1 PE/EtOAc); [𝛼]𝐷20 + 7.5 (c 0.72, CHCl3); IR (thin film, νmax/cm-1): 3459, 2952, 2343, 1520, 1445, 
1370, 1097, 834; 1H NMR (500 MHz, CDCl3): δH 7.25 (2H, d, J = 8.5 Hz, H-Ar), 6.86 (2H, d, J = 8.5 Hz, H-
Ar), 6.19 (1H, dd, J = 15.0, 10.8 Hz, H-20), 5.95 (1H, d, J = 10.8 Hz, H-19), 5.68 (1H, dd, J = 15.0, 7.9 Hz, H-
21), 5.55 (1H, t, J = 10.5 Hz, H-11), 5.30 (1H, dt, J = 10.5, 7.1 Hz, H-12), 4.56 (1H, d, J = 10.9 Hz, OCHaHbAr), 
4.43 (1H, d, J = 10.9 Hz, OCHaHbAr), 4.13 (1H, br d, J = 9.8 Hz, H-7), 3.80 (3H, s ArOCH3), 3.74 (1H, d, J = 
8.3 Hz, H-17), 3.63 (1H, d, J = 9.8 Hz, H-25a), 3.61 (1H, d, J = 8.0 Hz, H-15), 3.57 (1H, d, J = 8.3 Hz, H-16), 
3.50 (1H, d, J = 1.50 Hz, H-23), 3.42 (1H, d, J = 9.8 Hz, H-25b), 3.39 (1H, d, J = 9.5 Hz, H-1a), 3.31 (1H, d, J 
= 9.5 Hz, H-1b), 3.12-3.08 (4H, m, H-9, OCH3), 2.76 (1H, dqd, J = 7.9, 7.1, 1.5 Hz, H-22), 2.71-2.65 (1H, m, 
H-10), 2.46 (1H, dd, J = 13.5, 7.1 Hz, H-13a), 1.96-1.90 (1H, m, H-8), 1.84-1.79 (1H, m, H-13b), 1.65 (3H, 
s, Me-18), 1.50-1.20 (8H, m, H-3, H-4, H-5, H-6, H-14), 1.16 (3H, s, Me-24), 1.15 (3H, s, Me-2), 1.04-0.80 
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(78H, Me-5, Me-8, Me-10, Me-14, Me-22, 4 x SiC(CH3)3), 3 x Si(CH2CH3)3), 0.63-0.55 (18H, m, 3 x Si(CH2-
CH3)3), 0.12-0.01 (33H, 4 x Si(CH3)2, Si(CH3)3); 13C NMR (125 MHz, CDCl3): δC 158.7 (C-Ar), 141.2 (C-21), 
135.2 (C-11), 132.9 (C-18), 131.6 (C-19), 131.3 (C-Ar), 128.4 (C-Ar), 127.6 (C-12), 124.2 (C-20), 113.6 (C-
Ar), 86.6 (C-15), 84.6 (C-9), 80.9 (C-23), 79.7 (C-16), 76.8 (C-25), 75.9 (C-17), 74.0 (C-Bn), 69.9 (C-1), 69.5 
(C-7), 67.7 (C-24), 65.9 (C-2), 55.3 (OMe), 55.2 (OMe), 42.9, 41.4, 38.8, 37.3, 37.0, 36.4, 36.0, 33.9, 33.7, 
32.0, 31.3, 29.0, 27.7, 26.2, 26.0, 25.9, 25.3, 23.8, 22.6, 20.4, 19.4, 18.8, 18.5, 18.1, 14.3, 11.9, 11.4, 10.3, 
7.2, 6.8, 4.4, 0.7,  ̶3.7,   ̶3.8,   ̶4.1,   ̶4.1,   ̶4.6,   ̶4.6,   ̶5.3,   ̶5.4; HRMS (ES+) calc. for C87H178O11Si8N [M+NH4]+ 
1642.1884, found 1642.1881. 
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